Guideline sources
All 1950 entries in the guideline-source registry, generated at build time (2026-09-01). Referenced from note annotations by ID — see the "Sources" box at the top of an annotated note.
All
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| Approach to drug interactions | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/general-medicine/_shared/Approach to drug interactions - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Australian Journal of General Practice (AJGP) | RACGP | monthly journal | Clinical articles freely readable online. |
| Australian Medicines Handbook (AMH) | Australian Medicines Handbook Pty Ltd | updated twice yearly | This generic entry is for AMH content with no locally saved topic PDF - cite by name only, never copy content, since there is nothing on disk to verify a quote against. 2026-08-12: Steve supplied 12 individual AMH topic PDFs (Tirzepatide, four general drug-interaction/pharmacology references, four ophthalmology topics, and others) - these ARE locally saved and quotable per the same per-claim-evidence policy as eTG, and are catalogued under their own amh-<topic> ids (see evidence/*/_shared/ and evidence/*/<slug>/), not this one. |
| Australian Prescriber | NPS MedicineWise / Therapeutic Guidelines Ltd | per-article | Added Phase 4 (2026-07-08); used for hypercholesterolaemia/FH management and stroke secondary prevention articles. |
| Choosing Wisely Australia recommendations | NPS MedicineWise / Australian college partners (incl. IMSANZ) | per-recommendation | Added Phase 4 (2026-07-08) for the IMSANZ syncope-investigation recommendation. |
| Drugs and CYP enzymes | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/general-medicine/_shared/Drugs and CYP enzymes - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Drugs and P-glycoprotein | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/general-medicine/_shared/Drugs and P‑glycoprotein - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Drugs with anticholinergic effects | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/general-medicine/_shared/Drugs with anticholinergic effects - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Guidelines for preventive activities in general practice (Red Book) | RACGP | 10th edition (living web document; uses GRADE) | |
| Medical Journal of Australia (open-access clinical guidance and consensus statements) | AMPCo | per-article | Added Phase 4 (2026-07-08); first used for the 2022 heart failure pharmacotherapy consensus statement. |
| Therapeutic Guidelines (eTG complete) | Therapeutic Guidelines Ltd | living | Cite by name/topic only - never copy content. Primary source for drug dosing verification. 2026-07-11: Steve supplied 27 dermatology-module topic PDFs (Acne, Alopecia areata, Androgenetic alopecia, Angioedema, Asteatotic/Atopic/Contact/Discoid/Genital dermatitis, Blistering skin conditions, Cutaneous drug reactions, Flushing, Granuloma annulare, Hand or foot dermatitis, Lichen simplex, Nodular prurigo, Overview of hair loss disorders, Periorificial dermatitis, Principles of dermatitis management, Rosacea, Scarring alopecia, Seborrhoeic dermatitis, Telogen effluvium, Tinea, Trichotillomania, Urticaria, Venous dermatitis) — see evidence/dermatology/_shared/. Cross-checked against ~20 dermatology notes; found eTG's Alopecia areata topic (last amended 2022) to be out of date on JAK-inhibitor availability — see ajd-alopecia-areata-consensus-2025. |
Cardiology
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| 2023 ESC Guidelines for the management of cardiomyopathy | European Society of Cardiology, Eur Heart J 2023;44(37):3503-3626 | 2023 (first dedicated ESC cardiomyopathy guideline, unifies prior HCM/DCM-specific guidance) | First ESC guideline to cover cardiomyopathy as a unified phenotype-based framework (dilated, hypertrophic, restrictive, arrhythmogenic, non-dilated left ventricular) rather than separate disease-specific documents. Full text behind academic.oup.com's Cloudflare challenge (couldn't verify quotes by raw fetch) — full-text PDF held privately, evidence/cardiology/cardiomyopathies/. Applies to: cardiomyopathies. |
| 2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis | Bart et al., Heart, Lung and Circulation 2024;33:420-442 | 2024 | First Australia/NZ-specific consensus statement on cardiac amyloidosis diagnosis (incl. nuclear scintigraphy pathway to avoid biopsy in transthyretin amyloidosis) and management (tafamidis for ATTR-CM). No dedicated amyloidosis note currently exists in cardiology — relevant to the restrictive-cardiomyopathy section of cardiomyopathies.md. Applies to: cardiomyopathies. |
| A dizzying diagnosis (postural orthostatic tachycardia syndrome case study), AJGP Vol 54 No 12, December 2025 | Australian Journal of General Practice (RACGP) | ||
| AAA screening and surveillance | AJGP (RACGP) | ||
| Abdominal Aortic Aneurysm | StatPearls (NCBI Bookshelf) | current as at fetch | Risk factors, examination, screening-group and surveillance detail for cardiology/aaa.md, whose three prior cited sources (racgp-red-book, ajgp, anzsvs) are all generic landing pages with no AAA-specific text saved. |
| Abdominal aortic aneurysm: An update | AJGP (RACGP) | ||
| Abdominal Aortic Aneurysms (AAA) | MSD Manual Professional Edition | current as at fetch | Includes its own AAA-diameter/rupture-risk table (different cut points/percentages from the RACGP AFP table already cited on cardiology/aaa.md - flagged as a discrepancy, not silently substituted). |
| Acute Arterial Occlusion | StatPearls (NCBI Bookshelf) | archived article, content current as at fetch | Acute limb ischaemia (6 Ps, urgency window, causes) and acute arterial occlusion presentations (stroke/mesenteric/limb) for cardiology/peripheral-vascular-disease.md's Acute arterial occlusion section, stage E. |
| Acute Chest Pain | Community HealthPathways Hunter New England | GP-facing referral/management pathway for acute chest pain. Local copy (supplied by Steve, text-layer): evidence/common-presentations/chest-pain/hne-healthpathways-acute-chest-pain.pdf. Used for the common-presentations/chest-pain.md consolidation (2026-08-24). | |
| Acute coronary syndromes — clinical guideline overview (Heart Foundation, for professionals) | Heart Foundation | Named by hand from the document's own opening text. Local copy at evidence/cardiology/acute-coronary-syndromes/heart-foundation-acs-guideline-overview.html. | |
| Adenosine (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Alirocumab for hypercholesterolaemia | Australian Prescriber | ||
| ANZCOR Guideline 11.2 -- Protocols for Adult Advanced Life Support | ANZCOR | ||
| ANZCOR Guideline 11.2 — Protocols for Adult Advanced Life Support | Australian and New Zealand Committee on Resuscitation | reviewed/updated based on 2018-2020 ILCOR evidence reviews | Added 2026-08-16 for stage-E claim placement -- the generic anzcor registry id only has the anzcor.org landing page cached (site-level, not quotable); this is the actual Adult ALS protocol PDF with the algorithm content (shock/adrenaline/amiodarone timing, 4Hs/4Ts, post-resuscitation ABCDE). |
| ANZCOR Guideline 11.7 -- Post-resuscitation Therapy in Adult Advanced Life Support | Australian and New Zealand Committee on Resuscitation | 2021 CoSTR-informed review | Added 2026-08-16 for stage-E claim placement -- post-ROSC targets (SpO2 94-98%, normocapnia, normoglycaemia, temperature control) for cardiac-arrest.md. |
| ANZCOR Guideline 11.9 -- Managing Acute Dysrhythmias | Australian and New Zealand Committee on Resuscitation (ANZCOR) | current as at fetch | |
| ANZCOR resuscitation guidelines (Adult Advanced Life Support) | Australian and New Zealand Committee on Resuscitation | Adult ALS protocols revised June 2024 | Added Phase 4 (2026-07-08) for cardiac arrest / bradyarrhythmia drug doses and timing. |
| ANZSVS clinical and patient information (vascular surgery) | Australian and New Zealand Society for Vascular Surgery | living web resources | Added Phase 4 (2026-07-08) for AAA screening/surveillance positions. |
| Aortic Stenosis | StatPearls (NCBI Bookshelf) | ||
| Aortic stenosis: Update in monitoring and management | RACGP (AJGP) | AJGP 53(7), July 2024 | Australian severe AS prevalence (1.5% >55yrs, 3.5% >75yrs); 4-category echo classification (high-gradient, low-flow/low-gradient with reduced or preserved EF, normal-flow/low-gradient); surveillance intervals by severity (3-5yr mild, 1-2yr moderate, 6-12mo severe); TAVI vs SAVR decision via heart-team, TAVI often preferred >75yrs; ACEi safe/beneficial in symptomatic severe AS. Local copy: evidence/cardiology/_ajgp/ |
| Approach to Chest Pain | EM:RAP Corependium | Updated 8 Aug 2026 | Used for the common-presentations/chest-pain.md consolidation (2026-08-24): OLDCAAR history mnemonic, risk-factor and physical-exam pearls, ECG-timing rules, and especially its dedicated 'Urgent Care Considerations' section (EMS-activation threshold, aspirin/ECG while awaiting transfer, nitroglycerin caution without IV access, HEAR-without-troponin score, limited troponin/D-dimer availability outside hospital, discharge safety-netting) — the main new source for this page's GP/urgent-care/rural framing. Its ED/ICU-level material (RSI, push-dose vasopressors, PCI/fibrinolytic protocols, pericardiocentesis/thoracostomy technique, triple rule-out CTA) was deliberately left uncited as out of scope for this page. Local copy: evidence/common-presentations/chest-pain/emrap-chest-pain-presentation.pdf — originally supplied image-only (no text layer), replaced same day with a text-layer copy (Steve), now stage-E/F quotable via pdftotext (~8,500 words). |
| Approach to palpitations | AJGP (RACGP) | ||
| Approach to palpitations | RACGP (AJGP) | AJGP 48(4), April 2019 | Systematic approach to palpitations: 41% arrhythmic/31% anxiety/16% no cause in university medical centre patients (3.3yr diagnostic delay if mislabelled anxiety); up to 100 VEBs/24h Holter normal; sinus-rhythm ECG markers table; abnormal resting HR (<60 or >100) the only exam finding correlating with arrhythmia; Box 2 referral/when-to-worry criteria. |
| Assessing Fitness to Drive for commercial and private vehicle drivers 2022 | Austroads / National Transport Commission | Supplied by Steve 2026-08-31. Australian national medical standards for private and commercial driver licensing. | |
| Atrial fibrillation | AJGP (RACGP) | ||
| Atrial fibrillation clinical resources (Heart Foundation, for professionals) | Heart Foundation | Named by hand from the document's own opening text. Local copy at evidence/cardiology/atrial-fibrillation/heart-foundation-af-resources.html. | |
| Atrial fibrillation: an update on management | Australian Prescriber | ||
| Atrial Septal Defect | StatPearls (NCBI Bookshelf) | ||
| Atrial Septal Defect (ASD) | MSD Manual Professional Edition | ||
| Australian CVD risk calculator and guideline (check in browser) | Commonwealth of Australia | 2023 guideline | Not re-fetched this pass; widely used calculator URL. |
| Australian guideline and calculator for assessing and managing cardiovascular disease risk | Australian CVD Risk Calculator (cvdcheck.org.au) | Catalogued from the local copy at evidence/cardiology/cardiovascular-risk-assessment/cvdcheck-2023-guideline.html. | |
| Cardiac imaging 2022 update | AJGP (RACGP) | ||
| Cardiac implantable electronic devices: An update | RACGP (AJGP) | AJGP 53(7), July 2024 | Pacemaker/ICD/CRT/ILR indications tables; most modern CIEDs are now MRI-conditional/compatible with appropriate safety checks (previously a blanket contraindication); remote monitoring now standard, detecting arrhythmias/preclinical heart failure without in-clinic visits; leadless pacemakers and subcutaneous ICDs reduce lead-related infection/vascular complications; conduction system pacing is a newer physiological pacing technique. Local copy: evidence/cardiology/_ajgp/ |
| Cardiac murmurs in children | Australian Journal of General Practice | ||
| Cardiovascular drug access in Australia and New Zealand: new PBS and PHARMAC listings, 2023-2025 (check in browser) | Heart, Lung and Circulation | Heart Lung Circ 2026 | Review of recent Australian and New Zealand cardiovascular reimbursement changes. Used for the eplerenone PBS broadening effective 1 April 2026 - chronic heart failure NYHA II-IV with LVEF <=40%, no longer requiring prior myocardial infarction or hospital initiation within 14 days of an acute MI. NOT independently verified against the PBS schedule itself: sciencedirect.com serves a challenge page to automated fetches and pbs.gov.au search is JS-rendered, so the listing date is corroborated by a second secondary source rather than by primary PBS text. Check current PBS restrictions before prescribing. |
| Cardiovascular risk screening beyond the Australian Cardiovascular Risk calculator: A guide for general practitioners | AJGP (RACGP) | ||
| Chest pain | AJGP (RACGP) | AJGP 53(7), July 2024 | Rahman, primary-care-focused review. Source of the 'cardiac/possibly cardiac/non-cardiac' preferred-terminology recommendation (over 'atypical'), the typical-vs-less-likely-angina features table, community chest-pain epidemiology (83% non-ischaemic; musculoskeletal 36%, GI 19%, cardiac 16%, psychiatric 8%, pulmonary 5%), the point that troponin has a limited primary-care role except in regional/rural EDs, and brief PE/pneumothorax/oesophageal-rupture/aortic-dissection recognition points for the community setting. Local copy (supplied by Steve): evidence/common-presentations/chest-pain/AJGP-07-24-6810-FO-Rahman-Chest-Pain-WEB.pdf. Used for the common-presentations/chest-pain.md consolidation (2026-08-24), merging the former separate cardiology and respiratory chest-pain pages. Registered as a stub (no local copy, cardiology-only) during Resource Seeding; filled in and expanded here. |
| Chronic Mesenteric Ischemia | StatPearls (NCBI Bookshelf) | current as at fetch | Chronic mesenteric ischaemia triad (postprandial pain, weight loss, food fear), acute-on-chronic deterioration for cardiology/peripheral-vascular-disease.md, stage E. |
| Clinical Guidelines for Stroke Management — Summary for General Practice (June 2025) | Stroke Foundation | ||
| Coarctation of the Aorta | StatPearls (NCBI Bookshelf) | ||
| Consensus statement on the current pharmacological prevention and management of cardiovascular disease | Medical Journal of Australia 2022;217(4) | Named by hand from the document's own opening text. Local copy at evidence/cardiology/heart-failure/mja-2022-consensus-statement.html. | |
| Deep Vein Thrombosis (DVT) (check in browser) | Community HealthPathways Hunter New England | current as at upload (2026-07-10) | Clinician-login-gated regional pathway (not independently URL-verified; cited by name/content only). Practical diagnostic workflow: simplified Wells' score for DVT (score 0-1 low probability -> D-dimer; score >=2 high probability -> urgent leg vein ultrasound, start LMWH if ultrasound unavailable within 4 hours); distal vs proximal vs upper-limb DVT distinctions and risk of extension/PE; superficial venous thrombosis (SVT, formerly thrombophlebitis) risk-stratified by distance from saphenofemoral junction with its own anticoagulation duration rules; DOAC (apixaban/rivaroxaban) first-line unless pregnancy/breastfeeding, cancer, antiphospholipid syndrome, or severe renal impairment (use CrCl, not eGFR); explicit red flags for urgent vascular surgery referral (iliofemoral/IVC extension, phlegmasia cerulea dolens, upper-limb DVT with no provoking factor). |
| Diagnosis and management of acute coronary syndromes | Australian Prescriber | ||
| Diagnosis and Management of Familial Hypercholesterolaemia — Position Statement | Cardiac Society of Australia and New Zealand (Sullivan, Watts, Hamilton-Craig et al.) | 2016 (updates the 2013 CSANZ FH document) | Australian-specific FH position statement using the Dutch Lipid Clinic Network Score for phenotypic diagnosis; 2016 update added genetic/psychosocial counselling guidance and PCSK9-inhibitor/ezetimibe medication updates. Applies to: familial-hypercholesterolaemia. |
| Diagnosis and Management of Hypertrophic Cardiomyopathy — Position Statement | Cardiac Society of Australia and New Zealand (Semsarian et al.) | 2016 (updates the 2011 CSANZ HCM guideline) | Australian-specific HCM position statement; key updates from 2011 relate to sudden-death risk stratification (myocardial fibrosis burden, HCM Risk-SCORE) and more selective cascade genetic testing in asymptomatic relatives. Superseded in international scope by esc-cardiomyopathy-2023 but remains the CSANZ Australian reference. Applies to: cardiomyopathies. |
| Electrocardiogram (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Electrocardiography | MSD Manual Professional Edition | ||
| Familial hypercholesterolaemia: a guide for general practice | Brett T, Arnold-Reed D, AJGP 2019;48(8) | 2019 | Practical GP guide to phenotypic FH diagnosis via the Dutch Lipid Clinic Network Score, cascade testing of relatives, and treatment pathway including children. Applies to: familial-hypercholesterolaemia. |
| Genetics in relation to cardiac diseases: Implications for general practitioners | RACGP (AJGP) | AJGP 53(7), July 2024 | Overview of monogenic (cardiomyopathies, channelopathies e.g. Long QT), polygenic risk scores, and pharmacogenetic considerations in cardiovascular disease. Local copy: evidence/cardiology/_ajgp/ |
| Heart failure with preserved ejection fraction: A growing global epidemic | AJGP (RACGP) | ||
| Heart failure: medicines for patients with heart failure with reduced ejection fraction (HFrEF) — Therapeutic Brief, Autumn 2025 | Medicines Access and Insights (Therapeutic Brief) | Named by hand from the document's own opening text. Local copy at evidence/cardiology/heart-failure/maia-2025-hfref-therapeutic-brief.pdf. | |
| Heart Foundation clinical guidelines (ACS, hypertension, CVD risk, Heart Health Check) | National Heart Foundation of Australia | per-guideline (see individual documents) | |
| Hypertension - a major modifiable and undertreated risk factor (Hespe, Stocks, Nelson, Aust Prescr 2025;48:194-6) | Australian Prescriber / Therapeutic Guidelines Ltd | Current (Dec 2025) overview of hypertension as an undertreated CVD risk factor in Australia: prevalence/detection-treatment-control gaps, out-of-clinic BP measurement, lifestyle and pharmacological management principles. | |
| Hypertensive Retinopathy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Hypertriglyceridaemia: A practical approach for primary care | RACGP (AJGP) | AJGP 54(11), November 2025 | Severe hypertriglyceridaemia (>=5.6 mmol/L) as a pancreatitis-prevention target, distinct from mild-moderate (1.7-5.6 mmol/L) CVD-risk target. Local copy: evidence/gastroenterology/_ajgp/ |
| iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025 (with the accompanying CSANZ-journal editorial by its Australian co-authors) | iCARDIO Alliance / Heart, Lung and Circulation | Heart Lung Circ 2025 (editorial); guideline DOI 10.1016/j.hlc.2025.05.094 | The most current guidance applicable to Australian practice while the NHFA/CSANZ 2018 guideline remains un-updated. Aligns with the 2018 Australian LVEF <50% categorisation rather than the ESC mid-range category. HFrEF: four pillars strongly recommended with ARNI preferred over ACEI; vericiguat suggested after recent worsening HF (esp. NT-proBNP <5000 pg/mL); IV ferric carboxymaltose/derisomaltose strongly recommended for symptoms and now also to reduce HF hospitalisation and CV death; iron deficiency may be defined simply as TSAT <20%; cardiac contractility modulation for LVEF 25-45% unsuitable for CRT. HFpEF: SGLT2i strongly recommended regardless of LVEF, finerenone recommended as a second pillar (spironolactone if unavailable), ARNI at the lower end of the LVEF range especially in women, GLP-1 RA (semaglutide/tirzepatide) strongly recommended in obesity-related HFpEF. The guideline full text is paywalled; the open-access editorial by Atherton, Sindone and Coats is the citable local copy. Local copy: evidence/cardiology/heart-failure/ |
| Implantable loop recorder versus conventional diagnostic assessment for people with unexplained recurrent syncope (Cochrane Database of Systematic Reviews, 2016) | Cochrane | ||
| Implications of new clinical practice guidance on familial hypercholesterolaemia for Australian general practitioners | AJGP (RACGP) | ||
| Improving awareness of cardiovascular risk factors in young Australian adults | RACGP (AJGP) | AJGP 53(7), July 2024 | 96.6% of Australians aged 18-34 with high BP don't report being hypertensive (2017-18 ABS data); young adults have poor risk-factor awareness and low GP engagement - a primordial-prevention opportunity. Local copy: evidence/cardiology/_ajgp/ |
| Kawasaki Disease (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Lipid management and implications for Australian general practice | AJGP (RACGP) | ||
| Living Clinical Guidelines for Stroke Management | Stroke Foundation | living guidelines (AU/NZ) | |
| Management of heart failure with preserved ejection fraction | Australian Prescriber | ||
| Managing hypercholesterolaemia | Australian Prescriber | Named by hand from the document's own opening text. Local copy at evidence/cardiology/hypercholesterolaemia/aus-prescriber-managing-hypercholesterolaemia.html. | |
| Medicines for patients with heart failure with reduced ejection fraction (HFrEF) - Therapeutic Brief | Medicines Advice Initiative Australia (UniSA QUMPRC, with AMH, DATIS, Univ. of Adelaide, NACCHO, PSA, CATAG; Australian Government funded) | Autumn 2025 | Current Australian GP-level quadruple-therapy brief. Start two drugs first then the other two, titrating afterwards; congested -> RASi + SGLT2i, add MRA, add beta blocker once euvolaemic; euvolaemic -> RASi + beta blocker, add MRA and SGLT2i. Expected and acceptable on initiation: BP fall, creatinine rise up to 30%, K+ rise within normal range. MRA potassium rules: 5.5-5.9 halve the dose, >6.0 stop and restart lower once <5.0. Monitor U&E 1-2 weeks after each change, then 4-weekly x12 weeks, 6 months, then 6-monthly. Review within 7 days of hospital discharge; HMR reduces HF hospitalisation ~45% and a GPMP ~17%. Approx 318,000 Australians have HF; ~50% die within 5 years of first admission. Local copy: evidence/cardiology/heart-failure/ |
| Menopause, cardiovascular health and the role of hormone therapy | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/womens-health/_ajgp/menopause-cardiovascular-health-2026.pdf. |
| Midodrine for orthostatic hypotension, Aust Prescr 2021;44:31 | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Myocarditis and related complications | AJGP (RACGP) | ||
| National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 | Heart, Lung and Circulation 2018;27:1209-1266 | Named by hand from the document's own opening text. Local copy at evidence/cardiology/atrial-fibrillation/PIIS1443950618317785.pdf. | |
| New frontiers in the management of dyslipidaemia: PCSK9 inhibitors and siRNA | AJGP (RACGP) | ||
| NHFA/CSANZ Guidelines for the prevention, detection and management of heart failure in Australia 2018 | National Heart Foundation of Australia / Cardiac Society of Australia and New Zealand | Heart Lung Circ 2018;27(10):1123-208 | The Australian national HF guideline, still formally current in 2026 though 8 years old (see icardio-hf-2025). Defines HFrEF as symptoms +/- signs with LVEF <50% (NOT the ESC/US <40%), HFpEF as LVEF >=50% plus structural disease or diastolic dysfunction; requires additional criteria if LVEF is 41-49%. Section 3.3.3 explicitly declines to adopt a separate mid-range (HFmrEF) category. Table 4 BNP/NT-proBNP cut-offs: rule-out BNP <100 / NT-proBNP <300 ng/L; rule-in BNP >400, NT-proBNP >450 (<50yrs) / >900 (50-75yrs) / >1800 (>75yrs). Local copy: evidence/cardiology/heart-failure/ |
| Non-acute Chest Pain | Community HealthPathways Hunter New England | GP-facing referral/management pathway for non-acute (stable, community-presenting) chest pain. Local copy (supplied by Steve, text-layer): evidence/common-presentations/chest-pain/hne-healthpathways-non-acute-chest-pain.pdf. Used for the common-presentations/chest-pain.md consolidation (2026-08-24). | |
| Palpitations: A Practical Approach | Cureus | Cureus 17(11): e97748, 25 Nov 2025 | Ribero-Vargas, Jaramillo-Alvarez, Gandara-Ricardo. Open-access (CC-BY) review: history LR data (cardiac disease Hx LR+2.03, sleep-affected LR+2.29, work-related LR+2.17, duration<5min LR-0.38, regular neck pounding LR+177 for AVNRT), EHRA four-category classification (extrasystolic/tachycardic/anxiety-related/pounding), exam pearls (irregular pulse PPV 91% for arrhythmia on 24h ECG), ambulatory monitoring device diagnostic-yield table, 2017 ISHNE-HRS ambulatory monitoring indications. Local copy (supplied by Steve, text-layer): evidence/cardiology/palpitations/cureus-palpitations-practical-approach.pdf. Used for the cardiology/palpitations.md stage-F-style rewrite (2026-08-26). |
| Patent Ductus Arteriosus (PDA) — MSD Manual Professional Edition | MSD Manual Professional Edition | ||
| Patent Ductus Arteriosus (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| PCSK9 inhibitors – clinical applications | Australian Prescriber | ||
| Peripheral Arterial Disease | StatPearls (NCBI Bookshelf) | current as at fetch | PAD lifestyle/pharmacological management (smoking cessation, ACE inhibitors, diet, duplex ultrasound) for cardiology/peripheral-vascular-disease.md, stage E. |
| Peripheral artery disease in the lower limbs | AJGP (RACGP) | ||
| Pulmonary Embolism | Community HealthPathways Hunter New England | Last updated 2 Sep 2025 | Local copy: evidence/respiratory/_shared/HNE-HealthPathways-PulmonaryEmbolism.pdf. Simplified Wells' score + PERC rule, apixaban/rivaroxaban first-line dosing, CTEPH follow-up. Respiratory's chest-pain/dyspnoea pages cross-reference PE red flags from this; cardiology's dvt-ix.md remains the canonical full VTE/PE management page. Text-layer copy added 2026-08-18 (was image-only). |
| Risk assessment of drug-induced QT prolongation (Aust Prescr 2015;38:20-4) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Risk treatment thresholds for initiating cardiovascular disease prevention | AJGP (RACGP) | ||
| Sacubitril/valsartan for chronic heart failure | Australian Prescriber | ||
| Screening for primary aldosteronism | AJGP (RACGP) | ||
| Secondary Hypertension | StatPearls (NCBI Bookshelf) | StatPearls, updated 2026 | Dedicated secondary hypertension article: when to investigate, causes (renal, endocrine, coarctation, drug-induced), red-flag signs, initial and specialist work-up (renin/aldosterone ratio, metanephrines/catecholamines, renal imaging). |
| Sinus Bradycardia | StatPearls (NCBI Bookshelf) | ||
| Stable Angina | StatPearls (NCBI Bookshelf) | current as at fetch | Chronic coronary syndrome/stable angina definition, history, investigations and anti-anginal management detail for cardiology/stable-angina-ischaemic-heart-disease.md, which had no dedicated cited source. |
| Stable Angina | MSD Manual Professional Edition | current as at fetch | Chronic stable angina diagnosis/investigation/management detail for cardiology/stable-angina-ischaemic-heart-disease.md. |
| Statin doses after acute coronary syndrome | Australian Prescriber | ||
| Statin Medications | StatPearls (NCBI Bookshelf) | ||
| Statins and muscle symptoms | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Superficial Thrombophlebitis | StatPearls (NCBI Bookshelf) | ||
| Supraventricular Tachycardia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Syncope | StatPearls (NCBI Bookshelf) | Low-yield fallback source for cardiology/syncope.md. | |
| Tafamidis and tafamidis meglumine for amyloid cardiomyopathy | Australian Prescriber | ||
| THANZ venous thromboembolism diagnosis and management guidelines | Thrombosis and Haemostasis Society of Australia and New Zealand | 2019 (current) | Added Phase 4 (2026-07-08) for thrombophilia testing recommendations post-VTE. Also covers full VTE diagnosis/treatment: Wells/Geneva clinical prediction rules + D-dimer to guide imaging; duplex ultrasound first-line for DVT, CTPA/VQ for PE; DOACs (apixaban/rivaroxaban preferred, no parenteral lead-in needed) equally effective as warfarin and favoured for most patients; anticoagulate proximal DVT/PE >=3 months, distal DVT 6-12 weeks; extended anticoagulation decision for unprovoked/non-surgical-transient VTE weighs recurrence risk vs bleeding risk (low-dose apixaban 2.5mg bd or rivaroxaban 10mg daily equally effective as full dose beyond 6 months); routine thrombophilia testing not recommended except antiphospholipid screen if unprovoked VTE under 45; age-appropriate malignancy screening (not routine CT abdo/pelvis) after unprovoked VTE, ~10% diagnosed with cancer in the following year. |
| The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease | RHDAustralia / Medical Journal of Australia | 3rd edition, 2020 | Secondary prophylaxis duration shortened from the old blanket 10-years-minimum rule to 5 years post-ARF (no cardiac involvement) or 10 years (with cardiac involvement) after the most recent episode, or until age 21, whichever is longer. Benzathine benzylpenicillin G IM every 28 days remains first-line. |
| The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis | Clinical Infectious Diseases 2023;77(4):518-526 | Named by hand from the document's own opening text. Local copy at evidence/cardiology/infective-inflammatory-conditions/duke-iscvid-2023-pmc.html. | |
| The 2024 ESC guidelines for management of atrial fibrillation: AF-CARE as new credo, Herzschrittmachertherapie + Elektrophysiologie 2024;35:318-323 (English abstract; open access) | Herzschrittmachertherapie + Elektrophysiologie (Springer) | ||
| The diagnosis and management of venous thromboembolism: guidelines of the Thrombosis and Haemostasis Society of Australia and New Zealand | Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) | Named by hand from the document's own opening text. Local copy at evidence/cardiology/dvt-ix/thanz-vte-guidelines-2019.pdf. | |
| The evolving face of heart failure management | RACGP — Australian Journal of General Practice | Named by hand from the document's own opening text. Local copy at evidence/cardiology/heart-failure/ajgp-2022-09-evolving-hf-management.pdf. | |
| The evolving face of heart failure management | RACGP (AJGP) | AJGP 51(9), September 2022 | GP-facing practical prescribing detail for ARNI and SGLT2i. Sacubitril/valsartan titration table (full prior ACEI/ARB dose -> start 49/51mg BD, increase at 2-4 weeks to 97/103mg BD; low prior dose -> start 24/26mg BD); 36-hour washout required switching from ACEI (none from ARB); reduce loop diuretic 25-50% when starting ARNI or an SGLT2i; start ARNI lower if >75yrs, eGFR <60, Child-Pugh B, or transaminases >2x ULN; avoid if systolic BP <100mmHg. SGLT2i: reduce insulin ~20% and cease sulfonylureas/glitazones at initiation, sick-day plan for euglycaemic ketoacidosis. HF in CKD: tolerate eGFR fall up to 30%, act if K+ >5.5, avoid MRA in CKD 4-5. Confirms the Australian HFrEF LVEF <50% definition. Local copy: evidence/cardiology/heart-failure/ |
| Therapeutics for rheumatic fever and heart disease | Australian Prescriber | ||
| Time to rethink our approach to guidelines in heart failure (editorial) | Heart, Lung and Circulation 2025 | Named by hand from the document's own opening text. Local copy at evidence/cardiology/heart-failure/hlc-2025-icardio-hf-editorial.pdf. | |
| Torsade de Pointes | StatPearls (NCBI Bookshelf) | ||
| Update on familial hypercholesterolemia: an expert clinical consensus | National Lipid Association, J Clin Lipidol 2026;20:708-737 | 2026 | US-focused expert consensus update; useful cross-check against the Australian CSANZ 2016 statement for newer agents (PCSK9 inhibitors, inclisiran, bempedoic acid). URL is a best-effort DOI resolution, not independently verified by raw fetch — full-text PDF held privately, evidence/cardiology/familial-hypercholesterolaemia/. Applies to: familial-hypercholesterolaemia. |
| Varicose Veins | StatPearls (NCBI Bookshelf) | ||
| Ventricular Fibrillation | StatPearls (NCBI Bookshelf) | ||
| Ventricular Septal Defect (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Ventricular Septal Defect (VSD) — MSD Manual Professional Edition | MSD Manual Professional Edition | ||
| Ventricular Tachycardia | StatPearls (NCBI Bookshelf) | ||
| Which procedures are best for treating varicose veins in the leg? | Cochrane | ||
| Wolff-Parkinson-White Syndrome (StatPearls) | StatPearls (NCBI Bookshelf) |
Common Presentations
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| A review of tinnitus | AJGP | ||
| Abdominal pain - acute | Royal Children's Hospital Melbourne Clinical Practice Guidelines | Paediatric-specific acute abdominal pain guideline — replaces this page's existing unsourced paediatric section. Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/rch-abdominal-pain-acute.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). | |
| Abdominal Pain — Adult ECAT Protocol | Emergency Care Institute, Agency for Clinical Innovation (NSW) | A7.1, published December 2023, updated June 2024 | NSW rural/regional emergency-department protocol (Emergency Care Assessment and Treatment) — the main rural/peripheral-hospital-scoped source for this page. Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/ecat-abdominal-pain-adult.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). |
| Acute Abdominal Pain in Adults: Evaluation and Diagnosis | American Family Physician (AAFP) | Am Fam Physician. 2023;107(6):585-596 | Yew, George, Allred (Gundersen Health System family medicine). Comprehensive primary-care-facing review: pain-location differential, history/exam red flags, initial investigations, imaging choice by presentation (incl. pregnancy — MRI preferred over CT). Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/acute-abdominal-pain-adults.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). |
| Acute Chest Pain | Community HealthPathways Hunter New England | GP-facing referral/management pathway for acute chest pain. Local copy (supplied by Steve, text-layer): evidence/common-presentations/chest-pain/hne-healthpathways-acute-chest-pain.pdf. Used for the common-presentations/chest-pain.md consolidation (2026-08-24). | |
| Acute Lower Abdominal Pain in Women | Community HealthPathways Hunter New England | GP-facing pathway for gynaecological causes of acute lower abdominal pain in women (ectopic pregnancy, PID, ovarian torsion/cyst accident, etc). Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/hne-healthpathways-acute-lower-abdominal-pain-women.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). | |
| An approach to vertigo in general practice | Australian Family Physician (RACGP) | ||
| An update on epistaxis | RACGP (Australian Family Physician) | AFP 44(9), September 2015 | Yau. Epistaxis assessment and stepwise management (first aid, cautery, packing, posterior bleeds) and red flags for neoplasia. Already the note's cited source pre-stage-F (previously registry: check-in-browser, unregistered) — properly registered here for the common-presentations/epistaxis.md stage-F rewrite (2026-08-24). |
| Approach to Abdominal Pain | EM:RAP Corependium | Updated 6 Aug 2026 | Comer, Dixon. Used only for GP/urgent-care-relevant material (history/exam pearls, differential by location, red flags) — its ED/ICU-only procedural detail is deliberately left out, same policy as the chest-pain page. Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/emrap-abdominal-pain-presentation.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). |
| Approach to Chest Pain | EM:RAP Corependium | Updated 8 Aug 2026 | Used for the common-presentations/chest-pain.md consolidation (2026-08-24): OLDCAAR history mnemonic, risk-factor and physical-exam pearls, ECG-timing rules, and especially its dedicated 'Urgent Care Considerations' section (EMS-activation threshold, aspirin/ECG while awaiting transfer, nitroglycerin caution without IV access, HEAR-without-troponin score, limited troponin/D-dimer availability outside hospital, discharge safety-netting) — the main new source for this page's GP/urgent-care/rural framing. Its ED/ICU-level material (RSI, push-dose vasopressors, PCI/fibrinolytic protocols, pericardiocentesis/thoracostomy technique, triple rule-out CTA) was deliberately left uncited as out of scope for this page. Local copy: evidence/common-presentations/chest-pain/emrap-chest-pain-presentation.pdf — originally supplied image-only (no text layer), replaced same day with a text-layer copy (Steve), now stage-E/F quotable via pdftotext (~8,500 words). |
| Betahistine for tinnitus | Cochrane | ||
| Bleeding Disorders | StatPearls (NCBI Bookshelf) | General approach to the patient with a bleeding disorder: history/exam features distinguishing platelet-type from coagulation-factor-type bleeding, first-line investigations. Used for the common-presentations/bruising-bleeding.md and purpuric-rash.md stage-F rewrite (2026-08-24). | |
| Chest pain | AJGP (RACGP) | AJGP 53(7), July 2024 | Rahman, primary-care-focused review. Source of the 'cardiac/possibly cardiac/non-cardiac' preferred-terminology recommendation (over 'atypical'), the typical-vs-less-likely-angina features table, community chest-pain epidemiology (83% non-ischaemic; musculoskeletal 36%, GI 19%, cardiac 16%, psychiatric 8%, pulmonary 5%), the point that troponin has a limited primary-care role except in regional/rural EDs, and brief PE/pneumothorax/oesophageal-rupture/aortic-dissection recognition points for the community setting. Local copy (supplied by Steve): evidence/common-presentations/chest-pain/AJGP-07-24-6810-FO-Rahman-Chest-Pain-WEB.pdf. Used for the common-presentations/chest-pain.md consolidation (2026-08-24), merging the former separate cardiology and respiratory chest-pain pages. Registered as a stub (no local copy, cardiology-only) during Resource Seeding; filled in and expanded here. |
| Cognitive behavioural therapy for adults with tinnitus | Cochrane | ||
| Dealing with dizziness | Australian Prescriber | ||
| Exercise for Neck Pain | Cochrane | ||
| Falls Prevention Guidelines for Community Care | Australian Commission on Safety and Quality in Health Care (ACSQHC) | ||
| Fever of Unknown Origin (FUO) | MSD Manual Professional Edition | ||
| Fever of Unknown Origin (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Neck pain: What if it is not musculoskeletal? | AJGP (RACGP) | AJGP 47(5), May 2018 | |
| Non surgical therapy for anal fissure | Cochrane | Cochrane plain-language summary (Nelson R, 2003 review): topical GTN modestly more effective than placebo for healing chronic anal fissure but with frequent late recurrence and headache; botulinum toxin/topical calcium-channel blockers similarly effective with fewer side effects. Used for the common-presentations/pr-bleeding.md stage-F rewrite (2026-08-24). | |
| Non-acute Chest Pain | Community HealthPathways Hunter New England | GP-facing referral/management pathway for non-acute (stable, community-presenting) chest pain. Local copy (supplied by Steve, text-layer): evidence/common-presentations/chest-pain/hne-healthpathways-non-acute-chest-pain.pdf. Used for the common-presentations/chest-pain.md consolidation (2026-08-24). | |
| Pigs, pooches and pasteurisation: The changing face of brucellosis in Australia | AJGP | ||
| Sepsis | EM:RAP CorePendium | Supplied by Steve 2026-08-31. | |
| Sepsis Clinical Care Standard | Australian Commission on Safety and Quality in Health Care | ||
| Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 | Society of Critical Care Medicine / ESICM (Critical Care Medicine) | Supplied by Steve 2026-08-31. Hospital/ICU-scoped; use for definitions, screening, fluid/antibiotic timing. | |
| Tests of haemostasis: detection of the patient at risk of bleeding | Australian Prescriber | Australian Prescriber review of first-line haemostasis tests (FBC/platelets, PT/APTT, fibrinogen) and how to interpret an abnormal result when a patient presents with bruising/bleeding. Used for the common-presentations/bruising-bleeding.md and purpuric-rash.md stage-F rewrite (2026-08-24). | |
| The Epley manoeuvre for benign paroxysmal positional vertigo (BPPV) | Cochrane | ||
| There's blood in my underwear | AJGP (RACGP) | AJGP 48(3), March 2019 | AJGP case-based review of rectal bleeding assessment in general practice: differential by history pattern, red flags for colorectal cancer, when to refer/investigate. Used for the common-presentations/pr-bleeding.md stage-F rewrite (2026-08-24). |
| Tranexamic acid to help treat nosebleeds (epistaxis) | Cochrane | Cochrane plain-language summary (Joseph J, 2018 review): oral/topical tranexamic acid reduces re-bleeding after an initial nosebleed vs usual care (moderate-quality evidence); topical TXA may stop bleeding faster than usual first-aid measures. Used for the common-presentations/epistaxis.md stage-F rewrite (2026-08-24). | |
| What are the benefits and harms of antibiotics for acute bacterial conjunctivitis? | Cochrane |
Dermatology
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| A case of sore throat and vesicular hand lesions | AJGP (RACGP) | ||
| A guide to curettage and cautery | AJGP (RACGP) | ||
| A guide to curettage and cautery | RACGP — Australian Journal of General Practice | This procedure is a simple, quick and cost-effective option which, when used appropriately and correctly, has shown excellent clinical efficacy and favourable cosmetic outcomes. Catalogued from the local copy at evidence/dermatology/_ajgp/2021-12-curettage-and-cautery.html. | |
| A guide to curettage and cautery in the management of skin lesions | RACGP (AJGP) | AJGP 50(12), December 2021 | Curettage cure rates equal excision/cryotherapy/radiotherapy for suitable lesions (low-risk BCC, SCC-in-situ/Bowen's, keratoacanthoma) and outperform imiquimod/PDT; an underused technique (only 38% of Australian GPs used curettage for BCC per 2006 data). Local copy: evidence/dermatology/_ajgp/ |
| A practical reference for the management of stable vulval lichen sclerosus in general practice | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/womens-health/_ajgp/vulval-lichen-sclerosus-management-2026.pdf. |
| A pragmatic primary care approach to the patient with significant solar damage | RACGP — Australian Journal of General Practice | This article discusses an approach to managing patients with significant solar damage from a primary care perspective, focusing on the assessment and treatment of actinic keratoses. Catalogued from the local copy at evidence/dermatology/_ajgp/2024-08-solar-damage-primary-care-approach.html. | |
| Acne | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Acne - Therapeutic Guidelines.pdf. | |
| Acne (check in browser) | Community HealthPathways Hunter New England | last updated 28 October 2025, last reviewed 08 March 2023 | Clinician-login-gated regional pathway (cited by name/content only, not independently URL-verified). Severity-based approach: mild = comedones +/- few inflammatory lesions, first-line OTC benzoyl peroxide/salicylic acid/azelaic acid/niacinamide; moderate = more papules/pustules +/- comedones, add topical retinoid + benzoyl peroxide combination +/- oral antibiotic (doxycycline preferred over minocycline) +/- anti-androgen (COCP/spironolactone) in females; severe/scarring/significant psychological impact = early dermatology referral for oral isotretinoin. Oral antibiotics should always be combined with non-antibiotic topical therapy (resistance risk) - courses of ~6 weeks then reassess, continue topical after stopping antibiotics. Isotretinoin: 0.5mg/kg initially, up to 1mg/kg after 4 weeks, 4-7 month course, ~80% long-term remission; mandatory pregnancy prevention (potent teratogen, 2 forms of contraception, contraindicated in pregnancy/breastfeeding), mental health screening before/during, baseline+6-week bloods (lipids, LFT, EUC, FBC, bHCG). |
| Acne in primary care | RACGP — Australian Journal of General Practice | Acne is seen by registrars at a rate similar to that of their established general practitioner colleagues, but with modest continuity of care in its management. Catalogued from the local copy at evidence/dermatology/_ajgp/2019-11-acne-in-primary-care.html. | |
| Acute urticaria treated with systemic glucocorticoids | RACGP (AJGP) | AJGP 54(7), July 2025 | Evidence review: only 2 of 23 identified studies met inclusion criteria for systemic glucocorticoids in uncomplicated acute urticaria - thin evidence base for a common practice. Local copy: evidence/dermatology/_ajgp/ |
| Alopecia areata | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Alopecia areata - Therapeutic Guidelines.pdf. | |
| Amlodipine-induced cutaneous vasculitis | RACGP (AJGP) | AJGP 54(10), October 2025 | Case study: palpable purpura as the key differentiator of vasculitis from coagulopathy/thrombocytopenia/meningococcaemia; amlodipine as a common non-antibiotic drug trigger for cutaneous vasculitis. Local copy: evidence/dermatology/_ajgp/ |
| An update on the treatment of rosacea | Australian Prescriber | ||
| Androgenetic alopecia | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Androgenetic alopecia - Therapeutic Guidelines.pdf. | |
| Angioedema | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Angioedema - Therapeutic Guidelines.pdf. | |
| Apremilast for chronic plaque psoriasis and ulcerative colitis | RACGP (AJGP) | AJGP 54(8), August 2025 | Apremilast (PDE4 inhibitor) as a single agent for comorbid psoriasis+UC given the bidirectional psoriasis-IBD association; dermatologist-initiated, GP-managed maintenance. Local copy: evidence/dermatology/_ajgp/ |
| Asteatotic dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/dermatology/_shared/Asteatotic dermatitis - Therapeutic Guidelines.pdf. | |
| Asteatotic Eczema | StatPearls | ||
| Atopic dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Atopic dermatitis - Therapeutic Guidelines.pdf. | |
| Atypical Nevi (Moles) | MSD Manual Professional Edition | current as at fetch | Atypical (dysplastic) naevus clinical features, familial/sporadic pattern, size/border criteria for dermatology/naevi-and-moles.md. |
| Bacterial folliculitis | DermNet NZ | ||
| Bacterial skin and soft tissue infections (Aust Prescr 2016;39:159-63) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 39, No 5, October 2016 | Empirical oral antibiotic choice/dosing for uncomplicated staphylococcal/streptococcal skin and soft tissue infections (di/flucloxacillin, cefalexin, clindamycin, trimethoprim-sulfamethoxazole for MRSA-suspected), incision and drainage for abscess/boils. Low-yield fallback for dermatology/paronychia.md stage E (dermnet-nz's cached article has no Australian-specific dosing). |
| Battling a receding tide: Treatment for androgenic alopecia | RACGP (AJGP) | AJGP 54(11), November 2025 | Practical counselling piece: finasteride halves PSA (relevant to prostate-screening interpretation) and should be avoided in patients trying to conceive (infertility risk); notes the psychological burden of androgenic alopecia. Local copy: evidence/dermatology/_ajgp/ |
| Becker Melanosis (Becker Nevus) | StatPearls (NCBI Bookshelf) | current as at fetch | Becker naevus adolescent onset, male preponderance, hypertrichosis for dermatology/naevi-and-moles.md. |
| Benign and Premalignant Skin Lesions (check in browser) | Community HealthPathways Hunter New England | last updated/reviewed 26 November 2021 | Clinician-login-gated regional pathway (cited by name/content only, not independently URL-verified). Actinic keratosis: precursor lesion, annual SCC transformation rate 0.025-20%; with >10 AKs, lifetime SCC risk 10-15%; treat with cryotherapy, fluorouracil (Efudix, complete clearance ~50%) or imiquimod (Aldara, second-line, complete clearance 48-57%). Epidermal (sebaceous) cysts, seborrhoeic keratoses, and skin tags are benign and need no treatment unless symptomatic/QOL-affecting; prefer shave biopsy over cryotherapy for seborrhoeic keratosis if treatment wanted (histological confirmation). Minimal excision technique described for infected/inflamed epidermal cysts. |
| Benign pigmented skin lesions | AJGP (RACGP) | ||
| Bilastine for allergic rhinoconjunctivitis, urticaria | Australian Prescriber | ||
| Blistering skin conditions | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Blistering skin conditions - Therapeutic Guidelines.pdf. | |
| Boils (furunculosis) | DermNet NZ | ||
| Breaking out: The wild world of diagnosing and managing drug eruptions | RACGP (AJGP) | AJGP 54(11), November 2025 | Comprehensive drug-eruption review; HLA-B*58:01 screening before allopurinol for patients of Han Chinese, Thai, Korean or Indian descent given elevated SCAR risk. Local copy: evidence/dermatology/_ajgp/ |
| Bullous eruption on the limbs | RACGP — Australian Journal of General Practice | A man aged 78 years presented with a two-week history of erythematous urticarial patches and plaques that had started on the feet and spread to the legs, arms and hands. Catalogued from the local copy at evidence/dermatology/_ajgp/2022-05-bullous-eruption-limbs.html. | |
| Bullous eruption on the limbs | RACGP (AJGP) | AJGP 51(5), May 2022 | Case study: bullous pemphigoid triggered by a DPP-4 inhibitor (gliptin) antidiabetic drug in an elderly diabetic patient, distinct from idiopathic BP. Local copy: evidence/dermatology/_ajgp/ |
| Bullous pemphigoid | DermNet NZ | ||
| Cancer Council clinical practice guidelines and Optimal Care Pathways | Cancer Council Australia | per-guideline wiki | |
| Candidal Intertrigo (Candidiasis of Skin Folds) | DermNet NZ | ||
| Candidiasis (Mucocutaneous) | MSD Manual Professional Edition | Full Review: Oct 2025, Last updated: Jan 2026 | Local copy: evidence/gastroenterology/oral-candidiasis/. |
| Cellulitis and erysipelas | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Chickenpox | MSD Manual Professional Edition | current as at fetch | Chickenpox clinical features, prodrome, complications, management for dermatology/varicella-chickenpox.md (low-yield fallback). |
| Chickenpox (Varicella) | DermNet NZ | ||
| Chilblains (pernio) | DermNet NZ | ||
| Chondrodermatitis Nodularis Helicis | StatPearls (NCBI Bookshelf) | updated 2024 | Clinical features, epidemiology (M:F ~4:1, right ear predisposition), pathophysiology and management for dermatology/chondrodermatitis-nodularis-helicis.md, stage E low-yield fallback (the note's cited dermnet-nz source is only the DermNet homepage nav shell, no topic-specific content). |
| Common skin conditions of the feet and nails | RACGP — Australian Journal of General Practice | A number of common skin disorders have an altered and challenging appearance when arising on the foot. Catalogued from the local copy at evidence/dermatology/_ajgp/2020-05-skin-conditions-feet-and-nails.html. | |
| Compression therapy for venous disease (Vicaretti, Aust Prescr 2010;33:186-90) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 33, No 6, December 2010 | Indications, degree and methods of compression therapy for chronic venous disease/venous eczema; lists venous eczema/pigmentation/lipodermatosclerosis as skin changes indicating compression, and states compression therapy is the mainstay of prevention and treatment of venous/lymphatic dysfunction. |
| Congenital Melanocytic Nevi | StatPearls (NCBI Bookshelf) | current as at fetch | Congenital melanocytic naevus definition and size-related melanoma risk for dermatology/naevi-and-moles.md. |
| Contact dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Contact dermatitis - Therapeutic Guidelines.pdf. | |
| Corns | StatPearls | ||
| Corns and calluses (heloma, tyloma) (DermNet NZ) | DermNet NZ | ||
| Cradle cap (infantile seborrhoeic dermatitis) | DermNet NZ | ||
| Cryotherapy in Dermatology | StatPearls | ||
| Cryotherapy: Uses, Cautions, and Aftercare | DermNet NZ | ||
| Cutaneous candidiasis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/candidiasis/Cutaneous candidiasis - Therapeutic Guidelines.pdf. | |
| Cutaneous drug reactions | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Cutaneous drug reactions - Therapeutic Guidelines.pdf. | |
| Cutaneous vasculitis | DermNet NZ | ||
| Dermal Melanocytosis (Mongolian Spot) | StatPearls (NCBI Bookshelf) | ||
| Dermatitis Herpetiformis | StatPearls (NCBI Bookshelf) | updated 2023 | Clinical features (pruritic vesicles on extensor surfaces, excoriated before seen intact), coeliac/gluten-sensitive-enteropathy association, and management (gluten-free diet, dapsone) for dermatology/dermatitis-herpetiformis.md, stage E low-yield fallback (the note's cited dermnet-nz source is only the DermNet homepage nav shell, no topic-specific content). Dapsone dosing cross-checked against AMH/eTG before citing, per CLAUDE.md's drug-dose rule (StatPearls is not Therapeutic-Guidelines-affiliated). |
| Dermatofibroma (histiocytoma) — DermNet NZ | DermNet NZ | ||
| DermNet NZ | DermNet New Zealand Trust | living online resource | General clinical/patient reference for individual dermatological conditions (images, clinical features, management overview). Used to fill gaps for conditions without a dedicated Australian guideline (e.g. urticaria, granuloma annulare, pyoderma gangrenosum, bullous pemphigoid, viral exanthems, lichen planus). Cite the specific condition page, not just the homepage. |
| Dermoid Cyst | StatPearls | ||
| Dermoid cysts (DermNet NZ) | DermNet New Zealand Trust | living online resource | Specific condition page (registry's dermnet-nz id only had the site homepage cached): dermoid cyst definition, embryonic origin along lines of skin fusion, typical sites (face/neck/scalp, classically midline), congenital presentation, and management (surgical excision). |
| Diagnosis assessment and management of atopic dermatitis in children with skin of colour | RACGP — Australian Journal of General Practice | This paper synthesises the latest literature on the diagnosis, assessment, treatment outcomes and cultural considerations for managing atopic dermatitis in children with skin of colour. Catalogued from the local copy at evidence/dermatology/_ajgp/2023-10-atopic-dermatitis-skin-of-colour.html. | |
| Diaper Dermatitis | StatPearls (NCBI Bookshelf) | ||
| Discoid dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Discoid dermatitis - Therapeutic Guidelines.pdf. | |
| Discoid eczema (nummular dermatitis) | DermNet NZ | ||
| Dyshidrotic eczema (pompholyx) | DermNet NZ | ||
| Dysplastic Nevi | StatPearls (NCBI Bookshelf) | current as at fetch | Dysplastic (atypical) naevus stability/prognosis for dermatology/naevi-and-moles.md. |
| Eczema / Atopic Dermatitis in Adults (check in browser) | Community HealthPathways Hunter New England | last updated 29 May 2025, last reviewed 18 May 2020 | Clinician-login-gated regional pathway (cited by name/content only, not independently URL-verified). Topical corticosteroid potency table (very potent/potent/moderate/mild) with specific brand examples; treat aim is control not cure. Topical calcineurin inhibitors (pimecrolimus/tacrolimus) preferred for thin-skinned areas (face, genitals, flexures) as they don't cause atrophy. Eczema herpeticum (secondary HSV) is a red flag: vesicles/punched-out erosions/pustules with fever/lymphadenopathy, needs acute dermatology referral. Secondary bacterial infection: dicloxacillin/flucloxacillin first-line; dilute bleach baths for recurrent staphylococcal infection. Do not prescribe systemic/oral steroids for eczema except in rare severe/emergency situations after dermatology advice - eczema typically rebounds after oral steroids. |
| Eczema herpeticum | DermNet New Zealand Trust | DermNet update May 2023 | Dedicated eczema herpeticum condition page: cause, clinical features, diagnosis, treatment (oral aciclovir/valaciclovir dosing and duration). |
| Epidermoid cyst — DermNet NZ | DermNet NZ | ||
| Erysipelas | DermNet NZ | ||
| Erysipelas | StatPearls (NCBI Bookshelf) | ||
| Erysipeloid | MSD Manual Professional Edition | ||
| Erythema Infectiosum | StatPearls (NCBI Bookshelf) | current as at fetch | Fifth disease/slapped-cheek rash description, contagiousness window, and clinical course for dermatology/parvovirus-b19-fifth-disease.md, stage E low-yield fallback. |
| Erythema multiforme | DermNet NZ | ||
| Erythema Multiforme | StatPearls (NCBI Bookshelf) | ||
| Erythema nodosum | DermNet NZ | ||
| Erythema Nodosum | StatPearls (NCBI Bookshelf) | current as at fetch | Erythema nodosum clinical features, associations, workup and management for dermatology/erythema-nodosum.md (low-yield fallback — dermnet-nz citation is the DermNet homepage, not an erythema-nodosum-specific article). |
| Felon | StatPearls (NCBI Bookshelf) | ||
| Flushing | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Flushing - Therapeutic Guidelines.pdf. | |
| Fungal toenails and terbinafine (Aust Prescr 2023) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Genital dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Genital dermatitis - Therapeutic Guidelines.pdf. | |
| Granuloma annulare | DermNet NZ | ||
| Granuloma annulare | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Granuloma annulare - Therapeutic Guidelines.pdf. | |
| Hand Infection | StatPearls (NCBI Bookshelf) | ||
| Hand or foot dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Hand or foot dermatitis - Therapeutic Guidelines.pdf. | |
| Hand-Foot-and-Mouth Disease (HFMD) | MSD Manual Professional Edition | current as at fetch | HFMD clinical presentation, atypical (coxsackievirus A6) presentation, management for dermatology/hand-foot-and-mouth-disease.md (low-yield fallback). |
| Hand, Foot, and Mouth Disease | StatPearls (NCBI Bookshelf) | current as at fetch | HFMD aetiology, clinical features, management for dermatology/hand-foot-and-mouth-disease.md (low-yield fallback — dermnet-nz citation is the DermNet homepage, not an HFMD-specific article). |
| Head lice. Pediculosis capitis (DermNet) | DermNet | Dimeticone/malathion/permethrin resistance, cure rates, physical vs chemical treatment options. | |
| Hemangioma (StatPearls) | StatPearls (NCBI Bookshelf) | living online resource | Infantile hemangioma overview - epidemiology, clinical course, GLUT1 pathophysiology, propranolol treatment. |
| Herpes Simplex Type 1 | StatPearls (NCBI Bookshelf) | ||
| Herpes Simplex Type 1 | StatPearls (NCBI Bookshelf) | current as at fetch | Orolabial HSV-1 detail (gingivostomatitis, latency, epidemiology, triggers) for dermatology/herpes-simplex.md. |
| Herpes Simplex Type 2 | StatPearls (NCBI Bookshelf) | current as at fetch | Genital HSV clinical detail for dermatology/herpes-simplex.md. |
| Herpes Simplex Virus (HSV) Infections | MSD Manual Professional Edition | current as at fetch | Oral and genital HSV clinical/diagnostic detail for dermatology/herpes-simplex.md, which had no dedicated cited source (only the generic dermnet-nz landing page). |
| Herpes Zoster | StatPearls (NCBI Bookshelf) | current as at fetch | Herpes zoster (shingles) clinical features, pathophysiology, antiviral management, complications for dermatology/herpes-zoster-shingles.md (low-yield fallback - dermnet-nz citation is the DermNet homepage, not a zoster-specific article). |
| Herpetic Whitlow | StatPearls (NCBI Bookshelf) | ||
| Hidradenitis Suppurativa (Acne Inversa) | DermNet NZ | ||
| HIV and AIDS | StatPearls (NCBI Bookshelf) | updated 2026-01-14 | Pathophysiology, staged natural history, diagnostic work-up and ART management review for infectious-diseases/hiv.md, whose only prior dedicated sources were a PrEP-attitudes survey and a bare ASHM landing page. |
| Human Immunodeficiency Virus (HIV) Infection | MSD Manual Professional Edition | current as at fetch | Cross-check source for infectious-diseases/hiv.md natural history/transmission/diagnosis content alongside statpearls-hiv-aids. |
| Hyperpigmentation | MSD Manual Professional Edition | current as at fetch | Lentigines definition (flat tan-to-brown oval macules) for dermatology/naevi-and-moles.md. |
| Impetigo | StatPearls (NCBI Bookshelf) | ||
| Impetigo | DermNet NZ | ||
| Importance of skin of colour dermatology in the primary care setting in Australia | RACGP — Australian Journal of General Practice | This study discusses how skin in patients with skin of colour is biologically, functionally and structurally different to that of patients with lightly pigmented skin. Catalogued from the local copy at evidence/dermatology/_ajgp/2023-10-skin-of-colour-dermatology-importance.html. | |
| Improving diagnostic accuracy for suspicious melanocytic skin lesions | RACGP — Australian Journal of General Practice | Clinician/pathologist communication is important for accurate diagnosis of melanocytic skin tumours. Catalogued from the local copy at evidence/dermatology/_ajgp/2019-06-melanocytic-lesion-diagnostic-accuracy.html. | |
| Improving diagnostic accuracy of skin biopsies | AJGP (RACGP) | ||
| Infantile haemangioma: Complications and treatment | DermNet NZ | Page-level DermNet article: complications and treatment (propranolol) of infantile haemangioma. | |
| Infantile haemangioma: Definition and pathogenesis | DermNet NZ | Page-level DermNet article: epidemiology, clinical course, pathogenesis of infantile haemangioma. | |
| Infantile haemangiomas: Identifying high-risk lesions requiring specialist referral | AJGP (RACGP) | ||
| Infectious mononucleosis | DermNet NZ | ||
| Infectious Mononucleosis | MSD Manual Professional Edition | reviewed 2026 | Second stage E low-yield fallback for dermatology/ebv-infectious-mononucleosis-amoxicillin-rash.md, specifically for the spontaneous (non-antibiotic) EBV rash's frequency/character, which statpearls-mononucleosis does not quantify. |
| Ingrown Toenails | StatPearls (NCBI Bookshelf) | ||
| Ingrown toenails (onychocryptosis) | DermNet NZ | ||
| Initial Management of Minor Burns (ANZBA poster) | Australian & New Zealand Burn Association | Supplied by Steve 2026-08-31. Depth assessment, dressings and ANZBA referral criteria. | |
| Itch, pruritus | DermNet NZ | ||
| Itching | MSD Manual Professional Edition | reviewed 2024 | Itch-pain shared pathway, causes (localised/generalised, systemic), and evaluation for dermatology/pruritis.md, stage E low-yield fallback (prior citation was the bare eTG homepage, no topic-specific content). |
| Keratin and controversy: A common cutaneous tumour that confounds classification | AJGP (RACGP) | ||
| Keratoacanthoma | StatPearls (NCBI Bookshelf) | StatPearls overview: epidemiology, natural history, clinical/histological overlap with SCC, management (excision margins, alternatives). | |
| Kerion | DermNet NZ | Named by hand from the document's own opening text. Local copy at evidence/dermatology/kerion/dermnet-nz-kerion.html. | |
| Lichen Planus | StatPearls (NCBI Bookshelf) | current as at fetch | Lichen planus epidemiology, clinical features, nail/oral involvement, diagnosis and management for dermatology/lichen-planus.md (low-yield fallback -- dermnet-nz citation is the DermNet homepage, not a lichen-planus-specific article). |
| Lichen Planus | MSD Manual Professional Edition | current as at fetch | Lichen planus clinical features, nail involvement and management for dermatology/lichen-planus.md (low-yield fallback -- dermnet-nz citation is the DermNet homepage, not a lichen-planus-specific article). |
| Lichen simplex | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Lichen simplex - Therapeutic Guidelines.pdf. | |
| Lichen Simplex Chronicus | StatPearls (NCBI Bookshelf) | ||
| Lidocaine anaesthesia | Australian Medicines Handbook | Supplied by Steve 2026-08-31. Maximum-dose data for the local anaesthesia page. | |
| Lidocaine with adrenaline epinephrine | Australian Medicines Handbook | Supplied by Steve 2026-08-31. | |
| Lipoma (fatty lumps) — DermNet NZ | DermNet NZ | ||
| Local anaesthetics | Australian Medicines Handbook | Supplied by Steve 2026-08-31. AMH topic PDF - quotable, and its dosing needs no separate cross-check. | |
| Marking a surgical margin for excision of a keratinocyte cancer | AJGP (RACGP) | ||
| Measles | MSD Manual Professional Edition | current as at fetch | Measles clinical features, prodrome, exanthem, complications, diagnosis, management for dermatology/measles.md (low-yield fallback -- dermnet-nz citation is the DermNet homepage, not a measles-specific article). |
| Melanoma (check in browser) | Community HealthPathways Hunter New England | last updated/reviewed 09 May 2022 | Clinician-login-gated regional pathway (cited by name/content only, not independently URL-verified). ABCDEF rule (Asymmetry, Border, Colour, Diameter >6mm, Evolution, Funny-looking/ugly-duckling). Excisional biopsy with <=2mm margin preferred over punch/shave/referral-without-biopsy. Wide excision margins: melanoma in situ 5mm; invasive <1mm thick with mitotic count <2 and no ulceration, 10mm if primary closure feasible; all deeper/higher-risk invasive melanomas referred to a melanoma surgeon (preferably within 7 days) before any wide excision, since sentinel node biopsy cannot follow a completed wide local excision. Nodular melanoma often non-pigmented/amelanotic, accounts for ~15% of melanomas but >60% of melanomas >3mm thick. Immunotherapy/adjuvant therapy now PBS-available for high-risk stage 3. |
| Melanoma medicine | RACGP — Australian Journal of General Practice | This review summarises the evolving status of melanoma care, emphasising when to refer patients to medical oncologists as part of the multidisciplinary team. Catalogued from the local copy at evidence/dermatology/_ajgp/2024-09-melanoma-medicine-new-drugs.html. | |
| Melanoma medicine: New drugs for melanoma and the role of the GP | RACGP (AJGP) | AJGP 53(9), September 2024 | Immune-checkpoint inhibitors (ipilimumab/CTLA-4, nivolumab+pembrolizumab/PD-1, relatlimab/LAG-3) have taken advanced melanoma from ~6-month median survival to ~50% long-term survival, now used perioperatively in earlier-stage disease; covers GP-relevant immune-related adverse event recognition. Local copy: evidence/dermatology/_ajgp/ |
| Melanoma overdiagnosis | RACGP — Australian Journal of General Practice | This study considers the causes and magnitude of melanoma overdiagnosis in Australia, and speculates about a possible benefit of overdiagnosis in Australia. Catalogued from the local copy at evidence/dermatology/_ajgp/2024-09-melanoma-overdiagnosis.html. | |
| Melanoma overdiagnosis: What do we know and what do we do? | RACGP (AJGP) | AJGP 53(9), September 2024 | Estimates ~58% melanoma overdiagnosis rate (22% for invasive) using Welch et al methodology; discusses NNT/excision and inter-pathologist concordance problems - a balancing counterpoint to standard biopsy-everything advice, not a reason to change practice. Local copy: evidence/dermatology/_ajgp/ |
| Milia | StatPearls (NCBI Bookshelf) | ||
| Miliaria | StatPearls (NCBI Bookshelf) | ||
| Miliaria (heat rash) | DermNet NZ | ||
| Milker's nodules | DermNet NZ | Page-level DermNet article: milker's nodule (paravaccinia/pseudocowpox) - cause, transmission, clinical features, course. | |
| Minor burn management: potions and lotions | Australian Prescriber | Aust Prescr 2015;38:124-27. Carries the ANZBA burn-unit referral criteria box. Australian Prescriber dosing trusted as eTG-equivalent. | |
| Minor Burns | EM:RAP CorePendium | Supplied by Steve 2026-08-31. | |
| Moles (melanocytic naevi, pigmented nevi) | DermNet NZ | ||
| Molluscum Contagiosum | StatPearls (NCBI Bookshelf) | Last updated 2025-12-13. | |
| Molluscum contagiosum | DermNet NZ | The registry's generic dermnet-nz entry only has the site homepage cached (no article text); fetched the specific condition page directly. Local copy at evidence/dermatology/molluscum-contagiosum/dermnet-nz-molluscum-contagiosum.html. | |
| Mononucleosis | StatPearls (NCBI Bookshelf) | updated 2026 | Clinical features (fever/lymphadenopathy/pharyngitis triad, malaise, splenomegaly, rash including the amoxicillin/ampicillin-associated eruption), aetiology/transmission and management for dermatology/ebv-infectious-mononucleosis-amoxicillin-rash.md, stage E low-yield fallback (the note's cited dermnet-nz source is only the DermNet homepage nav shell, no topic-specific content). |
| Mumps | StatPearls (NCBI Bookshelf) | current as at fetch | Mumps clinical features, transmission, complications, management for dermatology/mumps.md (low-yield fallback — dermnet-nz citation is the DermNet homepage, not a mumps-specific article). |
| Mumps | MSD Manual Professional Edition | current as at fetch | Mumps overview, transmission, complications, diagnosis/treatment for dermatology/mumps.md (low-yield fallback). |
| Naevus simplex (salmon patch) | DermNet NZ | ||
| Napkin dermatitis | DermNet NZ | ||
| Necrotising soft tissue infection | RACGP (AJGP) | ||
| Necrotizing Fasciitis | StatPearls | ||
| Nevi (Moles) | MSD Manual Professional Edition | current as at fetch | General naevus classification (junctional/compound/intradermal/halo/blue naevus definitions and images) for dermatology/naevi-and-moles.md, which had only the generic dermnet-nz landing page cited. |
| Nevus Flammeus (Port-Wine Stain) | StatPearls (NCBI Bookshelf) | ||
| Nodular prurigo | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Nodular prurigo - Therapeutic Guidelines.pdf. | |
| Non-melanoma skin cancer in general practice: Radiotherapy is an effective treatment option | AJGP | ||
| Nummular Dermatitis | StatPearls | ||
| Onychomycosis | StatPearls | ||
| Optimising cryosurgery technique | RACGP (Australian Family Physician) | AFP 46(5), May 2017 | Source of the Table 2 cryosurgery treatment-regime table (lesion, technique, freeze-thaw times, margin, sessions, expected response) already cited in cryosurgery-technique.md by URL only; fetched locally 2026-08-15 for stage-E quoting. |
| Oral and oropharyngeal infection caused by Candida and related species | Therapeutic Guidelines Ltd (eTG complete) | Local copy: evidence/gastroenterology/oral-candidiasis/. Also cited from dermatology/candidiasis.md's oral thrush section, 2026-08-16. | |
| ORATANE (isotretinoin) product information | Therapeutic Goods Administration / sponsor product information | Named by hand from the document's own opening text. Local copy at evidence/dermatology/acne-rosacea/tga-oratane-pi.pdf. | |
| Oratane (isotretinoin) Product Information | Therapeutic Goods Administration (TGA) / Acino | current TGA-approved PI | Australian TGA-approved product information for an isotretinoin brand, used to independently verify the 'two forms of contraception' teaching point (which is not universal across sources - the Australian Prescriber overview article says only 'at least one effective contraceptive measure', while NZ Medsafe and DermNet NZ agree with two forms). The Oratane PI is unambiguous: 'It is recommended that two reliable forms of contraception be used simultaneously,' required without interruption from 1 month before therapy through to 1 month after stopping, with additional methods advised in the first cycle of a new hormonal contraceptive. |
| Orf (human parapoxvirus infection) | DermNet NZ | ||
| Orf Viral Infection | StatPearls (NCBI Bookshelf) | current as at fetch | Orf transmission, clinical course, lesion staging, management for dermatology/orf.md (low-yield fallback — dermnet-nz citation is the DermNet homepage, not an orf-specific article). |
| Overview and differentiation of hair loss disorders | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Overview and differentiation of hair loss disorders - Therapeutic Guidelines.pdf. | |
| Overview of acute odontogenic infections | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Paronychia (DermNet NZ) | DermNet New Zealand Trust | living online resource | Specific condition page (registry's dermnet-nz id only had the site homepage cached): acute vs chronic paronychia causes/organisms, clinical features, and management, for dermatology/paronychia.md stage E. |
| Paronychia (nail fold infection) | DermNet NZ | ||
| Parvovirus B19 Infection | StatPearls (NCBI Bookshelf) | current as at fetch | Aplastic crisis, pregnancy monitoring/ultrasound follow-up, chronic infection in immunocompromised hosts for dermatology/parvovirus-b19-fifth-disease.md, stage E low-yield fallback. |
| Penile dermatology for the general practitioner | RACGP — Australian Journal of General Practice | This article guides clinicians in risk stratification, treatment decisions and referral pathways for common male genital skin conditions. Catalogued from the local copy at evidence/dermatology/_ajgp/2024-11-penile-dermatology.html. | |
| Penile dermatology for the general practitioner: A pragmatic approach to diagnosis and management | RACGP (AJGP) | AJGP 53(11) supplement, November 2024 | Structured risk-stratification/referral framework for male genital skin conditions (lichen sclerosus, lichen planus, Zoon's balanitis, psoriasis, contact dermatitis, STIs, red-flag neoplastic change). Local copy: evidence/dermatology/_ajgp/ |
| Perianal streptococcal dermatitis | DermNet NZ | ||
| Perianal Streptococcal Dermatitis | StatPearls (NCBI Bookshelf) | ||
| Perianal streptococcal dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/perianal-streptococcal-infection/Perianal streptococcal dermatitis - Therapeutic Guidelines.pdf. | |
| Perioral Dermatitis | StatPearls (NCBI Bookshelf) | ||
| Periorificial dermatitis | DermNet NZ | ||
| Periorificial dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Periorificial dermatitis - Therapeutic Guidelines.pdf. | |
| Pityriasis alba | DermNet NZ | The registry's generic dermnet-nz entry only has the site homepage cached (no article text); fetched the specific condition page directly. Local copy at evidence/dermatology/pityriasis-alba/dermnet-nz-pityriasis-alba.html. | |
| Pityriasis Rosea | StatPearls (NCBI Bookshelf) | current as at fetch | Pityriasis rosea etiology, clinical features, epidemiology, management for dermatology/pityriasis-rosea.md (low-yield fallback — dermnet-nz citation is the DermNet homepage, not a pityriasis-rosea-specific article). |
| Pityriasis Rosea | MSD Manual Professional Edition | current as at fetch | Pityriasis rosea presentation, epidemiology, etiology for dermatology/pityriasis-rosea.md (low-yield fallback). |
| Pityriasis versicolor | DermNet NZ | ||
| Pre and post treatment care for actinic keratoses | RACGP — Australian Journal of General Practice | The objective of this article is to provide recommendations for the pre-treatment and post-treatment care for actinic keratoses to improve patient outcomes. Catalogued from the local copy at evidence/dermatology/_ajgp/2025-08-actinic-keratoses-treatment-care.html. | |
| Principles of dermatitis management | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Principles of dermatitis management - Therapeutic Guidelines.pdf. | |
| Propranolol for infantile haemangioma | DermNet NZ | Page-level DermNet article on propranolol as first-line treatment for infantile haemangioma - dosing, monitoring, safety. | |
| Prurigo Nodularis | StatPearls (NCBI Bookshelf) | updated 2023 | Clinical features, pathophysiology (itch-scratch cycle) and management (topical steroids, refer for intralesional steroid/systemic therapy/UVB) for dermatology/pruritis.md Nodular prurigo section, stage E. |
| Psoriasis (check in browser) | Community HealthPathways Hunter New England | last updated/reviewed 09 April 2026 | Clinician-login-gated regional pathway (cited by name/content only, not independently URL-verified). Australian lifetime prevalence ~2.8%; associated with cardiometabolic disease, malignancy, mental health disorders, IBD, hepatic/renal disease. Psoriatic arthritis affects up to 42% of psoriasis patients (underdiagnosed) - 50-80% of patients with nail psoriasis have concomitant arthritis. Severity: mild = <5% BSA, no high-impact-area involvement, DLQI <6; moderate-severe = >10% BSA or PASI >10 or high-impact-area involvement or DLQI >=6 or topical failure. First-line topical: calcipotriol+betamethasone combination (e.g. Wynzora, added to PBS ~2026) now preferred over calcipotriol monotherapy (no longer separately available). Systemic/biologic options: methotrexate, acitretin, ciclosporin, apremilast, deucravacitinib (JAK inhibitor), anti-IL17/IL23/IL12-23/TNF-alpha biologics. Urgent dermatology referral for erythrodermic or generalised pustular psoriasis (both can be fatal), or any pustular psoriasis in pregnancy. |
| Purpura | DermNet NZ | ||
| Pyoderma Gangrenosum | DermNet NZ | ||
| Pyoderma Gangrenosum | DermNet New Zealand Trust | living online resource | Dedicated pyoderma gangrenosum condition page: cause, clinical features, diagnosis, treatment. |
| Ranitidine safety alert and market status | Therapeutic Goods Administration (TGA) | 2019-2024 (withdrawal and re-approval) | Ranitidine suspended from Australian market 2019-2020 due to NDMA contamination; reformulated product re-approved October 2024. Famotidine was the standard H2-blocker alternative during the intervening years. |
| Red in the face Approach to diagnosis of red rashes on the face | RACGP — Australian Journal of General Practice | This article discusses the assessment of red rashes on the face in an adult patient. Catalogued from the local copy at evidence/dermatology/_ajgp/2024-04-red-in-the-face-red-rashes.html. | |
| Rosacea | DermNet NZ | ||
| Rosacea | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Rosacea - Therapeutic Guidelines.pdf. | |
| Roseola | DermNet NZ | Page-level DermNet article: roseola infantum (HHV-6/7) - cause, epidemiology, clinical features, complications, treatment. | |
| Roseola Infantum (StatPearls) | StatPearls (NCBI Bookshelf) | living online resource | Roseola infantum (exanthema subitum/sixth disease) overview - epidemiology, HHV-6/7 aetiology, clinical course, management. |
| Rubella | StatPearls (NCBI Bookshelf) | Updated 2023 | General rubella overview - epidemiology, transmission, clinical features (prodrome, rash, arthralgia, Forchheimer sign), congenital rubella syndrome, diagnosis, vaccination timing. Used for dermatology/rubella.md low-yield fallback, 2026-08-16. |
| Rubella | MSD Manual Professional Edition | 2026 | General rubella overview - clinical features, congenital rubella syndrome, diagnosis, prevention/vaccination. Used for dermatology/rubella.md low-yield fallback, 2026-08-16. |
| Rubella (german measles) | DermNet NZ | ||
| Rubeola (Measles) | StatPearls (NCBI Bookshelf) | current as at fetch | Measles epidemiology, clinical features, complications, diagnosis, management for dermatology/measles.md (low-yield fallback -- dermnet-nz citation is the DermNet homepage, not a measles-specific article). |
| Scabies | RACGP (AJGP) | Named by hand from the document's own opening text. Local copy at evidence/dermatology/_ajgp/2024-10-scabies.html. | |
| Scarring alopecia | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Scarring alopecia - Therapeutic Guidelines.pdf. | |
| Sebaceous hyperplasia (DermNet NZ) | DermNet New Zealand Trust | living online resource | Specific condition page (registry's dermnet-nz id only had the site homepage cached): clinical appearance, epidemiology, and treatment options, for dermatology/sebaceous-hyperplasia.md stage E. |
| Seborrhoeic dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Seborrhoeic dermatitis - Therapeutic Guidelines.pdf. | |
| Selecting appropriate dressings | RACGP — Australian Journal of General Practice | With an expanding global market of dressing products, selection of wound dressings remains an area of concern. Catalogued from the local copy at evidence/dermatology/_ajgp/2022-11-wound-dressings-selection.html. | |
| Skin Cancer (Non-pigmented) (check in browser) | Community HealthPathways Hunter New England | last updated/reviewed 26 November 2021 | Clinician-login-gated regional pathway (cited by name/content only, not independently URL-verified). BCC (~60% of skin cancers) vs SCC (~28%) clinical presentations and high-risk features (size, rapid growth, recurrence, perineural/perilymphatic invasion, high-risk sites). Margin table: suspected melanoma/benign lesion 2mm, well-defined BCC 3mm, aggressive/unclear BCC 4-5mm, SCC in situ 2mm, SCC <2cm 4-5mm. Low-risk lesions (well-defined, <15mm trunk/limb or <10mm face/scalp, <6mm thick) may be excised in general practice. Recurrence: 44% develop a second BCC and 18% a second SCC within 3 years. Follow-up: annual skin checks for life; 3-monthly then 6-12 monthly for up to 3 years after non-surgical treatment. |
| Skin checks in primary care | RACGP — Australian Journal of General Practice | Primary care carries a large burden of the diagnosis and management of skin cancer; having a structured approach with use of surveillance and diagnostic tools can facilitate early cancer detection. Catalogued from the local copy at evidence/dermatology/_ajgp/2019-09-skin-checks-in-primary-care.html. | |
| Skin manifestations of rheumatological disease | RACGP (AJGP) | AJGP 50(12), December 2021 | Cutaneous clues across SLE, dermatomyositis, scleroderma, vasculitis and Behcet's - cross-referenced from the relevant connective tissue disease/vasculitis pages rather than duplicated. Local copy: evidence/rheumatology/_ajgp/ |
| Superficial fungal infections | RACGP (AJGP) | AJGP Vol 48 No 10, October 2019. Covers tinea capitis presentations, indications for kerion referral. | |
| Superficial fungal infections | RACGP — Australian Journal of General Practice | Prompt recognition and management of tinea infection help reduce morbidity and its associated complications; practical approaches to the diagnosis and treatment are outlined. Catalogued from the local copy at evidence/dermatology/_ajgp/2019-10-superficial-fungal-infections.html. | |
| Syphilis | DermNet NZ | ||
| Syphilis the great mimic: Forgotten but not gone | AJGP | ||
| Systemic antifungal agents for cutaneous fungal infections (Ellis & Watson, Aust Prescr 1996;19:72-5) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Systemic Janus kinase inhibitors in inflammatory dermatoses: a primer for general practitioners | RACGP — Australian Journal of General Practice | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_ajgp/jak-inhibitors-inflammatory-disease-2025.pdf. | |
| Systemic Janus kinase inhibitors in inflammatory dermatoses: A primer for general practitioners | RACGP (AJGP) | AJGP 54(11), November 2025 | Primarily a dermatology-focused JAK-inhibitor primer, but includes a practical monitoring protocol applicable to rheumatological use (upadacitinib PBS-listed for severe RA/PsA/non-radiographic axSpA/AS): baseline FBC, renal/hepatic function, lipid panel, HBV/HCV/HIV/TB screen, pneumococcal + Shingrix vaccination before starting; repeat bloods at 8-12 weeks; ongoing CV/malignancy risk-factor caution per the TGA class warning. Local copy: evidence/rheumatology/_ajgp/ |
| Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement | Kushnir-Grinbaum D et al., Australasian Journal of Dermatology 2025 | 2025 | Found this while cross-checking eTG's Alopecia areata topic, which (last amended 2022) still describes JAK inhibitors as investigational/unregistered in Australia — now outdated. This 2025 Australian consensus statement confirms baricitinib (Olumiant) TGA-approved for severe alopecia areata 15 May 2023, and ritlecitinib TGA-approved 2024; neither is PBS-listed as of 2026-07-11 (TGA approval described as the first step toward PBS reimbursement). Verified independently via web search (TGA approval announcements, Dermatology Republic/Rheumatology Republic coverage), not via WebFetch of the paywalled AJD article itself — full text not independently read. Applies to: alopecia (Hair Loss & Alopecia page). |
| Telogen effluvium | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Telogen effluvium - Therapeutic Guidelines.pdf. | |
| The assessment of severe cutaneous adverse drug reactions | Australian Prescriber | ||
| The multiple comorbidities of psoriasis | RACGP — Australian Journal of General Practice | General practitioners are in a prime position to screen and diagnose common comorbidities of psoriasis and have the experience and knowledge to manage them accordingly. Catalogued from the local copy at evidence/dermatology/_ajgp/2020-07-psoriasis-comorbidities.html. | |
| Tinea | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Tinea - Therapeutic Guidelines.pdf. | |
| Tinea A concise synopsis | RACGP — Australian Journal of General Practice | A case presentation of a 2-week history of a painful and intensely pruritic rash on various parts of a patient's body. Catalogued from the local copy at evidence/dermatology/tinea/ajgp-tinea-concise-synopsis-2026.html. | |
| Tinea Capitis | StatPearls (NCBI Bookshelf) | Last updated 2023-08-08. Covers kerion as the inflammatory presentation of tinea capitis. | |
| Tinea: a concise synopsis | RACGP - Australian Journal of General Practice (AJGP) | March 2026 | Diagnosis: PCR now available in some Australian labs and preferred over microscopy and culture (MCS) for faster turnaround and superior sensitivity/specificity (MCS culture can take up to 6 weeks). Treatment: oral terbinafine 250mg daily for 2 weeks is preferred for most sites, with longer courses (up to 3 months) for nail or scalp involvement. Key update: high rates of terbinafine-resistant T. interdigitale/T. indotineae now reported in India, Europe, and Australia - consider resistant species (and alternative diagnoses) if treatment fails despite good compliance; corticosteroid-modified 'tinea incognito' masks the classical appearance and both delays diagnosis and likely contributes to resistant strains spreading undetected. Cross-referenced with a 2024 Medical Journal of Australia case report of treatment-resistant T. indotineae in Australia (Chua et al, MJA 2024;221(4)). |
| Topical treatments for skin warts (Cochrane, CD001781) | Cochrane | ||
| Trachyonychia (Twenty-Nail Dystrophy) | DermNet NZ | ||
| Transient acantholytic dermatosis (Grover disease) | DermNet NZ | ||
| Treatments for atopic dermatitis | Australian Prescriber | ||
| Treatments for ingrowing toenails | Cochrane | ||
| Trichotillomania | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/dermatology/_shared/Trichotillomania - Therapeutic Guidelines.pdf. | |
| Trifarotene for acne | Australian Prescriber | ||
| Tuberous sclerosis | DermNet NZ | ||
| Urticaria | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/dermatology/_shared/Urticaria - Therapeutic Guidelines.pdf. | |
| Urticaria – an overview | DermNet NZ | ||
| Varicella-Zoster Virus (Chickenpox) | StatPearls (NCBI Bookshelf) | current as at fetch | Chickenpox clinical features, transmission, complications, antiviral management for dermatology/varicella-chickenpox.md (low-yield fallback — dermnet-nz citation is the DermNet homepage, not a varicella-specific article). |
| Venous dermatitis | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/dermatology/_shared/Venous dermatitis - Therapeutic Guidelines.pdf. | |
| Venous eczema, gravitational eczema | DermNet NZ | ||
| Venous Insufficiency | StatPearls (NCBI Bookshelf) | ||
| Viral wart | DermNet NZ | ||
| Wart | StatPearls (NCBI Bookshelf) | current as at fetch | Cutaneous (non-genital) wart aetiology (HPV types 1/2/4/27/57), clinical features of plantar warts, natural history/spontaneous resolution, and treatment (cryotherapy, salicylic acid). Low-yield fallback for dermatology/warts.md, stage E (note's only cited source, dermnet-nz, is registered against the DermNet homepage with no condition-specific cached text). |
| Warts, Verrucas, Human Papillomavirus Infection | DermNet New Zealand Trust | living online resource | Dedicated cutaneous/viral wart condition page: HPV cause, clinical features, differentiating a plantar wart from a corn/callus, natural history, treatment options (cryotherapy, salicylic acid). Replaces the generic dermnet-nz homepage citation on dermatology/warts.md, stage E (dermnet-nz's cached text is just the site nav shell, no condition-specific content). |
| Zoonotic Skin Diseases | MSD Manual Professional Edition | current as at fetch | Covers contagious ecthyma (orf) among other zoonotic skin diseases for dermatology/orf.md (low-yield fallback). |
Emergency
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| ANZCOR Guideline 11.2 — Protocols for Adult Advanced Life Support | Australian and New Zealand Committee on Resuscitation | reviewed/updated based on 2018-2020 ILCOR evidence reviews | Added 2026-08-16 for stage-E claim placement -- the generic anzcor registry id only has the anzcor.org landing page cached (site-level, not quotable); this is the actual Adult ALS protocol PDF with the algorithm content (shock/adrenaline/amiodarone timing, 4Hs/4Ts, post-resuscitation ABCDE). |
| ANZCOR Guideline 11.7 -- Post-resuscitation Therapy in Adult Advanced Life Support | Australian and New Zealand Committee on Resuscitation | 2021 CoSTR-informed review | Added 2026-08-16 for stage-E claim placement -- post-ROSC targets (SpO2 94-98%, normocapnia, normoglycaemia, temperature control) for cardiac-arrest.md. |
| ANZCOR resuscitation guidelines (Adult Advanced Life Support) | Australian and New Zealand Committee on Resuscitation | Adult ALS protocols revised June 2024 | Added Phase 4 (2026-07-08) for cardiac arrest / bradyarrhythmia drug doses and timing. |
Endocrinology & Diabetes
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (check in browser) | Monash University (international multidisciplinary network) | 2023 (updates 2018 guideline) | Supersedes the 2018 Monash PCOS guideline; adds elevated cardiovascular disease risk screening emphasis and AMH as an alternative to ultrasound for polycystic ovarian morphology (especially useful in adolescents, where USS is unreliable). |
| 21-Hydroxylase Deficiency | StatPearls (NCBI Bookshelf) | ||
| ADIPS 2025 Consensus Recommendations on GDM — FAQ for health professionals | Australasian Diabetes in Pregnancy Society (ADIPS) | 2025 consensus recommendations | |
| Adrenal disease update | RACGP — Australian Journal of General Practice | Diseases of the adrenal gland occur rather more frequently than is appreciated and provide a series of challenges for the treating practitioner. Catalogued from the local copy at evidence/endocrinology-diabetes/_ajgp/adrenal-disease-update-2021.html. | |
| Adrenal disease: an update | Australian Journal of General Practice (RACGP) | AJGP Vol. 50, No. 1-2, Jan-Feb 2021 | Endocrine-themed issue Focus article. Covers primary/secondary adrenal insufficiency (Addison's), Cushing's syndrome, primary aldosteronism, phaeochromocytoma and adrenal incidentaloma work-up. Short Synacthen test is the mainstay of adrenal-reserve testing (private pathology); measure morning cortisol in hyponatraemia; 1mg overnight dexamethasone suppression + aldosterone:renin ratio + plasma/urine metanephrines for incidentaloma. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Adrenocortical tumour: A case of precocious puberty | AJGP (RACGP) | ||
| Adult Diabetic Ketoacidosis | StatPearls | ||
| Alendronate | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/endocrinology-diabetes/osteoporosis/Alendronate - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to the generic "amh" entry). | |
| Analysis of romosozumab for osteoporosis, February 2024 | pbs.gov.au | To review the utilisation of romosozumab for severe established osteoporosis as well as medicines for the treatment of osteoporosis. Catalogued from the local copy at evidence/endocrinology-diabetes/osteoporosis/pbs-romosozumab-dusc-feb2024.html. | |
| Androgen deficiency in older men | AJGP | ||
| Approach to the Patient With a Thyroid Nodule | MSD Manual Professional Edition | Full Review Jan 2026 | Added 2026-08-16 for stage-E claim placement on thyroid-cancer.md -- nodule aetiology (colloid goiter/cysts/adenomas), sonographic risk features, TSH-first workup and hot-nodule/radionuclide scanning, FNAB indications, and malignancy-suggestive exam signs. |
| Arginine Vasopressin Disorder (Diabetes Insipidus) | StatPearls (NCBI Bookshelf) | updated 2023 | Central/nephrogenic definitions, clinical features, investigations (fluid deprivation test) and management for endocrinology-diabetes/diabetes-insipidus.md, stage E low-yield fallback. |
| Assessing Fitness to Drive for commercial and private vehicle drivers 2022 | Austroads / National Transport Commission | Supplied by Steve 2026-08-31. Australian national medical standards for private and commercial driver licensing. | |
| Australian Type 2 Diabetes Glycaemic Management Algorithm (check in browser) | Australian Diabetes Society (ADS) / Diabetes Australia / NDSS | June 2024 | Uploaded directly by Steve as a PDF; specific hosted URL not independently verified (ADS site structure not confirmed by automated fetch), cited by name/content only. Monotherapy: metformin usual first-line (conditional recommendation). Dual/multiple therapy: SGLT2i or GLP-1RA recommended addition (not just metformin-failure fallback) for patients with CVD, multiple CVD risk factors, or kidney disease; conditional recommendation against sulfonylurea as the preferred first add-on (hypoglycaemia risk). Review response every 3 months; consider stopping any agent that hasn't cut HbA1c by >=0.5%. Weight loss >=10% may allow reduction/cessation of glucose-lowering medication - cross-refers to the Australian Obesity Management Algorithm. |
| Bariatric surgery and medicines: from first principles to practice | Australian Prescriber / Therapeutic Guidelines Ltd | Practical review of bariatric surgery types, expected weight loss/remission of comorbidities, and post-operative medicine changes (malabsorption/nutritional deficiency monitoring, dose-form changes, drugs needing review after surgery). | |
| Bisphosphonates | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/endocrinology-diabetes/osteoporosis/Bisphosphonates - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to the generic "amh" entry). | |
| Calcifediol high-strength formulation for vitamin D deficiency | Australian Prescriber | 2025 new-drug comment on calcifediol (Vistella) and current standard colecalciferol repletion dose, for endocrinology-diabetes/vitamin-d-deficiency.md, write-gap-pages. | |
| Congenital Adrenal Hyperplasia | StatPearls | ||
| Constitutional Growth Delay | StatPearls (NCBI Bookshelf) | ||
| Diabetes Medication (check in browser) | Community HealthPathways Hunter New England | current as at upload (2026-07-10) | Clinician-login-gated regional pathway (not independently URL-verified; cited by name/content only). Detailed eGFR-based dosing/cessation table across drug classes (e.g. metformin max 2g/day, consider ceasing <30 or with acute illness; SGLT2i cease <30; sulfonylureas - gliclazide/glipizide preferred with renal impairment; DPP-4i - linagliptin needs no dose reduction; GLP-1/GIP RA - semaglutide/exenatide approved eGFR>30, liraglutide/dulaglutide >15). Lists tirzepatide as a dual GIP/GLP-1 receptor agonist option (dose-dependent superiority for glycaemic control/weight loss over GLP-1 RAs alone) - not present in the June 2024 ADS algorithm. SGLT2i perioperative/sick-day cessation guidance (cease 3 days pre-surgery and during acute illness/dehydration - euglycaemic DKA risk). |
| Diabetes screening and management | RACGP — Australian Journal of General Practice | A strong adoption of the national screening guidelines introduced in 2015-16 was identified. Catalogued from the local copy at evidence/endocrinology-diabetes/_ajgp/diabetes-screening-management-2021.html. | |
| Diabetes screening and management | Australian Journal of General Practice (RACGP) | AJGP Vol. 50, No. 10, Oct 2021 | Screening with AUSDRISK; diagnostic thresholds (fasting glucose >=7.0, HbA1c >=6.5%/48, random >=11.1, OGTT); complication screening schedule. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Diabetes sick-day management | RACGP | Named by hand from the document's own opening text. Local copy at evidence/endocrinology-diabetes/t2dm-mx/racgp-diabetes-sickday-2024.pdf. | |
| Diabetes sick-day management | RACGP | 2024 (references current to Oct 2024) | More detailed than the existing sick-day-management-of-t2dm.md note: high-risk groups needing proactive review (type 1 diabetes, age >=65, insulin-requiring T2DM, SGLT2i users, unstable HbA1c >=8.5% or none recorded in 6-12 months, smokers); written individualised sick-day action plan (commence if unwell or BGL >15 mmol/L on two consecutive readings, monitor BGL 2-4 hourly, review metformin/SGLT2i/GLP-1RA if vomiting/diarrhoea or reduced intake, insulin dose adjustment guidance, seek help thresholds); cross-refers to the RACGP/ADS emergency hyperglycaemia statement for severe cases. |
| Diabetic ketoacidosis — RCH Clinical Practice Guideline | Royal Children's Hospital Melbourne | Paediatric DKA: diagnostic criteria, severity grading by pH/bicarbonate, fluid and insulin regimens, and cerebral oedema risk/management. Aligned to ISPAD 2022. | |
| Diabetic Retinopathy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline | Paget's Association / J Bone Miner Res | 2019 | Recommends symptom-directed treatment strategy over treat-to-target ALP normalisation for Paget disease of bone. |
| Differentiating between benign and malignant thyroid nodules | Australian Journal of General Practice (RACGP) | AJGP Vol. 47, No. 11, Nov 2018 | Thyroid nodule work-up (pre-2019 but current): TSH then ultrasound; FNA per sonographic risk; most nodules benign. Local copy: evidence/endocrinology-diabetes/_ajgp/thyroid-nodules-benign-malignant-2018.pdf. |
| Emergency management of hyperglycaemia in primary care | RACGP and Australian Diabetes Society (ADS) | 2018 (joint clinical position statement) | Defines the two hyperglycaemic emergencies (DKA and hyperosmolar hyperglycaemic state/HHS) with red-flag symptoms/signs and risk factors. Persistent capillary BGL >15 mmol/L for >8-12 hours (checked 2-hourly) in a known diabetic, or any BGL >15 with symptoms/signs of DKA/HHS, should trigger urgent point-of-care ketone testing and volume assessment; suspected DKA should be transferred to hospital without delay. High-risk groups: SGLT2i users (euglycaemic DKA risk), insulin pump users, pregnancy, elderly, corticosteroid/atypical antipsychotic use, past DKA, acute infection/sepsis/pancreatitis/MI/trauma/surgery. |
| Fatigue | MSD Manual Professional Edition | ||
| GLP-1 receptor agonist therapy in type 2 diabetes | Australian Journal of General Practice (RACGP) | AJGP Vol. 51, No. 7, Jul 2022 | GLP-1RA cardiovascular/renal benefit, weight loss, GI side effects, dose titration; place in therapy alongside SGLT2 inhibitors. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| GLP1RA therapy in type 2 diabetes | RACGP — Australian Journal of General Practice | Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety. Catalogued from the local copy at evidence/endocrinology-diabetes/_ajgp/glp1ra-therapy-t2dm-2022.html. | |
| How do healthcare providers support people with prediabetes | Australian Journal of General Practice (RACGP) | AJGP Vol. 50, No. 7, Jul 2021 | Prediabetes (impaired fasting glucose 6.1-6.9, impaired glucose tolerance, HbA1c 6.0-6.4%/42-46); lifestyle intervention first-line; metformin in high-risk; annual progression screening. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| How low to go with glucose control | Australian Prescriber | ||
| Hyperaldosteronism | StatPearls (NCBI Bookshelf) | Primary aldosteronism (Conn syndrome) causes (aldosterone-producing adenoma vs bilateral adrenal hyperplasia), hypokalaemia prevalence, ARR screening, confirmatory/subtyping workup and treatment, for endocrinology-diabetes/hyperaldosteronism.md, stage E. | |
| Hypercalcemia | StatPearls | ||
| Hypercortisolism (Cushing Syndrome) | StatPearls (NCBI Bookshelf) | updated 2025-11-28 | Aetiology (ACTH-dependent/independent split, % of endogenous cases), clinical features, diagnostic workup and treatment for endocrinology-diabetes/cushings-syndrome.md, stage E. |
| Hyperglycaemic presentations in type 2 diabetes | AJGP | ||
| Hyperosmolar Hyperglycemic Syndrome | StatPearls | ||
| Hyperthyroidism in a hypothyroid patient | RACGP — Australian Journal of General Practice | A woman aged 64 years presented with a few weeks of tiredness, night sweats and palpitations. Catalogued from the local copy at evidence/endocrinology-diabetes/_ajgp/hyperthyroid-in-hypothyroid-patient-2022.html. | |
| Hyperthyroidism in a hypothyroid patient (case) | Australian Journal of General Practice (RACGP) | AJGP Vol. 51, No. 7, Jul 2022 | Case: thyrotoxicosis developing in a patient on levothyroxine; illustrates over-replacement and interpreting discordant TFTs. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Hypocalcemia | StatPearls | ||
| Hypoparathyroidism | StatPearls | ||
| Hypopituitarism | StatPearls (NCBI Bookshelf) | current as at fetch | Low-yield fallback for endocrinology-diabetes/hypopituitarism.md stage-E pass (AJGP pituitary-disease-2021 source covers tumours/hypersecretion more than replacement therapy detail). |
| Iatrogenic Cushing's syndrome with inhaled fluticasone | Australian Prescriber | ||
| Injectable drugs for weight management (Yates & South, Aust Prescr 2025;48:197-202) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 48, No 6, December 2025 | Comprehensive review of GLP-1 (liraglutide, semaglutide) and dual GIP/GLP-1 (tirzepatide) injectables for weight management: mechanisms, TGA-approved indications, comparative trial efficacy (SCALE/STEP 1/SURMOUNT-1/SURMOUNT-5), adverse effects (GI, gallstones, pancreatitis, mental health/eating-disorder misuse risk, NAION signal), prescribing practicalities, and weight regain after stopping (~75% of lost weight regained per an unreviewed preprint). None of these drugs are PBS-listed for weight management as of the article date (PBS-subsidised for T2DM only, cf. pbac-obesity-2025 above for the one CVD-risk exception). |
| Insulin - Starting and Ongoing Management | Community HealthPathways Hunter New England | Local pathway for initiating and titrating insulin in type 2 diabetes. Cited from the local PDF copy in evidence/_sources/ — HealthPathways requires a clinician account, so the PDF is the citable copy. | |
| Insulin Pump Breakdown (check in browser) | Community HealthPathways Hunter New England | current as at upload (2026-07-31); last updated 09 November 2023, last reviewed 06 August 2021 | Clinician-login-gated regional pathway (not independently URL-verified - the #1520384 fragment is this pathway's own Topic ID from the supplied PDF, appended only to keep this entry's URL distinct from its sibling HNE T1D pathways for the citation-dedup logic, not a resolvable deep link; cited by name/content only, PDF supplied by Steve). Pump-failure bridging protocol: if total daily dose known, give 50% as long-acting basal insulin plus 50% as mealtime boluses split evenly across 3 meals; if unknown, weight-based estimate (long-acting 0.3 units/kg/24h; rapid-acting 0.1 units/kg per main meal). ED referral red flags: vomiting, dehydration, ketones, BGL >20 mmol/L. Lists Australian pump-company contact numbers. |
| Insulin pumps in general practice (Paldus et al, Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | Insulin pump therapy in type 1 diabetes for GPs: sick-day management with a pump (temporary basal rate increase, sometimes reduction with poor oral intake), glucose/ketone monitoring, corrective rapid-acting insulin dose by injection (not via the pump) if blood ketones moderately elevated, and pump failure/malfunction troubleshooting. | |
| International evidence-based guideline for the assessment and management of polyendocrine metabolic ovarian syndrome (formerly PCOS) — 2026 terminology update | Monash University / international guideline development group | Named by hand from the document's own opening text. Local copy at evidence/womens-health/menopause/Updated-PMOS-Guideline-12-June26.pdf. | |
| Investigating thyroid nodules | Australian Prescriber | ||
| Involuntary Weight Loss | MSD Manual Professional Edition | ||
| KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease | Kidney Disease: Improving Global Outcomes (KDIGO) | 2024 | SGLT2 inhibitors now foundational (1A) CKD-progression therapy regardless of diabetes status; finerenone established as add-on for diabetic CKD with albuminuria. |
| Male Hypogonadism | StatPearls | ||
| Management of type 2 diabetes: a handbook for general practice | RACGP / Diabetes Australia | 2024 (living handbook; 'Goals for optimum management' page updated 24 Sept 2025) | Living online handbook, updated section by section. 'Goals for optimum management' page (Sept 2025) sets current targets: HbA1c generally <=7% individualised; secondary-prevention LDL target <1.4 mmol/L with >=50% reduction from baseline; BP <130/80 with CKD, 140/90 general target; uACR <3.5 mg/mmol (women)/<2.5 mg/mmol (men); 5-10% weight loss goal; SMBG 4-7 mmol/L fasting, 5-10 mmol/L postprandial. |
| Measuring vitamin D | Australian Prescriber | 25-OHD testing thresholds, RCPA-aligned target level, re-testing interval for endocrinology-diabetes/vitamin-d-deficiency.md, write-gap-pages. | |
| Medication management of type 2 diabetes | RACGP — Australian Journal of General Practice | This article reviews best practice medication management of type 2 diabetes mellitus in residential aged care facilities and highlights practical details for clinicians providing care for residents. Catalogued from the local copy at evidence/endocrinology-diabetes/_ajgp/medication-management-t2dm-2018.html. | |
| Medication management of type 2 diabetes | Australian Journal of General Practice (RACGP) | AJGP Vol. 47, No. 10, Oct 2018 | Foundational stepwise T2DM pharmacotherapy (pre-2019 but framework current): metformin first-line, then add SGLT2i/GLP-1RA with CV/renal indications, sulfonylurea/DPP-4/insulin. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Medication management on sick days (Lea-Henry et al, Aust Prescr 2017;40:168-73) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 40, No 5, October 2017 | Sick-day medication adjustment principles: withhold ACE inhibitors/ARBs/diuretics/NSAIDs/metformin/SGLT2i during hypovolaemia risk (acute illness with vomiting/diarrhoea/poor intake); insulin and corticosteroid doses often need temporary increase, not withholding; SADMANS mnemonic origin article. |
| Medicines for long-term obesity management | Australian Prescriber | ||
| Menopause and osteoporosis: Epidemiology, pathophysiology, screening and diagnosis | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/endocrinology-diabetes/_ajgp/menopause-osteoporosis-epidemiology-screening-2026.pdf. |
| Menopause and osteoporosis: Non-pharmacological and pharmacological management | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/endocrinology-diabetes/_ajgp/menopause-osteoporosis-management-2026.pdf. |
| Metabolic Syndrome | StatPearls | ||
| Metformin in pregnancy and lactation | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206) | National Institute for Health and Care Excellence (NICE, UK) | 2021 | Explicitly recommends against fixed graded exercise therapy (GET) for ME/CFS; recognises post-exertional malaise (PEM) as a core diagnostic feature; repositions CBT as supportive only, not curative. |
| New warnings of romosozumab (Evenity) cardiovascular risks | Therapeutic Goods Administration (TGA) | Oct 2023 signal review | TGA cardiovascular safety update for romosozumab following pharmacovigilance signal investigation. |
| Nonfunctional Adrenal Masses | MSD Manual Professional Edition | Adrenal incidentaloma definition, prevalence of adenomas vs other causes, malignancy risk features on imaging, functional work-up, for endocrinology-diabetes/incidentaloma.md, stage E. | |
| Obesity and its management (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Ongoing Management of Type 1 Diabetes (check in browser) | Community HealthPathways Hunter New England | current as at upload (2026-07-31); last updated 09 June 2026, last reviewed 11 May 2026 | Clinician-login-gated regional pathway (not independently URL-verified - the #1208225 fragment is this pathway's own Topic ID from the supplied PDF, appended only to keep this entry's URL distinct from its sibling HNE T1D pathways for the citation-dedup logic, not a resolvable deep link; cited by name/content only, PDF supplied by Steve). Routine GP care of adult type 1 diabetes: HbA1c target <=53 mmol/mol (7%), fasting/preprandial BGL 4-7, 2h postprandial 6-10; cycle-of-care intervals (BMI/BP 6-monthly, lipids/kidney/autoimmune screen 12-monthly, foot exam 1-12-monthly by risk, comprehensive eye exam 2-yearly); hypoglycaemia-unawareness screening questions; NDSS-subsidised CGM eligibility for all T1D; MDI vs pump insulin-adjustment principles (correction dose, insulin:carb ratio, factors affecting requirement - exercise, alcohol, illness, THC/amphetamines); conditional-licence driving criteria (no severe hypo, >=6 week off-road period post severe hypo); diabetes distress/PHQ-2/PAID screening; urgent vs non-urgent specialist referral triggers. Notes December 2026 discontinuation of Protaphane Penfill, Levemir FlexPen/Penfill, Actrapid Penfill and NovoFine Autocover. |
| Osteomalacia | StatPearls | ||
| Osteoporosis and minimal-trauma fracture | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/endocrinology-diabetes/osteoporosis/Osteoporosis and minimal-trauma fracture - Therapeutic Guidelines.pdf. | |
| Paget's disease of bone: a clinical update | Australian Journal of General Practice (RACGP) | AJGP Vol. 50, No. 1-2, Jan-Feb 2021 | Endocrine-themed issue Focus article. Often asymptomatic, found on raised ALP or incidental X-ray. Diagnosis: raised ALP + characteristic X-ray, confirmed by nuclear bone scan for extent. Treatment: single-dose IV zoledronic acid for symptomatic disease; monitor by ALP. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Pagets disease of bone | RACGP — Australian Journal of General Practice | The clinical presentation, diagnosis and management of patients with Paget's disease of bone are described in this article. Catalogued from the local copy at evidence/endocrinology-diabetes/_ajgp/pagets-disease-bone-2021.html. | |
| Palliative management of type 2 diabetes mellitus | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 8, Aug 2025 | Deintensification/relaxation of glycaemic targets in advanced illness and end of life; deprescribing, avoiding hypoglycaemia. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Palliative management of type 2 diabetes mellitus in patients with advanced cancer | RACGP — Australian Journal of General Practice | This article summarises the evidence-based management of type 2 diabetes mellitus in patients with advanced cancer. Catalogued from the local copy at evidence/endocrinology-diabetes/_ajgp/palliative-t2dm-2025.html. | |
| PBAC advice on equitable access to GLP-1 obesity treatments (November 2025 meeting) | Pharmaceutical Benefits Scheme (Australian Government) | November 2025 PBAC meeting | Semaglutide (Wegovy) recommended for PBS listing for obesity only in patients with established cardiovascular disease; GLP-1/GIP agents (semaglutide, tirzepatide) now TGA-approved and first-line pharmacotherapy for chronic weight management, superseding older agents (orlistat, phentermine). |
| PBS listing — Romosozumab for severe established osteoporosis | Pharmaceutical Benefits Scheme (Australian Government) | PBAC March 2024 listing (expanded to first-line) | Romosozumab (Evenity) PBS-expanded to first-line for severe established osteoporosis, March 2024 (previously second-line only). |
| Pheochromocytoma | StatPearls (NCBI Bookshelf) | current as at fetch | Epidemiology (prevalence of adrenal masses/extra-adrenal paraganglioma proportion), false-positive drug list, continuous vs paroxysmal hypertension pattern, incidental discovery for endocrinology-diabetes/pheochromocytoma.md, stage E enrichment pass -- the dedicated ajgp-adrenal-disease-2021 source covers definition/screening-test/alpha-before-beta-blockade well but not these epidemiological/false-positive details. |
| Pituitary disease update | RACGP — Australian Journal of General Practice | There is a broad range of pathologies that may present as a sellar or parasellar mass. Catalogued from the local copy at evidence/endocrinology-diabetes/_ajgp/pituitary-disease-update-2021.html. | |
| Pituitary disease: an update | Australian Journal of General Practice (RACGP) | AJGP Vol. 50, No. 1-2, Jan-Feb 2021 | Endocrine-themed issue Focus article. Pituitary lesions in >10% of population; ~1/1000 have a symptomatic tumour. Covers mass effect, hormonal hypersecretion (prolactinoma, acromegaly, Cushing's disease), hypopituitarism, posterior pituitary (diabetes insipidus, SIADH). Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process (check in browser) | The Lancet / International PMOS Network (Monash MCHRI, AE-PMOS Society, Verity), in partnership with ASRM, Endocrine Society, ESE, ESHRE | May 2026 | PCOS formally renamed polyendocrine metabolic ovarian syndrome (PMOS) following a 14-year, 56-organisation global consensus process (22,000 survey responses; consensus reached Feb 2026). Diagnostic criteria and management recommendations are explicitly unchanged — only the name changes. 'PCOS' and 'PMOS' co-exist for a 3-year transition period. Corroborated via independent coverage from Yale Medicine, Johns Hopkins Medicine, University of Rochester Medicine, Endocrine Society, STAT News and AJMC (all May 2026). |
| Precocious Puberty | StatPearls (NCBI Bookshelf) | ||
| Premature ovarian insufficiency and infertility | AJGP | ||
| Primary Hyperparathyroidism | StatPearls | ||
| Primary Ovarian Insufficiency | StatPearls | ||
| Rickets | StatPearls | ||
| Risedronate | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/endocrinology-diabetes/osteoporosis/Risedronate - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to the generic "amh" entry). | |
| Risk factors for the development and progression of proliferative diabetic retinopathy (Cochrane, CD013775) | Cochrane | ||
| Screening for primary aldosteronism | AJGP (RACGP) | ||
| SGLT2 inhibitors: Think twice about diabetic ketoacidosis | AJGP | ||
| Sick Day Management in Type 1 Diabetes (check in browser) | Community HealthPathways Hunter New England | current as at upload (2026-07-31); last updated/reviewed 12 June 2026 | Clinician-login-gated regional pathway (not independently URL-verified - the #1179837 fragment is this pathway's own Topic ID from the supplied PDF, appended only to keep this entry's URL distinct from its sibling HNE T1D pathways for the citation-dedup logic, not a resolvable deep link; cited by name/content only, PDF supplied by Steve). Adult T1DM sick-day pathway: ED red flags; DKA/euglycaemic-DKA/HHS differentiation; blood (preferred) vs urine ketone interpretation table (<0.6 normal, 0.6-1.5 increased production, 1.5-3.0 impending DKA, >3.0 probable DKA); never withhold basal insulin; supplemental rapid-acting insulin dosing (5-20% of total daily dose, >=2h after previous dose); fluid/carbohydrate intake rules by BGL threshold (15 mmol/L); ED-re-presentation thresholds; medications to withhold with vomiting/diarrhoea (diuretics, ACEi/ARB, NSAIDs); sick day kit contents. Cites NDSS Clinical Guiding Principles for Sick Day Management v4.1.0 (2025). |
| Somatrogon for growth hormone deficiency (Aust Prescr 2022;45:181) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Syndrome of Inappropriate Antidiuretic Hormone Secretion | StatPearls | ||
| The assessment of premature thelarche | AJGP (RACGP) | ||
| Thyroid Cancers | MSD Manual Professional Edition | 2026 | Added 2026-08-16 for stage-E claim placement on thyroid-cancer.md -- papillary/follicular incidence proportions, 5-year survival, post-treatment thyroglobulin surveillance, and thyroidectomy/radioactive iodine treatment. |
| Thyroid disease Long term management of hyperthyroidism and hypothyroidism | RACGP — Australian Journal of General Practice | Long-term management requires an understanding of the range of causes and benefits from a shared decision-making approach, with discussion about potential risks and benefits of therapy. Catalogued from the local copy at evidence/endocrinology-diabetes/_ajgp/thyroid-longterm-management-2021.html. | |
| Thyroid disease: long-term management of hyperthyroidism and hypothyroidism | Australian Journal of General Practice (RACGP) | AJGP Vol. 50, No. 1-2, Jan-Feb 2021 | Endocrine-themed issue Focus article. Levothyroxine titration, review at 3-4 months once TSH normalised; discontinue LT4 for subclinical hypothyroidism if no symptom benefit. Hyperthyroidism: antithyroid drugs (carbimazole), radioactive iodine, surgery; shared decision-making. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Thyroid disease: using diagnostic tools effectively | Australian Journal of General Practice (RACGP) | AJGP Vol. 50, No. 1-2, Jan-Feb 2021 | Endocrine-themed issue Focus article. TSH-first testing; anti-TPO antibodies predict progression in subclinical hypothyroidism; TSH-receptor antibodies for Graves; radionuclide uptake patterns (diffuse=Graves, decreased=thyroiditis, focal=toxic adenoma); ultrasound/FNA only for palpable or known nodules. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Thyroid disorders in pregnancy and postpartum (Aust Prescr 2017, 40:214-9) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Tirzepatide | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/endocrinology-diabetes/obesity/Tirzepatide - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Type 2 diabetes remission in Australian primary care | Australian Journal of General Practice (RACGP) | AJGP Vol. 52, No. 1-2, Jan-Feb 2023 | Remission (HbA1c <6.5%/48 off glucose-lowering therapy for >=3 months) achievable via substantial weight loss (low-energy diets, bariatric surgery); greatest chance early in disease. Local copy: evidence/endocrinology-diabetes/_ajgp/. |
| Type 2 diabetes: goals for optimum management | RACGP | Named by hand from the document's own opening text. Local copy at evidence/endocrinology-diabetes/t2dm-mx/racgp-goals-for-optimum-management.pdf. | |
| Vitamin D and health in adults in Australia and New Zealand: a position statement | Medical Journal of Australia | ANZBMS/Endocrine Society of Australia/Osteoporosis Australia joint position statement — population maintenance dosing, sun-exposure guidance, target level, for endocrinology-diabetes/vitamin-d-deficiency.md, write-gap-pages. | |
| Vitamin D deficiency in adults | Australian Prescriber | Pathophysiology, at-risk groups, repletion/maintenance dosing for endocrinology-diabetes/vitamin-d-deficiency.md, write-gap-pages. | |
| Weight Management in Adults (check in browser) | Community HealthPathways Hunter New England | Last updated 20 August 2025; last reviewed 25 February 2025 | Clinician-login-gated regional pathway (not independently URL-verified; cited by name/content only, per the site's access restriction). Structures assessment around the 5 A's (Ask, Assess, Advise, Agree, Assist) with explicit reframing toward focusing on health/behaviour rather than weight number, and offers a 'Health at Every Size' (HAES) option for patients who prefer it. Specifies a review schedule (2-weekly for 3 months, medical review at 3 months, ongoing support 12+ months) and a multidisciplinary referral list (dietitian, psychologist, exercise physiology, physiotherapy, endocrinology, bariatric surgery, NSW Get Healthy Service). |
ENT
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| A primary care approach to the discharging ear | RACGP (AJGP) | AJGP 53(12) supplement, December 2024 | Systematic anatomy-based otorrhoea differential; red flags (meningism/facial weakness/cranial nerve dysfunction); imaging thresholds (CT for refractory/hearing loss, MRI for CSF leak/malignant OE). Local copy: evidence/ent/_ajgp/ |
| A review of tinnitus | AJGP | ||
| Acute Laryngitis (StatPearls) | StatPearls | ||
| Acute Otitis Media (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Acute Pharyngitis | StatPearls | ||
| Acute sinusitis and sore throat in primary care (Aust Prescr 2023) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Adenoidectomy for otitis media with effusion (OME or 'glue ear') in children (Cochrane Database of Systematic Reviews, 2023) | Cochrane | ||
| Adult onset dysphagia | RACGP — Australian Journal of General Practice | This article assists physicians through the work-up and management of dysphagia. Catalogued from the local copy at evidence/ent/_ajgp/adult-onset-dysphagia-2024.html. | |
| An approach to neck masses in adults | RACGP (AJGP) | AJGP 49(5), May 2020 | Core teaching point: all adult neck masses malignant until proven otherwise; HPV-driven oropharyngeal SCC rising in Australia; referral delay up to 180 days documented, 3x mortality increase; FNA + contrast CT neck first-line. Local copy: evidence/ent/_ajgp/ |
| An approach to the postoperative parotidectomy patient in primary care | RACGP — Australian Journal of General Practice | This paper is a guide to the assessment, evaluation and management of clinical presentations after parotid surgery. Catalogued from the local copy at evidence/ent/_ajgp/postoperative-parotidectomy-2024.html. | |
| An approach to the postoperative parotidectomy patient in primary care | RACGP (AJGP) | AJGP 53(11) supplement, November 2024 | Facial nerve weakness/GAN sensory loss frequency and resolution timelines, Frey syndrome (up to 60%), sialocele, first-bite syndrome. Local copy: evidence/ent/_ajgp/ |
| An approach to vertigo in general practice | Australian Family Physician (RACGP) | ||
| An update on epistaxis | RACGP (Australian Family Physician) | AFP 44(9), September 2015 | Yau. Epistaxis assessment and stepwise management (first aid, cautery, packing, posterior bleeds) and red flags for neoplasia. Already the note's cited source pre-stage-F (previously registry: check-in-browser, unregistered) — properly registered here for the common-presentations/epistaxis.md stage-F rewrite (2026-08-24). |
| Anatomy, Head and Neck: Tonsils | StatPearls | ||
| Anosmia | StatPearls | ||
| Antibiotic prescribing for tonsillopharyngitis in a general practice setting | RACGP (AJGP) | AJGP 48(6), June 2019 | Documented Modified Centor Criteria use associated with significantly lower antibiotic prescribing (77.7% vs 85.5%, OR 2.4) in Australian general practice. Local copy: evidence/ent/_ajgp/ |
| Antibiotics for adults and children with sore throats | Cochrane | ||
| Antibiotics for otitis media with effusion (OME or 'glue ear') in children (Cochrane Database of Systematic Reviews, 2023) | Cochrane | ||
| Antiviral drugs for sudden hearing loss (without known cause) | Cochrane | Plain-language Cochrane summary on antiviral drugs (alone or combined with steroids) for idiopathic sudden sensorineural hearing loss. | |
| Approach to allergic rhinitis in the primary care setting | RACGP (AJGP) | AJGP 53(11) supplement, November 2024 | Combination corticosteroid+antihistamine nasal sprays, CARAT-10 screening tool, sublingual immunotherapy wafers/tablets. Local copy: evidence/ent/_ajgp/ |
| Approach to otitis externa in Australian general practice | RACGP — Australian Journal of General Practice | This article discusses general practice's role in mitigating complications from acute otitis externa. Catalogued from the local copy at evidence/ent/_ajgp/otitis-externa-approach-2024.html. | |
| Approach to paediatric nasal obstruction | RACGP (AJGP) | AJGP 51(10), October 2022 | Developmental sinonasal anatomy (higher nasal airflow resistance in children), adenoid enlargement/regression timeline (peaks 5-7yrs, regresses by 12), don't-miss list. Local copy: evidence/ent/_ajgp/ |
| Atypical Mycobacterial Disease | StatPearls (NCBI Bookshelf) | current as at fetch | Nontuberculous/atypical mycobacterial disease clinical syndromes, skin/lymphadenitis presentation, treatment approach for ent/odd-neck-lumps-continued.md (low-yield fallback). |
| Auricular Hematoma | StatPearls (NCBI Bookshelf) | Auricular haematoma diagnosis, drainage technique, pressure dressing, complications. | |
| Benign Salivary Gland Tumors | StatPearls (NCBI Bookshelf) | current as at fetch | Pleomorphic adenoma, Warthin tumour, other benign salivary tumour subtypes for ent/odd-neck-lumps-continued.md (low-yield fallback). |
| Betahistine for tinnitus | Cochrane | ||
| Branchial Cleft Anomalies | StatPearls (NCBI Bookshelf) | ||
| Carotid Body and Vagal Paragangliomas: Epidemiology, Genetics, Clinicopathological Features, Imaging, and Surgical Management | NCBI Bookshelf (Codon Publications) | ||
| Cauliflower Ear | StatPearls (NCBI Bookshelf) | Cauliflower ear deformity as a delayed-treatment sequela; prevention and management. | |
| Cerumen Impaction Removal | StatPearls | ||
| Childhood otitis media I. General practitioner view (Australian Prescriber) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Childhood otitis media II. Specialist view (Australian Prescriber) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Chronic Suppurative Otitis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Cognitive behavioural therapy for adults with tinnitus | Cochrane | ||
| COVID 19 related anosmia | RACGP — Australian Journal of General Practice | On average, 47% of patients with COVID-19 self-report an olfactory disorder, although the inaccuracy of self-reporting means this figure may be higher. Catalogued from the local copy at evidence/ent/_ajgp/covid-19-related-anosmia.html. | |
| COVID-19-related anosmia | RACGP (AJGP) | AJGP Coronavirus supplement, first published 7 April 2022 | Smell training protocol (rose/eucalyptus/clove/lemon, twice daily for months) - GP-initiable, evidence-backed per British Rhinological Society; pharmacological treatments lack sufficient evidence. Local copy: evidence/ent/_ajgp/ |
| Dealing with dizziness | Australian Prescriber | ||
| Diuretics for the treatment of Ménière's disease or syndrome | Cochrane | Plain-language Cochrane summary on diuretics for vertigo/hearing loss/tinnitus/aural fullness in Meniere's disease. | |
| Diving related otological injuries | RACGP — Australian Journal of General Practice | Accurate diagnosis and treatment of diving-related otological injuries by general practitioners can have profound positive effects on a patient's long-term outcomes. Catalogued from the local copy at evidence/ent/_ajgp/diving-otological-injuries-2020.html. | |
| Diving-related otological injuries: Initial assessment and management | AJGP | ||
| Do dietary factors significantly influence tinnitus? | RACGP (AJGP) | AJGP 48(3), March 2019 | Dietary supplements ineffective for tinnitus; no evidence for caffeine/salt restriction; very weak evidence diet quality affects symptoms; ototoxic medication table. Local copy: evidence/ent/_ajgp/ |
| Dupilumab for chronic rhinosinusitis with nasal polyps — EPOS/EUFOREA biologic treatment indications (check in browser) | EPOS/EUFOREA | 2023 | Dupilumab (IL-4/IL-13 inhibitor) is now an established biologic option for severe/refractory chronic rhinosinusitis with nasal polyps (CRSwNP), particularly with comorbid asthma, approved in EU/US. Australian TGA/PBS listing status not independently confirmed as part of this review. |
| Dysphonia | StatPearls | ||
| Ear drops for the removal of ear wax (Cochrane plain-language summary) | Cochrane | ||
| Epistaxis | StatPearls | ||
| Foreign bodies in the ear and nose of the Australian paediatric population | RACGP (AJGP) | AJGP 53(11), November 2024 | Microsuction + alligator forceps as gold-standard retrieval; urgent ENT referral for button batteries/disc magnets (tissue necrosis risk); multiple failed attempts drives complications. Local copy: evidence/ent/_ajgp/ |
| Head and neck cancer surveillance | RACGP — Australian Journal of General Practice | This article aims to provide the general practitioner with a practical guide and an up-to-date evidence-based review on how to manage the head and neck cancer survivor. Catalogued from the local copy at evidence/ent/_ajgp/head-neck-cancer-surveillance-2024.html. | |
| Head and neck cancer surveillance: A guide past the five-year mark | RACGP (AJGP) | AJGP 53(12) supplement, December 2024 | GP-focused survivorship/surveillance framework post 5-year oncology discharge; red flags for urgent re-referral, skin checks for cutaneous-primary patients. Local copy: evidence/ent/_ajgp/ |
| Hyperbaric oxygen for sudden hearing loss and tinnitus (ringing in the ears) of unknown cause | Cochrane | Plain-language Cochrane summary on hyperbaric oxygen therapy for idiopathic sudden sensorineural hearing loss/tinnitus. | |
| Hyperbaric Treatment of Sensorineural Hearing Loss | StatPearls (NCBI Bookshelf) | Hyperbaric oxygen as adjunct/salvage therapy for sudden sensorineural hearing loss. | |
| Laryngeal Cancer | StatPearls (NCBI Bookshelf) | current as at fetch | Epidemiology, risk factors, staging, treatment for ent/laryngeal-cancer.md, stage E enrichment pass -- dedicated head-and-neck-cancer-surveillance AJGP source only covers post-treatment survivorship, not primary presentation/epidemiology/treatment. |
| Localised odontogenic infections | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Lymphangioma | StatPearls (NCBI Bookshelf) | current as at fetch | Lymphatic malformation/lymphangioma classification, clinical features, sclerotherapy/surgical management for ent/odd-neck-lumps-continued.md (low-yield fallback). |
| Lymphatic malformation (lymphangioma, cystic hygroma, lymphangioma circumscriptum) | DermNet NZ | Lymphatic malformation/cystic hygroma clinical features, associations, diagnosis, treatment. | |
| Malignant Salivary Gland Tumors | StatPearls (NCBI Bookshelf) | current as at fetch | Mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma, other malignant salivary tumour subtypes for ent/odd-neck-lumps-continued.md (low-yield fallback). |
| Management of sudden sensorineural hearing loss | RACGP — Australian Journal of General Practice | This article offers a framework to optimise patient care and improve outcomes in patients with sudden sensorineural hearing loss. Catalogued from the local copy at evidence/ent/_ajgp/sudden-sensorineural-hearing-loss-2024.html. | |
| Managing otitis media: an evidence-based approach (Australian Prescriber) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Mastoiditis | StatPearls | ||
| Middle Ear Cholesteatoma | StatPearls | ||
| Mononucleosis | StatPearls (NCBI Bookshelf) | updated 2026 | Clinical features (fever/lymphadenopathy/pharyngitis triad, malaise, splenomegaly, rash including the amoxicillin/ampicillin-associated eruption), aetiology/transmission and management for dermatology/ebv-infectious-mononucleosis-amoxicillin-rash.md, stage E low-yield fallback (the note's cited dermnet-nz source is only the DermNet homepage nav shell, no topic-specific content). |
| Nasal Fracture Reduction | StatPearls (NCBI Bookshelf) | ||
| Nasal Fractures | MSD Manual Professional Edition | ||
| Nasal Polyps | StatPearls (NCBI Bookshelf) | current as at fetch | Nasal polyps definition, associations (CF, AERD), red flags, management for ent/nasal-polyps.md (low-yield fallback). |
| Nasal Septal Fracture | StatPearls (NCBI Bookshelf) | ||
| Nasal Septal Hematoma (Archived) | StatPearls (NCBI Bookshelf) | ||
| Newborn Hearing Screening (StatPearls) | StatPearls | ||
| Obstructive sleep apnoea in children | RACGP — Australian Journal of General Practice | A boy aged five years presented to the paediatric outpatient clinic with a six-month history of snoring and noisy breathing during sleep. Catalogued from the local copy at evidence/ent/_ajgp/osa-in-children-2020.html. | |
| Obstructive sleep apnoea in children | RACGP (AJGP) | AJGP 49(12), December 2020 | Not all snoring is OSA; polysomnography gold standard, overnight oximetry screening; adenotonsillectomy effective for moderate-severe OSA with adenotonsillar hypertrophy. Local copy: evidence/ent/_ajgp/ |
| Odontogenic infections following dentoalveolar surgery | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Oral or topical nasal steroids for hearing loss associated with otitis media with effusion (glue ear) in children (Cochrane Database of Systematic Reviews) | Cochrane | ||
| Otitis Media (Chronic Suppurative) | MSD Manual Professional Edition | ||
| Otitis Media With Effusion (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Otosclerosis | StatPearls | ||
| Overview of acute odontogenic infections | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Paediatric neck lumps | RACGP — Australian Journal of General Practice | While paediatric cervical masses are most commonly benign and transient in nature, judicious consideration of red flag and congenital conditions is crucial. Catalogued from the local copy at evidence/ent/_ajgp/paediatric-neck-lumps-2019.html. | |
| Papillomas: A Multisystem Overview of HPV-Associated and HPV-Independent Lesions | StatPearls (NCBI Bookshelf) | Sinonasal (inverted/oncocytic) papilloma HPV association, presentation, malignant potential, management for ent/nasal-tumour.md (low-yield fallback). | |
| Paraganglioma (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ) | National Cancer Institute (PDQ) | ||
| Paranasal Sinus Cancer | MSD Manual Professional Edition | Sinonasal/paranasal sinus malignancy epidemiology, presentation, diagnosis, treatment for ent/nasal-tumour.md (low-yield fallback). | |
| Parotitis | StatPearls | ||
| Parotitis: An approach for general practitioners | RACGP (AJGP) | AJGP 54(9), September 2025 | Full aetiology table, red-flag referral table, imaging modality comparison (US first-line for sialoliths, CT 96%/100% sens/spec), mumps notifiable-disease + ATSI outbreak overrepresentation (60.5% 2016-19 cases). Local copy: evidence/ent/_ajgp/ |
| Pediatric Hearing Loss (StatPearls) | StatPearls | ||
| Peritonsillar Abscess | StatPearls (NCBI Bookshelf) | ||
| Preauricular Sinus: A Tale of Forgetful Rediscovery (Cureus, 2020) | Cureus | ||
| Presbycusis | StatPearls (NCBI Bookshelf) | Age-related sensorineural hearing loss: epidemiology, pathophysiology, clinical features, management. | |
| Pyogenic Granuloma | StatPearls | ||
| Retropharyngeal Abscess | StatPearls | ||
| Salivary Gland Tumors | MSD Manual Professional Edition | current as at fetch | Benign/malignant salivary tumour epidemiology, subtypes (pleomorphic adenoma, mucoepidermoid, adenoid cystic, acinic cell carcinoma), risk factors, symptoms, diagnosis, treatment for ent/odd-neck-lumps-continued.md (low-yield fallback). |
| SARS CoV 2 and the nose | RACGP — Australian Journal of General Practice | The sinonasal cavity is an important route of entry and infection for SARS-CoV-2 and carries the highest viral load in the respiratory tract. Catalogued from the local copy at evidence/ent/_ajgp/sars-cov-2-and-the-nose-2020.html. | |
| Snoring | MSD Manual Professional Edition | current as at fetch | Dedicated Snoring topic (pathophysiology/etiology/risk factors/evaluation). Low-yield fallback source for ent/snoring's adult risk-factor content. |
| Spreading odontogenic infections with severe local or systemic features including Ludwig angina | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Spreading odontogenic infections without severe local or systemic features | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Temporomandibular dysfunction | AJGP | ||
| Temporomandibular Syndrome (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease | RHDAustralia / Medical Journal of Australia | 3rd edition, 2020 | Secondary prophylaxis duration shortened from the old blanket 10-years-minimum rule to 5 years post-ARF (no cardiac involvement) or 10 years (with cardiac involvement) after the most recent episode, or until age 21, whichever is longer. Benzathine benzylpenicillin G IM every 28 days remains first-line. |
| The Epley manoeuvre for benign paroxysmal positional vertigo (BPPV) | Cochrane | ||
| Therapeutics for rheumatic fever and heart disease | Australian Prescriber | ||
| Thyroglossal Duct Cyst | StatPearls (NCBI Bookshelf) | ||
| Tonsillitis | StatPearls | ||
| Topical and oral steroids for otitis media with effusion (OME or 'glue ear') in children (Cochrane Database of Systematic Reviews, 2023) | Cochrane | ||
| Topical antibiotics with steroids for chronic suppurative otitis media (Cochrane Database of Systematic Reviews, 2025) | Cochrane | ||
| Tranexamic acid to help treat nosebleeds (epistaxis) | Cochrane | Cochrane plain-language summary (Joseph J, 2018 review): oral/topical tranexamic acid reduces re-bleeding after an initial nosebleed vs usual care (moderate-quality evidence); topical TXA may stop bleeding faster than usual first-aid measures. Used for the common-presentations/epistaxis.md stage-F rewrite (2026-08-24). | |
| Tympanic Membrane Perforation | StatPearls | ||
| Updates in the management of chronic rhinosinusitis | RACGP — Australian Journal of General Practice | A review of the pathophysiology, diagnosis and multimodal approach to the management of chronic rhinosinusitis. Catalogued from the local copy at evidence/ent/_ajgp/chronic-rhinosinusitis-updates-2024.html. | |
| Updates in the management of chronic rhinosinusitis | RACGP (AJGP) | AJGP 53(12), December 2024 | Mepolizumab (anti-IL-5) PBS-listed April 2023 as first Australian biologic for CRS with nasal polyposis (eosinophil >=300, failed/unsuitable for surgery, endoscopic polyp score >5); dupilumab/omalizumab also discussed. Local copy: evidence/ent/_ajgp/ |
| Ventilation tubes (grommets) for otitis media with effusion (OME or 'glue ear') in children (Cochrane Database of Systematic Reviews, 2023) | Cochrane | ||
| Vestibular Schwannoma | StatPearls (NCBI Bookshelf) | Acoustic neuroma/vestibular schwannoma: presentation, epidemiology, workup, management. | |
| Zygomatic Arch Fracture | StatPearls (NCBI Bookshelf) |
Gastroenterology
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| A child with recurrent vomiting | RACGP — Australian Journal of General Practice | Differential diagnoses and potential investigations are discussed for a boy, aged 10 years, who presented with a one-year history of intermittent nocturnal, non-bilious vomiting. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-child-recurrent-vomiting-2023.html. | |
| Abdominal pain - acute | Royal Children's Hospital Melbourne Clinical Practice Guidelines | Paediatric-specific acute abdominal pain guideline — replaces this page's existing unsourced paediatric section. Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/rch-abdominal-pain-acute.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). | |
| Abdominal Pain — Adult ECAT Protocol | Emergency Care Institute, Agency for Clinical Innovation (NSW) | A7.1, published December 2023, updated June 2024 | NSW rural/regional emergency-department protocol (Emergency Care Assessment and Treatment) — the main rural/peripheral-hospital-scoped source for this page. Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/ecat-abdominal-pain-adult.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). |
| Abnormal Liver Function Tests (check in browser) | Community HealthPathways Hunter New England | Last updated 6 Oct 2023 | Steve-supplied PDF. Referral thresholds (bilirubin >34, albumin <35, INR >1.7, ALT >200 for >1 month), red flags, and the MASLD/MASLD-terminology-current framework used to rewrite abnormal-lfts.md (merged with deranged-lfts.md). evidence/gastroenterology/_shared/HNE-Abnormal-Liver-Function-Tests.pdf. |
| Acute Abdominal Pain in Adults: Evaluation and Diagnosis | American Family Physician (AAFP) | Am Fam Physician. 2023;107(6):585-596 | Yew, George, Allred (Gundersen Health System family medicine). Comprehensive primary-care-facing review: pain-location differential, history/exam red flags, initial investigations, imaging choice by presentation (incl. pregnancy — MRI preferred over CT). Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/acute-abdominal-pain-adults.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). |
| Acute cholangitis | Therapeutic Guidelines Ltd (eTG complete) | eTG topic on acute cholangitis: diagnosis (Charcot triad, biliary obstruction), empirical antibiotic therapy and the need for urgent biliary drainage. Cited from the local PDF copy in evidence/_sources/ — the eTG topic itself is behind a subscription, so the PDF is the citable copy and the URL is a pointer for reading more. | |
| Acute cholecystitis | Therapeutic Guidelines Ltd (eTG complete) | eTG topic on acute cholecystitis: diagnosis, empirical antibiotic regimens and timing of cholecystectomy. Cited from the local PDF copy in evidence/_sources/. | |
| Acute Lower Abdominal Pain in Women | Community HealthPathways Hunter New England | GP-facing pathway for gynaecological causes of acute lower abdominal pain in women (ectopic pregnancy, PID, ovarian torsion/cyst accident, etc). Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/hne-healthpathways-acute-lower-abdominal-pain-women.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). | |
| Adult onset dysphagia | RACGP — Australian Journal of General Practice | This article assists physicians through the work-up and management of dysphagia. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-adult-onset-dysphagia-2024.html. | |
| Alcohol-Associated Liver Disease | StatPearls | ||
| An approach to managing gallbladder polyps for the GP | RACGP (AJGP) | AJGP 53(7), July 2024 | Size-based referral/surveillance algorithm for incidental gallbladder polyps: <=5mm discharge, 6-9mm surveil, >=10mm refer for cholecystectomy (malignancy risk 7.6-8.5%). Local copy: evidence/gastroenterology/_ajgp/ |
| Anal fissures | RACGP — Australian Journal of General Practice | Anal fissure is the second most common anorectal complaint in healthcare settings. This article reviews pathophysiology, clinical presentation and management of anal fissures under current guidelines. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-anal-fissures-2024.html. | |
| Anal fissures: An update on treatment options | RACGP (AJGP) | AJGP 53(1-2), January-February 2024 | Fibre/sitz baths first-line (87% healing at >=15g/day fibre); GTN vs CCB topical therapy (CCB preferred, lower side-effect burden); botulinum toxin; LIS vs fissurectomy+anoplasty by sphincter tone with specific incontinence-risk figures. Local copy: evidence/gastroenterology/_ajgp/ |
| Anorectal Abscess | StatPearls | ||
| Anorectal Fistula | StatPearls | ||
| Anti-sickness medication for vomiting in acute stomach upsets in children (Cochrane Database of Systematic Reviews, CD005506) | Cochrane | Plain-language summary: antiemetics (chiefly ondansetron) for children/adolescents with acute gastroenteritis-related vomiting reduce ongoing vomiting, hospital admission and need for IV fluids, at the cost of more diarrhoea; evidence mainly from ED settings. | |
| Appendicitis | StatPearls | ||
| Approach to Abdominal Pain | EM:RAP Corependium | Updated 6 Aug 2026 | Comer, Dixon. Used only for GP/urgent-care-relevant material (history/exam pearls, differential by location, red flags) — its ED/ICU-only procedural detail is deliberately left out, same policy as the chest-pain page. Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/emrap-abdominal-pain-presentation.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). |
| Assessment algorithm for a patient presenting with MAFLD | Gastroenterological Society of Australia (GESA) | Named by hand from the document's own opening text. Local copy at evidence/gastroenterology/fatty-liver-nash/gesa-mafld-assessment-algorithm.pdf. | |
| Autoimmune Hepatitis | StatPearls | ||
| Barrett Esophagus | StatPearls | ||
| Beyond the iron gate | RACGP — Australian Journal of General Practice | This study aimed to gain knowledge into the demographic characteristics of donors with haemochromatosis and to investigate their knowledge, compliance and experiences with their condition. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-haemochromatosis-beyond-iron-gate-2025.html. | |
| Beyond the iron gate: Therapeutic donation at Lifeblood for patients with haemochromatosis | RACGP (AJGP) | AJGP 54(9), September 2025 | Survey of blood-donor demographics/compliance for haemochromatosis patients using Lifeblood therapeutic donation; confirms venesection remains first-line, no new diagnostic/management thresholds. Local copy: evidence/gastroenterology/_ajgp/ |
| Biliary Disease (EM:RAP CorePendium) | EM:RAP CorePendium | CorePendium chapter covering biliary colic, acute cholecystitis, acute cholangitis and gallstone pancreatitis, including the critical-patient approach and empirical intravenous antibiotic regimens. Cited from the local PDF copy in evidence/_sources/. | |
| Bowel Cancer Screening (check in browser) | Community HealthPathways Hunter New England | Last updated 30 May 2025 | Steve-supplied PDF. Current NBCSP eligibility (45-49yrs can request first kit from 1 July 2024; 50-74 biennial), 3-tier family-history risk categories and screening intervals, aspirin chemoprevention. Used with the Colorectal Cancer Symptoms, Colorectal Polyp Surveillance and Past Colorectal Cancer Surveillance HNE pathways to rewrite the merged bowel-cancer-screening.md. evidence/gastroenterology/_shared/HNE-Bowel-Cancer-Screening.pdf. |
| Bowel Ischemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Cancer Council clinical practice guidelines and Optimal Care Pathways | Cancer Council Australia | per-guideline wiki | |
| Candidiasis (Mucocutaneous) | MSD Manual Professional Edition | Full Review: Oct 2025, Last updated: Jan 2026 | Local copy: evidence/gastroenterology/oral-candidiasis/. |
| Celiac Disease | StatPearls (NCBI Bookshelf) | tTG biology/wound-healing role and role as autoantigen, symptoms, serology non-specificity in other conditions. Low-yield fallback for paediatrics/coeliac-disease.md, stage E. | |
| Cirrhosis (check in browser) | Community HealthPathways Hunter New England | Last updated 26 Feb 2026, citing GESA/BSG guidance | Steve-supplied PDF. Comprehensive cirrhosis pathway: FIB-4/transient elastography, Child-Pugh/MELD referral thresholds, HCC 6-monthly surveillance, oesophageal varices/ascites/hepatic encephalopathy/SBP management detail, analgesia principles (paracetamol max 2g/day, avoid NSAIDs, opioid caution). Used to fully rewrite liver-cirrhosis-and-failure.md. evidence/gastroenterology/_shared/HNE-Cirrhosis.pdf. |
| Clinical Guidelines for Surveillance Colonoscopy | Cancer Council Australia / NHMRC | NHMRC-approved, last substantive update 2018 | First surveillance interval extended to 10 years for 1-2 small tubular adenomas (was 5 years in older Red Book editions); risk-stratified recommendations for higher-risk adenomas. |
| Colorectal Cancer Symptoms (check in browser) | Community HealthPathways Hunter New England | Last updated 21 Feb 2024 | Steve-supplied PDF. Symptomatic-patient triage (category 1/2/3 referral urgency by age+FOBT+symptom combination), faecal calprotectin MBS criteria, causes of rectal bleeding. evidence/gastroenterology/_shared/HNE-Colorectal-Cancer-Symptoms.pdf. |
| Colorectal Polyp Surveillance (check in browser) | Community HealthPathways Hunter New England | Last updated 24 Nov 2022 | Steve-supplied PDF. Detailed surveillance-interval tables by adenoma/serrated-polyp risk category, and the >=75yr/Charlson-score-based recommendation against surveillance colonoscopy in the elderly. evidence/gastroenterology/_shared/HNE-Colorectal-Polyp-Surveillance.pdf. |
| Comparative Efficacy of Advanced Therapies for Moderate-to-Severe Ulcerative Colitis — 2024 AGA Evidence Synthesis | American Gastroenterological Association | 2024 | IBD biologic/small-molecule landscape has expanded substantially since 2020: ustekinumab (IL-12/23 inhibitor) now well-established, risankizumab (IL-23 inhibitor, approved for Crohn disease 2022, UC 2024), and JAK inhibitors upadacitinib/tofacitinib now available for moderate-severe UC/CD, providing options beyond the older infliximab/vedolizumab/adalimumab-only paradigm, particularly after anti-TNF failure. |
| Correcting iron deficiency | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Correcting iron deficiency (Aust Prescr 2016;39:193-9) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Crohn Disease | StatPearls (NCBI Bookshelf) | History/physical by disease location, malabsorption/nutrient-deficiency complications, fistula formation, fecal calprotectin for monitoring activity. Low-yield fallback for paediatrics/paeds-inflammatory-bowel-disease.md, stage E (case-mix topic-match source turned out off-topic). | |
| Deprescribing proton pump inhibitors | RACGP — Australian Journal of General Practice | Evidence supports a patient-centred approach to proton pump inhibitor deprescribing involving stepping down the dose before ceasing or switching to pro re nata use. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-deprescribing-ppi-2022.html. | |
| Deprescribing proton pump inhibitors | AJGP (RACGP), November 2022 | Nov 2022 | Co-authored with GESA/RACGP input. PPI use beyond 8 weeks rarely indicated outside a defined long-term list (Barrett's, Zollinger-Ellison, LA grade C/D oesophagitis, peptic stricture, high-bleed-risk NSAID/aspirin gastroprotection); gradual dose-tapering then PRN is the preferred deprescribing method; rebound acid hypersecretion in 10-50% after abrupt stop often mistaken for symptom relapse. |
| Diagnosis and management of eosinophilic oesophagitis (Perananthan & Burgell, Aust Prescr 2024;47:20-5) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 47, No 1, February 2024 | Peer-reviewed review of adult EoE: AGREE 2017 diagnostic criteria (>=15 eosinophils/hpf), differentiating from GORD, EREFS endoscopic scoring, step-up vs step-down dietary elimination, swallowed topical corticosteroids (budesonide slurry superseded by orodispersible budesonide tablets, now PBS-listed with specialist-initiation criteria), PPI mechanism/response rates, food bolus impaction management, dilatation for fibrostenotic strictures, and emerging monoclonal antibodies (dupilumab, benralizumab, etrasimod). Local copy at evidence/_sources/austprescr-eosinophilic-oesophagitis-2024.pdf. |
| Diarrhea | StatPearls (NCBI Bookshelf) | current as at fetch | General acute diarrhoea overview (predisposing factors, rehydration, self-limiting course, antibiotic use) for gastroenterology/acute-infectious-diarrhoea-gastroenteritis.md, stage E low-yield fallback. |
| Diverticular Disease of the Colon | StatPearls | ||
| Drug therapy of irritable bowel syndrome | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for gastroenterology/irritable-bowel-syndrome.md. |
| Enteral nutritional therapy for treatment of active Crohn's disease | Cochrane | ||
| Eosinophilic Esophagitis | StatPearls | ||
| Esophageal Cancer (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Esophageal Motility Disorders | StatPearls | ||
| Functional Dyspepsia | StatPearls | ||
| Functional dyspepsia | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Gastric Cancer (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Gastroparesis | StatPearls | ||
| General practitioner perspectives on barriers and enablers to bowel cancer screening | RACGP — Australian Journal of General Practice | When detected early, nine in 10 Australians with bowel cancer can be successfully treated, yet participation in the National Bowel Cancer Screening Program remains low. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-bowel-screening-barriers-2021.html. | |
| GESA clinical practice resources and position statements (check in browser) | Gastroenterological Society of Australia | per-document | URL located via search 2026-07-07 (old /resources/clinical-guidelines-and-updates/ now 404); confirm in browser. |
| Haemorrhoids | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/gastroenterology/haemorrhoids/Haemorrhoids - Therapeutic Guidelines.pdf. | |
| Helicobacter Pylori (H. pylori) (check in browser) | Community HealthPathways Hunter New England | Last updated 5 Nov 2025, citing Therapeutic Guidelines Mar 2025 | Steve-supplied PDF. Confirms the current 14-day (not 7-day) first-line eradication regimen and local specialist-endorsed rationale, current clarithromycin resistance context, and salvage-therapy options. Corroborates the AJGP Oct 2025 'Rise of the resistance' article already reviewed this project. evidence/gastroenterology/_shared/HNE-Helicobacter-Pylori.pdf. |
| Helicobacter pylori: Rise of the resistance | AJGP (RACGP), October 2025 | Oct 2025 | 14-day PPI-triple therapy preferred over 7-day; clarithromycin resistance rising sharply in Australia; rescue regimens (levofloxacin, bismuth, rifabutin) after first-line failure, avoid repeat clarithromycin-based therapy. |
| Hepatic Cirrhosis | StatPearls | ||
| Hepatitis B Virus (HBV) (check in browser) | Community HealthPathways Hunter New England | Last updated 18 Oct 2024, citing GESA Hepatitis B Consensus Statement 2022 | Steve-supplied PDF. Four-phase infection model, current treatment thresholds (HBeAg+/ALT raised OR HBeAg- with viral load >2000IU/mL), entecavir/tenofovir first-line, HBIG/vaccination post-exposure prophylaxis table. Used to fully rewrite the hepatitis B half of viral-hepatitis.md. evidence/gastroenterology/_shared/HNE-Hepatitis-B-Virus.pdf. |
| Hepatitis C Virus (HCV) (check in browser) | Community HealthPathways Hunter New England | Under review as of 2026; last substantive update 19 Jun 2026, citing GESA Consensus Statement 2020 | Steve-supplied PDF. GP-led DAA prescribing pathway (glecaprevir+pibrentasvir 8wks, or sofosbuvir+velpatasvir 12wks), pre-treatment work-up, SVR confirmation at 12 weeks. Used to fully rewrite the hepatitis C half of viral-hepatitis.md. evidence/gastroenterology/_shared/HNE-Hepatitis-C-Virus.pdf. |
| Hyperbilirubinemia (Jaundice) | StatPearls | ||
| Hypertriglyceridaemia A practical approach for primary care | RACGP — Australian Journal of General Practice | The aim of this paper is to provide a contemporary approach to the management of patients with hypertriglyceridaemia in Australian primary care. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-hypertriglyceridaemia-2025.html. | |
| Hypertriglyceridaemia: A practical approach for primary care | RACGP (AJGP) | AJGP 54(11), November 2025 | Severe hypertriglyceridaemia (>=5.6 mmol/L) as a pancreatitis-prevention target, distinct from mild-moderate (1.7-5.6 mmol/L) CVD-risk target. Local copy: evidence/gastroenterology/_ajgp/ |
| Identification and surgical management of acute severe ulcerative colitis | RACGP — Australian Journal of General Practice | This review provides GPs with an understanding of acute severe ulcerative colitis evaluation and risk assessment, emphasising surgical management and complementing existing medical methods. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-acute-severe-uc-2024.html. | |
| Identification and surgical management of acute severe ulcerative colitis | RACGP (AJGP) | AJGP 53(4), April 2024 | Truelove & Witts criteria, day 3-5 steroid-response checkpoint before rescue therapy, Travis criteria for surgery prediction, 8-fold VTE risk, antibiotics don't improve outcomes outside severe sepsis. Local copy: evidence/gastroenterology/_ajgp/ |
| Inflammatory Bowel Disease (IBD) (check in browser) | Community HealthPathways Hunter New England | Last updated 6 Oct 2023, citing BSG 2019 consensus guideline | Steve-supplied PDF. IBS-vs-IBD differential features, severely-unwell/moderately-unwell triage criteria, faecal calprotectin MBS criteria, contraception/pregnancy nuances (COCP absorption in small-bowel Crohn's, DMPA/bone density). Added as new sections to inflammatory-bowel-disease.md alongside its existing eTG-derived dosing detail. evidence/gastroenterology/_shared/HNE-Inflammatory-Bowel-Disease.pdf. |
| Inflammatory bowel disease: Crohn's and ulcerative colitis (The Curbsiders #138) | The Curbsiders Internal Medicine Podcast | Named by hand from the document's own opening text. Local copy at evidence/gastroenterology/inflammatory-bowel-disease/curbsiders-138-ibd-handout.pdf. | |
| Internal Hemorrhoid | StatPearls (NCBI Bookshelf) | ||
| Interpreting tests for coeliac disease: Tips, pitfalls and updates (AJGP 2018;47(1-2)) | RACGP (Australian Journal of General Practice) | ||
| Intestinal Obstruction (MSD Manual Professional Edition) | MSD Manual Professional Edition | ||
| Intraductal papillary mucinous neoplasm | RACGP — Australian Journal of General Practice | This review focuses on the epidemiology, natural history, risk factors, diagnosis and management of intraductal papillary mucinous neoplasm of the pancreas. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-ipmn-2024.html. | |
| Intraductal papillary mucinous neoplasm: Overview of management | RACGP (AJGP) | AJGP 53(11), November 2024 | Premalignant pancreatic cystic lesion, increasingly incidental on imaging; main-duct/mixed vs branch-duct subtypes have different malignancy risk (~2-2.7%/year overall). Local copy: evidence/gastroenterology/_ajgp/ |
| Iron-Deficiency Anemia | StatPearls | ||
| Irritable Bowel Syndrome | StatPearls | ||
| Irritable Bowel Syndrome (IBS) (check in browser) | Community HealthPathways Hunter New England | Last updated 6 Oct 2023 | Steve-supplied PDF. Still cites Rome IV (not yet updated for Rome V, May 2026) but detailed on investigations-not-recommended, diet/FODMAP, and stepped symptom-targeted pharmacotherapy. Used with the Rome V update (see rome-v-2026 registry entry) to rewrite irritable-bowel-syndrome.md. evidence/gastroenterology/_shared/HNE-Irritable-Bowel-Syndrome.pdf. |
| Irritable bowel syndrome diagnosis | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for gastroenterology/irritable-bowel-syndrome.md. |
| Lactose Intolerance | StatPearls | ||
| Large Bowel Obstruction (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Management of constipation in people receiving palliative care | RACGP — Australian Journal of General Practice | This article provides an overview of the assessment and management of constipation in patients receiving palliative care. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-constipation-palliative-2025.html. | |
| Managing constipation in adults (Australian Prescriber) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Managing constipation in children (Australian Prescriber) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Median arcuate ligament syndrome | RACGP — Australian Journal of General Practice | The aim of this article is to provide GPs with a review of the current literature, summarise a diagnostic pathway and propose a treatment algorithm for median arcuate ligament syndrome. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-median-arcuate-ligament-2024.html. | |
| Median arcuate ligament syndrome | RACGP (AJGP) | AJGP 53(12) supplement, December 2024 | Coeliac axis extrinsic compression by the diaphragmatic crus; ~25% radiological prevalence, ~1% symptomatic; diagnosis of exclusion, mostly young women. Local copy: evidence/gastroenterology/_ajgp/ |
| Multisociety Delphi consensus statement on new fatty liver disease nomenclature (NAFLD to MASLD, NASH to MASH) | AASLD/EASL/ALEH | June 2023 | Global nomenclature change: NAFLD renamed MASLD (metabolic dysfunction-associated steatotic liver disease), NASH renamed MASH. New MASLD diagnosis requires hepatic steatosis plus at least one of five cardiometabolic risk factors. New MetALD category added for those with MASLD who also consume significant alcohol. Adopted by ~100 societies worldwide including AASLD, EASL, ALEH. |
| National Bowel Cancer Screening Program — lowered eligible age | Australian Government Department of Health, Disability and Ageing | From 1 July 2024 | NBCSP eligible screening age lowered from 50 to 45 from 1 July 2024, following updated colorectal cancer clinical guidelines recommending population screening from age 45. People 45-49 can request their first free iFOBT kit; those 50-74 continue to receive kits automatically every 2 years. |
| Nausea and Vomiting (MSD Manual Professional Edition) | MSD Manual Professional Edition | ||
| Non surgical therapy for anal fissure | Cochrane | Cochrane plain-language summary (Nelson R, 2003 review): topical GTN modestly more effective than placebo for healing chronic anal fissure but with frequent late recurrence and headache; botulinum toxin/topical calcium-channel blockers similarly effective with fewer side effects. Used for the common-presentations/pr-bleeding.md stage-F rewrite (2026-08-24). | |
| Non-anaemic iron deficiency | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Noncardiac chest pain | RACGP — Australian Journal of General Practice | Noncardiac chest pain is a cause of significant morbidity and can be responsible for a high personal cost and healthcare burden. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-noncardiac-chest-pain-2022.html. | |
| Oral and oropharyngeal infection caused by Candida and related species | Therapeutic Guidelines Ltd (eTG complete) | Local copy: evidence/gastroenterology/oral-candidiasis/. Also cited from dermatology/candidiasis.md's oral thrush section, 2026-08-16. | |
| Oral supplements and iron deficiency | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Overview of Inflammatory Bowel Disease | MSD Manual Professional Edition | Differentiating Crohn disease vs ulcerative colitis table (rectal bleeding pattern, fistula presence, perianal disease), paediatric malabsorption/growth-retardation complication. Low-yield fallback for paediatrics/paeds-inflammatory-bowel-disease.md, stage E. | |
| Pancreatic Cancer | StatPearls (NCBI Bookshelf) | current as at fetch | Epidemiology, risk factors, presentation (Courvoisier's sign, Trousseau syndrome, Virchow's node), diagnosis and management of pancreatic adenocarcinoma for gastroenterology/pancreatic-cancer.md's carcinoma-of-the-head-of-the-pancreas section, stage E low-yield fallback (no dedicated pancreatic-cancer source was previously cached -- ajgp-ipmn-2024 only covers IPMN). |
| Past Colorectal Cancer Surveillance (check in browser) | Community HealthPathways Hunter New England | Last updated 30 Nov 2022 | Steve-supplied PDF. Post-resection colonoscopy schedule (1, 6, 11 years). evidence/gastroenterology/_shared/HNE-Past-Colorectal-Cancer-Surveillance.pdf. |
| Perinatal management of inflammatory bowel disease | RACGP — Australian Journal of General Practice | Inflammatory bowel disease, comprising ulcerative colitis and Crohn's disease, commonly affects individuals of childbearing age. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-perinatal-ibd-2022.html. | |
| Pilonidal disease practice points: An update | AJGP (RACGP) | ||
| Primary Biliary Cholangitis | StatPearls (NCBI Bookshelf) | current as at fetch | PBC definition, epidemiology, autoimmune associations, LFT/autoantibody pattern, imaging, biopsy findings for gastroenterology/primary-biliary-cirrhosis-cholangitis.md (low-yield fallback — the only dedicated cite is a paywalled Springer abstract-only page). |
| Primary Sclerosing Cholangitis | StatPearls | ||
| Ranitidine safety alert and market status | Therapeutic Goods Administration (TGA) | 2019-2024 (withdrawal and re-approval) | Ranitidine suspended from Australian market 2019-2020 due to NDMA contamination; reformulated product re-approved October 2024. Famotidine was the standard H2-blocker alternative during the intervening years. |
| Recommendations for the assessment of metabolic dysfunction-associated fatty liver disease (MAFLD) in primary care — recommendations summary | Gastroenterological Society of Australia (GESA) | Named by hand from the document's own opening text. Local copy at evidence/gastroenterology/fatty-liver-nash/gesa-mafld-recommendations-summary.pdf. | |
| Recommendations for the assessment of metabolic dysfunction-associated fatty liver disease (MAFLD) in primary care: a consensus statement | Gastroenterological Society of Australia (GESA) | 2024 (21 recommendations first presented Sept 2023) | Australian primary-care consensus statement deliberately retaining the term MAFLD (metabolic dysfunction-associated fatty liver disease) rather than adopting the internationally proposed MASLD, because MAFLD's positive diagnostic criteria (steatosis + overweight/obesity, T2DM, or 2+ metabolic risk factors) allow for coexisting alcohol/other liver disease aetiologies common in undifferentiated primary-care presentations, whereas MASLD requires their exclusion. Central recommendation: FIB-4 as first-line non-invasive fibrosis test (<1.3 low risk, 1.3-2.7 indeterminate -> elastography/direct serum test, >2.7 refer), with comorbidity screening (obesity, T2DM, CVD risk, OSA, CKD) and monitoring intervals (repeat FIB-4 3-yearly if low risk; annual weight/BMI/waist circumference). Companion 1-page GESA documents: 'Recommendations Summary' and 'Assessment Algorithm for a Patient Presenting with MAFLD' (the algorithm diagram is embedded in the fatty liver disease page on this site). |
| Rectal Bleeding | StatPearls | ||
| Rome V international diagnostic criteria for disorders of gut-brain interaction | Rome Foundation / Gastroenterology, May 2026 | May 2026 | Replaces Rome IV (2016). For IBS: minimum symptom frequency reduced back to 3 days/month; terminology shifted from 'disorders of gut-brain interaction' to simply 'bowel disorders'. Confirmed independently via Lancet Gastroenterology & Hepatology validation study and Australian Prescriber 2026 (Morrison & Talley). |
| SAGES Guidelines for Peroral Endoscopic Myotomy (POEM) for Achalasia (2024 update) | Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) | 2024 update (first published 2021) | POEM (peroral endoscopic myotomy) is now an established, guideline-supported alternative to laparoscopic Heller myotomy and pneumatic dilation for achalasia, with comparable efficacy/safety and favoured specifically for achalasia subtype III. Not mentioned in the original note, which only lists myotomy, balloon dilation, and botulinum toxin. |
| Second-line therapies in primary biliary cholangitis (elafibranor, seladelpar, obeticholic acid) | FDA / Hepatology International review | 2024-2025 | UDCA remains first-line for PBC. For inadequate UDCA response, elafibranor (Iqirvo, PPAR-alpha/delta agonist) and seladelpar (Livdelzi, PPAR-delta agonist) received FDA accelerated approval in 2024 as new second-line options. Obeticholic acid (approved 2016 as second-line) was restricted in 2018 (boxed warning, contraindicated in cirrhosis/portal hypertension) and further restricted in late 2024 for hepatotoxicity even without cirrhosis, leading to voluntary market withdrawal by the manufacturer in September 2025. |
| SHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection | Infectious Diseases Society of America / SHEA | 2021 | Metronidazole is no longer recommended as first-line therapy for C. difficile infection of any severity — vancomycin (oral) or fidaxomicin are now preferred, with fidaxomicin preferred over vancomycin for both initial and recurrent episodes due to lower recurrence rates. This supersedes older guidance recommending metronidazole for mild-moderate disease. |
| Singultus (Hiccups) | StatPearls | ||
| Small Bowel Obstruction (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Testing for cirrhosis | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for gastroenterology/liver-cirrhosis-and-failure.md. |
| Testing for coeliac disease (Lewis, Haridy, Newnham, Aust Prescr 2017;40:105-8) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 40, No 3, June 2017 | Serological testing pathway (tTG-IgA first line, IgA deficiency caveat), genotype testing, endoscopy/biopsy gold standard, and ESPGHAN paediatric no-biopsy pathway (tTG >10x ULN) discussion. Low-yield fallback for paediatrics/coeliac-disease.md, stage E (case-mix topic-match source turned out off-topic). |
| The alarming rise of early-onset colorectal cancer | AJGP (RACGP), June 2025 | Jun 2025 | NBCSP age lowered to 45 (July 2024); evidence supports further reduction to 40; hereditary syndromes account for 35% of EOCRC vs 10% of CRC overall - refer <35yo EOCRC for genetic screening; low-dose aspirin chemoprevention (100-300mg/day, >=2.5yrs, age 50-70). |
| The lived experience of irritable bowel syndrome | RACGP — Australian Journal of General Practice | Patients have described a preference for dietary modifications over medications for management of symptoms, reporting that they felt this was a more holistic approach. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-ibs-lived-experience-2022.html. | |
| The management of gastro-oesophageal reflux disease | Australian Prescriber | ||
| There's blood in my underwear | AJGP (RACGP) | AJGP 48(3), March 2019 | AJGP case-based review of rectal bleeding assessment in general practice: differential by history pattern, red flags for colorectal cancer, when to refer/investigate. Used for the common-presentations/pr-bleeding.md stage-F rewrite (2026-08-24). |
| Treating chronic hepatitis C in general practice | RACGP (AJGP) | Named by hand from the document's own opening text. Local copy at evidence/gastroenterology/_ajgp/ajgp-hepatitis-c-2021.html. | |
| Treatment of irritable bowel syndrome | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for gastroenterology/irritable-bowel-syndrome.md. |
| Ulcerative Colitis | StatPearls (NCBI Bookshelf) | Main symptom bloody diarrhoea plus urgency/tenesmus, fecal calprotectin utility in diagnosis/ruling out IBD. Low-yield fallback for paediatrics/paeds-inflammatory-bowel-disease.md, stage E. | |
| Updates in fatty liver disease | RACGP — Australian Journal of General Practice | In 2020, Australian researchers led the development of an international consensus to rename and more precisely and positively define fatty liver disease associated with metabolic dysregulation. Catalogued from the local copy at evidence/gastroenterology/_ajgp/ajgp-fatty-liver-updates-2021.html. | |
| Upper Gastrointestinal Bleeding | StatPearls | ||
| Viral Gastroenteritis | StatPearls (NCBI Bookshelf) | current as at fetch | Viral gastroenteritis history features (close-contact clustering, onset, self-limiting course) for gastroenterology/acute-infectious-diarrhoea-gastroenteritis.md, stage E low-yield fallback. |
| Whipple Disease | StatPearls |
General Medicine
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| Aboriginal and Torres Strait Islander Peoples Health Assessment (Item 715) | Medicare Benefits Schedule (Australian Government Department of Health) | Item 715 descriptor and AN.0.43 explanatory notes: health assessment for Aboriginal or Torres Strait Islander patients, once per 9 months, fee $254.10. | |
| About the drug interactions content | Australian Medicines Handbook (AMH) | Catalogued from the local copy at evidence/general-medicine/_shared/About the drug interactions content - Australian Medicines Handbook.pdf. | |
| After vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Aged Care Clinical Guide (Silver Book), Part A: Falls | RACGP | ||
| An update on wound management (Aust Prescr 2023;46:29-35) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Approach to managing acute behavioural disturbance | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Approach to the Agitated Patient | EM:RAP CorePendium | Supplied by Steve 2026-08-31. | |
| Assessing Fitness to Drive for commercial and private vehicle drivers 2022 | Austroads / National Transport Commission | Supplied by Steve 2026-08-31. Australian national medical standards for private and commercial driver licensing. | |
| Australian Immunisation Handbook — Pertussis (whooping cough) | Australian Government Department of Health, Disability and Ageing | current (living document) | Childhood NIP schedule: 2, 4, 6, 18 months + 4yrs + 11-13yr booster. Pregnancy vaccination recommended 20-32 weeks gestation (not 28-32). |
| Australian Immunisation Handbook — Tetanus | Australian Technical Advisory Group on Immunisation (ATAGI) | Carries the tetanus-prone wound prophylaxis table. | |
| BreastScreen Australia Position Statement on Mammographic (Breast) Density and Screening | BreastScreen Australia Clinical Advisory Group / Australian Government Department of Health, Disability and Ageing | Version 2.0, advice dated 6 November 2024 (review November 2029) | National policy for BreastScreen Australia services. Key positions: women ARE to be informed in writing of their mammographic density measured on their screening mammogram (this supersedes the older 'Australia has no national density-notification policy' framing); mammography benefits women of all densities; BI-RADS a/b/c/d definitions, with c+d = 'dense breasts' and d = 'extremely dense'. Prevalence: ~33% of women 50-74 are BI-RADS c or d, ~10% are d (~25% of women under 50 are d). Program sensitivity ~90% (BI-RADS a/b), 84% (c), 64% (d). Relative risk vs BI-RADS b: category a ~half, c 1.6-fold, d 2.6-fold. Recommends a validated risk tool (iPrevent, Tyrer-Cuzick or CanRisk) to frame screening/prevention discussions. Confirms there is still NO consensus on the optimal supplemental screening test, and no RCT showing supplemental screening saves lives in asymptomatic average-risk women, though the DENSE trial showed MRI detects more cancers in extremely dense breasts. Supplemental screening sits outside the BreastScreen program (GP referral to public/private imaging), raising equity-of-access concerns. Local copy: evidence/womens-health/breast-cancer-and-screening/ (supplied by Steve 2026-07-29). |
| Bupivacaine | Australian Medicines Handbook | Supplied by Steve 2026-08-31. | |
| Catch-up vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Changes to the regulation of vapes | Therapeutic Goods Administration (TGA) | 2024 reforms | Three reform dates: 1 Jan 2024 disposable/single-use vape import ban; 1 Jul 2024 Vaping Reforms Act commenced (pharmacy-only supply nationally, normal prescription arrangements replacing the special-access-scheme pathway); 1 Oct 2024 vapes <=20mg/mL nicotine available from a pharmacist without a prescription for patients 18+, pharmacist-assessed. |
| Deprescribing in older people | Australian Prescriber | ||
| Drugs that may increase the risk of seizures | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/neurology/_shared/Drugs that may increase the risk of seizures - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Employment law: A guidance note for general practitioners on providing patient information to employers | RACGP — Australian Family Physician, August 2017 | ||
| Exercise for preventing falls in older people living in the community | Cochrane | ||
| Falls Prevention Guidelines for Community Care | Australian Commission on Safety and Quality in Health Care (ACSQHC) | ||
| Guidelines for preventive activities in general practice Red Book 10th edition | RACGP | Supplied by Steve 2026-08-31. Full Red Book; supersedes the 4.3k-word racgp-red-book fragment for age-band preventive activity tables. | |
| Incision and Drainage | StatPearls (NCBI Bookshelf) | ||
| Lidocaine anaesthesia | Australian Medicines Handbook | Supplied by Steve 2026-08-31. Maximum-dose data for the local anaesthesia page. | |
| Lidocaine with adrenaline epinephrine | Australian Medicines Handbook | Supplied by Steve 2026-08-31. | |
| Local anaesthetics | Australian Medicines Handbook | Supplied by Steve 2026-08-31. AMH topic PDF - quotable, and its dosing needs no separate cross-check. | |
| Management of polypharmacy: can we safely discontinue medications? | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for general-medicine/common-clinical-conditions-in-aged-care.md. |
| Medical certificates: More than just paperwork | RACGP — Australian Journal of General Practice, November 2024 supplement | ||
| Medication management on sick days (Lea-Henry et al, Aust Prescr 2017;40:168-73) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 40, No 5, October 2017 | Sick-day medication adjustment principles: withhold ACE inhibitors/ARBs/diuretics/NSAIDs/metformin/SGLT2i during hypovolaemia risk (acute illness with vomiting/diarrhoea/poor intake); insulin and corticosteroid doses often need temporary increase, not withholding; SADMANS mnemonic origin article. |
| National Immunisation Program Schedule PDF | Australian Department of Health, Disability and Ageing | Supplied by Steve 2026-08-31. health.gov.au blocks automated fetch. | |
| NSW Immunisation Schedule | NSW Health | Supplied by Steve 2026-08-31. | |
| Pharmacological management for acute behavioural disturbance in older people | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Pregabalin and gabapentin safety alert | Therapeutic Goods Administration (TGA) | 2021 boxed warning update | TGA added boxed warnings for misuse/abuse/dependence to pregabalin PI in 2021 following rising deaths/ambulance attendances; several states added gabapentinoids to real-time monitoring (e.g. Victoria SafeScript, 2023). |
| Preparing for vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| RACGP Aged Care Clinical Guide (Silver Book) — Part A: Common clinical conditions in aged care | RACGP | ||
| Ropivacaine | Australian Medicines Handbook | Supplied by Steve 2026-08-31. | |
| Sepsis Clinical Care Standard | Australian Commission on Safety and Quality in Health Care | ||
| Skin Lacerations — MSD Manual Professional Edition | MSD Manual Professional Edition | ||
| Supporting smoking cessation: A guide for health professionals | RACGP | 2nd edition 2021, living updates (evidence PDF last updated 22 May 2024; incl. vaping/nicotine) | Current RACGP smoking (and vaping) cessation guide. Brief advice to all who smoke; first-line pharmacotherapy is varenicline or combination NRT (each ~triples quit odds); Quitline referral. Updated for the TGA prescription-vape framework. Applies to: smoking-cessation. |
| The anticholinergic burden: from research to practice | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Time-Tiered Health Assessments (Items 701, 703, 705, 707, 224, 225, 226, 227) | Medicare Benefits Schedule (Australian Government Department of Health) | Item descriptors + explanatory notes AN.0.36-AN.0.42: brief/standard/long/prolonged health assessment fee tiers, 45-49yr at-risk assessment, 40-49yr Type 2 Diabetes Risk Evaluation, 75+ Older Persons Health Assessment, RACF comprehensive medical assessment, intellectual disability assessment, refugee/humanitarian entrant assessment. | |
| Vaccination for Aboriginal and Torres Strait Islander people | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vaccination for people at occupational risk | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vaccination for people who are immunocompromised | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Wound Closure Techniques | StatPearls |
Haematology
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| Actinic Purpura (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Acute Lymphoblastic Leukemia (ALL) | MSD Manual Professional Edition | ||
| Acute Lymphocytic Leukemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Acute Myeloid Leukemia (AML) | MSD Manual Professional Edition | ||
| Acute Myeloid Leukemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Andexxa (andexanet alfa) provisional registration history | Therapeutic Goods Administration (TGA) | Provisionally approved July 2023; lapsed May 2026 | Andexanet alfa (factor Xa inhibitor reversal agent) was provisionally TGA-approved 2023 then lapsed 2026 pending confirmatory RCT data; not currently routinely available in Australia. |
| Anemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Anemia of Chronic Disease | MSD Manual Professional Edition | ||
| Anemia of Chronic Disease (MSD Manual Professional Edition) | MSD Manual Professional Edition | ||
| Anticoagulant Therapy in Pregnancy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Anticoagulation Safety (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Aplastic Anemia | MSD Manual Professional Edition | ||
| Aplastic Anemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Appropriate use of tests for folate and vitamin B12 deficiency (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Beta Thalassemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Bleeding Disorders | StatPearls (NCBI Bookshelf) | General approach to the patient with a bleeding disorder: history/exam features distinguishing platelet-type from coagulation-factor-type bleeding, first-line investigations. Used for the common-presentations/bruising-bleeding.md and purpuric-rash.md stage-F rewrite (2026-08-24). | |
| Bleeding Disorders (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Blood Products | MSD Manual Professional Edition | ||
| Bone Marrow Failure (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Cancer Council clinical practice guidelines and Optimal Care Pathways | Cancer Council Australia | per-guideline wiki | |
| Chronic Anemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Chronic leukaemias in the community | Australian Prescriber | GP-facing overview of CLL and CML: presentation, monitoring, TKI/BTK-inhibitor era management, shared care. | |
| Chronic Lymphocytic Leukemia (CLL) | MSD Manual Professional Edition | ||
| Chronic Lymphocytic Leukemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Chronic Myelogenous Leukemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Chronic Myeloid Leukemia (CML) | MSD Manual Professional Edition | ||
| Disseminated Intravascular Coagulation (DIC) | MSD Manual Professional Edition | ||
| Disseminated Intravascular Coagulation (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Essential Thrombocythemia | MSD Manual Professional Edition | ||
| Evaluation of Anemia (MSD Manual Professional Edition) | MSD Manual Professional Edition | ||
| eviQ cancer treatment protocols | Cancer Institute NSW | living protocols | |
| Excessive Bleeding | MSD Manual Professional Edition | ||
| FDA approval of Casgevy and Lyfgenia gene therapies for sickle cell disease | US Food and Drug Administration (FDA) | December 2023 | First gene therapies (CRISPR-based Casgevy and lentiviral Lyfgenia) approved for sickle cell disease, offering a curative option alongside allogeneic HSCT for patients 12+. |
| Ferric carboxymaltose: A practical guide on the administration of iron infusions in general practice | RACGP (AJGP) | AJGP 54(5), May 2025 | GP-led FCM (Ferinject) iron infusion practical guide - PBS-listed 2014, favoured in community settings; hypophosphataemia (serum phosphate <0.65 mmol/L) is the most common side effect, especially with repeated dosing within 6 months, usually asymptomatic but can persist 80-180 days. Local copy: evidence/haematology/_ajgp/ |
| Glanzmann Thrombasthenia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Hemolytic Anemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Hemophilia | MSD Manual Professional Edition | ||
| Hemophilia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Hemorrhagic Shock (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Hodgkin Lymphoma | MSD Manual Professional Edition | ||
| Hodgkin Lymphoma (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| IgA Vasculitis (Henoch-Schonlein Purpura) (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Immune Thrombocytopenia (ITP) | MSD Manual Professional Edition | ||
| Immune Thrombocytopenia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Interpretation of biochemical tests for iron deficiency: diagnostic difficulties related to limitations of individual tests (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Iron-Deficiency Anemia | StatPearls | ||
| Laboratory Evaluation of Acute Leukemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Laboratory Evaluation of Coagulopathies (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Laboratory Evaluation of Immune Hemolytic Anemias (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Leukemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Leukocytosis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Long-term prescribing of new oral anticoagulants | NPS MedicineWise / Australian Prescriber | ||
| Lymphocytopenia | MSD Manual Professional Edition | ||
| Lymphocytosis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Lymphoma (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Massive Transfusion (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Monoclonal Gammopathy of Undetermined Significance (MGUS) | MSD Manual Professional Edition | ||
| Monoclonal Gammopathy of Undetermined Significance (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Multiple Myeloma | MSD Manual Professional Edition | ||
| Multiple Myeloma (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Myelodysplastic Syndrome (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Myelodysplastic Syndromes (MDS) | MSD Manual Professional Edition | ||
| Myeloproliferative neoplasms: Classifications and an approach to diagnosis | RACGP (AJGP) | AJGP 50(9), September 2021 | GP-focused approach to classifying and diagnosing MPNs (CML, PV, ET, primary myelofibrosis). Local copy: evidence/haematology/_ajgp/ |
| Neutropenia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Neutrophilia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Non-Hodgkin Lymphoma (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Non-Hodgkin Lymphomas | MSD Manual Professional Edition | ||
| Normal and Abnormal Complete Blood Count With Differential (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Optimal care pathway for adults with acute lymphoblastic leukaemia (1st edn, June 2023) | Cancer Council Australia / Leukaemia Foundation | ||
| Optimal care pathway for people with acute myeloid leukaemia (2nd edn, June 2021) | Cancer Council Australia / Leukaemia Foundation | ||
| Optimal care pathway for people with chronic lymphocytic leukaemia (1st edn, October 2021) | Cancer Council Australia / Leukaemia Foundation | ||
| Optimal care pathway for people with low-grade lymphomas (1st edn, October 2021) | Cancer Council Australia / Leukaemia Foundation | ||
| Optimal care pathway for people with multiple myeloma (1st edn, October 2021) | Cancer Council Australia / Leukaemia Foundation | ||
| Optimal care pathway for people with myeloproliferative neoplasms (1st edn, June 2023) | Cancer Council Australia / Leukaemia Foundation | ||
| Overview of Coagulation Disorders | MSD Manual Professional Edition | ||
| Overview of Hemolytic Anemia | MSD Manual Professional Edition | ||
| Overview of Leukemia | MSD Manual Professional Edition | ||
| Overview of Lymphomas | MSD Manual Professional Edition | ||
| Overview of Myeloproliferative Neoplasms | MSD Manual Professional Edition | ||
| Overview of Platelet Disorders | MSD Manual Professional Edition | ||
| Pernicious Anemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Physiology, Platelet (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Plasma Cell Cancer (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Polycythemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Polycythemia Vera | MSD Manual Professional Edition | ||
| Primary Myelofibrosis | MSD Manual Professional Edition | ||
| Prothrombin Complex Concentrate (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Purpura | DermNet NZ | ||
| Purpura Fulminans (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Screening for thalassaemia (Aust Prescr 2002;25:120-3) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Secondary Erythrocytosis | MSD Manual Professional Edition | ||
| Secondary Polycythemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Secondary Thrombocytosis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Sickle Cell Anemia | StatPearls (NCBI Bookshelf) | current as at fetch | Pathophysiology, clinical features, crisis types, diagnosis and management detail for haematology/sickle-cell-anaemia.md, whose only dedicated cited source (fda-sca-gene-therapy-2023) covers gene therapy approval only, not the underlying condition. |
| Sickle Cell Disease | MSD Manual Professional Edition | current as at fetch | Pathophysiology, clinical features, crisis types, diagnosis and management detail for haematology/sickle-cell-anaemia.md, whose only dedicated cited source (fda-sca-gene-therapy-2023) covers gene therapy approval only, not the underlying condition. |
| Tests of haemostasis: detection of the patient at risk of bleeding | Australian Prescriber | Australian Prescriber review of first-line haemostasis tests (FBC/platelets, PT/APTT, fibrinogen) and how to interpret an abnormal result when a patient presents with bruising/bleeding. Used for the common-presentations/bruising-bleeding.md and purpuric-rash.md stage-F rewrite (2026-08-24). | |
| Thalassemia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Thalassemias | MSD Manual Professional Edition | ||
| Thalassemias | MSD Manual Professional Edition | ||
| THANZ venous thromboembolism diagnosis and management guidelines | Thrombosis and Haemostasis Society of Australia and New Zealand | 2019 (current) | Added Phase 4 (2026-07-08) for thrombophilia testing recommendations post-VTE. Also covers full VTE diagnosis/treatment: Wells/Geneva clinical prediction rules + D-dimer to guide imaging; duplex ultrasound first-line for DVT, CTPA/VQ for PE; DOACs (apixaban/rivaroxaban preferred, no parenteral lead-in needed) equally effective as warfarin and favoured for most patients; anticoagulate proximal DVT/PE >=3 months, distal DVT 6-12 weeks; extended anticoagulation decision for unprovoked/non-surgical-transient VTE weighs recurrence risk vs bleeding risk (low-dose apixaban 2.5mg bd or rivaroxaban 10mg daily equally effective as full dose beyond 6 months); routine thrombophilia testing not recommended except antiphospholipid screen if unprovoked VTE under 45; age-appropriate malignancy screening (not routine CT abdo/pelvis) after unprovoked VTE, ~10% diagnosed with cancer in the following year. |
| The diagnosis and management of venous thromboembolism: guidelines of the Thrombosis and Haemostasis Society of Australia and New Zealand | Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) | Named by hand from the document's own opening text. Local copy at evidence/cardiology/dvt-ix/thanz-vte-guidelines-2019.pdf. | |
| Thrombocytopenia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Thrombocytopenia: Other Causes | MSD Manual Professional Edition | ||
| Thrombotic Thrombocytopenic Purpura (TTP) | MSD Manual Professional Edition | ||
| Thrombotic Thrombocytopenic Purpura Evaluation and Management (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Treatments for long-lasting and painful erection of the penis in boys and men with sickle cell disease | Cochrane | ||
| Vaccination for people who are immunocompromised | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vitamin B12 (Cobalamin) (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Vitamin B12 Deficiency | MSD Manual Professional Edition | ||
| Von Willebrand Disease | MSD Manual Professional Edition | ||
| Von Willebrand Disease (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Warfarin Toxicity (StatPearls) | StatPearls (NCBI Bookshelf) |
Infectious Diseases
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| ACI eligibility for COVID-19 antiviral medication | NSW Agency for Clinical Innovation (ACI) | Named by hand from the document's own opening text. Local copy at evidence/infectious-diseases/_shared/covid/ACI eligibility for antiviral medication.docx. | |
| After vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Alphaviruses (Togaviridae) and Flaviviruses (Flaviviridae) — Medical Microbiology, 4th edition | Medical Microbiology (Baron S, ed.), 4th edition — NCBI Bookshelf | No dedicated StatPearls/MSD article exists for Ross River virus or Barmah Forest virus specifically; this alphavirus-family chapter names Ross River virus repeatedly with matching clinical-manifestation, differential-diagnosis and epidemiology detail — used for infectious-diseases/ross-river-fever-barmah-forest, stage E low-yield fallback. | |
| Amebiasis | StatPearls | ||
| Animal Bites | StatPearls (NCBI Bookshelf) | current as at fetch | Epidemiology, wound care and antibiotic-prophylaxis risk factors for infectious-diseases/bites-clenched-fist-injuries.md, stage E low-yield fallback -- the page cited only ajgp-injuries-in-travellers-2025, which turned out to cover road/water/falls injuries only, with zero bite content. |
| Antibiotic prescribing in primary care: Therapeutic Guidelines summary table 2025 | Therapeutic Guidelines Ltd | Named by hand from the document's own opening text. Local copy at evidence/TG2025 Antibiotic-Summary-table.pdf. | |
| Antibiotics for adults and children with sore throats | Cochrane | ||
| Assessing fever in the returned traveller (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | Fever-in-returned-traveller assessment: exposure-history table (mosquito/tick/fly/flea bites etc mapped to likely diagnoses), physical-finding table, and an Australian public-health-response section listing Australia's eight quarantinable diseases (cholera, H5N1 avian influenza, plague, rabies, SARS, smallpox, viral haemorrhagic fevers, yellow fever) and the 65-disease clinician notification requirement. | |
| ATAGI recommended doses and vaccines (COVID-19) | Australian Technical Advisory Group on Immunisation (ATAGI) | Named by hand from the document's own opening text. Local copy at evidence/infectious-diseases/_shared/covid/atagi-recommended-covid-19-doses-and-vaccines.pdf. | |
| Australian Immunisation Handbook (check in browser) | Australian Government Department of Health | living online handbook | Connection resets on automated fetch (gov bot-blocking); well-known stable URL - confirm in browser. |
| Australian Immunisation Handbook — Rabies and other lyssaviruses | Australian Government Department of Health, Disability and Ageing | current (living document) | Fetched directly (curl, not blocked). 4 pre-exposure prophylaxis schedules, no preferential recommendation between them: 3-visit IM or ID (days 0, 7, 21-28), or 2-visit IM or ID (days 0, 7). 2-visit schedules give only short-term protection and must NOT be used in immunocompromised people; the 2-visit ID schedule additionally must not be used in adults >50y (poor seroconversion). A single IM booster is recommended 1 year after a 2-visit course if further protection is needed, regardless of original route. ID route is off-label, restricted to providers experienced in the technique, and contraindicated with chloroquine/mefloquine/hydroxychloroquine at time of vaccination or within 1 month after. This is more detailed than the 2025 AJGP article's brief 'two-visit (days 0,7)' summary - AJGP didn't mention the 3-visit option, the >50y ID restriction, or the immunocompromise exclusion. |
| Australian Immunisation Handbook — Tetanus | Australian Technical Advisory Group on Immunisation (ATAGI) | Carries the tetanus-prone wound prophylaxis table. | |
| Australian Immunisation Handbook — Yellow fever | Australian Government Department of Health, Disability and Ageing | current (page updated 2025-05-02, per page's own "Updates made" note) | Fetched directly (curl, not blocked). Confirms: single dose recommended for age >=9 months travelling to at-risk areas, ICVP valid for life since 2016-06-16 policy but becomes valid 10 days after vaccination; booster after >=10 years recommended for specific groups (pregnant/HIV-positive at time of 1st dose, extended stay in high-risk location, ongoing outbreak, post-HSCT). Contraindications: anaphylaxis to vaccine/eggs, infants <9 months (routine), severe immunocompromise, any thymus disorder history. Precaution: adults >=60y have higher risk of severe AEs (neurotropic/viscerotropic disease) - vaccinate only if travelling to endemic country, counsel on (very low absolute) risk. Not recommended in pregnancy/breastfeeding <9-month-old infant except unavoidable exposure. YF-AVD (viscerotropic disease) occurs in 3-4 cases per million doses; cites Lindsey et al 2008 Vaccine as the source for age-stratified adverse event reporting rates, corroborating the age-related AE rate table Steve supplied separately. |
| Australian STI Management Guidelines for primary care | ASHM | living online guidelines | Includes a dedicated Populations & Situations > Adult sexual assault page (post-assault STI testing/prophylaxis, HIV PEP, hepatitis B) used in Phase 4 (2026-07-08). |
| Babesiosis | StatPearls | ||
| Brucellosis | StatPearls | ||
| Catch-up vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Cellulitis and erysipelas | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Chagas Disease | StatPearls | ||
| Changes to HPV vaccine dose schedule for young Australians | Australian Government Department of Health, Disability and Ageing (National Immunisation Program) | 2023 | From 6 Feb 2023, routine NIP schedule moved from 2-dose to single-dose Gardasil 9 (9-valent, already replaced the quadrivalent vaccine in 2018) for ages 12-25 (immunocompromised still need 3 doses); catch-up program extended to age 25. |
| Chikungunya Fever | StatPearls | ||
| Chlamydia | Australian STI Management Guidelines (ASHM) | 2023-2024 review | Doxycycline 100mg BD 7 days is first-line for uncomplicated urogenital/pharyngeal and anorectal chlamydia; azithromycin 1g stat is the alternative (poor adherence, partner-matching), except pregnancy where azithromycin 1g stat is preferred. Anorectal + gonorrhoea co-infection: ceftriaxone 500mg IMI stat plus doxycycline. Test of cure only for pregnancy or azithromycin-treated anorectal infection, NAAT no earlier than 4 weeks. Contact tracing back 6 months; presumptive contact treatment if exposure within 2 weeks; patient-delivered partner therapy an option in some jurisdictions. |
| Chlamydia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Cryptosporidiosis | StatPearls | ||
| Cutaneous Larva Migrans (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Debilitating Symptom Complexes Attributed to Ticks (DSCATT) | Australian Government Department of Health | 2018 terminology; National DSCATT Clinical Pathway | No convincing evidence of locally-acquired Lyme borreliosis in Australia (the Ixodes vectors that transmit it in the northern hemisphere do not occur here). DSCATT is the accepted Australian term for the symptom complex; investigate for recognised Australian tick-borne diseases (rickettsioses, Q fever) and avoid unvalidated overseas 'chronic Lyme' testing/treatment. Cite by name. |
| Dengue Fever | StatPearls (NCBI Bookshelf) | updated 2026-03-29 | Low-yield fallback for infectious-diseases/dengue-fever.md, whose only prior dedicated source was the AJGP unwell-returned-traveller article. |
| Ebola Virus Disease | StatPearls | ||
| Ebola Virus Disease (StatPearls) | StatPearls (NCBI Bookshelf) | Covers Ebola virus disease epidemiology, transmission, nonspecific flu-like/GI presentation progressing to bleeding/DIC in a minority, isolation and PPE precautions, and supportive management (no approved antiviral for all species; monoclonal antibodies/vaccine for Zaire ebolavirus). | |
| Echinococcus Granulosus (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Enterobius Vermicularis (Pinworm) | StatPearls | ||
| Enterobius Vermicularis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Fever of Unknown Origin (FUO) | MSD Manual Professional Edition | ||
| Fever of Unknown Origin (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Filariasis | StatPearls | ||
| Giardiasis | StatPearls | ||
| Glanders and Melioidosis | StatPearls | ||
| Gonorrhoea | Australian STI Management Guidelines (ASHM) | Rewrite source for womens-health/gonorrhoea.md, whose Treatment/Diagnosis sections were trapped in garbled OCR image alt-text from the OneNote export (e.g. '500mg' as 'soomg', '1g' as 'Ig'). | |
| Helminthiasis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| HIV and AIDS | StatPearls (NCBI Bookshelf) | updated 2026-01-14 | Pathophysiology, staged natural history, diagnostic work-up and ART management review for infectious-diseases/hiv.md, whose only prior dedicated sources were a PrEP-attitudes survey and a bare ASHM landing page. |
| HIV pre exposure prophylaxis | RACGP — Australian Journal of General Practice | This study provided a timely assessment of general practitioner knowledge and attitudes to prescribing pre-exposure prophylaxis for HIV. Catalogued from the local copy at evidence/infectious-diseases/_ajgp/hiv-prep-2019.html. | |
| HIV pre-exposure prophylaxis | Australian Journal of General Practice (RACGP) | AJGP Vol. 48, No. 10, Oct 2019 | PrEP (tenofovir/emtricitabine) PBS-listed since April 2018; any doctor/NP can prescribe; daily or on-demand (2-1-1) dosing; baseline and 3-monthly HIV/renal/STI monitoring. Local copy: evidence/infectious-diseases/_ajgp/. |
| Human Bites | StatPearls (NCBI Bookshelf) | current as at fetch | Clenched-fist fight-bite injury mechanism, MCP-joint involvement and management for infectious-diseases/bites-clenched-fist-injuries.md, stage E low-yield fallback (same page as statpearls-animal-bites). |
| Human Immunodeficiency Virus (HIV) Infection | MSD Manual Professional Edition | current as at fetch | Cross-check source for infectious-diseases/hiv.md natural history/transmission/diagnosis content alongside statpearls-hiv-aids. |
| Infectious Mononucleosis | MSD Manual Professional Edition | reviewed 2026 | Second stage E low-yield fallback for dermatology/ebv-infectious-mononucleosis-amoxicillin-rash.md, specifically for the spontaneous (non-antibiotic) EBV rash's frequency/character, which statpearls-mononucleosis does not quantify. |
| Injuries in travellers Clinical considerations for general practitioners | RACGP — Australian Journal of General Practice | This article aims to describe common injury categories among travellers; these include road injuries, water (and water safety), selfies, drugs and alcohol, and children and older adults. Catalogued from the local copy at evidence/infectious-diseases/_ajgp/injuries-in-travellers-2025.html. | |
| Injuries in travellers: clinical considerations for GPs | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 10, Oct 2025 (Travel Medicine themed issue) | Travel injuries incl. animal bites and rabies post-exposure prophylaxis, road trauma, envenomation. Local copy: evidence/infectious-diseases/_ajgp/. |
| Japanese encephalitis clinical update | RACGP — Australian Journal of General Practice | This article aims to provide Australian general practitioners with an overview of Japanese encephalitis virus, given its recent expansion, and the potential for sustained endemicity. Catalogued from the local copy at evidence/infectious-diseases/_ajgp/japanese-encephalitis-update-2023.html. | |
| Japanese encephalitis clinical update: changing epidemiology | Australian Journal of General Practice (RACGP) | AJGP Vol. 52, No. 5, May 2023 | JEV detected on mainland Australia (Murray-Darling basin) since 2022 with human cases/deaths; declared a Communicable Disease Incident of National Significance. Mosquito-borne flavivirus; most infections asymptomatic, <1% develop encephalitis but high case-fatality/sequelae. Vaccines (JEspect/Imojev) funded for at-risk residents/occupations. Local copy: evidence/infectious-diseases/_ajgp/. |
| Leishmaniasis | StatPearls | ||
| Leprosy | StatPearls | ||
| Leptospirosis | StatPearls | ||
| Listeria monocytogenes Infection (Listeriosis) | StatPearls | ||
| Lyme Disease | StatPearls (NCBI Bookshelf) | Clinical staging (early localised/early disseminated/late), erythema migrans, treatment in endemic-acquired disease. US-facing source; not used for Australian-context claims (see acdc-tick-bite-diseases for those). | |
| Malaria prevention guideline | Australasian College of Tropical Medicine (ACTM) | 2025 | First Australia/NZ-specific malaria chemoprophylaxis guideline (ACTM also publishes rabies and Japanese encephalitis guidelines). Table: atovaquone-proguanil, doxycycline, mefloquine, tafenoquine — site of activity, dosing interval, start/stop timing relative to travel. Cited by AJGP 2025 (ajgp-preparing-for-travel-2025) as a resource alongside CDC Yellow Book/NaTHNaC/CATMAT. |
| Management of tick bites in Australia (factsheet) | Australian Centre for Disease Control | November 2022 | Added 2026-08-16 for stage-E claim placement on tick-bite.md -- current ASCIA/ACDC first-aid advice on tick removal (freeze in situ with ether-containing spray). Note: this factsheet's community first-aid advice (freeze all adult ticks in situ) differs from the note's forceps-removal-first framing sourced to eTG -- flagged as an Open discrepancy, not used to correct the note. |
| Marine envenomations | RACGP (Australian Family Physician) | AFP 44(1-2), January-February 2015 (reprinted) | Comprehensive Australian review of jellyfish stings (linear/tentacle vs Irukandji-like) and penetrating venomous marine injuries (fish/stingray/urchin/sponge), with RCT-level evidence for hot water immersion in bluebottle stings. Sponge stings were a previously-uncovered topic, folded into penetrating-venomous-marine-injuries.md. Local copy: evidence/travel-toxicology/_ajgp/. Table 2's organism note (Vibrio in marine/Aeromonas in freshwater wounds) also cited by infectious-diseases/bites-clenched-fist-injuries.md's water-immersed-wound antibiotic bullets, stage E 2026-08-16. |
| Mononucleosis | StatPearls (NCBI Bookshelf) | updated 2026 | Clinical features (fever/lymphadenopathy/pharyngitis triad, malaise, splenomegaly, rash including the amoxicillin/ampicillin-associated eruption), aetiology/transmission and management for dermatology/ebv-infectious-mononucleosis-amoxicillin-rash.md, stage E low-yield fallback (the note's cited dermnet-nz source is only the DermNet homepage nav shell, no topic-specific content). |
| Mpox | STI Guidelines Australia (ASHM) | Australian mpox diagnosis, testing, isolation, treatment and vaccination guidance for primary care. | |
| National Immunisation Program Schedule | Australian Government Department of Health, Disability and Ageing | current from June 2026 | Official NIP schedule table (childhood/adolescent/adult/pregnancy/medical-risk-condition schedules). Current schedule gives MMR alone at 18 months (Priorix) and moves varicella to the 4-year dose combined with MMR as MMRV (Priorix-Tetra), alongside the DTaP/IPV booster. |
| National Immunisation Program Schedule PDF | Australian Department of Health, Disability and Ageing | Supplied by Steve 2026-08-31. health.gov.au blocks automated fetch. | |
| Nirmatrelvir and ritonavir PBS item 12996b eligibility criteria | Pharmaceutical Benefits Scheme | Supplied by Steve 2026-08-31. Current PBS eligibility - pbs.gov.au is JS-rendered and cannot be scraped. | |
| Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge | New England Journal of Medicine 2022 | Named by hand from the document's own opening text. Local copy at evidence/infectious-diseases/_shared/covid/nejmoa2204919-paxlovid-isreal-retrospective-cohort.pdf. | |
| NSW Immunisation Schedule | NSW Health | Supplied by Steve 2026-08-31. | |
| Overview of Arbovirus, Arenavirus, and Filovirus Infections | MSD Manual Professional Edition | Diseases table names Ross River virus and Barmah Forest virus (Togaviridae/Alphavirus, mosquito vector, distribution) under the arthralgia+rash+fever/malaise/headache/myalgia syndrome row; used for infectious-diseases/ross-river-fever-barmah-forest, stage E low-yield fallback. | |
| Paired serology for Ross River virus and Barmah Forest virus | AJGP | ||
| Paralysis from tick bites (factsheet) | Australian Centre for Disease Control | November 2022 | Added 2026-08-16 for stage-E claim placement on tick-bite.md -- tick paralysis progression, 48h post-removal observation window, and severe-envenoming ventilation. Note: this factsheet says tick antitoxin 'is available', which appears to conflict with the note's/healthdirect's 'no longer available (ARTG-delisted)' -- flagged as Open, not used to source the antitoxin-availability claim. |
| PBS eligibility for COVID-19 antiviral medication (July 2022) | Pharmaceutical Benefits Scheme | Named by hand from the document's own opening text. Local copy at evidence/infectious-diseases/_shared/covid/PBS eligibility for antiviral medication July 2022.docx. | |
| PEP to Prevent HIV Infection | StatPearls (NCBI Bookshelf) | ||
| Pigs, pooches and pasteurisation: The changing face of brucellosis in Australia | AJGP | ||
| Plague (Yersinia pestis Infection) | StatPearls | ||
| Preexposure Prophylaxis for HIV Prevention | StatPearls (NCBI Bookshelf) | updated 2024-01-28 | Dedicated PrEP article — the note's only prior sources were a GP-attitudes survey (ajgp-hiv-prep-2019, no clinical content) and a bare ASHM landing page (ashm-sti, nav only). |
| Preparing for vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Preparing patients for travel | RACGP — Australian Journal of General Practice | The aim of this article is to show the natural fit of travel medicine within general practice, outline the pre-travel consultation and suggest strategies for improving delivery of travel medicine. Catalogued from the local copy at evidence/infectious-diseases/_ajgp/preparing-patients-for-travel-2025.html. | |
| Preparing patients for travel: a primary care perspective | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 10, Oct 2025 (Travel Medicine themed issue) | Pre-travel consultation framework: risk assessment by itinerary/traveller factors, routine/required/recommended vaccines, malaria chemoprophylaxis, traveller's diarrhoea self-management, bite avoidance. Local copy: evidence/infectious-diseases/_ajgp/. |
| Protecting travellers from vaccine-preventable diseases | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 10, Oct 2025 (Travel Medicine themed issue) | Travel vaccination: routine catch-up, required (yellow fever - ICVP certificate; meningococcal for Hajj), and recommended (hepatitis A/B, typhoid, JE, rabies, cholera) vaccines by destination/risk. Local copy: evidence/infectious-diseases/_ajgp/. 2026-07-31: also source for the Pre-Travel Vaccinations page's Table 2 (commonly available vaccines) and Table 3 (new/emerging/hard-to-source vaccines, incl. chikungunya, dengue, TBE, mpox, TB) recreations, and the incidence-vs-impact figure (Steffen/Chen/Leggat 2023). |
| Q Fever (StatPearls) | StatPearls | ||
| Q fever following a tick bite | RACGP — Australian Journal of General Practice | A man aged 41 years was brought to hospital with fever, sweats, headache, myalgia, arthralgia and increasing confusion of six days' duration. Catalogued from the local copy at evidence/infectious-diseases/_ajgp/q-fever-after-tick-bite-2020.html. | |
| Queensland tick typhus | RACGP — Australian Journal of General Practice | Tick typhus is an infection typically presenting with eschar at bite site, fevers, lethargy and arthralgias in patients who have visited endemic areas in eastern Australia. Catalogued from the local copy at evidence/infectious-diseases/_ajgp/queensland-tick-typhus-2018.html. | |
| Queensland tick typhus (Rickettsia australis) after a tick bite (case) | Australian Journal of General Practice (RACGP) | AJGP Vol. 47, No. 6, Jun 2018 | Australian spotted-fever rickettsiosis: fever, eschar at bite site, maculopapular rash; doxycycline treatment. A real endemic Australian tick-borne disease (contrast the absence of locally-acquired Lyme). Local copy: evidence/infectious-diseases/_ajgp/. |
| Rash in a returned traveller from Bali | RACGP — Australian Journal of General Practice | Dengue is a common cause of fever and rash in returned travellers from South-East Asia. Catalogued from the local copy at evidence/infectious-diseases/_ajgp/rash-returned-traveller-bali-2019.html. | |
| Rash in a returned traveller from Bali (case) | Australian Journal of General Practice (RACGP) | AJGP Vol. 48, No. 6, Jun 2019 | Case-based approach to rash + fever in a returned traveller (dengue and other differentials). Local copy: evidence/infectious-diseases/_ajgp/. |
| Respiratory syncytial virus (RSV) vaccine — maternal immunisation (Abrysvo) | Australian Government Department of Health, Disability and Ageing / Australian Immunisation Handbook | TGA approved March 2024; NIP-funded from 3 February 2025 | New addition to routine antenatal immunisation not covered in the original 2020 note: Abrysvo (bivalent RSV prefusion F vaccine, Category A) recommended from 28 weeks gestation (ideally before 36 weeks) each pregnancy, to protect infants from RSV via transplacental antibody transfer. Window corroborated by HNE HealthPathways (28-36 weeks; infant not protected unless born ≥2 weeks post-vaccination). |
| Schistosomiasis | StatPearls | ||
| Sepsis | EM:RAP CorePendium | Supplied by Steve 2026-08-31. | |
| Sepsis Clinical Care Standard | Australian Commission on Safety and Quality in Health Care | ||
| Sexual history (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached) covering how to take a sexual history: last sexual contact, regular vs casual partner, gender of partner(s), condom use, type of sex (vaginal/oral/anal), contact in the last 3 months. |
| Standard Asymptomatic Checkup (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached): routine STI screening for asymptomatic people, and which subpopulations (MSM, sex workers, pregnant people, Aboriginal and Torres Strait Islander people, trans and gender diverse people) have special testing requirements. Source of the note's existing pre-claims-system quote about subpopulations. |
| STIs: syphilis, gonorrhoea and chlamydia (The Curbsiders #127) | The Curbsiders Internal Medicine Podcast | Named by hand from the document's own opening text. Local copy at evidence/mens-health/sti-screening/curbsiders-127-sti-shownotes.pdf. | |
| Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 | Society of Critical Care Medicine / ESICM (Critical Care Medicine) | Supplied by Steve 2026-08-31. Hospital/ICU-scoped; use for definitions, screening, fluid/antibiotic timing. | |
| Syphilis | Australian STI Management Guidelines (ASHM) | ||
| Tapeworm (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Testing for COVID-19: a 2023 update | Australian Prescriber | ||
| The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis | Clinical Infectious Diseases 2023;77(4):518-526 | Named by hand from the document's own opening text. Local copy at evidence/cardiology/infective-inflammatory-conditions/duke-iscvid-2023-pmc.html. | |
| The unwell returned traveller | RACGP — Australian Journal of General Practice | The objective of this article is to provide GPs with a framework they can use when faced with an unwell returned traveller. Catalogued from the local copy at evidence/infectious-diseases/_ajgp/unwell-returned-traveller-2025.html. | |
| The unwell returned traveller | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 10, Oct 2025 (Travel Medicine themed issue) | Approach to fever in the returned traveller: malaria must be excluded first (thick/thin films or RDT); differential by incubation period and exposure; red flags for haemorrhagic fever/sepsis; notifiable diseases. Local copy: evidence/infectious-diseases/_ajgp/. |
| Therapeutics for rheumatic fever and heart disease | Australian Prescriber | ||
| Tick bites and tick bite diseases | Australian Centre for Disease Control | Last updated 23 February 2026 | Added 2026-08-16 for stage-E claim placement on tick-bite.md/lyme-disease.md -- covers Q fever/spotted fever/paralysis/alpha-gal as tick-bite illnesses and the CSIRO finding that Australian ticks do not carry Borrelia burgdorferi (Lyme disease not locally acquired). |
| TORCH Complex (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Toxoplasmosis | StatPearls | ||
| Trichomoniasis | Australian STI Management Guidelines (ASHM) | Rewrite/correction source for womens-health/trichomoniasis.md — the generic ashm-sti registry entry only has the ASHM landing page cached (no article text); this is the actual disease page. Current guideline recommends metronidazole 400mg PO BD for 7 days as first-line, with metronidazole/tinidazole 2g stat as the alternative — the note's OneNote-era image alt-text had these reversed (2g stat as 'Recommended', 400mg BD for 5 days as 'Alternative'). | |
| Typhoid Fever | StatPearls (NCBI Bookshelf) | updated 2024-04-19 | Enteric fever pathophysiology, clinical features, diagnosis and treatment (incl. fluoroquinolone resistance) for infectious-diseases/typhoid-fever.md, stage E. |
| Vaccination for Aboriginal and Torres Strait Islander people | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vaccination for international travellers | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vaccination for migrants refugees and people seeking asylum in Australia | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vaccination for people at occupational risk | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vaccination for people who are immunocompromised | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Viral Hemorrhagic Fevers | StatPearls | ||
| West Nile Virus | StatPearls | ||
| Zika Virus | StatPearls |
Men's Health
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| A middle-aged man with indurated scrotal nodules | RACGP (AJGP) | Resource Seeding 2026-08-23, AJGP Jan-Feb 2019 GP case study on scrotal nodules/masses. Addition alongside pre-existing statpearls-hydrocele/statpearls-varicocele/statpearls-testicular-cancer for mens-health/scrotal-lump.md (those 3 were registered 2026-08-16 but never cited by the note — citation-linking gap, flagged for stage-F). | |
| Acute Bacterial Prostatitis | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/acute-prostatitis.md. Last updated May 22, 2023. | |
| Anogenital Ulcers | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/penile-ulcers.md. Australian national STI management guideline syndrome page. | |
| Anogenital Warts | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/genital-warts.md. | |
| Australian STI Management Guidelines for primary care | ASHM | living online guidelines | Includes a dedicated Populations & Situations > Adult sexual assault page (post-assault STI testing/prophylaxis, HIV PEP, hepatitis B) used in Phase 4 (2026-07-08). |
| Balanitis | StatPearls (NCBI Bookshelf) | current as at fetch | Low-yield fallback for mens-health/balanitis.md stage-E pass. |
| Balanitis Xerotica Obliterans (Male Penile Lichen Sclerosus) | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/balanitis-xerotica-obliterans.md. Last updated Dec 11, 2024. | |
| Balanitis Xerotica Obliterans (Male Penile Lichen Sclerosus) | StatPearls (NCBI Bookshelf) | ||
| Benign Prostatic Hyperplasia | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/benign-prostatic-hypertrophy.md. Last updated Oct 20, 2024. | |
| Benign prostatic hyperplasia: A review and update for general practice | RACGP (AJGP) | Resource Seeding 2026-08-23, AJGP July 2018, verified via og:title. Companion to statpearls-benign-prostatic-hyperplasia for mens-health/benign-prostatic-hypertrophy.md. | |
| Cancer Council clinical practice guidelines and Optimal Care Pathways | Cancer Council Australia | per-guideline wiki | |
| Chronic Prostatitis and Chronic Pelvic Pain Syndrome in Men | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/chronic-prostatitis.md. Last updated Jan 11, 2024. | |
| Concealed penis: A review of multilevel classification and surgical reconstruction techniques | BJUI Compass | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/buried-penis.md — no dedicated StatPearls/MSD chapter exists for this topic; this open-access BJUI Compass review (published 2 Jan 2025) is the best available on-topic, current source. Surgical/specialist-leaning content — GP note should draw on its classification/overview sections, not operative detail. | |
| Condylomata Acuminata (Genital Warts) | StatPearls (NCBI Bookshelf) | current as at fetch | HPV transmission mechanism, HPV 6/11 as cause of ~90% of cases, diagnosis (usually clinical/visual), biopsy for atypical lesions. Low-yield fallback for womens-health/genital-warts.md, stage E (note's only cited source, ashm-sti, is the ASHM landing page with no cached article text). Also on-topic for mens-health/genital-warts.md (Resource Seeding, 2026-08-23) alongside the existing ajgp-penile-dermatology-2024 (already covers genital warts in its STI section). |
| Donovanosis | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/penile-ulcers.md. | |
| Epididymitis | StatPearls (NCBI Bookshelf) | Low-yield fallback source for mens-health/epididymo-orchitis.md. | |
| Evolution of hormonal therapy for prostate cancer | RACGP (AJGP) | AJGP 53(5), May 2024 | Androgen receptor pathway inhibitors (abiraterone, enzalutamide, apalutamide, darolutamide) alongside classical ADT for metastatic/high-risk prostate cancer. Local copy: evidence/mens-health/_ajgp/ |
| Genital Herpes Simplex Virus (HSV) | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/penile-ulcers.md. | |
| Genital Ulcer Disease Syndrome — Guidelines for the management of symptomatic sexually transmitted infections | World Health Organization (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/penile-ulcers.md — WHO 2021 syndromic-management chapter covering the genital-ulcer differential (HSV, syphilis, chancroid, LGV, granuloma inguinale) as no single StatPearls overview chapter exists for genital ulcers as a presentation. | |
| Gonorrhoea | Australian STI Management Guidelines (ASHM) | Rewrite source for womens-health/gonorrhoea.md, whose Treatment/Diagnosis sections were trapped in garbled OCR image alt-text from the OneNote export (e.g. '500mg' as 'soomg', '1g' as 'Ig'). | |
| Healthy Male (Andrology Australia) clinical summary guides | Healthy Male (Australian Government funded) | living resources | |
| Hematospermia | MSD Manual Professional Edition | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/haematospermia.md. Continuously revised MSD topic page, content last updated March 2026. | |
| Hydrocele | StatPearls (NCBI Bookshelf) | Low-yield fallback source for mens-health/scrotal-lump.md. | |
| Hypospadias | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/hypospadias.md. Last updated July 31, 2023. | |
| Lymphogranuloma Venereum | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/penile-ulcers.md. | |
| Major changes with reduced harms in prostate cancer diagnosis and management | RACGP (AJGP) | AJGP 52(3), March 2023 | Editorial framing the mpMRI-before-biopsy and transperineal-biopsy shifts as reducing overdiagnosis/overtreatment harms. Local copy: evidence/mens-health/_ajgp/ |
| Making informed decisions about prostate cancer testing | RACGP (AJGP) | AJGP 52(3), March 2023 | Locally tailored patient factsheets on the burden of prostate cancer in Australia, supporting the shared decision-making consult. Local copy: evidence/mens-health/_ajgp/ |
| Male Infertility | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep companion source for mens-health/male-infertility.md (already had ajgp-surgical-mgmt-male-infertility-2023). Last updated June 19, 2026. | |
| Male sexual dysfunction: Clinical diagnosis and management strategies for common sexual problems | RACGP (AJGP) | AJGP 52(1-2), Jan-Feb 2023 | Classifies male sexual dysfunction into low desire, erectile dysfunction, Peyronie's disease, and ejaculatory/orgasmic disorders; premature ejaculation (dapoxetine 30-60mg, stop-start/squeeze technique), delayed ejaculation, and low libido (testosterone therapy options) management detail. Local copy: evidence/mens-health/_ajgp/ |
| Navigating the shift: New RACGP Red Book guidelines for prostate-specific antigen testing in general practice | RACGP (AJGP) | AJGP 54(12), December 2025 | The headline finding of the mens-health re-consolidation: RACGP Red Book PSA testing guidance reversed from the 9th edition (2016, not recommended for any risk group) to the 10th edition (2024, risk-based offer from age 50/45/40 depending on family history, 2-yearly if <3.0 ng/mL). Local copy: evidence/mens-health/_ajgp/ |
| Paraphimosis | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/phimosis-paraphimosis.md (paired with statpearls-phimosis — same note covers both conditions). Last updated May 30, 2023. | |
| Penile Cancer and Penile Intraepithelial Neoplasia | StatPearls (NCBI Bookshelf) | Low-yield fallback source for mens-health/penile-cancer.md (rank's category-wide topic matches were statpearls-testicular-cancer and prostate-cancer AJGP articles, both mismatches confirmed off-topic). | |
| Penile dermatology for the general practitioner: A pragmatic approach to diagnosis and management | RACGP (AJGP) | AJGP 53(11) supplement, November 2024 | Structured risk-stratification/referral framework for male genital skin conditions (lichen sclerosus, lichen planus, Zoon's balanitis, psoriasis, contact dermatitis, STIs, red-flag neoplastic change). Local copy: evidence/dermatology/_ajgp/ |
| Penile Fracture | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/fractured-penis.md. Last updated March 1, 2024. | |
| Peyronie Disease | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/peyronies-disease.md. Last updated Oct 6, 2024. | |
| Peyronie's disease: Watch out for the bend | RACGP (Australian Family Physician) | Resource Seeding 2026-08-23, AFP September 2017 (verified via og:title), the RACGP journal that preceded AJGP. Companion to statpearls-peyronie-disease for mens-health/peyronies-disease.md. | |
| Phimosis | StatPearls (NCBI Bookshelf) | Low-yield fallback source for paediatrics/surgical.md (physiological vs pathological phimosis, BXO). Also on-topic for mens-health/phimosis-paraphimosis.md (Resource Seeding, 2026-08-23). | |
| Priapism | MSD Manual Professional Edition | ||
| Priapism | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/priapism.md. Last updated Sept 14, 2025. | |
| Prostate Cancer Screening | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep companion source for mens-health/prostate-cancer.md (already had ajgp-navigating-the-shift-psa-2025). Last updated Oct 26, 2023. | |
| Prostate-specific antigen (PSA) testing for prostate cancer: Time to reconsider the approach to screening | RACGP (AJGP) | AJGP 52(3), March 2023 | Sets out the evidence base (ERSPC vs PLCO trial contamination) behind the RACGP's subsequent shift to risk-based PSA screening. Local copy: evidence/mens-health/_ajgp/ |
| Sexual history (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached) covering how to take a sexual history: last sexual contact, regular vs casual partner, gender of partner(s), condom use, type of sex (vaginal/oral/anal), contact in the last 3 months. |
| Shared decision making in prostate cancer screening: An update | RACGP (AJGP) | AJGP 52(3), March 2023 | Practical framework for the PSA risks/benefits discussion now central to the risk-based screening approach. Local copy: evidence/mens-health/_ajgp/ |
| Standard Asymptomatic Checkup (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached): routine STI screening for asymptomatic people, and which subpopulations (MSM, sex workers, pregnant people, Aboriginal and Torres Strait Islander people, trans and gender diverse people) have special testing requirements. Source of the note's existing pre-claims-system quote about subpopulations. |
| STIs: syphilis, gonorrhoea and chlamydia (The Curbsiders #127) | The Curbsiders Internal Medicine Podcast | Named by hand from the document's own opening text. Local copy at evidence/mens-health/sti-screening/curbsiders-127-sti-shownotes.pdf. | |
| Surgical management of male infertility: An overview | RACGP (AJGP) | AJGP 52(1-2), Jan-Feb 2023 | Male factor contributes to ~50% of infertile couples but the male partner goes unevaluated in 18-27% of cases; varicocele repair (microsurgical recurrence 0.4%), vasectomy reversal (~82% patency even after 10+ years, more vasoepididymostomy needed with longer intervals), and sperm retrieval (MESA/PESA/TESA for obstructive, microTESE for non-obstructive azoospermia) detail. Local copy: evidence/mens-health/_ajgp/ |
| Syphilis | Australian STI Management Guidelines (ASHM) | ||
| Testicular Cancer | StatPearls (NCBI Bookshelf) | Low-yield fallback source for mens-health/scrotal-lump.md. | |
| Testicular Torsion | StatPearls (NCBI Bookshelf) | Low-yield fallback source for mens-health/testicular-torsion.md (rank's category-wide topic match was statpearls-testicular-cancer, a mismatch — confirmed no mention of torsion in that source). | |
| Treatments for long-lasting and painful erection of the penis in boys and men with sickle cell disease | Cochrane | ||
| Trichomoniasis | Australian STI Management Guidelines (ASHM) | Rewrite/correction source for womens-health/trichomoniasis.md — the generic ashm-sti registry entry only has the ASHM landing page cached (no article text); this is the actual disease page. Current guideline recommends metronidazole 400mg PO BD for 7 days as first-line, with metronidazole/tinidazole 2g stat as the alternative — the note's OneNote-era image alt-text had these reversed (2g stat as 'Recommended', 400mg BD for 5 days as 'Alternative'). | |
| Trichomoniasis | StatPearls (NCBI Bookshelf) | current as at fetch | Epidemiology (most common nonviral STI worldwide), clinical presentation, diagnosis, and metronidazole/tinidazole treatment. Low-yield fallback for womens-health/trichomoniasis.md, stage E (note's only cited source, ashm-sti, is the ASHM landing page with no cached article text on trichomoniasis itself). Also on-topic for mens-health/trichomoniasis.md (Resource Seeding, 2026-08-23). |
| Varicocele | StatPearls (NCBI Bookshelf) | Low-yield fallback source for mens-health/scrotal-lump.md. | |
| Vasectomy | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep fill for mens-health/vasectomy.md — its pre-existing citation (ajgp-surgical-mgmt-male-infertility-2023) is about surgical infertility management, not vasectomy itself specifically; this is a dedicated procedural source. Last updated May 18, 2025. | |
| When less is more: Updates in active surveillance and watchful waiting in the management of prostate cancer | RACGP (AJGP) | AJGP 53(5), May 2024 | EAU-based active-surveillance-vs-watchful-waiting framework; active surveillance now standard for low-risk (PSA <10, ISUP 1, T1-T2a) and selected favourable-intermediate-risk (low-volume ISUP 2) disease. Local copy: evidence/mens-health/_ajgp/ |
Mental Health
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity | StatPearls Publishing (NCBI Bookshelf) | Last Update: January 17, 2024 | |
| A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease | Kidney International 2012 | Named by hand from the document's own opening text. Local copy at evidence/renal-urology/_shared/depression-in-dialysis-patients-ki-2012.pdf. | |
| A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease (check in browser) | Kidney International (review) | 2012 | Review of depression management specifically in CKD/dialysis patients (antidepressant selection, dialysability). Source URL not confirmed, cite by name only — held privately, evidence/renal-urology/_shared/. |
| Abuse and violence: working with our patients in general practice (White Book) | RACGP | 5th edition | |
| ADHD with Dr Kevin Simon (The Curbsiders #374) | The Curbsiders Internal Medicine Podcast | Named by hand from the document's own opening text. Local copy at evidence/paediatrics/adhd/curbsiders-374-adhd-podcast-notes.pdf. | |
| Adjustment Disorders | MSD Manual Professional Edition | Resource Seeding 2026-08-23, full-sweep fill for mental-health/adjustment-disorder.md (previously zero registry sources, in-review). Continuously revised MSD topic page. | |
| Adjustment Disorders | MSD Manual Professional Edition | reviewed 2024 | Definition, prevalence, stressor types, symptom timeline, diagnosis and management for mental-health/adjustment-disorder.md, stage E low-yield fallback (prior citation was the bare eTG homepage, no topic-specific content). |
| Adult ADHD Self-Report Scale (ASRS-v1.1) symptom checklist | World Health Organization | Named by hand from the document's own opening text. Local copy at evidence/paediatrics/adhd/asrs-v1.1-screening-questionnaire.pdf. | |
| Agoraphobia | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep fill for mental-health/agoraphobia.md (previously bare etg only). Last updated Nov 11, 2024. | |
| Agoraphobia | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Agoraphobia - Therapeutic Guidelines.pdf. | |
| Amphetamine Toxicity | StatPearls Publishing (NCBI Bookshelf) | Last Update: May 6, 2024 | |
| Amphetamine-Related Psychiatric Disorders | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep fill for mental-health/stimulants.md (previously bare etg only) — chosen over the generic Amphetamine pharmacology chapter since this note covers amphetamine/stimulant toxicity psychiatric presentations (paranoid psychosis, agitation) specifically. | |
| Antidepressant prescribing in general practice (AJGP) | RACGP - Australian Journal of General Practice | AJGP December 2021 | GP guidance on initiating antidepressants more selectively and reviewing/deprescribing more actively (tapering to avoid discontinuation symptoms). Applies to: major-depression, melancholic-depression, generalised-anxiety-disorder. |
| Antidepressants in pregnancy and breastfeeding (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Antipsychotic drugs in pregnancy and breastfeeding (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Antisocial Personality Disorder | StatPearls Publishing (NCBI Bookshelf) | Last Update: June 17, 2026 | Local copy: evidence/mental-health/anti-social-personality-disorder/. |
| ANZAED eating disorder treatment principles and clinical practice/training standards | Australia & New Zealand Academy for Eating Disorders (ANZAED), J Eat Disord 2020 | 2020 (the RANZCP eating disorders CPG 2014 is retired) | Current Australian eating-disorder practice/training standards (supersedes the retired RANZCP 2014 eating disorders CPG for practical purposes). Eight treatment principles incl. early intervention, evidence-based (family-based treatment for adolescent anorexia; CBT-E), multidisciplinary care, involvement of significant others. See also the National Eating Disorders Collaboration (NEDC) and InsideOut Institute for GP resources. Applies to: anorexia-nervosa, bulimia-nervosa, eating-problems. |
| Approach to managing acute behavioural disturbance | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Approach to the Agitated Patient | EM:RAP CorePendium | Supplied by Steve 2026-08-31. | |
| Assessing Fitness to Drive for commercial and private vehicle drivers 2022 | Austroads / National Transport Commission | Supplied by Steve 2026-08-31. Australian national medical standards for private and commercial driver licensing. | |
| Australian evidence-based clinical practice guideline for ADHD | Australian ADHD Professionals Association (AADPA) | October 2022 | First dedicated Australian national ADHD guideline; confirms stimulants (methylphenidate, dexamfetamine, lisdexamfetamine) as first-line for children 6+; atomoxetine/guanfacine as alternatives. Summary of Recommendations doc (Oct 2022) verified directly 2026-07-11: 'Methylphenidate or dexamfetamine or lisdexamfetamine should be offered as the first-line pharmacological treatment' (rec 5.3.1 children/adolescents, 5.4.1 adults); multimodal treatment (pharmacological + non-pharmacological concurrently) recommended; parent/family training for young children; an ECG is not needed before starting stimulants/atomoxetine/guanfacine unless specific cardiac risk features are present. |
| Australian evidence-based clinical practice guideline for attention deficit hyperactivity disorder (ADHD), 1st edition 2022 — full guideline | Australian ADHD Professionals Association (AADPA) | Named by hand from the document's own opening text. Local copy at evidence/paediatrics/adhd/aadpa-adhd-full-guideline-2022.pdf. | |
| Australian Guidelines for the Prevention and Treatment of Acute Stress Disorder, PTSD and Complex PTSD | Phoenix Australia (NHMRC-approved; RANZCP-endorsed) | 3rd edition, 2020 (updated Dec 2021) | Current Australian PTSD guideline; NHMRC-approved (2020, updated 2021) and RANZCP-endorsed. First edition to include complex PTSD. Trauma-focused psychological therapy (TF-CBT, EMDR) is first-line; medication (e.g. SSRIs) second-line. Applies to: post-traumatic-stress-disorder. |
| Australian PTSD Guidelines - Phoenix Australia | phoenixaustralia.org | Catalogued from the local copy at evidence/mental-health/_shared/phoenix-ptsd-landing-page.html. | |
| Autism in Australia | Australian Institute of Health and Welfare (AIHW) | 2023 (2022 data) | 4.3% of Australians aged 5-14 were autistic in 2022 (up from 3.2% in 2018) — much higher than older ~1 in 160 estimates, reflecting broadened diagnostic criteria and improved recognition. |
| Autism in Australia, 2022 | Australian Bureau of Statistics (ABS) | 2022 | 4.3% of people aged 5-14 were autistic in 2022, up from 3.2% in 2018. |
| Autism Spectrum Disorder | StatPearls (NCBI Bookshelf) | Updated 17 Jan 2025 | Comprehensive overview: epidemiology, DSM-5 criteria, comorbidities, evaluation, management. |
| Avoidant Personality Disorder | StatPearls Publishing (NCBI Bookshelf) | StatPearls | Used for the Cluster C row on mental-health/personality-disorders.md. |
| Bipolar Disorder | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep fill for mental-health/bipolar-affective-disorder-mania.md (previously bare etg only). Last updated Feb 20, 2023. | |
| Body dysmorphic disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Body dysmorphic disorder - Therapeutic Guidelines.pdf. | |
| Borderline Personality Disorder | StatPearls Publishing (NCBI Bookshelf) | StatPearls | Used for the Cluster B Borderline row on mental-health/personality-disorders.md. |
| Brief Psychotic Disorder | StatPearls (NCBI Bookshelf) | updated 2023-06-25 | DSM-5 definition/duration/prognosis detail for the Brief psychotic disorder section of mental-health/psychosis-other-than-schizophrenia.md, which the page's only prior source (RANZCP schizophrenia CPG) explicitly scopes out. |
| Cannabis Use Disorder | StatPearls (NCBI Bookshelf) | current as at fetch | Intoxication symptoms, transient psychosis/anxiety, and cannabis dependence treatment (CBT, no approved pharmacotherapy for withdrawal). Low-yield fallback for mental-health/cannabis.md, stage E (note's only cited source, etg, is subscription-gated with no cached article text). |
| Clinical guideline for the diagnosis and management of work-related mental health conditions in general practice | RACGP-endorsed | current | RACGP-endorsed guideline specifically for work-related mental health conditions (certification, workers' compensation interface, return-to-work planning) — a gap not covered by the general RANZCP CPGs already in the registry. Applies to: work-related mental health topics generally (no single dedicated note currently — check occupational-health-adjacent content). |
| Clinical practice guidelines previously developed by the RANZCP | RANZCP | ranzcp.org | Catalogued from the local copy at evidence/mental-health/_shared/ranzcp-previously-developed-cpgs-page.html. | |
| Delirium Clinical Care Standard | Australian Commission on Safety and Quality in Health Care (ACSQHC) | revised 2021 | Eight quality statements on prevention, early diagnosis (screening at-risk patients), and management of delirium in adults, minimising antipsychotic use. Applies to: delirium. |
| Delusional Disorder | StatPearls (NCBI Bookshelf) | updated 2023-03-27 | Definition, delusion subtypes and course detail for the Delusional (paranoid) disorder section of mental-health/psychosis-other-than-schizophrenia.md. |
| Dependent Personality Disorder | StatPearls Publishing (NCBI Bookshelf) | Last Update: August 17, 2024 | Used for the Cluster C row on mental-health/personality-disorders.md. |
| Depression in dementia (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Depressive Disorders | MSD Manual Professional Edition | Resource Seeding 2026-08-23, full-sweep fill for mental-health/melancholic-depression.md (previously bare etg only) — general depressive-disorders MSD page with a dedicated melancholic-features subsection; no MSD/StatPearls chapter dedicated solely to melancholic depression exists. | |
| Depressive Disorders | MSD Manual Professional Edition | current as at fetch | Psychotic-features-of-depression content (delusion themes, ECT efficacy) for the Psychotic depression section of mental-health/psychosis-other-than-schizophrenia.md; does not carry the note's specific treatment-efficacy percentages (see nice-psychotic-depression). |
| Depressive episodes in bipolar disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Depressive episodes in bipolar disorder - Therapeutic Guidelines.pdf. | |
| Drugs that may increase the risk of seizures | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/neurology/_shared/Drugs that may increase the risk of seizures - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Early identification of personality disorder (AJGP) | RACGP - Australian Journal of General Practice | AJGP May 2021 | GP-focused early identification of personality disorder; supports the shift away from BPD-specific labelling toward early, stage-appropriate intervention. Complements the 2025 AJGP article on providing effective treatment for borderline personality disorder. Applies to: personality-disorders, borderline-personality-disorder, anti-social-personality-disorder, narcisistic-personality-disorder. |
| Early intensive behavioral intervention (EIBI) for increasing functional behaviors and skills in young children with autism spectrum disorders (ASD) | Cochrane | Plain-language summary: EIBI evidence supports use for some children but quality is weak/low-certainty, only one optimally-designed RCT. | |
| Gender Dysphoria | StatPearls (NCBI Bookshelf) | updated 2023-07-11 | Dedicated gender dysphoria article — the note's only prior source was a bare offline eTG landing page (etg, no clinical content); the note was written from scratch without a fetched guideline PDF. |
| Gender Incongruence and Gender Dysphoria | MSD Manual Professional Edition | updated 2026-02-12 | Dedicated gender dysphoria/incongruence article — same rationale as statpearls-gender-dysphoria. |
| Generalised anxiety disorder | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/etg-mental-health/Generalised anxiety disorder - Therapeutic Guidelines.pdf. | |
| Generalized Anxiety Disorder | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep fill for mental-health/generalised-anxiety-disorder.md (previously bare etg only). | |
| Grief and Prolonged Grief Disorder | StatPearls (NCBI Bookshelf) | current as at fetch | Low-yield fallback for population-social-health/illness-loss-death-of-child-partner-family.md: the page's category-wide topic-matched sources (AJGP domestic/family violence, IPV, coercive control) share only the word 'family'/'partner'/'child' and are a different topic entirely, so treated as no dedicated evidence. Covers stages/phases of grief, acute vs prolonged grief disorder criteria and prevalence, risk factors, and at-risk groups. |
| Guidelines for the treatment of alcohol problems (4th edition, 2021) | Specialty of Addiction Medicine, University of Sydney | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/alcohol-treatment-guidelines-2021.pdf. | |
| Hoarding disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Hoarding disorder - Therapeutic Guidelines.pdf. | |
| Hypomanic episodes in bipolar disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Hypomanic episodes in bipolar disorder - Therapeutic Guidelines.pdf. | |
| Identifying and supporting autistic preschoolers and their families | AJGP | AJGP Vol 50, No 3, March 2021 | Early recognition and family support for autism in preschool-age children; local copy: evidence/paediatrics/_ajgp/ |
| INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia (check in browser) | McCutcheon RA, Pillinger T et al., Health Policy | current | Algorithmic (stepwise) treatment guideline for schizophrenia, a useful practical supplement to the narrative RANZCP 2016 CPG. URL is a best-effort placeholder, not independently verified by raw fetch — full-text PDF held privately, evidence/mental-health/_shared/integrate_scz_guideline.pdf. Applies to: schizophrenia. |
| Kubler-Ross Stages of Dying and Subsequent Models of Grief (Archived) | StatPearls (NCBI Bookshelf) | current as at fetch | Same low-yield-fallback context as statpearls-grief-prolonged-grief-disorder. Covers the Kubler-Ross five-stage model (denial, anger, bargaining, depression, acceptance) and later grief models (Worden's tasks, dual-process model). |
| Late-life depression: what can be done? (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Lecanemab in Early Alzheimer's Disease (CLARITY AD trial) | van Dyck CH et al., N Engl J Med 2023;388(1):9-21 | 2023 | Anti-amyloid monoclonal antibody (lecanemab, Leqembi) slowed cognitive/functional decline by ~27% over 18 months in early Alzheimer's disease vs placebo — first disease-modifying (rather than purely symptomatic) Alzheimer's therapy with positive phase 3 data. TGA/PBS status in Australia not confirmed as at 2026-07-11 — check before citing as an available option. Applies to: dementia-and-depression. |
| Lecanemab in early Alzheimer's disease (CLARITY AD) | New England Journal of Medicine 2023;388(1) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/dementia-and-depression/nejm-lecanemab-clarity-ad-2023.pdf. | |
| Lithium Toxicity and Poisoning | EM:RAP Corependium | current as at upload (2026-08-14) | Used to add GP/urgent-care-relevant detail to lithium-toxicity.md: acute-vs-chronic distinction, renal-clearance-driven risk factors (dehydration, NSAIDs, ACEi/ARB, thiazides, salt restriction), tremor prevalence, nephrogenic diabetes insipidus and thyroid effects on chronic use, the green-top-tube (lithium heparin) sample-collection pitfall, and hemodialysis threshold levels. It is an ED/toxicology-level source, so most of its hospital-admission/hemodialysis-protocol detail was deliberately left uncited on this GP-facing page. |
| Major depression | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Major depression - Therapeutic Guidelines.pdf. | |
| Management of insomnia in primary care | Australian Prescriber | Resource Seeding 2026-08-23, full-sweep fill for mental-health/insomnia.md (previously bare etg only). Aust Prescr 2021;44:124-8, verified via fetched byline. | |
| Managing behavioural and psychological symptoms in dementia (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Manic episodes in bipolar disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Manic episodes in bipolar disorder - Therapeutic Guidelines.pdf. | |
| Mental health disorders following trauma exposure | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Mental health disorders following trauma exposure - Therapeutic Guidelines.pdf. | |
| Mood disorders | RANZCP | ranzcp.org | Catalogued from the local copy at evidence/mental-health/_shared/ranzcp-mood-2020-library-page.html. | |
| Narcissistic Personality Disorder | StatPearls Publishing (NCBI Bookshelf) | Last Update: March 1, 2024 | Local copy: evidence/mental-health/narcisistic-personality-disorder/. |
| Narcissistic Personality Disorder (NPD) | MSD Manual Professional Edition | Full Review: Sept 2023, Last updated: Jan 2026 | Local copy: evidence/mental-health/narcisistic-personality-disorder/. |
| Narcissistic Personality Disorder and Suicidal Behavior in Mood Disorders | Journal of Psychiatric Research (PMC author manuscript) | J Psychiatr Res. 2017 Feb;85:24-28. doi:10.1016/j.jpsychires.2016.10.020 | Coleman, Lawrence, Parekh, Galfalvy, Blasco-Fontecilla, Brent, Mann, Baca-Garcia, Oquendo. Mood-disordered patients (N=657); NPD patients 2.4x less likely to attempt suicide than non-NPD patients in the same sample (OR=.41, 95% CI .19-.88), controlling for aggression/hostility/substance use — NOT a general-population comparison (that figure, 1.7x, is a different cited study, Bolton & Robinson 2010 NESARC). NPD not associated with attempt lethality. Local copy: evidence/mental-health/narcisistic-personality-disorder/. |
| National guidelines for medication-assisted treatment of opioid dependence | Australian Government Department of Health | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/matod-opioid-national.pdf. | |
| National guidelines for medication-assisted treatment of opioid dependence | Australian Government Department of Health, Disability and Ageing | 2014 national edition (framework implemented via state/territory MATOD programs; evidence PDF saved) | National framework for opioid agonist treatment (methadone, buprenorphine, buprenorphine-naloxone) combined with psychosocial support. The consolidated national document is the 2014 edition; jurisdictions maintain their own current MATOD program guidance, and depot buprenorphine (Buvidal, Sublocade) is now also available. Applies to: opioids, substance-use-disorders. |
| Neuroleptic Malignant Syndrome | StatPearls (NCBI Bookshelf) | current as at fetch | NMS etiology, clinical presentation, investigations, management for mental-health/neuroleptic-malignant-syndrome.md (low-yield fallback — the only dedicated cite was the generic eTG homepage/offline-shell id). |
| Neuroleptic Malignant Syndrome | MSD Manual Professional Edition | current as at fetch | NMS cause, risk factors, onset, diagnosis, management for mental-health/neuroleptic-malignant-syndrome.md (low-yield fallback). |
| Obsessive compulsive disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Obsessive compulsive disorder - Therapeutic Guidelines.pdf. | |
| Obsessive-Compulsive Personality Disorder | StatPearls Publishing (NCBI Bookshelf) | StatPearls | Used for the Cluster C Obsessional row on mental-health/personality-disorders.md. |
| Overview of anxiety and associated disorders | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Overview of anxiety and associated disorders - Therapeutic Guidelines.pdf. | |
| Overview of bipolar disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Overview of bipolar disorder - Therapeutic Guidelines.pdf. | |
| Overview of depressive disorders | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Overview of depressive disorders - Therapeutic Guidelines.pdf. | |
| Panic attack | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Panic attack - Therapeutic Guidelines.pdf. | |
| Panic disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Panic disorder - Therapeutic Guidelines.pdf. | |
| Perinatal depression | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Perinatal depression - Therapeutic Guidelines.pdf. | |
| Perinatal Depression (StatPearls) | StatPearls | ||
| Pharmacological management for acute behavioural disturbance in adults | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Pharmacological management for acute behavioural disturbance in children and adolescents | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Pharmacological management for acute behavioural disturbance in older people | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Physical exercise and the patient with schizophrenia (AJGP Dec 2020) | Australian Journal of General Practice (RACGP) | ||
| Physical health monitoring for people with schizophrenia (Aust Prescr 2024;47:2-9) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Prescribing drugs of dependence in general practice (Parts A/B/C) | RACGP | living series (Part B benzodiazepines; Part C1/C2 opioids) | RACGP series on safe prescribing of dependence-forming drugs. Part B = benzodiazepines (short-term only, avoid long-term, taper); Part C = opioids (lowest effective dose, shortest duration, caution with combined benzodiazepine/opioid use and in substance use disorder). Applies to: benzodiazepines-zolpidem-and-zopiclone, opioids, substance-use-disorders. |
| Prescribing drugs of dependence in general practice, Part B: benzodiazepines | RACGP | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/racgp-drugs-of-dependence-partB-benzos.pdf. | |
| Prescribing drugs of dependence in general practice, Part C1: opioids | RACGP | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/racgp-drugs-of-dependence-partC1-opioids.pdf. | |
| Prescribing drugs of dependence in general practice, Part C2: the role of opioids in pain management | RACGP | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/racgp-drugs-of-dependence-partC2-opioids-pain.pdf. | |
| Prescribing medicinal cannabis | Australian Prescriber | Resource Seeding 2026-08-23, full-sweep fill for mental-health/cannabis.md (previously bare etg only). Aust Prescr 2020;43:152-9, verified via fetched byline. | |
| Prophylaxis of bipolar disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Prophylaxis of bipolar disorder - Therapeutic Guidelines.pdf. | |
| Providing effective treatment for borderline personality disorder | RACGP — Australian Journal of General Practice | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/ajgp-bpd-treatment-2025.pdf. | |
| Providing effective treatment for borderline personality disorder (AJGP) | RACGP - Australian Journal of General Practice | AJGP Vol 54 No 3, March 2025 | Current AJGP guidance on GP management of BPD: structured psychological therapy is first-line; medication has a limited, adjunctive role only. Applies to: borderline-personality-disorder, personality-disorders. |
| Psychotic depression | National Institute for Health and Care Excellence (NICE), evidence review | 2022-06 | NICE evidence review comparing antipsychotic/antidepressant combination vs monotherapy for psychotic depression; general diagnostic-difficulty and combination-treatment framing for mental-health/psychosis-other-than-schizophrenia.md. Does not contain the note's specific 80%/33%/25%/5% efficacy figures - those remain stage-C-only pending a source that states them. |
| RANZCP — ADHD across the lifespan (resource) | RANZCP | current resource | RANZCP resource page on ADHD across the lifespan; complements (does not replace) the AADPA 2022 national ADHD clinical practice guideline, which is the definitive Australian source. |
| RANZCP clinical guidelines and publications library | RANZCP | publications library | Legacy static CPGs are retired/reference-only; cite the current publications library. |
| RANZCP clinical practice guidelines for deliberate self-harm (2016) | RANZCP, Aust NZ J Psychiatry 2016 | 2016 (formally retired by RANZCP; citable via journal) | Last RANZCP guideline on deliberate self-harm assessment/management; formally withdrawn (NHMRC 5-year lifespan). For current primary-care suicide-risk practice see the GPMHSC suicide-prevention resource. Applies to: suicide-risk-assessment-incl-youth-suicide. Full text held privately (evidence/mental-health/_shared/ranzcp-self-harm-cpg-2016-fulltext.pdf, added by Steve 2026-07-11). |
| RANZCP clinical practice guidelines for mood disorders (2020) | RANZCP (Malhi et al.), Aust NZ J Psychiatry 2021;55(1) | 2020 (published 2021); most recent RANZCP mood CPG | The most recent RANZCP CPG covering both major depression and bipolar disorder; updates the 2015 edition. Treatment framed as 'actions', 'choices' and 'alternatives' rather than rigid stepped care. Applies to: major-depression, melancholic-depression, dementia-and-depression, bipolar-affective-disorder-mania. NB RANZCP is retiring static CPGs (NHMRC 5-year lifespan) in favour of a Best Practice Resources framework, but this 2020 mood CPG remains the current reference; also citable via its ANZJP journal summaries (Malhi et al 2021). Full text held privately (evidence/mental-health/_shared/ranzcp-mood-disorders-cpg-2020-fulltext.pdf, added by Steve 2026-07-11) — not journal-gated for our purposes. |
| RANZCP clinical practice guidelines for panic disorder, social anxiety disorder and generalised anxiety disorder (2018) | RANZCP (Andrews et al.), Aust NZ J Psychiatry 2018;52(12) | 2018 (formally retired by RANZCP; citable via journal) | Covers panic disorder, social anxiety disorder and GAD; psychological therapy (CBT) first-line, SSRIs/SNRIs pharmacotherapy of choice, benzodiazepines discouraged for maintenance. RANZCP has withdrawn this as an active CPG (NHMRC 5-year lifespan) but it remains the last RANZCP anxiety guideline. Does NOT cover OCD (reclassified out of anxiety disorders in DSM-5), agoraphobia as standalone, or specific phobia - for those, eTG/RACGP is the practical primary-care reference. Applies to: generalised-anxiety-disorder, panic-disorder, social-anxiety-disorder (and, by extension for GP management, agoraphobia/specific-phobia). |
| RANZCP clinical practice guidelines for the management of schizophrenia and related disorders (2016) | RANZCP (Galletly et al.), Aust NZ J Psychiatry 2016;50(5):410-472 | 2016 (formally retired by RANZCP; last RANZCP schizophrenia CPG, citable via journal) | Covers ultra-high-risk syndromes, first-episode and prolonged psychosis (incl. substance-related). Increased emphasis on physical-health comorbidity, psychological treatment and vocational recovery. RANZCP has WITHDRAWN this from active use (exceeds the NHMRC 5-year lifespan) but it remains the last RANZCP schizophrenia guideline and is accessible via the ANZJP journal (Galletly et al 2016). Applies to: schizophrenia, psychosis-an-approach, psychosis-other-than-schizophrenia, organic-psychosis. Full text held privately (evidence/mental-health/_shared/ranzcp-schizophrenia-cpg-2016-fulltext.pdf, added by Steve 2026-07-11); see also integrate-schizophrenia-algorithm for a complementary algorithmic guideline. |
| Recognising attention deficit hyperactivity disorder across the lifespan (Poulton) | RACGP - Australian Journal of General Practice (AJGP) | AJGP Vol 50 No 3, March 2021, pp.110-113 | GP-focused framework for recognising ADHD across the lifespan. ADHD affects ~10% of children and ~5% of adults; best considered a spectrum rather than categorical. Key to diagnosis is functional impairment across two or more settings (not just symptom counts). ODD is commonly part of the ADHD presentation (~40% of primary-school children with ADHD have diagnosable ODD; another ~40% have subthreshold ODD features). Intellectually able people may mask ADHD with coping strategies; it can be overlooked when another psychiatric diagnosis is present. Stimulant medication is effective for ODD as well as ADHD (often at higher dose). |
| Recognising, supporting and understanding Autistic adults in general practice settings | AJGP | AJGP Vol 50, No 3, March 2021 | Adult ASD presentation, camouflaging/masking, GP practical accommodations — complements the language-focused companion article already registered (ajgp-autism-language-gp-2021). |
| Schizoaffective Disorder | StatPearls (NCBI Bookshelf) | updated 2023-03-27 | Definition and management-principle detail for the Schizoaffective disorder section of mental-health/psychosis-other-than-schizophrenia.md. |
| Schizophreniform Disorder | MSD Manual Professional Edition | Full Review Jul 2025 | No dedicated StatPearls article exists for schizophreniform disorder; used for the Schizophreniform disorder section of mental-health/psychosis-other-than-schizophrenia.md (duration criteria, progression to schizophrenia/schizoaffective/bipolar disorder). |
| Schizotypal Personality Disorder | StatPearls Publishing (NCBI Bookshelf) | Last Update: May 7, 2024 | Used for the Cluster A row on mental-health/personality-disorders.md. |
| Seasonal affective disorder | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/etg-mental-health/Seasonal affective disorder - Therapeutic Guidelines.pdf. | |
| Separation anxiety disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Separation anxiety disorder - Therapeutic Guidelines.pdf. | |
| Serotonin Syndrome | StatPearls (NCBI Bookshelf) | current as at fetch | Serotonin syndrome pathophysiology, triad (neuromuscular excitation/autonomic instability/altered mental status), implicated drugs, severity, management for mental-health/serotonin-syndrome.md (low-yield fallback — the only dedicated cite was the generic eTG homepage id). |
| Social anxiety disorder | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/etg-mental-health/Social anxiety disorder - Therapeutic Guidelines.pdf. | |
| Somatic Symptom Disorder | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep fill for mental-health/somatic-symptom-and-related-disorders.md (previously bare etg only). Last updated Mar 13, 2023. | |
| Specific Phobia | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep fill for mental-health/specific-phobia.md (previously bare etg only). Last updated Aug 12, 2024. | |
| Specific phobias | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Specific phobias - Therapeutic Guidelines.pdf. | |
| Stahl's Essential Psychopharmacology — Antidepressant classes (ch.7) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter7_01 Antidepressant Classes.pdf. | |
| Stahl's Essential Psychopharmacology — Antidepressants (ch.7) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter7_00 Antidepressants.pdf. | |
| Stahl's Essential Psychopharmacology — Antidepressants: chapter summary (ch.7) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter7_05 Summary.pdf. | |
| Stahl's Essential Psychopharmacology — Antipsychotic agents (ch.5) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter5_00 - 1st Gen Antipsychotics.pdf. | |
| Stahl's Essential Psychopharmacology — Antipsychotics in clinical practice (ch.5) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter5_04-ClinicalPrac.pdf. | |
| Stahl's Essential Psychopharmacology — Atypical antipsychotics (ch.5) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter5_01-2nd Gen.pdf. | |
| Stahl's Essential Psychopharmacology — Augmenting antidepressants (ch.7) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter7_02 - Augmenting Antidepressants.pdf. | |
| Stahl's Essential Psychopharmacology — Future treatments for mood disorders (ch.7) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter7_04 Future treatments.pdf. | |
| Stahl's Essential Psychopharmacology — How to choose an antidepressant (ch.7) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter7_03 Choosing an Antidepressant.pdf. | |
| Stahl's Essential Psychopharmacology — Links between antipsychotic binding properties and clinical actions (ch.5) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter5_02-Antimanic.pdf. | |
| Stahl's Essential Psychopharmacology — Pharmacologic properties of individual antipsychotics (ch.5) | Stahl SM, Stahl's Essential Psychopharmacology (Cambridge University Press) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_copyright-flagged/stahl-essential-psychopharmacology/chapter5_03-Individual Antipsychotics.pdf. | |
| Stuttering (Stammering) | StatPearls (NCBI Bookshelf) | Developmental stuttering (childhood-onset fluency disorder): prevalence ~5-10% of preschoolers, onset typically age 2-6, disfluency types (repetitions, prolongations, blocks), distinguishing normal developmental disfluency from a pathological fluency disorder, and management including speech-language pathology referral. Low-yield fallback for paediatrics/behavioural-problems-in-childhood.md, stage E. Also the zero-source fill for mental-health/stammering-stuttering.md (Resource Seeding, 2026-08-23). | |
| Substance- or drug-induced depressive disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Substance- or drug-induced depressive disorder - Therapeutic Guidelines.pdf. | |
| Subthreshold depressive symptoms | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/mental-health/_shared/etg-mental-health/Subthreshold depressive symptoms - Therapeutic Guidelines.pdf. | |
| Suicide prevention — Risk assessment in general practice (GPMHSC) | General Practice Mental Health Standards Collaboration (GPMHSC) / RACGP | current GPMHSC resource | GP-focused suicide risk-assessment guidance: a structured conversation about suicidal thoughts/plans/intent, current mental state, risk and protective factors, stressors and supports - rather than a numerical risk score. Applies to: suicide-risk-assessment-incl-youth-suicide. |
| Suicide prevention: risk assessment in general practice | General Practice Mental Health Standards Collaboration (GPMHSC) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/_shared/gpmhsc-suicide-risk-page.html. | |
| Supporting smoking cessation: A guide for health professionals | RACGP | 2nd edition 2021, living updates (evidence PDF last updated 22 May 2024; incl. vaping/nicotine) | Current RACGP smoking (and vaping) cessation guide. Brief advice to all who smoke; first-line pharmacotherapy is varenicline or combination NRT (each ~triples quit odds); Quitline referral. Updated for the TGA prescription-vape framework. Applies to: smoking-cessation. |
| The role of drugs in the treatment of autism | Australian Prescriber | Aust Prescr 2023;46:49-53 | Pharmacological management of autism-associated irritability/comorbid symptoms (risperidone, aripiprazole, melatonin) — no drug treats core ASD features. |
| Treatment of panic disorder (Aust Prescr 2000;23:124-6) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 23, No 6, 2000 | Dedicated agoraphobia section: agoraphobia usually develops as a complication of recurrent panic attacks, essential agoraphobic features (fear/avoidance of situations where escape is difficult or embarrassing or help unavailable, e.g. public transport, crowds, being away from home), and management (treat the panic first, higher benzodiazepine/antidepressant doses often needed for agoraphobia than panic alone, cognitive behaviour therapy). Low-yield fallback for mental-health/agoraphobia.md, stage E (note's only cited source, etg, is registered against the eTG homepage with no condition-specific cached text — agoraphobia is paywalled within eTG's anxiety-disorders topic). |
| Update on binge eating disorder (AJGP) | RACGP - Australian Journal of General Practice | AJGP June 2023 | GP update on screening for eating disorders across the weight spectrum, and diagnosing/treating/monitoring binge eating disorder. Applies to: eating-problems, bulimia-nervosa. |
| Withdrawal Syndromes | StatPearls Publishing (NCBI Bookshelf) | Last Update: September 2, 2024 |
Musculoskeletal
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| 5th Metatarsal Fracture | StatPearls (NCBI Bookshelf) | current as at fetch | Base-of-5th-metatarsal fracture zones (tuberosity/pseudo-Jones, Jones, diaphyseal stress), watershed blood supply and non-union rate, non-operative vs surgical management. Low-yield fallback for musculoskeletal/foot-fractures.md, stage E (see statpearls-lisfranc-dislocation note for why the page's own dedicated sources aren't quotable). |
| A summary of the first Australian and Aotearoa New Zealand Clinical Practice Guideline for the management of mild traumatic brain injury/concussion and persisting post-concussion symptoms | Australian Journal of General Practice (RACGP) | AJGP Vol. 55, No. 1-2, Jan-Feb 2026 | Summary of the first Aus/NZ CPG for mTBI/concussion and persisting post-concussion symptoms - assessment, red flags, imaging thresholds, return-to-play/return-to-learn. |
| Acromioclavicular Joint Injury | StatPearls (NCBI Bookshelf) | StatPearls overview: epidemiology, Rockwood classification, exam, management by grade. Low-yield fallback for musculoskeletal/shoulder-injuries.md, stage E. | |
| Acute Ankle Sprain | StatPearls (NCBI Bookshelf) | current as at fetch | Epidemiology/mechanism of ankle sprain (inversion injury, ATFL most common), associated fractures, Ottawa ankle rules, grading, RICE/functional management. Low-yield fallback for musculoskeletal/foot-ankle-pain.md, stage E (the page's own category-wide topic match, emrap-xray-lower-limb-2023, is a radiology-anatomy reference that doesn't support the note's clinical differential-diagnosis content). |
| Adolescent Idiopathic Scoliosis | StatPearls (NCBI Bookshelf) | ||
| Adult Isthmic Spondylolisthesis | Orthobullets | ||
| Anterior Glenohumeral Joint Dislocation | StatPearls (NCBI Bookshelf) | StatPearls overview: epidemiology (anterior vs posterior proportion, paediatric rarity, axillary nerve injury rate), mechanism, management. Low-yield fallback for musculoskeletal/shoulder-injuries.md's brief dislocation cross-reference, stage E. | |
| Anterior Hip Dislocation | StatPearls (NCBI Bookshelf) | ||
| Approach to Orthopedic Radiology - Lower Extremity | EM:RAP Corependium | Updated 5 Dec 2023 | Used for the systematic foot and ankle X-ray review sections on both new pages, and for the calcaneal fracture (Bohler's angle, tongue-type Essex-Lopresti pattern, Mondor sign, associated lumbar-spine-fracture rate) and talar fracture (Hawkins classification, AVN risk from 1mm displacement) sections on foot-fractures.md - both previously entirely absent from the site. Local copy: evidence/musculoskeletal/foot-ankle-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only; the knee/hip/femur sections of this chapter were out of scope and not used). Text-layer copy added 2026-08-18 (was image-only). |
| Approach to Orthopedic Radiology - Upper Extremity | EM:RAP Corependium | current as at upload (2026-08-18) | Steve-supplied text-layer PDF (browser print-to-PDF), added 2026-08-18 - the upper-limb sibling of emrap-xray-lower-limb-2023, not previously registered. Systematic hand/wrist/forearm/elbow/humerus/shoulder X-ray review; potential source for forearm-elbow-injuries.md, wrist-hand-injuries.md and shoulder-injuries.md's own X-ray-interpretation sections. Local copy: evidence/musculoskeletal/upper-limb-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Approach to the Limping Child | EM:RAP Corependium | current as at upload (2026-08-06) | Used for the new limping-child.md page: age-based differential framework, pyomyositis, benign acute childhood myositis, Seymour fracture, plantar puncture wound/retained foreign body management, osteoid osteoma, and Kocher-criteria/synovial-fluid reasoning for excluding septic arthritis (cross-linked to existing dedicated pages for septic arthritis/osteomyelitis/JIA/HSP/bone malignancy rather than duplicating them). Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Avascular Necrosis | StatPearls (NCBI Bookshelf) | ||
| Basal thumb arthritis | RACGP — Australian Journal of General Practice | Management of basal thumb arthritis is dependent on both the clinical stage of the disease and patient expectations and demands. Catalogued from the local copy at evidence/musculoskeletal/_ajgp/basal-thumb-arthritis-2020.html. | |
| Basal thumb arthritis | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 11, Nov 2020 | First CMC joint OA: common in older women; splinting, analgesia, hand therapy, intra-articular corticosteroid; surgery (trapeziectomy) for refractory cases. Local copy: evidence/musculoskeletal/_ajgp/. |
| Basic fracture management in general practice | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 11, Nov 2025 | GP fracture management principles: describe/classify, when to reduce/refer, immobilisation, follow-up. Local copy: evidence/musculoskeletal/_ajgp/basic-fracture-management-2025.pdf. |
| Basilar Skull Fractures | StatPearls (NCBI Bookshelf) | Base of skull fracture clinical signs (Battle sign, raccoon eyes, CSF otorrhoea/rhinorrhoea), conservative management. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Battle Sign (Archived) | StatPearls (NCBI Bookshelf) | Battle sign as basilar skull fracture indicator; depressed skull fracture >5mm surgical elevation criterion. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Best practice care for acute low back pain | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 9, Sept 2024 | Current best-practice acute LBP: reassurance + stay active + self-management; avoid imaging and opioids; guideline-concordant care; simple analgesia (NSAIDs) if needed, not routine. Local copy: evidence/musculoskeletal/_ajgp/. |
| Biceps Tendon Rupture | StatPearls (NCBI Bookshelf) | ||
| Buckled, bent or broken? A guide to paediatric forearm fractures | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 11, Nov 2020 | Paediatric forearm fractures: buckle (torus) fractures managed with a removable splint/cast for 3-4 weeks; greenstick and complete fractures; growth-plate (Salter-Harris) considerations. Local copy: evidence/musculoskeletal/_ajgp/. |
| Bunions: a review of management | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 11, Nov 2020 | Hallux valgus: conservative measures (footwear, orthoses) don't correct deformity but relieve symptoms; surgery (osteotomy) for pain/function, not cosmesis. Local copy: evidence/musculoskeletal/_ajgp/. |
| Bupivacaine | Australian Medicines Handbook | Supplied by Steve 2026-08-31. | |
| Calcaneus Fractures | StatPearls (NCBI Bookshelf) | current as at fetch | Calcaneal fracture: axial-load mechanism, Bohler's angle, associated lumbar spine fracture and bilaterality, high-energy/orthopaedic-referral management. Low-yield fallback for musculoskeletal/foot-fractures.md, stage E (see statpearls-lisfranc-dislocation note for why the page's own dedicated sources aren't quotable). |
| Carpal Tunnel Syndrome | Orthobullets | ||
| Carpal Tunnel Syndrome | StatPearls (NCBI Bookshelf) | ||
| Cauda equina syndrome and severe lumbar-sacral radiculopathy in general practice: Finding the needle in the haystack | RACGP (AJGP) | AJGP 54(7), July 2025 | GP-focused approach to distinguishing cauda equina syndrome / severe radiculopathy from routine low back pain; red-flag clinical findings and referral urgency. Local copy: evidence/neurology/_ajgp/ |
| Central Cord Syndrome | StatPearls (NCBI Bookshelf) | Most common incomplete SCI; hyperextension injury on a stenotic cervical canal; disproportionate upper-limb weakness with sacral sensation preserved. Low-yield fallback for musculoskeletal/head-and-spinal-injuries.md, stage E. | |
| Cervical Radiculopathy | StatPearls (NCBI Bookshelf) | current as at fetch | Nerve-root compression pathophysiology, epidemiology/prevalence, dermatomal/myotomal patterns, provocative tests (Spurling’s, shoulder abduction relief, upper limb tension test), imaging and conservative-first management. Low-yield fallback for musculoskeletal/cervical-radiculopathy.md, stage E top-up (the page’s own category-wide topic match, ajgp-cauda-equina-lumbar-radiculopathy-2025, is entirely about LUMBAR-sacral radiculopathy/cauda equina and never mentions the cervical spine). |
| Cervical Spine Fractures Overview | StatPearls (NCBI Bookshelf) | Cervical spine fracture epidemiology and imaging, C1/C2/subaxial classification. Low-yield fallback for musculoskeletal/head-and-spinal-injuries.md, stage E. | |
| Cervical Spondylosis | StatPearls (NCBI Bookshelf) | ||
| Chilblains (pernio) | DermNet NZ | ||
| Chronic lateral ankle instability may be treated with or without surgery (Cochrane) | Cochrane | Cochrane review: chronic ankle instability after sprain, conservative (bracing/neuromuscular training) vs surgical management. | |
| Clavicle Fracture | StatPearls (NCBI Bookshelf) | StatPearls overview: epidemiology, mechanism, classification, non-operative vs surgical management. Low-yield fallback for musculoskeletal/shoulder-injuries.md, stage E (dedicated EM:RAP sources are image-only PDFs with no text layer). | |
| Claw Toe | Orthobullets | ||
| Coccyx Pain | StatPearls (NCBI Bookshelf) | Coccydynia/coccygeal fracture, traumatic history, conservative management. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Complex regional pain syndrome (Aust Prescr 2015;38:82-6) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 38, No 3, June 2015 | CRPS types 1/2, diagnostic (Budapest) criteria, pathophysiology, and management (physiotherapy/graded motor imagery mainstay, limited evidence for pharmacotherapy). Low-yield fallback for musculoskeletal/arm-hand-pain.md, stage E. |
| Congenital Muscular Torticollis | Orthobullets | ||
| Congenital Torticollis | StatPearls (NCBI Bookshelf) | ||
| Corns and calluses (heloma, tyloma) (DermNet NZ) | DermNet NZ | ||
| Corticosteroid Injections for Common Musculoskeletal Conditions | American Family Physician (AAFP) | ||
| Corticosteroid-induced osteoporosis and fractures (Romas, Aust Prescr 2008;31:45-9) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 31, No 2, April 2008 | Vertebral compression fractures as a consequence of osteoporosis. Low-yield fallback for musculoskeletal/thoracic-back-pain.md, stage E. |
| Costochondritis (StatPearls, NCBI Bookshelf) | StatPearls (NCBI Bookshelf) | Chest wall pain mimic of thoracic back pain / ACS. Stage F dedicated source for musculoskeletal/thoracic-back-pain.md. | |
| Creatine Supplementation: An Update | Hall M, Manetta E, Tupper K, Current Sports Medicine Reports 2021;20(7) | 2021 | Update on creatine monohydrate supplementation evidence (strength/muscle mass) and safety (no consistent evidence of renal harm in healthy individuals). No dedicated sports-medicine/supplements note currently exists — held as _shared evidence pending one. |
| De Quervain Tenosynovitis | StatPearls (NCBI Bookshelf) | ||
| Developmental Dysplasia of the Hip | StatPearls (NCBI Bookshelf) | ||
| Disk Herniation (StatPearls, NCBI Bookshelf) | StatPearls (NCBI Bookshelf) | Covers thoracic disk herniation location/presentation. Stage F dedicated source for musculoskeletal/thoracic-back-pain.md. | |
| Dupuytren Contracture | StatPearls (NCBI Bookshelf) | ||
| Dupuytren's Disease | Orthobullets | ||
| Epidural Hematoma | StatPearls (NCBI Bookshelf) | Extradural haematoma mechanism (middle meningeal artery, temporal bone fracture), classic lucid-interval presentation, biconvex CT appearance. Low-yield fallback for musculoskeletal/head-and-spinal-injuries.md, stage E. | |
| Exercise for Neck Pain | Cochrane | ||
| Female Athlete Triad | StatPearls (NCBI Bookshelf) | ||
| Femoral Head Avascular Necrosis | StatPearls (NCBI Bookshelf) | ||
| Femoroacetabular Impingement | StatPearls (NCBI Bookshelf) | ||
| Femoroacetabular Impingement (FAI) | Orthobullets | ||
| Fibromyalgia | StatPearls (NCBI Bookshelf) | StatPearls overview: epidemiology, diagnostic criteria (2010/2016 ACR), pathophysiology, comorbidities, management approach. | |
| Foot pain from exercise: Diagnosis and treatment | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 3, March 2024 | Exercise-related foot pain differential: stress fracture, plantar fasciitis, foot/ankle arthritis - clinical features, exam, imaging, management. |
| Ganglion Cyst | StatPearls (NCBI Bookshelf) | ||
| Ganglion Cysts | Orthobullets | ||
| Greater Trochanteric Pain Syndrome (Greater Trochanteric Bursitis) | StatPearls (NCBI Bookshelf) | ||
| Guide to paediatric forearm fractures | RACGP — Australian Journal of General Practice | Management of individual fractures depends on the fracture pattern and age of the child. Catalogued from the local copy at evidence/musculoskeletal/_ajgp/paediatric-forearm-fractures-2020.html. | |
| Hammer Toe | Orthobullets | ||
| Hammertoe | StatPearls (NCBI Bookshelf) | ||
| Herpes zoster: epidemiology, clinical features, treatment and prevention (Wehrhahn & Dwyer, Aust Prescr 2012;35:143-7) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 35, No 5, October 2012 | Herpes zoster clinical features including dermatomal pain that can precede the rash, a recognised pitfall in thoracic/radicular back pain assessment. Low-yield fallback for musculoskeletal/thoracic-back-pain.md, stage E. |
| Hip Osteonecrosis | Orthobullets | ||
| Hoffa Pad Impingement Syndrome | StatPearls (NCBI Bookshelf) | ||
| Idiopathic frozen shoulder | RACGP — Australian Journal of General Practice | The primary care physician plays a pivotal part in the identification and management of idiopathic frozen shoulder, with the vast majority of patients responding to conservative management. Catalogued from the local copy at evidence/musculoskeletal/_ajgp/idiopathic-frozen-shoulder-2019.html. | |
| Idiopathic frozen shoulder | Australian Journal of General Practice (RACGP) | AJGP Vol. 48, No. 11, Nov 2019 (Upper limb) | Adhesive capsulitis: freezing/frozen/thawing phases; strong association with diabetes; imaging to exclude other causes; management (analgesia, physio, intra-articular corticosteroid, hydrodilatation); usually self-limiting over 1-3 years. Local copy: evidence/musculoskeletal/_ajgp/. |
| Iliotibial Band Syndrome | StatPearls (NCBI Bookshelf) | ||
| Interdigital (Morton's) Neuroma | Orthobullets | ||
| Is exercise an effective therapy for hip osteoarthritis? | Cochrane | ||
| Knee Meniscal Tears | StatPearls (NCBI Bookshelf) | Mechanism (twisting vs valgus), locking/catching/effusion presentation, McMurray/Apley/Thessaly exam, imaging. Low-yield fallback for musculoskeletal/knee-pain.md, stage E. | |
| Lateral epicondylitis | RACGP — Australian Journal of General Practice | Appropriate education of patients regarding the nature of the illness, lifestyle modifications to avoid aggravating activities and appropriate use of analgesics are critical in effective management. Catalogued from the local copy at evidence/musculoskeletal/_ajgp/lateral-epicondylitis-2020.html. | |
| Lateral epicondylitis: current concepts | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 11, Nov 2020 | Tennis elbow is a degenerative tendinopathy (not inflammatory); self-limiting; load management/eccentric exercise first-line; corticosteroid injection gives short-term but worse long-term outcomes; avoid routine imaging. Local copy: evidence/musculoskeletal/_ajgp/. |
| Legg-Calve-Perthes Disease | StatPearls (NCBI Bookshelf) | ||
| Lidocaine anaesthesia | Australian Medicines Handbook | Supplied by Steve 2026-08-31. Maximum-dose data for the local anaesthesia page. | |
| Lisfranc Dislocation | StatPearls (NCBI Bookshelf) | current as at fetch | Lisfranc/tarsometatarsal fracture-dislocation: mechanism, missed-diagnosis rate, alignment/fleck-sign findings, weight-bearing imaging, management. Low-yield fallback for musculoskeletal/foot-fractures.md, stage E (note's own dedicated EM:RAP/case-deck sources are image-only PDFs with no text layer; the category-wide topic-matched source, eor-scaphoid-fracture-2020, is about wrist scaphoid fractures and explicitly not used for this page per evidence/musculoskeletal/foot-ankle-fractures/README.md). |
| Local anaesthetics | Australian Medicines Handbook | Supplied by Steve 2026-08-31. AMH topic PDF - quotable, and its dosing needs no separate cross-check. | |
| Low dose naltrexone in the treatment of fibromyalgia | RACGP — Australian Journal of General Practice | This article summarises the literature around the pathophysiology of fibromyalgia, as well as the evidence on low-dose naltrexone as a potential treatment option. Catalogued from the local copy at evidence/musculoskeletal/_ajgp/low-dose-naltrexone-fibromyalgia-2023.html. | |
| Low-dose naltrexone in the treatment of fibromyalgia | Australian Journal of General Practice (RACGP) | AJGP Vol. 52, No. 4, Apr 2023 | Fibromyalgia pathophysiology (central sensitisation) and emerging evidence for low-dose naltrexone as an off-label option; multimodal non-pharmacological first-line. Local copy: evidence/musculoskeletal/_ajgp/. |
| Lumbar Spinal Stenosis | StatPearls (NCBI Bookshelf) | ||
| Maisonneuve Fracture | EM:RAP Corependium | Updated 22 Jun 2024 | Used for ankle-fractures-dislocations.md's Maisonneuve fracture section - previously entirely absent from the site. Mechanism (external rotation force through the interosseous membrane exiting the proximal fibula), the always-palpate-the-fibular-head pearl (not part of the Ottawa Ankle Rules but important), peroneal nerve injury risk (foot drop, 1st/2nd toe web space sensory loss), and the usually-needs-operative-repair management. Local copy: evidence/musculoskeletal/foot-ankle-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). Text-layer copy added 2026-08-18 (was image-only). |
| Mallet Toe | Orthobullets | ||
| Managing osteoarthritis (Yu & Hunter, Aust Prescr 2015;38:115-19) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 38, No 4, August 2015 | Topical NSAIDs appropriate for both knee and hand osteoarthritis; intra-articular corticosteroid injections for short-term pain relief. Low-yield fallback for musculoskeletal/hand-oa.md, stage E. |
| Mandible Dislocation | StatPearls (NCBI Bookshelf) | TMJ/mandible dislocation presentation and manual reduction technique. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Mandible Fracture | StatPearls (NCBI Bookshelf) | Mandibular fracture presentation/examination. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Morton Neuroma | StatPearls (NCBI Bookshelf) | ||
| Musculoskeletal Injections: A Review of the Evidence | American Family Physician (AAFP) | ||
| Neck pain: What if it is not musculoskeletal? | AJGP (RACGP) | AJGP 47(5), May 2018 | |
| Neurogenic thoracic outlet syndrome | RACGP — Australian Journal of General Practice | AJGP Vol. 52, No. 9, Sep 2023 | nTOS = 97% of thoracic outlet syndrome cases; chronic brachial plexus compression at the scalene triangle; symptoms range from mild arm/shoulder pain on exertion to disabling motor wasting/sensory loss; typically age 20s-40s, 70% female. Local copy: evidence/musculoskeletal/_ajgp/. |
| Non-radicular low back pain: assessment and evidence-based treatment | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 11, Nov 2020 | Non-specific LBP: screen for red flags and radiculopathy; avoid routine imaging; first-line is advice to stay active, education/reassurance, exercise; limited role for medication; address yellow flags. Local copy: evidence/musculoskeletal/_ajgp/. |
| Nursemaid Elbow | StatPearls (NCBI Bookshelf) | ||
| Olecranon Bursitis | StatPearls (NCBI Bookshelf) | ||
| Orbital Floor Fracture | StatPearls (NCBI Bookshelf) | Blow-out/orbital floor fracture with malar/ZMC fracture, diplopia and extraocular entrapment. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Orthopedic Fundamentals: Ankle Dislocations | EM:RAP Corependium | Updated 31 Oct 2024 | Used for ankle-fractures-dislocations.md's ankle dislocation section: reduction technique (hip/knee flexed 90 deg, longitudinal traction + countertraction, 3-sided short-leg splint), near-universal need for surgical stabilisation, and posterior/posterolateral dislocation specifics (pilon fracture with superior dislocation, tibialis posterior tendon blocking reduction posterolaterally). Local copy: evidence/musculoskeletal/foot-ankle-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). Text-layer copy added 2026-08-18 (was image-only) - the last of ankle-fractures-dislocations.md's four EM:RAP sources to be fixed. |
| Orthopedic Fundamentals: Ankle Fractures | EM:RAP Corependium | Updated 29 May 2026 | Used for the new ankle-fractures-dislocations.md and foot-fractures.md pages, splitting the old lower-limb-fractures.md/foot-ankle-injuries.md content: Weber A/B/C classification and treatment thresholds, unimalleolar-vs-multimalleolar stability rule, basic ankle-fracture reduction technique, pilon fracture, and paediatric physeal-fracture-over-ligament-injury pearl. Local copy: evidence/musculoskeletal/foot-ankle-fractures/ — replaced 2026-08-17 with a text-layer copy (Steve's browser print-to-PDF, not the original image-only scan), so it is now stage-E quotable via pdftotext. Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Orthopedic Fundamentals: Elbow Fractures | EM:RAP Corependium | Updated 10 April 2024 | Used for forearm-elbow-injuries.md's elbow fracture section: posterior fat pad sign (always abnormal) vs anterior 'sail sign' (can be normal), radiocapitellar line and anterior humeral line for alignment, Mayo classification for olecranon fractures, Mason classification for radial head fractures, Regan and Morrey classification for coronoid fractures, and the 'terrible triad' (radial head fracture + coronoid fracture + elbow dislocation) and Essex-Lopresti injury as always-refer patterns. Local copy: evidence/musculoskeletal/upper-limb-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). Text-layer copy added 2026-08-18 (was image-only). |
| Orthopedic Fundamentals: Forearm Fractures | EM:RAP Corependium | Updated 13 March 2024 | Used for forearm-elbow-injuries.md's forearm shaft section: Monteggia (ulna shaft fracture + radial head dislocation, more common in children, radial nerve at risk) and Galeazzi (distal radius fracture + DRUJ disruption, radial nerve at risk) definitions and always-refer status, Essex-Lopresti (radial head fracture + interosseous membrane tear + DRUJ dislocation) as a frequently-missed injury needing wrist imaging as well as elbow, acute plastic bowing deformity in children, and the pearl that distal radius fractures are the most common forearm fracture to cause compartment syndrome. Local copy: evidence/musculoskeletal/upper-limb-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). Text-layer copy added 2026-08-18 (was image-only). |
| Orthopedic Fundamentals: Hip Fracture | EM:RAP Corependium | current as at upload (2026-08-06) | Used to restructure neck-of-femur-fracture.md around GP/urgent-care scope: low-energy-fall-is-the-norm and occult-fracture-can-still-weight-bear not-to-miss points, axial-loading/log-roll exam, don't-apply-traction pitfall, 48-hour-to-surgery outcome data, and the fragility-fracture/bone-health-assessment trigger. Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Orthopedic Fundamentals: Humerus Fracture | EM:RAP Corependium | Updated 27 April 2024 | Used for the proximal humerus fracture (shoulder-injuries.md) and humeral shaft/distal humerus fracture (forearm-elbow-injuries.md) content: non-operative angulation/shortening thresholds for shaft fractures (<20 deg anterior, <30 deg varus/valgus, <2-3cm shortening), radial nerve injury rate (8-18%) with midshaft fractures, fat pad sign for occult distal humerus fractures, and surgical indications for distal humerus fractures. Local copy: evidence/musculoskeletal/upper-limb-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). Text-layer copy added 2026-08-18 (was image-only). |
| Orthopedic Fundamentals: Knee Dislocations | EM:RAP Corependium | current as at upload (2026-08-06) | Used for the knee-fractures-dislocations.md 'don't miss' knee dislocation box: ~2/3 spontaneously reduce before assessment, multi-ligament laxity gives a presumptive diagnosis, vascular injury in ~1/3 (popliteal artery), hard signs of vascular injury, and the urgent-referral principle. Full hospital-level reduction/surgical-timing/vascular-imaging-algorithm detail was deliberately left out of scope per Steve's request (urgent-care clinic, not ED). Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Orthopedic Fundamentals: Knee Fractures | EM:RAP Corependium | current as at upload (2026-08-06) | Used for the new knee-fractures-dislocations.md page: tibial spine (intercondylar eminence) avulsion fracture (Meyers-McKeever classification, anterior drawer test, lipohaemarthrosis), tibial tuberosity avulsion fracture (vs Osgood-Schlatter, compartment syndrome risk), tibial subcondylar fracture, and proximal fibula fracture (posterolateral corner association, Maisonneuve link). Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Orthopedic Fundamentals: Ligamentous Injuries of the Knee | EM:RAP Corependium | current as at upload (2026-08-06) | Used to enrich ligament-injuries.md: precise exam-test sensitivities/specificities (Lachman, lever/Lelli sign, anterior drawer, pivot-shift, posterior sag, posterior drawer, valgus/varus stress grading), Segond/Stieda avulsion X-ray signs, and the occult-knee-dislocation pitfall (multi-ligament laxity should raise suspicion for a spontaneously-reduced dislocation). Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Orthopedic Fundamentals: Metatarsal Fractures and Dislocations | EM:RAP Corependium | current as at upload (2026-08-17) | Steve-supplied text-layer PDF (browser print-to-PDF), added 2026-08-17 as a stage-E low-yield-fallback replacement for musculoskeletal/foot-fractures.md's own dedicated EM:RAP sources, which were image-only with no text layer. Local copy: evidence/musculoskeletal/foot-ankle-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Orthopedic Fundamentals: Shoulder Dislocations | EM:RAP Corependium | Updated 7 December 2024 | Used to add a few GP-relevant facts to the existing shoulder-injuries.md cross-reference to shoulder-dislocations-stabilisation.md: anterior dislocation ~97% of all shoulder dislocations, arterial injury rare (<1%, axillary artery most commonly), post-reduction neurological deficit in ~13.5% (mostly neurapraxia, excellent recovery), and paediatric shoulder dislocation is rare (<2%) before physeal closure (14-17yo) - children more often sustain a proximal humerus fracture instead. Local copy: evidence/musculoskeletal/upper-limb-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). Text-layer copy added 2026-08-18 (was image-only) - now also usable directly for shoulder-dislocations-stabilisation.md, not just as a cross-reference source. |
| Orthopedic Fundamentals: Shoulder Injuries | EM:RAP Corependium | Updated 22 March 2024 | Used for the shoulder-injuries.md rewrite/split of the old upper-limb-fractures.md page: clavicle fracture Allman classification and referral thresholds (>1.5cm shortening, 100% displacement), scapular fracture epidemiology/floating-shoulder criteria, proximal humerus fracture Neer classification and axillary-nerve/AVN risk, and the Rockwood classification for AC joint separation (types I-VI, CC/AC distance grading, type III controversy, surgical thresholds for IV-VI). Local copy: evidence/musculoskeletal/upper-limb-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). Text-layer copy added 2026-08-18 (was image-only). |
| Orthopedic Fundamentals: Tibial and Fibular Shaft Fractures | EM:RAP Corependium | current as at upload (2026-08-06) | Used for the new tibial/fibular shaft fracture section of lower-limb-fractures.md: high-risk-of-compartment-syndrome pearl, open-fracture-from-puncture-wound-over-subcutaneous-tibia pearl, syndesmosis squeeze/dorsiflexion-external-rotation tests, peroneal nerve vulnerability at the fibular neck, and splinting/weight-bearing/DVT-risk management. Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Orthopedic Fundamentals: Wrist Fractures | EM:RAP Corependium | Updated 30 January 2026 | Used for wrist-hand-injuries.md's distal radius/carpal fracture section: Colles/Smith/Barton/Hutchinson (chauffeur) distal radius fracture patterns and mechanisms, die-punch fracture, radiographic reduction targets (radial height 10-13mm, radial inclination 15-25deg, volar tilt 10-25deg, <2mm radial shortening/ulnar variance), the pearl that distal radius fractures are the most common cause of acute carpal tunnel syndrome, and brief carpal fracture patterns beyond scaphoid (triquetrum 'chip' fracture as the 2nd most common carpal fracture, hook of hamate test, TFCC/Galeazzi-type DRUJ injury). Local copy: evidence/musculoskeletal/upper-limb-fractures/. Not independently verified beyond the source page itself (subscription content, cite by name only). Text-layer copy added 2026-08-18 (was image-only). |
| Osgood Schlatter's Disease (Tibial Tubercle Apophysitis) | Orthobullets | ||
| Osgood-Schlatter Disease | StatPearls (NCBI Bookshelf) | ||
| Osteoarthritis | StatPearls (NCBI Bookshelf) | General OA overview incl. glenohumeral OA discussion — companion to statpearls-primary-osteoarthritis (hand-OA-focused) for shoulder-osteoarthritis.md and hand-oa.md. | |
| Osteochondritis Dissecans | StatPearls (NCBI Bookshelf) | ||
| Osteochondritis Dissecans (Knee) | Orthobullets | ||
| Osteochondritis Dissecans of the Knee | StatPearls (NCBI Bookshelf) | ||
| Paediatric rotational abnormalities: a primer | AJGP | AJGP Vol 50, No 3, March 2021 | In-toeing/out-toeing/torsional lower-limb abnormalities in children -- normal variation over time, referral thresholds; local copy: evidence/paediatrics/_ajgp/ |
| Paget-Schroetter Syndrome | StatPearls (NCBI Bookshelf) | Effort-induced axillary/subclavian vein thrombosis (venous form of thoracic outlet syndrome) in young, healthy, athletic patients after repetitive overhead activity; presents with arm pain, swelling, discolouration; risk of pulmonary embolism if missed. Low-yield fallback for musculoskeletal/arm-hand-pain.md, stage F. | |
| Paronychia | Orthobullets | ||
| Paronychia | StatPearls (NCBI Bookshelf) | ||
| Patellar Fractures | EM:RAP Corependium | current as at upload (2026-08-06) | Used for the patella fracture section of knee-fractures-dislocations.md: horizontal-vs-vertical distinction, extensor mechanism/straight-leg-raise as the key exam step, sunrise view for vertical fractures, inferior-pole AVN risk, and operative-vs-nonoperative displacement/step-off thresholds. Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Patellar Tendinopathy (Jumper's Knee) | StatPearls (NCBI Bookshelf) | ||
| Patellofemoral Syndrome | StatPearls (NCBI Bookshelf) | Anterior knee pain epidemiology/prognosis (most common cause of anterior knee pain, good prognosis). Low-yield fallback for musculoskeletal/knee-pain.md, stage E. | |
| Pediatric Lower Extremity Fractures | EM:RAP Corependium | current as at upload (2026-08-06) | Used for: toddler's fracture enrichment on lower-limb-fractures.md (occult-fracture rate ~93% on follow-up film, walking-boot-vs-cast equivalence, internal oblique view); the new paediatric-ankle-fractures section of ankle-fractures-dislocations.md (Salter-Harris classification, X-ray-negative Salter-Harris I vs sprain equivalence, Tillaux and triplane fracture patterns); and the SCFE enrichment of childhood-hip-disorders.md (Klein line/modified Klein line, Drehmann sign, shaft angle of Southwick, bilateral-slip risk). Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Pelvic Fracture | StatPearls (NCBI Bookshelf) | Sacral fracture and S2-S5 nerve root injury with bowel/bladder/sexual dysfunction. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Pernio (Chilblains) | StatPearls (NCBI Bookshelf) | ||
| Peroneal Tendon Syndromes | StatPearls (NCBI Bookshelf) | current as at fetch | Peroneal tendinopathy, subluxation/dislocation and tenosynovitis around the lateral ankle. Low-yield fallback for musculoskeletal/ankle-tendon-disorders.md, stage E (see statpearls-progressive-collapsing-foot-deformity note for why the page's own category-wide topic matches don't check out). |
| Pes Anserine Bursitis | StatPearls (NCBI Bookshelf) | ||
| Plantar Fasciitis | StatPearls (NCBI Bookshelf) | ||
| Post-concussion symptoms after mild traumatic brain injury in adults: Management of neuropsychological symptoms | Australian Journal of General Practice (RACGP) | AJGP Vol. 55, No. 1-2, Jan-Feb 2026 | Persistent post-concussion symptoms (PPCS) after mTBI - prevalence (~30%), neuropsychological symptom management, based on the 2023 Aus/NZ CPG. |
| Posterior Hip Dislocation | StatPearls (NCBI Bookshelf) | ||
| Pre-operative optimisation for hip and knee arthroplasty | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 11, Nov 2020 | Pre-op optimisation (weight, glycaemia, smoking, anaemia, dental) before joint replacement; GP role. Local copy: evidence/musculoskeletal/_ajgp/. |
| Prepatellar Bursitis | StatPearls (NCBI Bookshelf) | ||
| Prescribing and dosing exercise in primary care | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 4, Apr 2020 (Exercise) | Exercise prescription (FITT), dosing and progression; central to OA and tendinopathy management. Local copy: evidence/musculoskeletal/_ajgp/. |
| Prescribing for polymyalgia rheumatica (Liew, Owen & Buchanan, Aust Prescr 2018;41:14-19) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 41, No 1, February 2018 | PMR epidemiology (age >50, more common in elderly), diagnosis, and corticosteroid-based management. Low-yield fallback for musculoskeletal/arm-hand-pain.md, stage E. |
| Primary Osteoarthritis | StatPearls (NCBI Bookshelf) | Hand-OA physical exam findings (Heberden's nodes at DIP, Bouchard's nodes at PIP, basal-thumb squaring), general OA features/pathophysiology. Low-yield fallback for musculoskeletal/hand-oa.md, stage E. | |
| Progressive Collapsing Foot Deformity | StatPearls (NCBI Bookshelf) | current as at fetch | Current name for posterior tibial tendon dysfunction/adult-acquired flatfoot; covers the 'too many toes' sign, single heel-rise test, and progressive flatfoot deformity from PTT failure. Low-yield fallback for musculoskeletal/ankle-tendon-disorders.md, stage E (the page's own category-wide topic matches, ajgp-achilles-tendon-2020 and emrap-xray-lower-limb-2023, don't actually discuss the tibialis posterior/peroneal tendons this note covers). |
| Proximal Biceps Tendinitis and Tendinopathy | StatPearls (NCBI Bookshelf) | ||
| Proximal Humerus Fracture | StatPearls (NCBI Bookshelf) | StatPearls overview: epidemiology, Neer classification, axillary nerve/AVN risk, non-operative vs surgical management. Low-yield fallback for musculoskeletal/shoulder-injuries.md, stage E. | |
| RACGP guideline for the non-surgical management of hip and knee osteoarthritis | RACGP | 2nd edition, 2018 (current key RACGP OA guideline) | Core non-surgical OA management: education/self-management, exercise (land-based and aquatic), weight loss; simple analgesia/topical NSAIDs before oral NSAIDs; intra-articular corticosteroid for short-term relief; strong recommendation AGAINST arthroscopy for degenerative knee OA; glucosamine/opioids not recommended. Cite by name. |
| Raynaud Disease (Phenomenon) | StatPearls (NCBI Bookshelf) | ||
| Raynaud's Syndrome | Orthobullets | ||
| Rib Fracture | StatPearls (NCBI Bookshelf) | Rib fracture presentation, imaging (x-ray often negative, look for pneumo/haemothorax), lower rib fracture visceral injury risk. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Rib Fracture | MSD Manual Professional Edition | Rib fracture pain-related atelectasis/pneumonia risk, deep breathing/analgesia management. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Ropivacaine | Australian Medicines Handbook | Supplied by Steve 2026-08-31. | |
| Rotator Cuff Syndrome | StatPearls (NCBI Bookshelf) | ||
| Sacroiliac Joint Dysfunction | Orthobullets | ||
| Sacroiliac Joint Pain | StatPearls (NCBI Bookshelf) | ||
| Sarcopenia in general practice | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 10, Oct 2024 | Sarcopenia: screening (SARC-F), assessment (grip strength, gait speed), and management (resistance exercise, protein); relevant to frailty/falls. Local copy: evidence/musculoskeletal/_ajgp/sarcopenia-2024.pdf. |
| Sarilumab for relapsing polymyalgia rheumatica (SAPHYR trial) | FDA / Lancet Rheumatology | FDA approved Feb 2023 | Sarilumab (IL-6 receptor inhibitor) FDA-approved Feb 2023 as the first biologic for PMR, for patients relapsing on ≥7.5mg/day prednisone during taper — reduces cumulative steroid exposure substantially (median 777mg vs 2044mg over 52 weeks). Australian TGA/PBS status not confirmed. Tocilizumab also shows benefit in glucocorticoid-dependent PMR. |
| Scaphoid fractures: evaluation and management | EFORT Open Reviews 2020;5(2):96-103 | 2020 | Review covering scaphoid fracture diagnosis (incl. CT/MRI when x-ray negative but clinically suspected) and management (cast vs percutaneous fixation for minimally displaced fractures). Applies to: upper-limb-fractures. |
| Scapula Fracture | StatPearls (NCBI Bookshelf) | StatPearls overview: epidemiology, mechanism, associated injuries, management. Low-yield fallback for musculoskeletal/shoulder-injuries.md, stage E. | |
| Scheuermann Disease | StatPearls (NCBI Bookshelf) | ||
| Scheuermann's Kyphosis | Orthobullets | ||
| Slipped Capital Femoral Epiphysis | StatPearls (NCBI Bookshelf) | ||
| Spinal immobilisation for trauma patients (Cochrane) | Cochrane | Cochrane review: evidence base for routine pre-hospital spinal immobilisation after trauma is limited; risk of harm from unnecessary immobilisation. | |
| Splinting | StatPearls (NCBI Bookshelf) | ||
| Spondylolisthesis | StatPearls (NCBI Bookshelf) | ||
| Sports nutrition for the recreational athlete | AJGP (RACGP) | ||
| Sternal Fractures | StatPearls (NCBI Bookshelf) | Sternal fracture mechanism, associated intrathoracic injury (myocardial contusion, tamponade), ED evaluation with ECG. Low-yield fallback for musculoskeletal/head-spine-chest-fractures.md, stage E. | |
| Steroid injections for painful soles of heels in adults (Cochrane) | Cochrane | Cochrane review of corticosteroid injection for plantar heel pain/plantar fasciitis. | |
| Stress Fractures | StatPearls (NCBI Bookshelf) | ||
| Subdural Hematoma | StatPearls (NCBI Bookshelf) | Bridging-vein rupture mechanism, acute (hyperdense) vs chronic (hypodense) CT appearance, presentation and management. Low-yield fallback for musculoskeletal/head-and-spinal-injuries.md, stage E. | |
| Superior Labrum Lesions | StatPearls (NCBI Bookshelf) | ||
| Syringomyelia (StatPearls, NCBI Bookshelf) | StatPearls (NCBI Bookshelf) | Fluid-filled spinal cord cavity, often incidental MRI finding. Stage F dedicated source for musculoskeletal/thoracic-back-pain.md. | |
| Talus Fracture | StatPearls (NCBI Bookshelf) | current as at fetch | Talar fracture: retrograde/precarious blood supply and AVN risk, Hawkins classification, operative management of displaced talar neck fractures. Low-yield fallback for musculoskeletal/foot-fractures.md, stage E (see statpearls-lisfranc-dislocation note for why the page's own dedicated sources aren't quotable). |
| Tarsal Navicular Fractures | StatPearls (NCBI Bookshelf) | ||
| Tenosynovitis | StatPearls (NCBI Bookshelf) | ||
| The Achilles tendon | RACGP — Australian Journal of General Practice | Management of acute Achilles tendon rupture has evolved, with increasing evidence that non-operative management is appropriate providing patients participate in a functional rehabilitation protocol. Catalogued from the local copy at evidence/musculoskeletal/_ajgp/achilles-tendon-2020.html. | |
| The Achilles tendon: management of acute and chronic conditions | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 11, Nov 2020 | Achilles tendinopathy (mid-portion vs insertional): eccentric/heavy-slow-resistance loading first-line; avoid corticosteroid injection (rupture risk); Achilles rupture (Simmonds/Thompson calf-squeeze test) - functional rehab vs surgery. Local copy: evidence/musculoskeletal/_ajgp/. |
| The Female Athlete | Orthobullets | ||
| Therapeutic ultrasound for acute ankle sprains (Cochrane) | Cochrane | Cochrane review: therapeutic ultrasound does not appear to improve recovery, pain or swelling after acute ankle sprain. | |
| Tibial Plateau Fracture | EM:RAP Corependium | current as at upload (2026-08-06) | Used for the tibial plateau fracture section of knee-fractures-dislocations.md: varus/valgus + axial load mechanism (can be low-energy in elderly osteoporotic falls, not just MVA), lipohaemarthrosis as sole X-ray sign, Segond fracture as pathognomonic for ACL injury, gross instability suggesting knee dislocation, and splinting/non-weight-bearing/urgent-follow-up management for uncomplicated fractures. Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Topical treatments for skin warts (Cochrane, CD001781) | Cochrane | ||
| Torticollis | StatPearls (NCBI Bookshelf) | ||
| Trigger Finger | StatPearls (NCBI Bookshelf) | ||
| Winging of the Scapula (StatPearls, NCBI Bookshelf) | StatPearls (NCBI Bookshelf) | Long thoracic nerve injury / serratus anterior palsy causing scapular winging. Stage F dedicated source for musculoskeletal/thoracic-back-pain.md. |
Neurology
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| A dizzying diagnosis (postural orthostatic tachycardia syndrome) | RACGP (AJGP) | ||
| A false dichotomy: Functional gait overlay in neurological disorders | RACGP (AJGP) | AJGP 54(7), July 2025 | Functional gait disorder as a clinical diagnosis based on positive examination findings (variability/inconsistency), not just exclusion of organic disease; can co-exist with a genuine underlying neurological gait disorder. Local copy: evidence/neurology/_ajgp/ |
| A headache in the elderly (AJGP 2021;50(10):733-736) | RACGP / Australian Journal of General Practice | ||
| A young child with a headache | RACGP (AJGP) | ||
| Acute Sinusitis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| ALS/MND pharmacotherapy updates: edaravone, tofersen | MND Australia / Australian Prescriber | 2023-2024 | Edaravone (Radicava) available in Australia as a second option alongside riluzole (modest benefit, most effective started early). Tofersen — first gene-targeted MND therapy — available via compassionate access for SOD1-mutation ALS specifically; listed for PBAC review November 2025. |
| An approach to vertigo in general practice | Australian Family Physician (RACGP) | ||
| Anti-CD20 monoclonal antibodies (ocrelizumab, ofatumumab) as first-line high-efficacy MS DMTs | MS Australia / Australian Prescriber / PBS | 2018 (PBS listing) - 2024 | The MS disease-modifying therapy landscape has expanded far beyond interferon-beta/glatiramer/natalizumab/alemtuzumab: oral options (fingolimod, dimethyl fumarate, teriflunomide, siponimod, cladribine) and anti-CD20 monoclonal antibodies (ocrelizumab/Ocrevus PBS-listed 2018, ofatumumab/Kesimpta) are now commonly used first-line high-efficacy therapy, reflecting an evidence-based shift toward early aggressive treatment. Note: PBS funding for ocrelizumab/ofatumumab was under review/at risk as of 2024-2026 due to pricing negotiations. |
| Anti-NMDA receptor encephalitis — review (check in browser) | uploaded by Steve, not independently re-verified | 2016 | Review of anti-NMDAR encephalitis diagnosis and management (paraneoplastic and non-paraneoplastic). No dedicated NMDAR-encephalitis note currently exists in neurology — relevant to meningitis-encephalitis.md's autoimmune/paraneoplastic differential. Held privately (evidence/neurology/_shared/); source URL not confirmed, cite by name only. |
| Anti-NMDA receptor encephalitis (Biological Perspectives) | Perspectives in Psychiatric Care 2015 | Named by hand from the document's own opening text. Local copy at evidence/neurology/_shared/anti-nmdar-encephalitis-biological-perspectives-2015.pdf. | |
| Antiepileptic drugs in pregnancy and lactation | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Assessing Fitness to Drive for commercial and private vehicle drivers 2022 | Austroads / National Transport Commission | Supplied by Steve 2026-08-31. Australian national medical standards for private and commercial driver licensing. | |
| Bell Palsy | StatPearls (NCBI Bookshelf) | ||
| Benign Paroxysmal Positional Vertigo (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Botulinum neurotoxin for the treatment of movement disorders | RACGP — Australian Journal of General Practice | Botulinum neurotoxin is an effective treatment for various movement disorders that are disabling and frequently under-recognised. Catalogued from the local copy at evidence/neurology/_ajgp/botulinum-toxin-movement-disorders-2018.html. | |
| Botulinum neurotoxin for the treatment of movement disorders | RACGP (AJGP) | AJGP 47(9), September 2018 | Botulinum toxin A for focal dystonias (blepharospasm, cervical dystonia, hemifacial spasm) and other movement disorders; under-recognised/under-treated indication. Local copy: evidence/neurology/_ajgp/ |
| Botulinum toxin type A injections for the treatment of lower limb spasticity in cerebral palsy (Cochrane review) | Cochrane | ||
| Botulism (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Brain Abscess (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Carbamazepine for chronic neuropathic pain and fibromyalgia in adults | Cochrane | ||
| Carotid artery stenosis | RACGP — Australian Journal of General Practice | Carotid artery stenosis is one of the major causes of acute ischaemic stroke, accounting for approximately 20% of cases. Catalogued from the local copy at evidence/neurology/_ajgp/carotid-artery-stenosis-2021.html. | |
| Carotid artery stenosis: An approach to its diagnosis and management | RACGP (AJGP) | AJGP 50(11), November 2021 | Symptomatic vs asymptomatic carotid stenosis management thresholds (endarterectomy 70-99%, grey-zone 50-69%, medical management <50% or asymptomatic); reinforces intensive medical therapy over stenting for asymptomatic disease. Local copy: evidence/neurology/_ajgp/ |
| Cauda equina syndrome and severe lumbar-sacral radiculopathy in general practice: Finding the needle in the haystack | RACGP (AJGP) | AJGP 54(7), July 2025 | GP-focused approach to distinguishing cauda equina syndrome / severe radiculopathy from routine low back pain; red-flag clinical findings and referral urgency. Local copy: evidence/neurology/_ajgp/ |
| Central Vertigo (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Cerebral Palsy | StatPearls (NCBI Bookshelf) | current as at fetch | Definition, epidemiology, risk factors (prenatal/perinatal/postnatal), classification (topography, tone/motor type, GMFCS severity), clinical presentation, diagnosis (no routine imaging required for diagnosis itself), and GP/multidisciplinary management of cerebral palsy. Low-yield fallback for neurology/cerebral-palsy.md, stage E (page had no dedicated evidence; the only topic-matched category-wide source, statpearls-cvst, is about cerebral venous sinus thrombosis, unrelated). |
| Cerebral Venous Sinus Thrombosis | StatPearls (NCBI Bookshelf) | current as at fetch | Epidemiology/incidence, risk factors, clinical presentation (headache, seizures, focal deficits, papilloedema/raised ICP signs), diagnostic imaging, and management (anticoagulation even in the presence of venous haemorrhagic infarction, decompressive craniectomy for refractory raised ICP) of cerebral venous sinus thrombosis. Low-yield fallback for neurology/cerebral-venous-sinus-thrombosis.md, stage E (note's only cited source, cvst-doac-anticoagulation-2022-2023, has no readable cached text). |
| Cervical Myelopathy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| CGRP monoclonal antibodies (galcanezumab) for cluster headache | Australian Prescriber / FDA / PBS | 2021-2024 | Galcanezumab is FDA-approved specifically for episodic cluster headache prevention (failed to show benefit for chronic cluster headache). In Australia, galcanezumab/fremanezumab are PBS-listed for chronic migraine only, not cluster headache — off-label use would be required and is not reflected in current PBS criteria. |
| CGRP monoclonal antibodies for migraine — PBS listing | PBS / Australian Prescriber / Migraine Australia | 2021 | Galcanezumab (Emgality) PBS-listed 1 June 2021, fremanezumab (Ajovy) PBS-listed 1 August 2021, both for chronic migraine (>=6 months, inadequate response/intolerance/contraindication to other preventives). Eptinezumab (Vyepti) TGA-approved but not yet PBS-listed. Erenumab (Aimovig) TGA-approved, private script only (not PBS-listed). |
| Charcot-Marie-Tooth Disease (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Clinical Guidelines for Stroke Management — Summary for General Practice (June 2025) | Stroke Foundation | ||
| Cluster Headache | StatPearls (NCBI Bookshelf) | Last Update: July 4, 2023 | Diagnostic criteria, acute/preventive treatment detail for neurology/cluster-headache.md, stage E low-yield fallback. |
| Cluster headache in adults | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for neurology/headache.md. |
| Congenital Hydrocephalus | MSD Manual Professional Edition | ||
| Current approaches to the pharmacological treatment of Alzheimers disease | RACGP — Australian Journal of General Practice | Medications may be used in conjunction with non-pharmacological treatments to manage cognition, function and behaviour in people with Alzheimer's disease. Catalogued from the local copy at evidence/neurology/_ajgp/alzheimers-pharmacotherapy-2018.html. | |
| Dealing with dizziness | Australian Prescriber | ||
| Direct Oral Anticoagulants vs Warfarin for Cerebral Venous Thrombosis (RE-SPECT CVT, ACTION-CVT) | Multiple RCTs/registries (RE-SPECT CVT trial; ACTION-CVT international registry) | 2022-2023 | DOACs (dabigatran, rivaroxaban, apixaban) now a viable alternative to warfarin for long-term anticoagulation in cerebral venous sinus thrombosis, with comparable efficacy and lower major haemorrhage risk in the ACTION-CVT registry. |
| Discontinuation of antiepileptic drugs in adults with epilepsy | NPS MedicineWise / Australian Prescriber | ||
| Drugs in secondary stroke prevention (Tremonti & Thieben, Aust Prescr 2021;44:85-90) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Drugs that may increase the risk of seizures | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/neurology/_shared/Drugs that may increase the risk of seizures - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Embolic Stroke | StatPearls (NCBI Bookshelf) | ||
| Epilepsy in pregnancy — management principles and focus on valproate (Int J Mol Sci 2022;23(3):1369) | International Journal of Molecular Sciences | ||
| Essential tremor | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/neurology/essential-tremors/Essential tremor - Therapeutic Guidelines.pdf. | |
| Facial Palsy | Community HealthPathways Hunter New England | last reviewed 08 May 2025, last updated 08 June 2026 | Steve-supplied text-layer PDF, local copy at evidence/neurology/bells-palsy-ramsay-hunt-syndrome/Facial Palsy - Community HealthPathways Hunter New England.pdf. Covers assessment (frontalis/forehead sparing as central-vs-peripheral discriminator, red flags for stroke/TIA, Ramsay Hunt exam) and management (prednisone/prednisolone 1mg/kg up to 75mg daily for 5 days within 3 days of onset for Bells palsy; add famciclovir/valaciclovir/aciclovir for Ramsay Hunt; eye protection; referral triggers). |
| Foslevodopa/foscarbidopa (Produodopa/Vyalev) for advanced Parkinson's disease | TGA / Australian Prescriber | TGA approved March 2024 | New device-assisted therapy for advanced Parkinson's disease with motor fluctuations: continuous 24-hour subcutaneous infusion pump delivering foslevodopa/foscarbidopa, alongside existing device-assisted options (deep brain stimulation, levodopa-carbidopa intestinal gel/Duodopa). |
| Gait assessment in general practice | RACGP — Australian Journal of General Practice | Mobility has a disproportionate impact on independence and function, as walking underpins most other activities of daily living. Catalogued from the local copy at evidence/neurology/_ajgp/gait-assessment-2021.html. | |
| Gait assessment in general practice | RACGP (AJGP) | AJGP 50(11), November 2021 | Structured office-based gait assessment approach; gait as a marker of independence/falls risk beyond specific neurological diagnosis. Local copy: evidence/neurology/_ajgp/ |
| Giant cell arteritis presenting as a unilateral sixth nerve palsy | RACGP (AJGP) | AJGP 54(7), July 2025 | Case of GCA presenting as isolated binocular diplopia (6th nerve palsy) rather than classic visual loss/headache; reinforces GCA as a differential for acute diplopia in patients >50. Prolonged prednisolone taper (1-2 years) with steroid-sparing agents (methotrexate, tocilizumab) now standard adjunct. Local copy: evidence/neurology/_ajgp/ |
| Glossopharyngeal Neuralgia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Guillain-Barre Syndrome (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| How to Localize Neurologic Lesions by Physical Examination | StatPearls (NCBI Bookshelf) | ||
| Huntington Disease (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Hydrocephalus | StatPearls (NCBI Bookshelf) | ||
| Hypokalemic Periodic Paralysis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Imaging in headache disorders | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for neurology/headache.md. |
| Interventions during pregnancy and childbirth for preventing cerebral palsy: an overview of Cochrane reviews (CD012077) | Cochrane | ||
| Intracranial Hemorrhage Overview (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Labyrinthitis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Lecanemab in Early Alzheimer's Disease (CLARITY AD trial) | van Dyck CH et al., N Engl J Med 2023;388(1):9-21 | 2023 | Anti-amyloid monoclonal antibody (lecanemab, Leqembi) slowed cognitive/functional decline by ~27% over 18 months in early Alzheimer's disease vs placebo — first disease-modifying (rather than purely symptomatic) Alzheimer's therapy with positive phase 3 data. TGA/PBS status in Australia not confirmed as at 2026-07-11 — check before citing as an available option. Applies to: dementia-and-depression. |
| Lecanemab in early Alzheimer's disease (CLARITY AD) | New England Journal of Medicine 2023;388(1) | Named by hand from the document's own opening text. Local copy at evidence/mental-health/dementia-and-depression/nejm-lecanemab-clarity-ad-2023.pdf. | |
| Living Clinical Guidelines for Stroke Management | Stroke Foundation | living guidelines (AU/NZ) | |
| Management of Bell's palsy | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Medication Overuse Headache | MSD Manual Professional Edition | ||
| Medication overuse headache | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for neurology/headache.md. |
| Medication overuse headache (Williams, Aust Prescr 2005;28:59-62) | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a dedicated topic source for neurology/medication-overuse-headache.md — a distinct, substantial full-length article (not the thin 2006 Letter to the Editor already registered as austprescr-medication-overuse-headache), covering classification, risk factors, diagnosis, pathophysiology, withdrawal management and relapse. |
| Medication-Overuse Headache (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Meniere Disease (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Migraine Headache in Childhood (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Migraine-Associated Vertigo | StatPearls (NCBI Bookshelf) | ||
| Multidisciplinary management of motor neurone disease | RACGP — Australian Journal of General Practice | MND is a group of neurodegenerative disorders best managed using a multidisciplinary approach, with the general practitioner as an integral part of the team. Catalogued from the local copy at evidence/neurology/_ajgp/mnd-multidisciplinary-management-2018.html. | |
| Multidisciplinary management of motor neurone disease | RACGP (AJGP) | AJGP 47(9), September 2018 | GP's coordinating role in MND multidisciplinary care (respiratory, nutrition/PEG, communication aids, palliative planning). Local copy: evidence/neurology/_ajgp/ |
| Multiple Sclerosis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Muscle Contraction Tension Headache | StatPearls (NCBI Bookshelf) | ||
| Muscular Dystrophy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Myasthenia Gravis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Myotonic Dystrophy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Neurofibromatosis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Neuropathy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Non motor symptoms of Parkinsons disease | RACGP — Australian Journal of General Practice | Regular assessment and monitoring of non-motor symptoms enable the clinician to support the implementation of effective interventions. Catalogued from the local copy at evidence/neurology/_ajgp/parkinsons-non-motor-symptoms-2021.html. | |
| Non-motor symptoms of Parkinson's disease | RACGP (AJGP) | AJGP 50(11), November 2021 | Systematic approach to non-motor Parkinson's symptoms (autonomic, neuropsychiatric, sleep, sensory) — often under-recognised and more disabling than motor symptoms; regular structured screening recommended. Local copy: evidence/neurology/_ajgp/ |
| Occipital Neuralgia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Office-based assessment of cognitive impairment | RACGP — Australian Journal of General Practice | Named by hand from the document's own opening text. Local copy at evidence/neurology/_ajgp/cognitive-impairment-assessment-2018.pdf. | |
| Optic Atrophy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Overview of Central Nervous System Tumors | MSD Manual Professional Edition | ||
| Overview of Intracranial Tumors | MSD Manual Professional Edition | ||
| Papilledema (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Parkinson Disease (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| PBS listings for SMA disease-modifying therapies (nusinersen, onasemnogene abeparvovec, risdiplam) | Pharmaceutical Benefits Scheme (Australian Government) | 2018 (nusinersen), 2021 (risdiplam), 2022 (onasemnogene abeparvovec) | Disease-modifying SMA therapies now PBS-funded in Australia, substantially changing prognosis for Type 1 SMA diagnosed early. |
| Peroneal Nerve Injury (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Plasma exchange for Guillain-Barre syndrome | Cochrane | ||
| Poliomyelitis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Polyarteritis Nodosa | StatPearls (NCBI Bookshelf) | ||
| Postherpetic Neuralgia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Pregabalin and gabapentin safety alert | Therapeutic Goods Administration (TGA) | 2021 boxed warning update | TGA added boxed warnings for misuse/abuse/dependence to pregabalin PI in 2021 following rising deaths/ambulance attendances; several states added gabapentinoids to real-time monitoring (e.g. Victoria SafeScript, 2023). |
| Pseudotumor Cerebri (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Putting the patient first | RACGP — Australian Journal of General Practice | This paper aims to assist GPs who wish to collaborate with their patient with probable Parkinson's disease to improve access to appropriate medication. Catalogued from the local copy at evidence/neurology/_ajgp/levodopa-probable-parkinsons-2025.html. | |
| Putting the patient first: Should GPs start people with probable Parkinson's disease on levodopa while awaiting diagnostic confirmation? | RACGP (AJGP) | AJGP 54(7), July 2025 | Discusses GP-initiated levodopa trial in probable (not yet specialist-confirmed) Parkinson's disease, weighing diagnostic-masking risk against harms of treatment delay while awaiting neurology review. Local copy: evidence/neurology/_ajgp/ |
| Ramsay Hunt Syndrome | StatPearls (NCBI Bookshelf) | ||
| Seizure (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Spinal Stenosis and Neurogenic Claudication (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Status Epilepticus (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Syringomyelia (StatPearls, NCBI Bookshelf) | StatPearls (NCBI Bookshelf) | Fluid-filled spinal cord cavity, often incidental MRI finding. Stage F dedicated source for musculoskeletal/thoracic-back-pain.md. | |
| Temporomandibular Syndrome (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Tetanus (Clostridium tetani Infection) (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| The Epley manoeuvre for benign paroxysmal positional vertigo (BPPV) | Cochrane | ||
| The perils of antiepileptic toxicity | NPS MedicineWise / Australian Prescriber | ||
| The state of migraine — an update on current understanding and management (AJGP 2021;50(12):915-919) | RACGP / Australian Journal of General Practice | ||
| The use of anticonvulsants for neuropathic pain (Bashford, Aust Prescr 1999;22:140-1) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 22, No 6, December 1999 | Low-yield fallback source for neurology/trigeminal-neuralgia.md and glossopharyngeal-neuralgia.md. Cites Level 1 RCT evidence (~70% significant response) for carbamazepine in trigeminal neuralgia specifically. |
| Treatment of restless legs syndrome and periodic limb movement disorder — AASM clinical practice guideline | American Academy of Sleep Medicine | 2024 | Recommends against long-term use of dopaminergic agents (levodopa, pramipexole, ropinirole, rotigotine) for RLS due to high augmentation risk (7-10%/year) — a major reversal from older guidance. Alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin) are now preferred first-line; iron studies (ferritin/transferrin saturation) should be checked and treated. |
| Trigeminal Neuralgia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Tuberous sclerosis | DermNet NZ | ||
| Tuberous Sclerosis Complex (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Understanding long-term neurodevelopmental outcomes of very and extremely preterm infants (AJGP 2019;48(1-2):26-32) | RACGP / Australian Journal of General Practice | ||
| Vasculitis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Vertebrobasilar Insufficiency (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Vertigo in Clinical Practice: Evidence-Based Diagnosis and Treatment (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Vestibular Neuronitis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Vestibular Schwannoma | StatPearls (NCBI Bookshelf) | Acoustic neuroma/vestibular schwannoma: presentation, epidemiology, workup, management. | |
| Wernicke Encephalopathy (StatPearls) | StatPearls (NCBI Bookshelf) |
Ophthalmology
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| 'Spots' the sign: Retinal detachment and vision loss prevention | RACGP (AJGP) | AJGP 55(7), July 2026 | Flashes/floaters red-flag recognition and same-day referral pathway for retinal tear/detachment. Local copy: evidence/ophthalmology/_ajgp/ |
| Acute Bacterial Conjunctivitis | MSD Manual Professional Edition | ||
| Acute red eye in children: A practical approach | RACGP (AJGP) | AJGP 49(12), December 2020 | Paediatric-specific red eye differential and referral thresholds. Local copy: evidence/ophthalmology/_ajgp/ |
| Age-related macular degeneration: Updates for general practitioners | RACGP (AJGP) | AJGP 55(7), July 2026 | Current GP-relevant AMD update. Local copy: evidence/ophthalmology/_ajgp/ |
| Allergic conjunctivitis | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/ophthalmology/_shared/Allergic conjunctivitis - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Approach to the watery eye | RACGP (AJGP) | AJGP 53, Supplement November 2024 | Assessment/management algorithm for epiphora in primary care. Local copy: evidence/ophthalmology/_ajgp/ |
| AREDS2 formula — National Eye Institute (NIH) | National Eye Institute / NIH | AREDS2, ongoing follow-up to 2022 (Report 28) | AREDS2 formula replaces beta-carotene with lutein/zeaxanthin — beta-carotene nearly doubled lung cancer risk in smokers/former smokers in the original AREDS formula; lutein/zeaxanthin has no such risk and AREDS2 was more effective at slowing AMD progression. Current recommended supplement formula for intermediate/advanced dry AMD. |
| Assessing Fitness to Drive for commercial and private vehicle drivers 2022 | Austroads / National Transport Commission | Supplied by Steve 2026-08-31. Australian national medical standards for private and commercial driver licensing. | |
| Assessing fitness to drive: Visual standards and general practitioner responsibilities | RACGP (AJGP) | AJGP 55(7), July 2026 | Austroads visual-acuity/visual-field standards for private vs commercial licences, monocular/diplopia standards, state-based mandatory-reporting variation, GP screening questions. Local copy: evidence/ophthalmology/_ajgp/ |
| Astigmatism (StatPearls) | StatPearls | ||
| Bacterial Conjunctivitis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Behind an acrobat's eye | RACGP (AJGP) | AJGP 50(12), December 2021 | Case report: orbital emphysema from blunt facial trauma (handstand fall) mimicking more sinister orbital pathology. Local copy: evidence/ophthalmology/_ajgp/ |
| Blepharitis (StatPearls) | StatPearls | ||
| Cataract (StatPearls) | StatPearls | ||
| Central Retinal Vein Occlusion | StatPearls (NCBI Bookshelf) | ||
| Chlamydia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Common eye infections (Aust Prescr 2018;41:67-72) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Conjunctivitis | AJGP | ||
| Corneal Abrasion | EM:RAP CorePendium | Supplied by Steve 2026-08-31. | |
| Corneal Foreign Body and Rust Ring Removal | EM:RAP CorePendium | Supplied by Steve 2026-08-31. | |
| Corneal ulcers in general practice | RACGP (AJGP) | AJGP 51(11), November 2022 | Corneal ulcer complications (scarring, perforation, vision loss) and referral urgency. Local copy: evidence/ophthalmology/_ajgp/ |
| Diabetic Retinopathy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Diplopia (StatPearls) | StatPearls | ||
| Dry eye syndrome | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/ophthalmology/dry-eye/Dry eye syndrome - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Ectropion (StatPearls) | StatPearls | ||
| Endophthalmitis (StatPearls) | StatPearls | ||
| Entropion (StatPearls) | StatPearls | ||
| Episcleritis (StatPearls) | StatPearls | ||
| Eye Foreign Bodies | EM:RAP CorePendium | Supplied by Steve 2026-08-31. | |
| Eye infections | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/ophthalmology/_shared/Eye infections - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Eye injuries: Understanding ocular trauma | RACGP (AJGP) | AJGP 51(7), July 2022 | Ocular trauma classification framework. Local copy: evidence/ophthalmology/_ajgp/ |
| General principles: topical eye drugs | Australian Medicines Handbook (AMH) | Catalogued from the local copy at evidence/ophthalmology/_shared/General principles_ topical eye drugs - Australian Medicines Handbook.pdf. | |
| Giant cell arteritis presenting as a unilateral sixth nerve palsy | RACGP (AJGP) | AJGP 54(7), July 2025 | Case of GCA presenting as isolated binocular diplopia (6th nerve palsy) rather than classic visual loss/headache; reinforces GCA as a differential for acute diplopia in patients >50. Prolonged prednisolone taper (1-2 years) with steroid-sparing agents (methotrexate, tocilizumab) now standard adjunct. Local copy: evidence/neurology/_ajgp/ |
| Glaucoma in general practice: An updated framework for Australian general practitioners | RACGP (AJGP) | AJGP 55(7), July 2026 | Updated GP framework for glaucoma risk-stratification, acute angle-closure emergency recognition, and specialist care coordination. Local copy: evidence/ophthalmology/_ajgp/ |
| Glaucomas | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/ophthalmology/_shared/Glaucomas - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). url scraped from the PDF's own footer (2026-08-14, stage-E acute-glaucoma pass) — was missing entirely, which passes `apply --dry` but fails every claim at resolve-claims.mjs with "source has no url to open". | |
| Herpes Zoster Ophthalmicus (StatPearls) | StatPearls | ||
| Hordeolum (Stye) (StatPearls) | StatPearls | ||
| Hypertensive Retinopathy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Luxturna (voretigene neparvovec) — TGA registration | Therapeutic Goods Administration | 2020-08-05 (TGA registration) | First TGA-approved gene therapy (2020) — subretinal injection for inherited retinal dystrophy (including a subset of retinitis pigmentosa) caused by biallelic RPE65 mutations. Only relevant to the specific RPE65-mutation subgroup, not RP broadly; genetic testing needed to identify eligible patients. |
| Management of Central Retinal Artery Occlusion — AHA Scientific Statement | American Heart Association / Stroke journal | 2021 | CRAO reframed as an acute ischaemic stroke equivalent; IV tPA (alteplase) within a 4.5-hour window may improve visual recovery in non-arteritic CRAO, though evidence remains limited/experimental. Represents a shift from purely supportive/ineffective management toward urgent stroke-pathway activation. |
| Management of conjunctivitis and other causes of red eye during the COVID-19 pandemic | RACGP (AJGP) | AJGP 49(10), October 2020 | Red eye differential and telehealth-era assessment framework. Local copy: evidence/ophthalmology/_ajgp/ |
| Management of microbial keratitis in general practice | RACGP (AJGP) | AJGP 48(8), August 2019 | Urgent-referral red flags for microbial keratitis; contact-lens-wear risk factors. Local copy: evidence/ophthalmology/_ajgp/ |
| Meibomian Gland Disease (StatPearls) | StatPearls | ||
| Myopia (StatPearls) | StatPearls | ||
| Ocular causes of visual distortions | RACGP (AJGP) | AJGP 48(8), August 2019 | Metamorphopsia/visual distortion as a marker of macular pathology (AMD, epiretinal membrane, central serous retinopathy). Local copy: evidence/ophthalmology/_ajgp/ |
| Ophthalmic associations in pregnancy | RACGP (AJGP) | AJGP 49(10), October 2020 | Pre-existing eye conditions exacerbated by pregnancy (diabetic retinopathy progression) plus new-onset pregnancy-specific ocular conditions. Local copy: evidence/ophthalmology/_ajgp/ |
| Ophthalmic trauma: First-line management in primary care | RACGP (AJGP) | AJGP 55(7), July 2026 | Practical first-line assessment/management framework for ocular trauma in general practice. Local copy: evidence/ophthalmology/_ajgp/ |
| Optic Atrophy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Paediatric photophobia: The pressure of a timely diagnosis | RACGP (AJGP) | AJGP 50(10), October 2021 | Photophobia in children as a red flag for paediatric glaucoma - timely diagnosis framework. Local copy: evidence/ophthalmology/_ajgp/ |
| Papilledema (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Pediatric Cataract (StatPearls) | StatPearls | ||
| Periorbital Cellulitis (StatPearls) | StatPearls | ||
| Retinitis Pigmentosa | MSD Manual Professional Edition | updated 2024-04-19 | Definition, examination triad, diagnosis and vitamin A/omega-3/lutein/vitamin E management detail for ophthalmology/retinitis-pigmentosa.md, stage E. |
| Retinitis Pigmentosa | StatPearls (NCBI Bookshelf) | updated 2024-02-12 | Epidemiology, genetics, syndromic associations, presentation, examination, diagnosis and management for ophthalmology/retinitis-pigmentosa.md, stage E (only prior dedicated source was a TGA Luxturna registration page). |
| Retinoblastoma (StatPearls) | StatPearls | ||
| Risk factors for the development and progression of proliferative diabetic retinopathy (Cochrane, CD013775) | Cochrane | ||
| Scleritis (StatPearls) | StatPearls | ||
| Strabismus (StatPearls) | StatPearls | ||
| Subconjunctival Hemorrhage (StatPearls) | StatPearls | ||
| The Funduscopic Examination (Clinical Methods, NCBI Bookshelf) | NCBI Bookshelf / Clinical Methods 3rd ed. | ||
| Thyroid Eye Disease | StatPearls (NCBI Bookshelf) | Low-yield fallback source for ophthalmology/thyroid-eye-disease.md. | |
| Thyroid eye disease: Primary care recognition and referral | RACGP (AJGP) | AJGP 55(7), July 2026 | TED/Graves' orbitopathy screening (CAS score), EUGOGO severity grading, teprotumumab (TGA-approved March 2025) and other ophthalmologist-led therapies, referral thresholds. Local copy: evidence/ophthalmology/_ajgp/ |
| Trachoma (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Uveitis (StatPearls) | StatPearls | ||
| Vitreous Floaters (StatPearls) | StatPearls | ||
| What are the benefits and harms of antibiotics for acute bacterial conjunctivitis? | Cochrane | ||
| When the eyes are dry | RACGP (AJGP) | AJGP 50(6), June 2021 | Dry eye differential in general practice including Sjogren-associated keratoconjunctivitis sicca. Local copy: evidence/rheumatology/_ajgp/ |
| When the eyes are dry: An algorithm approach and management in general practice | RACGP (AJGP) | AJGP 50(6), June 2021 | Dry eye disease assessment/management algorithm; underappreciated and underdiagnosed due to vague symptoms. Local copy: evidence/ophthalmology/_ajgp/ |
Paediatrics
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| 2019 ISCD Official Pediatric Positions: Skeletal Health Assessment in Children from Infancy to Adolescence | International Society for Clinical Densitometry (ISCD) | Approved 28 May 2019 | Official diagnostic criteria for paediatric osteoporosis: >=1 vertebral compression fracture is diagnostic regardless of BMD; otherwise need BOTH a clinically significant fracture history (>=2 long bone fractures by age 10, or >=3 by age 19) AND BMD Z-score <=-2.0. DXA reporting/terminology rules: T-scores and the term 'osteopenia' should never appear in paediatric DXA reports; 'low bone mineral mass or density' is the preferred term when Z-score <=-2.0 without a qualifying fracture history; minimum 6-12 month interval between follow-up scans; short-stature children need height-adjusted BMD. Applies to: paediatric osteoporosis. |
| A case of prolonged hyperbilirubinaemia in a neonate | Australian Journal of General Practice | ||
| A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence | Ward LM, Frontiers in Endocrinology 2024;14:1266986 | 25 January 2024 | Step-wise diagnostic algorithm for a child presenting with fractures: (1) rule out rickets and non-accidental injury first; (2) determine primary (congenital, e.g. osteogenesis imperfecta) vs secondary (acute/chronic illness - glucocorticoids, neuromuscular disease e.g. DMD, leukaemia, IBD) osteoporosis via history/exam/biochemistry; (3) assess potential for growth-mediated 'spontaneous' recovery (younger age, transient risk factors, milder vertebral collapse) before committing to drug therapy; (4-5) IV bisphosphonate (pamidronate or zoledronic acid) is specialist-led standard of care when recovery potential is limited, continued to epiphyseal fusion (primary) or resolution of risk factors (secondary). Low-trauma defined as a fall from standing height or less at no more than walking speed. Applies to: paediatric osteoporosis. |
| Abdominal pain - acute | Royal Children's Hospital Melbourne Clinical Practice Guidelines | Paediatric-specific acute abdominal pain guideline — replaces this page's existing unsourced paediatric section. Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/rch-abdominal-pain-acute.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). | |
| Abuse and violence: working with our patients in general practice (White Book) — Child abuse and neglect chapter | RACGP | 5th edition | The actual 'Child abuse and neglect' chapter content, as distinct from the existing racgp-white-book registry entry, which only caches the guideline's landing/preamble page (a table of contents with no chapter text) -- its ★ topic match on population-social-health/child-abuse-nai.md, stage E, looked plausible but didn't check out until this chapter-specific URL was fetched. Covers definitions/types of abuse, prevalence (13% of Australian adults report childhood abuse), risk factors (alcohol/drug abuse, mental illness, poor attachment), Table 9.2 signs/symptoms by abuse type, the stepped recognise-assess-respond-notify approach, Table 9.5 state-by-state mandatory reporting legislative thresholds (NSW 'risk of significant harm' definition verbatim), and post-report ongoing care. |
| ADHD with Dr Kevin Simon (The Curbsiders #374) | The Curbsiders Internal Medicine Podcast | Named by hand from the document's own opening text. Local copy at evidence/paediatrics/adhd/curbsiders-374-adhd-podcast-notes.pdf. | |
| Adrenocortical tumour: A case of precocious puberty | AJGP (RACGP) | ||
| Adult ADHD Self-Report Scale (ASRS-v1.1) symptom checklist | World Health Organization | Named by hand from the document's own opening text. Local copy at evidence/paediatrics/adhd/asrs-v1.1-screening-questionnaire.pdf. | |
| After vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Anatomy, Abdomen and Pelvis: Umbilical Cord (StatPearls) | StatPearls | ||
| Ankyloglossia (Tongue-Tie) | StatPearls (NCBI Bookshelf) | current as at fetch | Definition, prevalence (4-10%, more common in males), clinical impact (mainly impairs breastfeeding, also linked to speech disorders/malocclusion/gingival recession), evaluation and management of tongue-tie (management remains controversial; frenotomy the most common surgical option). Low-yield fallback for paediatrics/infant-feeding-speech-path.md, stage E (the page's category-wide topic matches — ajgp-paediatric-case-mix-2025 on "referral", heads-trial-plagiocephaly/ajgp-head-neck-pits-infant-2025 on "infant" — don't cover infant feeding or tongue-tie). |
| Anti-sickness medication for vomiting in acute stomach upsets in children (Cochrane Database of Systematic Reviews, CD005506) | Cochrane | Plain-language summary: antiemetics (chiefly ondansetron) for children/adolescents with acute gastroenteritis-related vomiting reduce ongoing vomiting, hospital admission and need for IV fluids, at the cost of more diarrhoea; evidence mainly from ED settings. | |
| Antihistamines and allergy | Australian Prescriber | ||
| Approach to the Limping Child | EM:RAP Corependium | current as at upload (2026-08-06) | Used for the new limping-child.md page: age-based differential framework, pyomyositis, benign acute childhood myositis, Seymour fracture, plantar puncture wound/retained foreign body management, osteoid osteoma, and Kocher-criteria/synovial-fluid reasoning for excluding septic arthritis (cross-linked to existing dedicated pages for septic arthritis/osteomyelitis/JIA/HSP/bone malignancy rather than duplicating them). Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Assessment of severity of respiratory conditions — RCH Clinical Practice Guideline | Royal Children's Hospital Melbourne / Paediatric Improvement Collaborative | Severity grading table (mild/moderate/severe/life-threatening) across behaviour, colour, respiratory rate, work of breathing, oxygenation, heart rate, blood pressure for paediatric respiratory conditions (asthma, bronchiolitis, croup, pneumonia). | |
| Atrial Septal Defect | StatPearls (NCBI Bookshelf) | ||
| Atrial Septal Defect (ASD) | MSD Manual Professional Edition | ||
| Australasian Bronchiolitis Guideline: 2025 Update | PREDICT network / Journal of Paediatrics and Child Health | 2025 update (supersedes 2016 guideline) | Genuine guideline update: HFNC no longer first-line for moderate bronchiolitis (reserved for persistent hypoxaemia after low-flow O2); age-stratified O2 saturation targets (<90% if >=6 weeks old and no comorbidity, <92% if <6 weeks or comorbidity); refined risk factors and biomarker guidance. URL switched 2026-08-15 from the Wiley DOI landing page (blocks automated fetch behind a cookie wall) to the free PMC full-text mirror, which fetches cleanly. |
| Australian Asthma Handbook | National Asthma Council Australia | living online handbook | |
| Australian evidence-based clinical practice guideline for ADHD | Australian ADHD Professionals Association (AADPA) | October 2022 | First dedicated Australian national ADHD guideline; confirms stimulants (methylphenidate, dexamfetamine, lisdexamfetamine) as first-line for children 6+; atomoxetine/guanfacine as alternatives. Summary of Recommendations doc (Oct 2022) verified directly 2026-07-11: 'Methylphenidate or dexamfetamine or lisdexamfetamine should be offered as the first-line pharmacological treatment' (rec 5.3.1 children/adolescents, 5.4.1 adults); multimodal treatment (pharmacological + non-pharmacological concurrently) recommended; parent/family training for young children; an ECG is not needed before starting stimulants/atomoxetine/guanfacine unless specific cardiac risk features are present. |
| Australian evidence-based clinical practice guideline for attention deficit hyperactivity disorder (ADHD), 1st edition 2022 — full guideline | Australian ADHD Professionals Association (AADPA) | Named by hand from the document's own opening text. Local copy at evidence/paediatrics/adhd/aadpa-adhd-full-guideline-2022.pdf. | |
| Australian Immunisation Handbook (check in browser) | Australian Government Department of Health | living online handbook | Connection resets on automated fetch (gov bot-blocking); well-known stable URL - confirm in browser. |
| Australian Immunisation Handbook — Pertussis (whooping cough) | Australian Government Department of Health, Disability and Ageing | current (living document) | Childhood NIP schedule: 2, 4, 6, 18 months + 4yrs + 11-13yr booster. Pregnancy vaccination recommended 20-32 weeks gestation (not 28-32). |
| Autism in Australia | Australian Institute of Health and Welfare (AIHW) | 2023 (2022 data) | 4.3% of Australians aged 5-14 were autistic in 2022 (up from 3.2% in 2018) — much higher than older ~1 in 160 estimates, reflecting broadened diagnostic criteria and improved recognition. |
| Autism in Australia, 2022 | Australian Bureau of Statistics (ABS) | 2022 | 4.3% of people aged 5-14 were autistic in 2022, up from 3.2% in 2018. |
| Autism Spectrum Disorder | StatPearls (NCBI Bookshelf) | Updated 17 Jan 2025 | Comprehensive overview: epidemiology, DSM-5 criteria, comorbidities, evaluation, management. |
| Autistic or with autism? Why the way GPs view and talk about autism matters | AJGP | AJGP Vol 50, No 3, March 2021 | Identity-first vs person-first language for autism, and why GP framing matters for care; local copy: evidence/paediatrics/_ajgp/ |
| Bacterial skin and soft tissue infections (Aust Prescr 2016;39:159-63) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 39, No 5, October 2016 | Empirical oral antibiotic choice/dosing for uncomplicated staphylococcal/streptococcal skin and soft tissue infections (di/flucloxacillin, cefalexin, clindamycin, trimethoprim-sulfamethoxazole for MRSA-suspected), incision and drainage for abscess/boils. Low-yield fallback for dermatology/paronychia.md stage E (dermnet-nz's cached article has no Australian-specific dosing). |
| Botulinum toxin type A injections for the treatment of lower limb spasticity in cerebral palsy (Cochrane review) | Cochrane | ||
| Branchial Cleft Anomalies | StatPearls (NCBI Bookshelf) | ||
| Breastfeeding: Expressing and supplementing | AJGP (RACGP) | Volume 51, Issue 3, March 2022 | Reasons for breastfeeding disruption (lactation risk factors, physiological, psychological, socioeconomic), supplementing, expressing, formula feeding options for GPs. |
| Breath-Holding Spells | StatPearls (NCBI Bookshelf) | Breath-holding spells in children: up to 5% prevalence, cyanotic (after crying/anger) vs pallid (after pain/fright) subtypes, benign course with normal neurodevelopment, triggers/precipitants, distraction-based management, natural history and reassurance. Low-yield fallback for paediatrics/behavioural-problems-in-childhood.md, stage E. | |
| Capillary vascular malformation (red birthmarks, port wine stain) | DermNet NZ | ||
| Cardiac murmurs in children | Australian Journal of General Practice | ||
| Catch-up vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Celiac Disease | StatPearls (NCBI Bookshelf) | tTG biology/wound-healing role and role as autoantigen, symptoms, serology non-specificity in other conditions. Low-yield fallback for paediatrics/coeliac-disease.md, stage E. | |
| Cerebral Palsy | StatPearls (NCBI Bookshelf) | current as at fetch | Definition, epidemiology, risk factors (prenatal/perinatal/postnatal), classification (topography, tone/motor type, GMFCS severity), clinical presentation, diagnosis (no routine imaging required for diagnosis itself), and GP/multidisciplinary management of cerebral palsy. Low-yield fallback for neurology/cerebral-palsy.md, stage E (page had no dedicated evidence; the only topic-matched category-wide source, statpearls-cvst, is about cerebral venous sinus thrombosis, unrelated). |
| Child Abuse and Neglect (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Child Intussusception | StatPearls (NCBI Bookshelf) | Low-yield fallback source for paediatrics/surgical.md (paediatric intussusception). | |
| Childhood Development | MSD Manual Professional Edition | ||
| Childhood otitis media I. General practitioner view (Australian Prescriber) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Childhood otitis media II. Specialist view (Australian Prescriber) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Choanal Atresia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Cleft Lip | StatPearls (NCBI Bookshelf) | ||
| Cleft Lip and Cleft Palate | MSD Manual Professional Edition | ||
| Cleft Palate | StatPearls (NCBI Bookshelf) | ||
| Clinical features of viral exanthems | AJGP | ||
| Coarctation of the Aorta | StatPearls (NCBI Bookshelf) | ||
| Common neonatal presentations | AJGP (RACGP) | ||
| Congenital Cytomegalovirus Infection | StatPearls (NCBI Bookshelf) | ||
| Congenital Hydrocephalus | MSD Manual Professional Edition | ||
| Constitutional Growth Delay | StatPearls (NCBI Bookshelf) | ||
| Cradle cap (infantile seborrhoeic dermatitis) | DermNet NZ | ||
| Crohn Disease | StatPearls (NCBI Bookshelf) | History/physical by disease location, malabsorption/nutrient-deficiency complications, fistula formation, fecal calprotectin for monitoring activity. Low-yield fallback for paediatrics/paeds-inflammatory-bowel-disease.md, stage E (case-mix topic-match source turned out off-topic). | |
| Cryptorchidism (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Cyanotic Heart Disease | StatPearls (NCBI Bookshelf) | ||
| Dehydration in Children — MSD Manual Professional Edition | MSD Manual Professional Edition | ||
| Delayed Puberty (StatPearls) | StatPearls | ||
| Dermal Melanocytosis (Mongolian Spot) | StatPearls (NCBI Bookshelf) | ||
| Developmental Coordination Disorder (Dyspraxia) | StatPearls (NCBI Bookshelf) | DCD/dyspraxia: neurodevelopmental disorder of motor coordination in an otherwise healthy child with normal neurological exam, ~5% prevalence, fine/gross motor impairment, not explained by intellectual disability, impact on socialisation and academic performance, persistence into adulthood in a substantial proportion. Low-yield fallback for paediatrics/behavioural-problems-in-childhood.md, stage E. | |
| Developmental Milestones (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Diabetic ketoacidosis — RCH Clinical Practice Guideline | Royal Children's Hospital Melbourne | Paediatric DKA: diagnostic criteria, severity grading by pH/bicarbonate, fluid and insulin regimens, and cerebral oedema risk/management. Aligned to ISPAD 2022. | |
| Diaper Dermatitis | StatPearls (NCBI Bookshelf) | ||
| Early intensive behavioral intervention (EIBI) for increasing functional behaviors and skills in young children with autism spectrum disorders (ASD) | Cochrane | Plain-language summary: EIBI evidence supports use for some children but quality is weak/low-certainty, only one optimally-designed RCT. | |
| Educating antenatal patients about cytomegalovirus infection | AJGP | ||
| Enteral nutritional therapy for treatment of active Crohn's disease | Cochrane | ||
| Enterobius Vermicularis (Pinworm) | StatPearls | ||
| Enuresis | StatPearls (NCBI Bookshelf) | ||
| Epiglottitis | MSD Manual Professional Edition | ||
| Epiglottitis | StatPearls (NCBI Bookshelf) | ||
| Erythema Toxicum (StatPearls) | StatPearls | ||
| Evaluating squints in children | O'Dowd C, Australian Family Physician 2013;42(12) | December 2013 | Practical GP screening framework for childhood strabismus: primary/secondary causes, differential diagnosis (ocular instability of infancy, pseudostrabismus, >15 degrees/>3 month abnormality threshold), the four bedside screening tests (light reflex, red reflex, cover, uncover), and referral principles. Applies to: strabismus. |
| Exanthems (reactive rashes) | DermNet NZ | ||
| Eye turns or squints (Strabismus) - pre-referral guideline | Royal Children's Hospital Melbourne, Primary Care Liaison | Reviewed Aug 2009, last updated Aug 2011 | Concrete age- and type-based referral urgency triage (esotropia/exotropia) for childhood strabismus, including which presentations need immediate same-day ophthalmology contact vs semi-urgent or routine referral. Applies to: strabismus. |
| Failure to Thrive (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Febrile child — RCH Clinical Practice Guideline | Royal Children's Hospital Melbourne / Paediatric Improvement Collaborative | Age-stratified fever workup (neonate/young infant/older infant), unwell features red flags, occult bacteraemia note, illness-severity predictors. | |
| Febrile seizure (RCH Melbourne Clinical Practice Guideline) | Royal Children's Hospital Melbourne | ||
| Febrile Seizure (StatPearls, NCBI Bookshelf) | StatPearls (NCBI Bookshelf) | ||
| Fever in Infants and Children — MSD Manual Professional Edition | MSD Manual Professional Edition | ||
| Fibreoptic phototherapy for neonatal jaundice | Cochrane | ||
| Frenotomy for tongue-tie in newborn infants | Cochrane | Published 11 March 2017 (CD011065) | 5 RCTs, n=302: frenotomy does not consistently improve infant feeding but likely improves maternal nipple pain; quality of evidence very low to moderate. |
| Functional abdominal pain disorders in children | AJGP | AJGP Vol 54, No 6, June 2025 | Rome IV-based functional abdominal pain disorders in children -- assessment and management; local copy: evidence/paediatrics/_ajgp/ |
| Growth and Weight Faltering in Children | MSD Manual Professional Edition | ||
| Growth Hormone Deficiency in Children | MSD Manual Professional Edition | ||
| Guidelines for Preventive Activities in General Practice (Red Book) — Childhood Development | RACGP | ||
| Head and neck pits in an infant | AJGP | AJGP Vol 54, No 6, June 2025 | Congenital head/neck pits and branchial arch anomalies (pre-auricular sinus, branchial cleft remnants); local copy: evidence/paediatrics/_ajgp/ |
| Head lice. Pediculosis capitis (DermNet) | DermNet | Dimeticone/malathion/permethrin resistance, cure rates, physical vs chemical treatment options. | |
| HElmet therapy Assessment in infants with Deformed Skulls (HEADS) randomised controlled trial | BMJ / academic RCT (Netherlands) | RCT protocol/results | RCT found helmet therapy for positional plagiocephaly no more effective than natural course; 2024 systematic review confirms evidence base remains weak (mostly retrospective, low-quality studies). |
| Hemangioma (StatPearls) | StatPearls (NCBI Bookshelf) | living online resource | Infantile hemangioma overview - epidemiology, clinical course, GLUT1 pathophysiology, propranolol treatment. |
| Hirschsprung Disease | MSD Manual Professional Edition | ||
| Hirschsprung Disease | StatPearls (NCBI Bookshelf) | ||
| Hydrocephalus | StatPearls (NCBI Bookshelf) | ||
| Identifying and supporting autistic preschoolers and their families | AJGP | AJGP Vol 50, No 3, March 2021 | Early recognition and family support for autism in preschool-age children; local copy: evidence/paediatrics/_ajgp/ |
| IgA Vasculitis (Henoch-Schonlein Purpura) (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Immunisation and allergy in children and adults | AJGP | ||
| Infantile colic | Australian Prescriber | ||
| Infantile Colic | StatPearls (NCBI Bookshelf) | ||
| Infantile haemangioma: Complications and treatment | DermNet NZ | Page-level DermNet article: complications and treatment (propranolol) of infantile haemangioma. | |
| Infantile haemangioma: Definition and pathogenesis | DermNet NZ | Page-level DermNet article: epidemiology, clinical course, pathogenesis of infantile haemangioma. | |
| Inguinal Hernia (Archived) | StatPearls (NCBI Bookshelf) | Low-yield fallback source for paediatrics/surgical.md (inguinal hernia epidemiology/pathophysiology). Archived StatPearls topic but content is stable descriptive/anatomical material. | |
| Inguinal hernias in children | RACGP — Australian Journal of General Practice | Inguinal hernia/hydrocoele/undescended testis differentiation in children, epidemiology, referral timing. Local copy: evidence/paediatrics/_ajgp/inguinal-hernias-in-children-2020.html. | |
| Interpreting tests for coeliac disease: Tips, pitfalls and updates (AJGP 2018;47(1-2)) | RACGP (Australian Journal of General Practice) | ||
| Intervention overuse in paediatric care in Australian metropolitan general practice | AJGP | AJGP Vol 54, No 6, June 2025 | About 1 in 10 paediatric GP consultations involve low-value care (unnecessary antibiotics for URTI, imaging); local copy: evidence/paediatrics/_ajgp/ |
| Interventions during pregnancy and childbirth for preventing cerebral palsy: an overview of Cochrane reviews (CD012077) | Cochrane | ||
| Juvenile Idiopathic Arthritis | StatPearls (NCBI Bookshelf) | ||
| Kawasaki Disease (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Labial Adhesions | StatPearls (NCBI Bookshelf) | ||
| Lactose Intolerance | StatPearls | ||
| Laryngomalacia | StatPearls (NCBI Bookshelf) | ||
| Laxatives for the management of childhood constipation (Cochrane Database of Systematic Reviews, 2016) | Cochrane | ||
| Lymphatic malformation (lymphangioma, cystic hygroma) | DermNet NZ | ||
| Management of umbilical granuloma in infants | Australian Family Physician / RACGP | ||
| Managing constipation in children (Aust Prescr 2002;25:131-2) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 25, No 4, August 2002 | Assessment/management review: Hirschsprung's suspected if meconium delayed >48h or constipation in early infancy; rectal exam usually unnecessary/distressing, inspection of perineum usually sufficient; no need for routine abdominal X-ray to diagnose constipation; general exam should check growth and neurological status, abdominal palpation for distension/faecal loading; laxative-first stepped approach (dated — predates macrogol/PEG as first-line, treat drug-choice specifics as historical, not current). Low-yield fallback for paediatrics/constipation-in-childhood.md, stage E (the page's category-wide topic matches, fendo-ward-paediatric-osteoporosis-2024 and nip-schedule-2026, only share the word "childhood" and don't cover constipation). |
| Managing constipation in children (Australian Prescriber) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Managing otitis media: an evidence-based approach (Australian Prescriber) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Managing urinary incontinence that begins in childhood | AJGP (RACGP) | ||
| Midgut Malrotation | StatPearls (NCBI Bookshelf) | Low-yield fallback source for paediatrics/surgical.md (bilious vomiting/malrotation caution). | |
| Milia | StatPearls (NCBI Bookshelf) | ||
| Miliaria | StatPearls (NCBI Bookshelf) | ||
| Miliaria (heat rash) | DermNet NZ | ||
| Multiple short courses of corticosteroids in children | AJGP | AJGP Vol 50, No 3, March 2021 | Cumulative risk of repeated short oral corticosteroid courses in children (asthma, croup, IBD, nephrotic syndrome) -- growth/weight/behavioural/immunosuppression effects; local copy: evidence/paediatrics/_ajgp/ |
| Naevus simplex (salmon patch) | DermNet NZ | ||
| Napkin dermatitis | DermNet NZ | ||
| National Immunisation Program Schedule | Australian Government Department of Health, Disability and Ageing | current from June 2026 | Official NIP schedule table (childhood/adolescent/adult/pregnancy/medical-risk-condition schedules). Current schedule gives MMR alone at 18 months (Priorix) and moves varicella to the 4-year dose combined with MMR as MMRV (Priorix-Tetra), alongside the DTaP/IPV booster. |
| National Immunisation Program Schedule PDF | Australian Department of Health, Disability and Ageing | Supplied by Steve 2026-08-31. health.gov.au blocks automated fetch. | |
| Navigating heart murmurs in children | AJGP | AJGP Vol 54, No 6, June 2025 | GP assessment framework for paediatric heart murmurs; local copy: evidence/paediatrics/_ajgp/ |
| Neonatal Jaundice | StatPearls (NCBI Bookshelf) | ||
| Nevus Flammeus (Port-Wine Stain) | StatPearls (NCBI Bookshelf) | ||
| Newborn Hearing Screening (StatPearls) | StatPearls | ||
| NSW Immunisation Schedule | NSW Health | Supplied by Steve 2026-08-31. | |
| Orbital cellulitis in the paediatric population | AJGP | AJGP Vol 54, No 6, June 2025 | Recognition of orbital cellulitis (vision/life-threatening) vs preseptal cellulitis in children; local copy: evidence/paediatrics/_ajgp/ |
| Overcoming challenges faced by breastfeeding mothers | Australian Family Physician (RACGP) | AFP August 2016 | Maternal-side breastfeeding problems (nipple pain/attachment, mastitis, low supply) — GP management. Fetched but not deep-read/cited for infant-feeding-speech-path stage-F pass (2026-08-21); more maternal-focused, kept in registry for future use. |
| Overview of Inflammatory Bowel Disease | MSD Manual Professional Edition | Differentiating Crohn disease vs ulcerative colitis table (rectal bleeding pattern, fistula presence, perianal disease), paediatric malabsorption/growth-retardation complication. Low-yield fallback for paediatrics/paeds-inflammatory-bowel-disease.md, stage E. | |
| Paediatric care in general practice: case mix, referral patterns and healthcare costs | AJGP | AJGP Vol 54, No 6, June 2025 | Context on GP paediatric consultation types/referral/cost patterns; local copy: evidence/paediatrics/_ajgp/ |
| Paediatric constipation: An approach and evidence-based treatment regimen | AJGP | AJGP Vol 47, No 5, May 2018 | Rome IV criteria, organic causes, weight-based PEG disimpaction/maintenance dosing, stimulant laxative dosing, referral criteria, prognosis stats. |
| Paediatric head shape and craniosynostosis | AJGP | AJGP Vol 51, No 1-2, Jan-Feb 2022 | Distinguishing positional plagiocephaly from craniosynostosis, red flags and referral; local copy: evidence/paediatrics/_ajgp/ |
| Paediatric inhaled airway foreign bodies: An update | AJGP (RACGP) | AJGP Vol 48, Issue 4, April 2019 (Clinical) | Classic three-phase presentation (acute impaction -> asymptomatic latent phase -> chronic complications); ~50% present asymptomatically, >90% have a history of aspiration/choking; up to 25% have a normal CXR; any suspected case warrants tertiary ENT referral for bronchoscopy regardless of normal exam/imaging. Prevention guidance (foods to avoid by age) and the Australian Resuscitation Council choking first-aid algorithm (back blows -> chest thrusts). Local copy: evidence/respiratory/_ajgp/paediatric-inhaled-foreign-bodies.html |
| Paediatric neck lumps | AJGP | ||
| Paediatric recurrent urinary tract infections and vesicoureteric reflux | AJGP | AJGP Vol 50, No 7, July 2021 | Recurrent paediatric UTI workup and VUR management -- new topic gap; local copy: evidence/paediatrics/_ajgp/ |
| Paediatric rotational abnormalities: a primer | AJGP | AJGP Vol 50, No 3, March 2021 | In-toeing/out-toeing/torsional lower-limb abnormalities in children -- normal variation over time, referral thresholds; local copy: evidence/paediatrics/_ajgp/ |
| Patent Ductus Arteriosus (PDA) — MSD Manual Professional Edition | MSD Manual Professional Edition | ||
| Patent Ductus Arteriosus (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| PBS listings for SMA disease-modifying therapies (nusinersen, onasemnogene abeparvovec, risdiplam) | Pharmaceutical Benefits Scheme (Australian Government) | 2018 (nusinersen), 2021 (risdiplam), 2022 (onasemnogene abeparvovec) | Disease-modifying SMA therapies now PBS-funded in Australia, substantially changing prognosis for Type 1 SMA diagnosed early. |
| Pediatric Appendicitis | StatPearls (NCBI Bookshelf) | Low-yield fallback source for paediatrics/surgical.md (paediatric appendicitis presentation). | |
| Pediatric Feeding Disorders: Recognition, Diagnosis, and Management | StatPearls (NCBI Bookshelf) | Last Update: June 13, 2025 | Consensus (2019) definition of pediatric feeding disorders across 4 domains (medical, nutritional, feeding skill, psychosocial); etiology, evaluation, multidisciplinary management. |
| Pediatric Functional Constipation (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Pediatric Hearing Loss (StatPearls) | StatPearls | ||
| Pediatric Lower Extremity Fractures | EM:RAP Corependium | current as at upload (2026-08-06) | Used for: toddler's fracture enrichment on lower-limb-fractures.md (occult-fracture rate ~93% on follow-up film, walking-boot-vs-cast equivalence, internal oblique view); the new paediatric-ankle-fractures section of ankle-fractures-dislocations.md (Salter-Harris classification, X-ray-negative Salter-Harris I vs sprain equivalence, Tillaux and triplane fracture patterns); and the SCFE enrichment of childhood-hip-disorders.md (Klein line/modified Klein line, Drehmann sign, shaft angle of Southwick, bilateral-slip risk). Not independently verified beyond the source page itself (subscription content, cite by name only). |
| Pediatric Umbilical Hernia | StatPearls (NCBI Bookshelf) | Low-yield fallback source for paediatrics/surgical.md (umbilical hernia natural history/referral). | |
| Pediculosis (StatPearls) | StatPearls (NCBI Bookshelf) | Head/body/pubic lice — epidemiology, diagnosis, treatment, resistance, differential diagnosis. Updated Apr 2026. | |
| Periorbital Cellulitis (StatPearls) | StatPearls | ||
| Pharmacological management for acute behavioural disturbance in children and adolescents | Therapeutic Guidelines Ltd | Supplied by Steve 2026-08-31. | |
| Phimosis | StatPearls (NCBI Bookshelf) | Low-yield fallback source for paediatrics/surgical.md (physiological vs pathological phimosis, BXO). Also on-topic for mens-health/phimosis-paraphimosis.md (Resource Seeding, 2026-08-23). | |
| Preauricular Sinus: A Tale of Forgetful Rediscovery (Cureus, 2020) | Cureus | ||
| Precocious Puberty | MSD Manual Professional Edition | ||
| Precocious Puberty | StatPearls (NCBI Bookshelf) | ||
| Preparing for vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Propranolol for infantile haemangioma | DermNet NZ | Page-level DermNet article on propranolol as first-line treatment for infantile haemangioma - dosing, monitoring, safety. | |
| Pulmonary Atresia With Ventricular Septal Defect | StatPearls (NCBI Bookshelf) | ||
| Pyloric Stenosis | StatPearls (NCBI Bookshelf) | Low-yield fallback source for paediatrics/surgical.md (infantile hypertrophic pyloric stenosis). | |
| RANZCP — ADHD across the lifespan (resource) | RANZCP | current resource | RANZCP resource page on ADHD across the lifespan; complements (does not replace) the AADPA 2022 national ADHD clinical practice guideline, which is the definitive Australian source. |
| RCH Clinical Practice Guidelines | Royal Children's Hospital Melbourne / Paediatric Improvement Collaborative | living A-Z guidelines | |
| Recognising attention deficit hyperactivity disorder across the lifespan (Poulton) | RACGP - Australian Journal of General Practice (AJGP) | AJGP Vol 50 No 3, March 2021, pp.110-113 | GP-focused framework for recognising ADHD across the lifespan. ADHD affects ~10% of children and ~5% of adults; best considered a spectrum rather than categorical. Key to diagnosis is functional impairment across two or more settings (not just symptom counts). ODD is commonly part of the ADHD presentation (~40% of primary-school children with ADHD have diagnosable ODD; another ~40% have subthreshold ODD features). Intellectually able people may mask ADHD with coping strategies; it can be overlooked when another psychiatric diagnosis is present. Stimulant medication is effective for ODD as well as ADHD (often at higher dose). |
| Recognising, supporting and understanding Autistic adults in general practice settings | AJGP | AJGP Vol 50, No 3, March 2021 | Adult ASD presentation, camouflaging/masking, GP practical accommodations — complements the language-focused companion article already registered (ajgp-autism-language-gp-2021). |
| Recognition of the seriously unwell neonate and young infant — RCH Clinical Practice Guideline | Royal Children's Hospital Melbourne / Paediatric Improvement Collaborative | Red-flag features and sepsis-recognition framework for neonates/young infants. | |
| Red Nose Australia — Six Safe Sleep Recommendations | Red Nose Australia | current (2025 refresh) | Six recommendations: back sleeping, uncovered head/face, smoke-free (incl. vaping), safe sleep space, room-share for at least 6 months, breastfeed if possible. Also covers safer bed-sharing practices if families choose to co-sleep. |
| Respiratory syncytial virus (RSV) vaccine — maternal immunisation (Abrysvo) | Australian Government Department of Health, Disability and Ageing / Australian Immunisation Handbook | TGA approved March 2024; NIP-funded from 3 February 2025 | New addition to routine antenatal immunisation not covered in the original 2020 note: Abrysvo (bivalent RSV prefusion F vaccine, Category A) recommended from 28 weeks gestation (ideally before 36 weeks) each pregnancy, to protect infants from RSV via transplacental antibody transfer. Window corroborated by HNE HealthPathways (28-36 weeks; infant not protected unless born ≥2 weeks post-vaccination). |
| Roseola | DermNet NZ | Page-level DermNet article: roseola infantum (HHV-6/7) - cause, epidemiology, clinical features, complications, treatment. | |
| Roseola Infantum (StatPearls) | StatPearls (NCBI Bookshelf) | living online resource | Roseola infantum (exanthema subitum/sixth disease) overview - epidemiology, HHV-6/7 aetiology, clinical course, management. |
| Scarlet Fever (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Septic Shock (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Short Stature | StatPearls (NCBI Bookshelf) | ||
| Skin care interventions for preventing eczema and food allergy | Cochrane | ||
| Somatrogon for growth hormone deficiency (Aust Prescr 2022;45:181) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Staphylococcal Scalded Skin Syndrome | StatPearls (NCBI Bookshelf) | ||
| Staphylococcal scalded skin syndrome (SSSS) | DermNet NZ | ||
| Strabismus (StatPearls) | StatPearls | ||
| Stuttering (Stammering) | StatPearls (NCBI Bookshelf) | Developmental stuttering (childhood-onset fluency disorder): prevalence ~5-10% of preschoolers, onset typically age 2-6, disfluency types (repetitions, prolongations, blocks), distinguishing normal developmental disfluency from a pathological fluency disorder, and management including speech-language pathology referral. Low-yield fallback for paediatrics/behavioural-problems-in-childhood.md, stage E. Also the zero-source fill for mental-health/stammering-stuttering.md (Resource Seeding, 2026-08-23). | |
| Talipes Equinovarus | StatPearls (NCBI Bookshelf) | ||
| Talipes Equinovarus (Clubfoot) and Other Congenital Foot Anomalies | MSD Manual Professional Edition | ||
| Temper Tantrums | MSD Manual Professional Edition | Age of onset/prevalence, causes, presentation, management (redirect rather than address the trigger; remove from situation) for paediatrics/behavioural-problems-in-childhood.md, stage F. | |
| Testing for coeliac disease (Lewis, Haridy, Newnham, Aust Prescr 2017;40:105-8) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 40, No 3, June 2017 | Serological testing pathway (tTG-IgA first line, IgA deficiency caveat), genotype testing, endoscopy/biopsy gold standard, and ESPGHAN paediatric no-biopsy pathway (tTG >10x ULN) discussion. Low-yield fallback for paediatrics/coeliac-disease.md, stage E (case-mix topic-match source turned out off-topic). |
| Tetralogy of Fallot | StatPearls (NCBI Bookshelf) | ||
| The assessment of premature thelarche | AJGP (RACGP) | ||
| The management of croup | Australian Prescriber | current | Low-dose dexamethasone (0.15 mg/kg) as effective as higher doses; nebulised budesonide adds no benefit over oral dexamethasone alone. |
| The role of drugs in the treatment of autism | Australian Prescriber | Aust Prescr 2023;46:49-53 | Pharmacological management of autism-associated irritability/comorbid symptoms (risperidone, aripiprazole, melatonin) — no drug treats core ASD features. |
| Thyroglossal Duct Cyst | StatPearls (NCBI Bookshelf) | ||
| Topical corticosteroids for treating phimosis in boys | Cochrane | Cochrane review (2024 update, CD008973.pub3): topical corticosteroids vs placebo/no treatment for phimosis resolution/retraction, GRADE certainty ratings, adverse effects. Local copy: evidence/_sources/cochrane-phimosis-topical-corticosteroids.html. | |
| TORCH Complex (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Tourette syndrome in children | AJGP | AJGP Vol 50, No 3, March 2021 | Tourette syndrome prevalence/recognition/management in the school-age population; local copy: evidence/paediatrics/_ajgp/ |
| Tracheomalacia | StatPearls (NCBI Bookshelf) | ||
| Transposition of the Great Arteries | StatPearls (NCBI Bookshelf) | ||
| Treating head lice (Wargon, Aust Prescr 2000;23:62-3) | Australian Prescriber / Therapeutic Guidelines Ltd | Vol 23, No 3, June 2000 | Review of head lice (Pediculosis capitis) treatment: diagnosis by finding live lice/viable eggs; permethrin (10 min application, not ovicidal so repeat after a week) vs maldison (organophosphate, applied then washed off after 12 hours) vs oral ivermectin for resistant cases; systematic review supports permethrin efficacy; advice to wash clothing/headgear/combs (lice survive off-host ~3 days, eggs ~10 days) and examine/treat contacts. Low-yield fallback for paediatrics/head-lice.md, stage E. |
| Treatment of vulvovaginitis | Australian Prescriber | ||
| Tricuspid Atresia | StatPearls (NCBI Bookshelf) | ||
| Truncus Arteriosus | StatPearls (NCBI Bookshelf) | ||
| Ulcerative Colitis | StatPearls (NCBI Bookshelf) | Main symptom bloody diarrhoea plus urgency/tenesmus, fecal calprotectin utility in diagnosis/ruling out IBD. Low-yield fallback for paediatrics/paeds-inflammatory-bowel-disease.md, stage E. | |
| Understanding long-term neurodevelopmental outcomes of very and extremely preterm infants (AJGP 2019;48(1-2):26-32) | RACGP / Australian Journal of General Practice | ||
| Upper Respiratory Tract Infections With Focus on The Common Cold (StatPearls) | StatPearls (NCBI Bookshelf) | Common cold/URTI: rhinovirus, coronavirus, RSV, parainfluenza and other viral aetiology, self-limited course, clinical features, postviral/post-infectious cough mechanism (bronchial hyperresponsiveness), and supportive management (no role for antibiotics). | |
| Vaginitis in Children | MSD Manual Professional Edition | ||
| Ventricular Septal Defect (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Ventricular Septal Defect (VSD) — MSD Manual Professional Edition | MSD Manual Professional Edition | ||
| Your baby and the first few weeks | Healthdirect Australia |
Palliative Care
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| A National Core Community Palliative Care Medicines List | RACGP (AJGP) | AJGP 54(9), September 2025 | National standard 4-medicine list for community terminal-phase symptom control: clonazepam drops, haloperidol injection, hyoscine butylbromide injection, morphine injection. GPs should pre-emptively prescribe and coordinate with the patient regular pharmacy. |
| A primary care approach to bereavement (British Journal of General Practice 2026;76(765):189-191) | British Journal of General Practice (RCGP) | BJGP 2026;76(765):189-191 | |
| Advance care planning | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/_shared/Advance care planning - Therapeutic Guidelines.pdf. | |
| Anorexia and Cachexia (StatPearls) | StatPearls | ||
| Assessing pain in palliative care | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/pain-control-in-palliative-care/Assessing pain in palliative care - Therapeutic Guidelines.pdf. | |
| Carcinoid Syndrome (StatPearls) | StatPearls | ||
| Communicating with and supporting patients with palliative care needs | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/_shared/Communicating with and supporting patients with palliative care needs - Therapeutic Guidelines.pdf. | |
| Decision-making and ethical challenges in palliative care | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/_shared/Decision-making and ethical challenges in palliative care - Therapeutic Guidelines.pdf. | |
| Delirium Clinical Care Standard | Australian Commission on Safety and Quality in Health Care (ACSQHC) | revised 2021 | Eight quality statements on prevention, early diagnosis (screening at-risk patients), and management of delirium in adults, minimising antipsychotic use. Applies to: delirium. |
| Deprescribing in older people | Australian Prescriber | ||
| Drugs that may increase the risk of seizures | Australian Medicines Handbook (AMH) | Catalogued by hand from the local copy at evidence/neurology/_shared/Drugs that may increase the risk of seizures - Australian Medicines Handbook.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Emergencies in palliative care | Therapeutic Guidelines Ltd (eTG complete) | Catalogued by hand from the local copy at evidence/palliative-care/_shared/Emergencies in palliative care - Therapeutic Guidelines.pdf (fell through the automatic cataloguer: already fuzzy-matched to a wrong existing source). | |
| Grief and Prolonged Grief Disorder | StatPearls (NCBI Bookshelf) | current as at fetch | Low-yield fallback for population-social-health/illness-loss-death-of-child-partner-family.md: the page's category-wide topic-matched sources (AJGP domestic/family violence, IPV, coercive control) share only the word 'family'/'partner'/'child' and are a different topic entirely, so treated as no dedicated evidence. Covers stages/phases of grief, acute vs prolonged grief disorder criteria and prevalence, risk factors, and at-risk groups. |
| Grief, loss and the COVID-19 pandemic | RACGP (AJGP) | AJGP 49 Suppl 20, May 2020 | |
| How low to go with glucose control | Australian Prescriber | ||
| Interventions for supporting family and friends of patients at the end of life (Cochrane, CD007617) | Cochrane | ||
| Kubler-Ross Stages of Dying and Subsequent Models of Grief (Archived) | StatPearls (NCBI Bookshelf) | current as at fetch | Same low-yield-fallback context as statpearls-grief-prolonged-grief-disorder. Covers the Kubler-Ross five-stage model (denial, anger, bargaining, depression, acceptance) and later grief models (Worden's tasks, dual-process model). |
| Making an Advance Care Directive (information booklet) | NSW Ministry of Health | ||
| Malignancy-Related Hypercalcemia (StatPearls) | StatPearls | ||
| Management of constipation in people receiving palliative care | RACGP (AJGP) | AJGP 54(8), August 2025 | Osmotic + stimulant laxative combination first-line, not monotherapy; bulking/fibre agents not recommended (inadequate fluid intake); prophylactic laxative essential when starting opioids; methylnaltrexone for refractory opioid-induced constipation (contraindicated in bowel obstruction/gastric ulcer/peritoneal carcinomatosis); constipation increasingly patient-defined. |
| National Elder Abuse Phone Line (1800 ELDERHelp) | Australian Government Department of Health, Disability and Ageing | living service | Added Phase 4 (2026-07-08); redirects to state/territory elder abuse services. |
| Nonpharmacological management of pain in palliative care | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/pain-control-in-palliative-care/Nonpharmacological management of pain in palliative care - Therapeutic Guidelines.pdf. | |
| palliAGED - palliative care evidence for aged care | CareSearch, Flinders University (Australian Government funded) | 27 evidence summaries, living | |
| Palliative management of breathlessness | RACGP (AJGP) | AJGP 54(8), August 2025 | RCT evidence for fans/air movement and walking aids (rollators); CBT reduces breathlessness/anxiety/depression together; recent RCT found sustained-release morphine ineffective for COPD-related breathlessness specifically, shifting emphasis toward reserving opioids for limited-option cases; corticosteroid trial dosing for suspected inflammatory cause. |
| Palliative management of depression in advanced cancer | RACGP (AJGP) | AJGP 54(8), August 2025 | Exclude biological mimics first (hypothyroidism, hypercalcaemia, steroids, cerebral mets). Routine screening not recommended (tools unvalidated for this population). Tamoxifen interaction: avoid fluoxetine/paroxetine/bupropion. Time toxicity concept for non-pharmacological interventions. |
| Palliative management of nausea and vomiting in advanced cancer | RACGP (AJGP) | AJGP 53 supplement, November 2024 | RCT found no difference in response rates between mechanism-based and empiric antiemetic selection (53% both); haloperidol now regarded as evidence-based first-line; levomepromazine non-inferior but more sedating; ondansetron limited benefit in advanced cancer despite chemo-nausea evidence, constipating/costly. |
| Palliative management of type 2 diabetes mellitus in patients with advanced cancer | RACGP (AJGP) | AJGP 54(8), August 2025 | De-intensification approach: target glucose ranges by prognosis timeframe (weeks-months 6-15, days <20, end-of-life symptom-based only); stop sulfonylureas/GLP-1/SGLT2 first, continue metformin/DPP-4 longer; avoid HbA1c and CGM at end-of-life; beta-cell burnout/type 3c diabetes exception needs ongoing insulin. |
| Palliative sedation: a safety net for the relief of refractory and intolerable symptoms at the end of life | RACGP — Australian Journal of General Practice | Named by hand from the document's own opening text. Local copy at evidence/palliative-care/_ajgp/ajgp-palliative-sedation.pdf. | |
| Palliative sedation: A safety net for the relief of refractory and intolerable symptoms at the end of life | RACGP (AJGP) | AJGP 48(12), December 2019 | Palliative sedation as a defined third-line intervention distinct from euthanasia/PAS: deliberate reduction of consciousness for refractory + intolerable symptoms, <2 week prognosis, multidisciplinary planning and informed consent. Drug choices: midazolam first-line, levomepromazine (nausea/delirium), phenobarbitone, propofol as last resort. Local copy: evidence/palliative-care/_ajgp/ |
| Paraneoplastic Syndromes (StatPearls) | StatPearls | ||
| Pharmacological management of pain in palliative care | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/pain-control-in-palliative-care/Pharmacological management of pain in palliative care - Therapeutic Guidelines.pdf. | |
| Pregabalin and gabapentin | tga.gov.au | Safety advisory - enhanced warnings relating to abuse and dependence Catalogued from the local copy at evidence/palliative-care/pain-control-in-palliative-care/tga-pregabalin-gabapentin-2021.html. | |
| Pregabalin and gabapentin safety alert | Therapeutic Goods Administration (TGA) | 2021 boxed warning update | TGA added boxed warnings for misuse/abuse/dependence to pregabalin PI in 2021 following rising deaths/ambulance attendances; several states added gabapentinoids to real-time monitoring (e.g. Victoria SafeScript, 2023). |
| Principles of managing pain in palliative care | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/pain-control-in-palliative-care/Principles of managing pain in palliative care - Therapeutic Guidelines.pdf. | |
| Principles of paediatric palliative care | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/_shared/Principles of paediatric palliative care - Therapeutic Guidelines.pdf. | |
| Principles of symptom management in palliative care | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/_shared/Principles of symptom management in palliative care - Therapeutic Guidelines.pdf. | |
| RACGP aged care clinical guide (Silver Book) | RACGP | 5th edition (Parts A/B/C) | |
| RACGP Aged Care Clinical Guide (Silver Book) — Part A: Common clinical conditions in aged care | RACGP | ||
| Support for carers in palliative care | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/palliative-care/_shared/Support for carers in palliative care - Therapeutic Guidelines.pdf. | |
| Syndrome of Inappropriate Antidiuretic Hormone Secretion | StatPearls | ||
| Using Resuscitation Plans in End of Life Decisions (PD2014_030) | NSW Ministry of Health | Policy directive, status Review since 2021 transfer to ACI but not superseded/withdrawn; hospital/inpatient-facing, used here only for GP-relevant context on the Resuscitation Plan document and Person Responsible hierarchy. |
Population & Social Health
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| 1800RESPECT national domestic, family and sexual violence counselling service | Australian Government (delivered by Curtin University / Medibank Health Solutions) | living service | Added Phase 4 (2026-07-08) for domestic violence referral. |
| A primary care approach to bereavement (British Journal of General Practice 2026;76(765):189-191) | British Journal of General Practice (RCGP) | BJGP 2026;76(765):189-191 | |
| Aboriginal and Torres Strait Islander Peoples Health Assessment (Item 715) | Medicare Benefits Schedule (Australian Government Department of Health) | Item 715 descriptor and AN.0.43 explanatory notes: health assessment for Aboriginal or Torres Strait Islander patients, once per 9 months, fee $254.10. | |
| Aboriginal primary health care: an evidence-based approach | Australian Prescriber | Evidence-based approach to Aboriginal and Torres Strait Islander primary health care in general practice. | |
| Abuse and violence: working with our patients in general practice (White Book) | RACGP | 5th edition | |
| Abuse and violence: working with our patients in general practice (White Book) — Child abuse and neglect chapter | RACGP | 5th edition | The actual 'Child abuse and neglect' chapter content, as distinct from the existing racgp-white-book registry entry, which only caches the guideline's landing/preamble page (a table of contents with no chapter text) -- its ★ topic match on population-social-health/child-abuse-nai.md, stage E, looked plausible but didn't check out until this chapter-specific URL was fetched. Covers definitions/types of abuse, prevalence (13% of Australian adults report childhood abuse), risk factors (alcohol/drug abuse, mental illness, poor attachment), Table 9.2 signs/symptoms by abuse type, the stepped recognise-assess-respond-notify approach, Table 9.5 state-by-state mandatory reporting legislative thresholds (NSW 'risk of significant harm' definition verbatim), and post-report ongoing care. |
| Access Clinic | RACGP (AJGP) | AJGP 48(12), December 2019 | Case description of an access-clinic model of care for patients experiencing homelessness: bringing services to where people already gather, using preventive screening as an engagement tool, and bridging to mainstream general practice. |
| Australian STI Management Guidelines for primary care | ASHM | living online guidelines | Includes a dedicated Populations & Situations > Adult sexual assault page (post-assault STI testing/prophylaxis, HIV PEP, hepatitis B) used in Phase 4 (2026-07-08). |
| Catch-up vaccination | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Child Abuse and Neglect (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Clinical management of patients presenting following a sexual assault | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 7, July 2020 | GP response to a disclosure of recent sexual assault: refer to a specialist sexual assault service for forensic examination (patient-led, time-sensitive), emergency contraception, STI testing/prophylaxis and baseline serology, HIV PEP if <72h, HBV vaccination, injury care, careful contemporaneous documentation, mandatory reporting for minors, and psychosocial/safety support. Local copy: evidence/womens-health/_ajgp/. |
| Coercive control: Recognising relational patterns that affect patient wellbeing | RACGP (AJGP) | AJGP 54(12), December 2025 | Coercive control as a distinct, often non-physical, abuse pattern preceding most domestic homicides. Sense of Safety Framework: invasion/confusion/isolation patterns. Practice points: avoid couple therapy where coercive control exists, watch for perpetrator image management, GP longitudinal-relationship pattern recognition. |
| Elder abuse | RACGP (AJGP) | AJGP 47(4), April 2018 | Reviews 5 validated elder-abuse screening tools; VASS (Vulnerability to Abuse Screening Scale, Australian, 17-item) has the best local validation of the available options, an addition to this note which previously only covered EASI. Also covers health-justice-partnership referral model. |
| Grief and Prolonged Grief Disorder | StatPearls (NCBI Bookshelf) | current as at fetch | Low-yield fallback for population-social-health/illness-loss-death-of-child-partner-family.md: the page's category-wide topic-matched sources (AJGP domestic/family violence, IPV, coercive control) share only the word 'family'/'partner'/'child' and are a different topic entirely, so treated as no dedicated evidence. Covers stages/phases of grief, acute vs prolonged grief disorder criteria and prevalence, risk factors, and at-risk groups. |
| Grief, loss and the COVID-19 pandemic | RACGP (AJGP) | AJGP 49 Suppl 20, May 2020 | |
| Guide to the NDIS for GPs and health professionals | National Disability Insurance Agency (NDIS) | NDIS official guidance for treating GPs/health professionals on their role: understanding eligibility requirements, connecting patients with the NDIS, and providing evidence of disability (Section 2 of the access request form, letters/reports, or other treating-professional reports). | |
| Guidelines for preventive activities in general practice Red Book 10th edition | RACGP | Supplied by Steve 2026-08-31. Full Red Book; supersedes the 4.3k-word racgp-red-book fragment for age-band preventive activity tables. | |
| Health of people with disability (AIHW, Australia's health topic summary) | Australian Institute of Health and Welfare (AIHW) | AIHW web article, release date 9 Jul 2026, drawing on ABS Survey of Disability, Ageing and Carers (SDAC) 2022 and National Health Survey (NHS) 2022. Covers self-assessed health status, health conditions, health risk factors, medicine and health-service use, and healthcare-sector attitudes for people with disability vs without. | |
| How to determine whether your patient is eligible (NDIS guide for GPs) | National Disability Insurance Agency (NDIS) | NDIS guidance on the disability/early-intervention eligibility requirements, the 6-point checklist, and the evidence a treating GP can supply — the NDIA itself assesses evidence against its legal requirements to make the eligibility decision. | |
| Improving Aboriginal and Torres Strait Islander people's access to the Pharmaceutical Benefits Scheme | Australian Prescriber | Section 100 remote-area Aboriginal Health Services PBS supply arrangements and Closing the Gap PBS Co-payment Measure. | |
| Interventions for supporting family and friends of patients at the end of life (Cochrane, CD007617) | Cochrane | ||
| Kubler-Ross Stages of Dying and Subsequent Models of Grief (Archived) | StatPearls (NCBI Bookshelf) | current as at fetch | Same low-yield-fallback context as statpearls-grief-prolonged-grief-disorder. Covers the Kubler-Ross five-stage model (denial, anger, bargaining, depression, acceptance) and later grief models (Worden's tasks, dual-process model). |
| National Elder Abuse Phone Line (1800 ELDERHelp) | Australian Government Department of Health, Disability and Ageing | living service | Added Phase 4 (2026-07-08); redirects to state/territory elder abuse services. |
| National guide to preventive healthcare for Aboriginal and Torres Strait Islander people | RACGP / NACCHO | 4th edition | |
| Putting prevention into practice (Green Book) | RACGP | 2018 | |
| Recognising and responding to domestic and family violence in general practice | RACGP — Australian Journal of General Practice | Named by hand from the document's own opening text. Local copy at evidence/population-social-health/_ajgp/ajgp-recognising-dfv-2022.pdf. | |
| Services Australia (Centrelink) health professional resources | Services Australia | living, forms/criteria change frequently | Added Phase 4 (2026-07-08) for DSP and other Centrelink medical evidence forms — always verify current form numbers/criteria in browser, this changes often. |
| Sexual history (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached) covering how to take a sexual history: last sexual contact, regular vs casual partner, gender of partner(s), condom use, type of sex (vaginal/oral/anal), contact in the last 3 months. |
| Social determinants of health (AIHW, Australia's health topic summary) | AIHW | ||
| Standard Asymptomatic Checkup (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached): routine STI screening for asymptomatic people, and which subpopulations (MSM, sex workers, pregnant people, Aboriginal and Torres Strait Islander people, trans and gender diverse people) have special testing requirements. Source of the note's existing pre-claims-system quote about subpopulations. |
| Time-Tiered Health Assessments (Items 701, 703, 705, 707, 224, 225, 226, 227) | Medicare Benefits Schedule (Australian Government Department of Health) | Item descriptors + explanatory notes AN.0.36-AN.0.42: brief/standard/long/prolonged health assessment fee tiers, 45-49yr at-risk assessment, 40-49yr Type 2 Diabetes Risk Evaluation, 75+ Older Persons Health Assessment, RACF comprehensive medical assessment, intellectual disability assessment, refugee/humanitarian entrant assessment. | |
| Vaccination for Aboriginal and Torres Strait Islander people | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vaccination for migrants refugees and people seeking asylum in Australia | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| What do I do when they disclose? Responding to intimate partner violence and coercive control in primary care | RACGP (AJGP) | AJGP 54(12), December 2025 | WHO LIVES disclosure-response framework; four-component risk assessment (survivor self-assessment most important); CARE model for restoring agency; practice-changing documentation guidance (neutral wording, do not manage both parties); warm referrals; ATSI women ~32x hospitalisation rate; inform protective parent before mandatory reporting. |
Preventive Health
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| Australian CVD risk calculator and guideline (check in browser) | Commonwealth of Australia | 2023 guideline | Not re-fetched this pass; widely used calculator URL. |
| Australian Immunisation Handbook (check in browser) | Australian Government Department of Health | living online handbook | Connection resets on automated fetch (gov bot-blocking); well-known stable URL - confirm in browser. |
| Cancer Council clinical practice guidelines and Optimal Care Pathways | Cancer Council Australia | per-guideline wiki | |
| Guidelines for preventive activities in general practice (Red Book) | RACGP | 10th edition (living web document; uses GRADE) | |
| Heart Foundation clinical guidelines (ACS, hypertension, CVD risk, Heart Health Check) | National Heart Foundation of Australia | per-guideline (see individual documents) | |
| National guide to preventive healthcare for Aboriginal and Torres Strait Islander people | RACGP / NACCHO | 4th edition | |
| Putting prevention into practice (Green Book) | RACGP | 2018 |
Renal & Urology
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease | Kidney International 2012 | Named by hand from the document's own opening text. Local copy at evidence/renal-urology/_shared/depression-in-dialysis-patients-ki-2012.pdf. | |
| A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease (check in browser) | Kidney International (review) | 2012 | Review of depression management specifically in CKD/dialysis patients (antidepressant selection, dialysability). Source URL not confirmed, cite by name only — held privately, evidence/renal-urology/_shared/. |
| Acute Pyelonephritis | StatPearls (NCBI Bookshelf) | per-article | Stage F rewrite of renal-urology/uti.md — epidemiology/pathogens/resistance-risk-factors/complicated-pyelonephritis content; dosing not cited from this source (US-facing, would need eTG/AMH cross-check). |
| Advanced chronic kidney disease: Considerations for renin-angiotensin system inhibitor use | RACGP (AJGP) | AJGP 52(4), April 2023 | RASI therapy in CKD G4-G5 is a genuinely unresolved evidence question (KDIGO weak/no-consensus recommendation); conflicting observational data on continuing vs stopping. Local copy: evidence/renal-urology/_ajgp/ |
| ALTAR non-inferiority RCT (NIHR HTA) — Methenamine hippurate vs antibiotic prophylaxis for recurrent UTI | NIHR Journals Library / BMJ | 2022 | Methenamine hippurate shown non-inferior to daily low-dose antibiotic prophylaxis for recurrent UTI in women over 12 months — upgrades its evidence base from previously "poor and inconsistent" to a viable first-line non-antibiotic option, relevant given antimicrobial stewardship. |
| An update on management of renal colic | RACGP (AJGP) | AJGP 50(7), July 2021 | Evidence-based renal colic assessment/management; paracetamol+NSAIDs superior to opioids for analgesic efficacy. Local copy: evidence/renal-urology/_ajgp/ |
| ANCA-Associated Vasculitis | StatPearls (NCBI Bookshelf) | ||
| Antibiotics for adults and children with sore throats | Cochrane | ||
| Assessment and management of haematuria in the general practice setting | RACGP (AJGP) | AJGP 50(7), July 2021 | Haematuria work-up framework and urological-malignancy risk stratification. Local copy: evidence/renal-urology/_ajgp/ |
| Assessment and management of lower urinary tract infection in adults | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a dedicated topic source for renal-urology/uti.md. |
| Bladder Cancer (StatPearls) | StatPearls | ||
| Care for survivors of acute kidney injury | RACGP (AJGP) | AJGP 50(7), July 2021 | Post-AKI follow-up priorities: doubled subsequent mortality risk, case-finding for diabetes/hypertension/CKD, sick-day medication review framework. Local copy: evidence/renal-urology/_ajgp/ |
| Chronic Kidney Disease Management in Primary Care handbook | Kidney Health Australia | 5th edition | |
| Common incidental urological lesions on computed tomography images | RACGP (AJGP) | ||
| Drug management of autosomal dominant polycystic kidney disease (Aust Prescr 2023) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| EV-302/KEYNOTE-A39: Enfortumab vedotin plus pembrolizumab vs chemotherapy for untreated locally advanced or metastatic urothelial cancer | Lancet Oncology / NEJM (phase 3 RCT) | 2023-2024 | Enfortumab vedotin plus pembrolizumab is now first-line standard of care for metastatic urothelial cancer, replacing platinum chemotherapy — nearly doubled median overall survival in the pivotal trial. |
| Female Urinary Retention | StatPearls (NCBI Bookshelf) | ||
| From microscopic haematuria to kidney failure: The hidden progression of IgA nephropathy | RACGP (AJGP) | AJGP 54(10), October 2025 | IgA nephropathy natural history/progression risk and the case for earlier nephrology involvement. Local copy: evidence/renal-urology/_ajgp/ |
| Goodpasture Syndrome (StatPearls) | StatPearls | ||
| Granulomatosis With Polyangiitis | StatPearls (NCBI Bookshelf) | ||
| Gross and Microscopic Hematuria (StatPearls) | StatPearls | ||
| Hemodialysis (StatPearls) | StatPearls | ||
| Hyperkalemia — MSD Manual Professional Edition | MSD Manual Professional Edition | Hyperkalaemia causes, ECG changes, and correction regimens (calcium gluconate, insulin-dextrose, salbutamol, resins, dialysis) for renal-urology/electrolyte-disorders.md, write-gap-pages. | |
| Hypokalemia — MSD Manual Professional Edition | MSD Manual Professional Edition | Hypokalaemia causes, ECG changes, and oral/IV replacement for renal-urology/electrolyte-disorders.md, write-gap-pages. | |
| Infection-Related Glomerulonephritis | StatPearls (NCBI Bookshelf) | ||
| Interventions for renal vasculitis in adults | Cochrane | Walters GD et al, Cochrane Database Syst Rev 2020 Issue 1, CD003232.pub4 — plasma exchange, cyclophosphamide dosing regimens, rituximab/MMF induction, azathioprine/methotrexate/leflunomide maintenance in renal (ANCA-associated) vasculitis. | |
| KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease | Kidney Disease: Improving Global Outcomes (KDIGO) | 2024 | SGLT2 inhibitors now foundational (1A) CKD-progression therapy regardless of diabetes status; finerenone established as add-on for diabetic CKD with albuminuria. |
| Magnesium: the forgotten electrolyte | Australian Prescriber | Hypomagnesaemia causes and replacement for renal-urology/electrolyte-disorders.md, write-gap-pages. | |
| Male Urinary Retention: Acute and Chronic | StatPearls (NCBI Bookshelf) | ||
| Management of proteinuria: blockade of the renin-angiotensin-aldosterone system (Aust Prescr 2020;43:121-5) | Australian Prescriber | ||
| Managing female stress urinary incontinence in a post mesh era | RACGP (AJGP) | AJGP 53(5), May 2024 | Female SUI diagnosis/management principles and referral thresholds in the post-transvaginal-mesh-restriction era. Local copy: evidence/renal-urology/_ajgp/ |
| Metformin and patients on dialysis (Aust Prescr 2016;39:74-5) | Australian Prescriber | ||
| Minimally invasive interventions for lower urinary tract symptoms | RACGP (AJGP) | AJGP 53(5), May 2024 | Minimally invasive BPH/bladder-outlet-obstruction procedures (Rezum, UroLift, etc.) sitting between medical therapy and TURP. Local copy: evidence/renal-urology/_ajgp/ |
| Nephritic Syndrome (StatPearls) | StatPearls | ||
| Nephrotic Syndrome (StatPearls) | StatPearls | ||
| Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems (Aust Prescr 2019;42:14-9) | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Stage F rewrite of renal-urology/uti.md — resistant-UTI/fosfomycin treatment option not previously covered. |
| Paraphimosis | StatPearls (NCBI Bookshelf) | Resource Seeding 2026-08-23, full-sweep zero-source fill for mens-health/phimosis-paraphimosis.md (paired with statpearls-phimosis — same note covers both conditions). Last updated May 30, 2023. | |
| Pelvic Organ Prolapse | StatPearls (NCBI Bookshelf) | ||
| Peritoneal Dialysis (StatPearls) | StatPearls | ||
| Phimosis | StatPearls (NCBI Bookshelf) | Low-yield fallback source for paediatrics/surgical.md (physiological vs pathological phimosis, BXO). Also on-topic for mens-health/phimosis-paraphimosis.md (Resource Seeding, 2026-08-23). | |
| Polyarteritis Nodosa | StatPearls (NCBI Bookshelf) | ||
| Polycystic Kidney Disease In Adults (StatPearls) | StatPearls / NCBI Bookshelf | ||
| Proteinuria (StatPearls) | StatPearls | ||
| Renal Cell Carcinoma | MSD Manual Professional Edition | ||
| Renal Infarction | StatPearls (NCBI Bookshelf) | ||
| Renal Mass | StatPearls (NCBI Bookshelf) | ||
| Rhabdomyolysis | StatPearls (NCBI Bookshelf) | ||
| Severe hyponatraemia: recognition and management | Australian Prescriber | Correction rate limits and causes of severe hyponatraemia for renal-urology/electrolyte-disorders.md, write-gap-pages. | |
| Simple Renal Cyst | StatPearls (NCBI Bookshelf) | ||
| The Renal Drug Handbook (check in browser) | CRC Press (Ashley & Currie, eds.) | 3rd edition | Comprehensive drug-dosing reference for renal impairment, uploaded by Steve. A full reference textbook, likely copyrighted — cite by name only, never copy dosing tables verbatim into notes; cross-check any specific dose against current eTG/AMH before prescribing, since editions age. Held privately, evidence/renal-urology/_shared/. |
| Therapeutics for rheumatic fever and heart disease | Australian Prescriber | ||
| Thin Basement Membrane Nephropathy | StatPearls (NCBI Bookshelf) | ||
| Transvaginal mesh for incontinence and prolapse: Where are we now and how did we get here? | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 1-2, Jan-Feb 2024 | History/current status of transvaginal mesh: transvaginal mesh for prolapse was removed from the Australian market (TGA 2017) after a high complication rate; mid-urethral slings for stress incontinence remain but under scrutiny. GPs should recognise mesh complications (chronic pain, erosion, dyspareunia, recurrent UTI) and refer affected women to a specialist mesh service. Local copy: evidence/womens-health/_ajgp/. |
| Urethritis (StatPearls) | StatPearls | ||
| Urinary Retention | MSD Manual Professional Edition | ||
| Urological focus on gender affirmation surgery | RACGP (AJGP) | AJGP 53(5), May 2024 | Overview of female-to-male and male-to-female genital gender affirmation surgical techniques, urological complications, and GP follow-up role. Local copy: evidence/renal-urology/_ajgp/ |
| What to do about recurrent urinary tract infections: A review of evidence behind emerging therapies | RACGP (AJGP) | AJGP 53(5), May 2024 | Stepwise recurrent-UTI prevention (behavioural -> non-antibiotic incl. methenamine hippurate/vaginal oestrogen -> antibiotic prophylaxis). Local copy: evidence/renal-urology/_ajgp/ |
| Wilms Tumor (StatPearls) | StatPearls |
Respiratory
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| A chronic obstructive pulmonary disease risk assessment tool in preventive lung healthcare: An unmet need? | AJGP (RACGP) | AJGP Vol 52, Issue 9, September 2023 (Viewpoint) | Proposes PRECURSOR, a validated risk-prediction questionnaire for detecting early/undiagnosed COPD in smokers/ex-smokers in their 40s, as a structured alternative to opportunistic case-finding. Not yet standard Australian practice as of the article date. Local copy: evidence/respiratory/_ajgp/copd-risk-assessment-tool.html |
| A clinical approach to chronic respiratory disorders in Aboriginal and Torres Strait Islander Austra | RACGP — Australian Journal of General Practice | This paper describes a clinical approach to chronic respiratory disorders for clinicians working with Aboriginal and Torres Strait Islander people, particularly in the remote Australian context. Catalogued from the local copy at evidence/respiratory/_ajgp/atsi-chronic-respiratory-disorders.html. | |
| A clinical approach to chronic respiratory disorders in Aboriginal and Torres Strait Islander Australians | RACGP (AJGP) | AJGP supplement, Dec 2024 | COPD/bronchiectasis/asthma commonly overlap/coexist (rather than being cleanly distinguished) in Aboriginal and Torres Strait Islander patients, with earlier onset and higher severity. Local copy: evidence/respiratory/_ajgp/ |
| A COPD risk assessment tool in preventive lung healthcare | RACGP (AJGP) | AJGP, Sep 2023 | Proactive risk-prediction case-finding, complementing the GOLD 2023/2024 A/B/E restructure. Local copy: evidence/respiratory/_ajgp/ |
| Acute Bronchitis (StatPearls) | StatPearls | ||
| Acute Chest Pain | Community HealthPathways Hunter New England | GP-facing referral/management pathway for acute chest pain. Local copy (supplied by Steve, text-layer): evidence/common-presentations/chest-pain/hne-healthpathways-acute-chest-pain.pdf. Used for the common-presentations/chest-pain.md consolidation (2026-08-24). | |
| Acute Laryngitis (StatPearls) | StatPearls | ||
| Acute management of anaphylaxis in pregnancy | RACGP — Australian Journal of General Practice | Dosage and administration of adrenaline for anaphylaxis is the same in pregnant and non-pregnant patients. Catalogued from the local copy at evidence/respiratory/_ajgp/anaphylaxis-pregnancy-2022.html. | |
| Amid the breathless | RACGP — Australian Journal of General Practice | It is well known that the stressors of medical work can lead to burnout, and general practitioners are not an exception. Catalogued from the local copy at evidence/respiratory/_ajgp/amid-the-breathless.html. | |
| Antimicrobials for respiratory tract infections | RACGP — Australian Journal of General Practice | Upper respiratory tract infections have higher rates of prescribing than would be expected according to local guidelines. Catalogued from the local copy at evidence/respiratory/_ajgp/antimicrobials-respiratory-infections.html. | |
| Approach to Chest Pain | EM:RAP Corependium | Updated 8 Aug 2026 | Used for the common-presentations/chest-pain.md consolidation (2026-08-24): OLDCAAR history mnemonic, risk-factor and physical-exam pearls, ECG-timing rules, and especially its dedicated 'Urgent Care Considerations' section (EMS-activation threshold, aspirin/ECG while awaiting transfer, nitroglycerin caution without IV access, HEAR-without-troponin score, limited troponin/D-dimer availability outside hospital, discharge safety-netting) — the main new source for this page's GP/urgent-care/rural framing. Its ED/ICU-level material (RSI, push-dose vasopressors, PCI/fibrinolytic protocols, pericardiocentesis/thoracostomy technique, triple rule-out CTA) was deliberately left uncited as out of scope for this page. Local copy: evidence/common-presentations/chest-pain/emrap-chest-pain-presentation.pdf — originally supplied image-only (no text layer), replaced same day with a text-layer copy (Steve), now stage-E/F quotable via pdftotext (~8,500 words). |
| ASCIA Acute Management of Anaphylaxis Guideline | Australasian Society of Clinical Immunology and Allergy (ASCIA) | 2024, Action Plans updated 2025-2026 | Four TGA-approved adrenaline devices in Australia as of 2026: EpiPen, Anapen (500mcg strength replacing discontinued 150/300), Jext, and neffy - a needle-free intranasal adrenaline spray, a genuinely new development not available in 2020. Action Plans updated to say Prescribers reflecting nurse-practitioner prescribing changes. |
| Aspiration pneumonia and pneumonitis | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for respiratory/pneumonia.md. |
| Assessment and investigation of adult OSA | RACGP — Australian Journal of General Practice | Medicare Benefits Schedule rules regarding sleep study eligibility have recently changed and incorporate validated questionnaires of obstructive sleep apnoea risk and subjective sleepiness. Catalogued from the local copy at evidence/respiratory/_ajgp/osa-assessment-investigation-2019.html. | |
| Assessment of severity of respiratory conditions — RCH Clinical Practice Guideline | Royal Children's Hospital Melbourne / Paediatric Improvement Collaborative | Severity grading table (mild/moderate/severe/life-threatening) across behaviour, colour, respiratory rate, work of breathing, oxygenation, heart rate, blood pressure for paediatric respiratory conditions (asthma, bronchiolitis, croup, pneumonia). | |
| Australian Asthma Handbook | National Asthma Council Australia | living online handbook | |
| Australian Asthma Handbook — Diagnosing asthma in adults and adolescents | National Asthma Council Australia | Named by hand from the document's own opening text. Local copy at evidence/respiratory/_shared/asthma-handbook-diagnosing-asthma-adults-adolescents.pdf. | |
| Australian Asthma Handbook — Quick Reference Guide (asthma in adults and adolescents) | National Asthma Council Australia | Named by hand from the document's own opening text. Local copy at evidence/respiratory/_shared/asthma-handbook-quick-reference-guide-2026.pdf. | |
| Australian Asthma Handbook (National Asthma Council Australia), 2025 update | National Asthma Council Australia | 2025 update (GINA-aligned, following GINA 2019+ strategy shift) | SABA (salbutamol) alone as reliever is now considered inadequate treatment for adults/adolescents with asthma. Low-dose ICS-formoterol (budesonide-formoterol) taken as needed — anti-inflammatory reliever (AIR) therapy — has replaced SABA-only as first-line reliever/initial treatment, reducing risk of severe exacerbations requiring oral corticosteroids. Major paradigm shift from the SABA-centric approach reflected in older notes. |
| Australian Immunisation Handbook — Pertussis (whooping cough) | Australian Government Department of Health, Disability and Ageing | current (living document) | Childhood NIP schedule: 2, 4, 6, 18 months + 4yrs + 11-13yr booster. Pregnancy vaccination recommended 20-32 weeks gestation (not 28-32). |
| Bacterial Pneumonia | StatPearls (NCBI Bookshelf) | current as at fetch | |
| Barriers to spirometry in Australian general practice | RACGP — Australian Journal of General Practice | A systematic review assessing barriers to correct spirometry in Australian general practice. Catalogued from the local copy at evidence/respiratory/_ajgp/barriers-to-spirometry.html. | |
| Bronchiectasis | AJGP (RACGP) | AJGP Vol 51, Issue 12, December 2022 (Clinical) | Comprehensive management summary: 14-day oral antibiotics for exacerbations (tailored to sputum culture), P. aeruginosa eradication regimen on new isolation (up to 3 months), long-term macrolide prophylaxis (azithromycin/erythromycin) for patients with ≥3 exacerbations/year, long-term mucolytics for poor-QoL patients failing standard clearance, inhaled antibiotics (evidence for reduced exacerbation frequency but not QoL — ORBIT-3/4, RESPIRE 1 trials), routine COVID-19/influenza/pneumococcal vaccination. Notes markedly higher prevalence and worse outcomes in Australian Aboriginal communities. Local copy: evidence/respiratory/_ajgp/bronchiectasis-ajgp-2022.html |
| Bronchiectasis | Community HealthPathways (Hunter New England-branded template; content appears sourced from a New Zealand HealthPathways instance - Maori/Pacific-specific and NZ-funding-scheme content not applicable to Australian practice) | as supplied | Local copy: evidence/respiratory/_shared/HNE-HealthPathways-Bronchiectasis.pdf. CAUTION: content mismatch - page header says Hunter New England but body content references Canterbury/West Coast NZ, Maori/Pacific peoples, and NZ funding schemes (ECAP, SIA). Only the generalisable clinical content (antibiotic choices, diagnostic pathway, referral triggers) used; NZ-specific administrative/equity content not cited into Australian pages. Text-layer copy added 2026-08-18 (was image-only) - re-confirmed the same NZ-content mismatch is still present on the live page, not a one-off scan artefact. |
| BTS Guideline for Pleural Disease | British Thoracic Society | 2023 (first full update since 2010) | Pneumothorax: symptom-based (not size-based) approach - conservative/ambulatory management now the default starting point for stable primary spontaneous pneumothorax regardless of size if asymptomatic/mildly symptomatic. Malignant pleural effusion: indwelling pleural catheters (IPC) now first-choice management, ahead of talc pleurodesis (a reversal from pre-2020 practice). Pleural infection: small-bore chest tube +/- intrapleural tPA/DNase. |
| Central Sleep Apnea | StatPearls (NCBI Bookshelf) | ||
| Chest pain | AJGP (RACGP) | AJGP 53(7), July 2024 | Rahman, primary-care-focused review. Source of the 'cardiac/possibly cardiac/non-cardiac' preferred-terminology recommendation (over 'atypical'), the typical-vs-less-likely-angina features table, community chest-pain epidemiology (83% non-ischaemic; musculoskeletal 36%, GI 19%, cardiac 16%, psychiatric 8%, pulmonary 5%), the point that troponin has a limited primary-care role except in regional/rural EDs, and brief PE/pneumothorax/oesophageal-rupture/aortic-dissection recognition points for the community setting. Local copy (supplied by Steve): evidence/common-presentations/chest-pain/AJGP-07-24-6810-FO-Rahman-Chest-Pain-WEB.pdf. Used for the common-presentations/chest-pain.md consolidation (2026-08-24), merging the former separate cardiology and respiratory chest-pain pages. Registered as a stub (no local copy, cardiology-only) during Resource Seeding; filled in and expanded here. |
| Chronic Cough | Community HealthPathways Hunter New England | Last updated June 2026 | Local copy: evidence/respiratory/_shared/HNE-HealthPathways-ChronicCough.pdf. CICADA-based (2010 statement referenced); red-flag/alarm-symptom table; diagnostic algorithm for normal-CXR chronic cough. Text-layer copy added 2026-08-18 (was image-only). |
| Chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand - TSANZ position statement | Thoracic Society of Australia and New Zealand (TSANZ) | Endorsed 15 Feb 2023, published Respirology 2023 | Supersedes the 2015 guideline. First to fold Aboriginal/Torres Strait Islander/Maori-specific epidemiology and care pathways into the core statement rather than an addendum - remote-community Indigenous children have markedly higher prevalence (~1470/100,000) and die ~20yrs earlier than non-Indigenous patients. |
| Community Acquired Pneumonia (Adult) | Community HealthPathways Hunter New England | Last updated 26 Aug 2025 | Local copy: evidence/respiratory/_shared/HNE-HealthPathways-CAP-Adult.pdf. Severity-tiered (low/moderate/high) empiric antibiotics: low = amoxicillin 1g TDS 5 days OR doxycycline 100mg BD 5 days (monotherapy); moderate = amoxicillin+doxycycline combination 5 days; high = ceftriaxone + azithromycin. Directed therapy tables for Legionella/Mycoplasma/Staph aureus/resistant pneumococcus. CXR at 6-8wks follow-up; spirometry if smoker. Used as the primary CAP source per instruction to prefer this over the 2025 US ATS guideline (not IDSA co-endorsed). Text-layer copy added 2026-08-18 (was image-only). |
| Community-Acquired Pneumonia | StatPearls (NCBI Bookshelf) | current as at fetch | |
| Connective tissue-related interstitial lung disease primer | American Thoracic Society | Named by hand from the document's own opening text. Local copy at evidence/respiratory/_shared/2020_ats_ctd-ild_v13_web.pdf. | |
| Contemporary Concise Review 2023: Interstitial lung disease | Respirology (Moodley et al.) | Respirology 2024 | Local copy: evidence/respiratory/_shared/Respirology - 2024 - Moodley - Contemporary Concise Review 2023 Interstitial lung disease.pdf. Concise contemporary review of ILD diagnostic/treatment landscape including antifibrotics and PPF framework. |
| COPD-X Handbook: summary clinical practice guidelines for the management of chronic obstructive pulmonary disease | Lung Foundation Australia / Thoracic Society of Australia and New Zealand | Named by hand from the document's own opening text. Local copy at evidence/respiratory/_shared/COPD-X_Handbook_Version1-1.pdf. | |
| COPD-X Plan: Australian and New Zealand guidelines for COPD management | Lung Foundation Australia / TSANZ | V2.78 (Dec 2025); V3.0 redevelopment underway | |
| Corticosteroids for pulmonary sarcoidosis | Cochrane | ||
| Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA) | TSANZ / Lung Foundation Australia | MJA 220(1), 15 Jan 2024 (updates the 2010 CICADA statement) | Separate adult vs paediatric diagnostic algorithms; adult chronic-cough algorithms have a thinner trial-evidence base than the paediatric ones; culturally-specific First Nations chronic-wet-cough management strategies flagged as a priority. |
| Current management of adult OSA | RACGP — Australian Journal of General Practice | Various contributing factors to obstructive sleep apnoea have resulted in the development of a number of potential treatment modalities, some of which are in evolution. Catalogued from the local copy at evidence/respiratory/_ajgp/osa-management-2019.html. | |
| Cystic Fibrosis | Community HealthPathways Hunter New England | current | Local copy: evidence/respiratory/_shared/HNE-HealthPathways-CysticFibrosis.pdf. Reproductive carrier screening (MBS-funded), NSW newborn screening since 1981, CFTR modulators (Trikafta/Orkambi/Kalydeco/Symdeko via PBS Section 100), pancreatic enzyme replacement (Creon), fat-soluble vitamin replacement, physiotherapy, JHH multidisciplinary referral pathway. Text-layer copy added 2026-08-18 (was image-only). |
| Diagnosis and Detection of Sarcoidosis (Medscape summary of the ATS 2020 guideline) | Medscape | Summary of the 2020 ATS/ERS/JRS/ALAT guideline | A Medscape summary OF the ATS 2020 guideline, not the guideline itself - registered separately so a quote located in it is attributed to Medscape rather than to the ATS, which is what the words in the file actually are. Use ats-ers-jrs-alat-sarcoidosis-2020 when citing the guideline by name. Supplied by Steve 2026-08-31. |
| Diagnosis and Detection of Sarcoidosis: An Official ATS Clinical Practice Guideline | American Thoracic Society (ATS/ERS/JRS/ALAT) | 2020 (first official ATS sarcoidosis practice guideline) | Cite by name only - full guideline not independently fetched. First official ATS sarcoidosis guideline: diagnosis requires compatible clinical presentation + non-necrotising granulomatous inflammation on tissue + exclusion of alternative causes; strong recommendation for baseline hypercalcaemia screening; conditional recommendations for baseline renal (creatinine) and hepatic (ALP) screening even without organ-specific symptoms; cardiac MRI preferred over PET/echo for suspected cardiac sarcoidosis. A companion 2021 ERS treatment guideline recommends starting prednisone at 20mg/day (not a fixed weight-based dose) for 1-3 months before reassessment. |
| Diagnosis and treatment of early lung cancer | RACGP — Australian Journal of General Practice | Prevention and early diagnosis coupled with curative treatments are key strategies for reducing lung cancer mortality by avoiding the sequelae of metastatic disease. Catalogued from the local copy at evidence/respiratory/_ajgp/early-lung-cancer-diagnosis-2020.html. | |
| Diagnosis of obstructive sleep apnoea in primary care | RACGP (AJGP) | AJGP, Jun 2024 | Supersedes the 2019 AJGP OSA-assessment article in currency. Local copy: evidence/respiratory/_ajgp/ |
| Difficult to treat and severe asthma in adults | RACGP — Australian Journal of General Practice | Despite the availability of effective therapies and a national medicines subsidy scheme, a significant burden of disease still exists in Australia, with high mortality by international standards. Catalogued from the local copy at evidence/respiratory/_ajgp/severe-asthma-adults.html. | |
| Dyspnea (StatPearls) | StatPearls | ||
| ERS clinical practice guidelines on treatment of sarcoidosis | European Respiratory Society (Baughman et al., Eur Respir J 2021) | 2021 | Companion treatment guideline to the ATS/ERS/JRS/ALAT 2020 diagnosis guideline. Source of the prednisone 20 mg/day starting dose for symptomatic pulmonary sarcoidosis, and of the methotrexate-as-second-line and infliximab-as-third-line sequence. Supplied by Steve 2026-08-31. |
| General practitioner management of comorbid insomnia and sleep apnoea | RACGP — Australian Journal of General Practice | An overview of the prevalence, consequences, assessment and management of patients with comorbid insomnia and sleep apnoea in Australian general practice. Catalogued from the local copy at evidence/respiratory/_ajgp/comorbid-insomnia-sleep-apnoea.html. | |
| Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report | GOLD | 2023/2024 report | Major restructure of initial COPD pharmacotherapy: replaced the old A-D grouping (which factored in spirometric severity) with symptom/exacerbation-based groups A, B, E. LAMA+LABA combination is now first-line initial therapy for symptomatic patients and for Group E (frequent exacerbators), rather than starting with bronchodilator monotherapy. ICS/LABA (without LAMA) as an initial regimen has been eliminated; triple therapy (ICS+LABA+LAMA) reserved for Group E patients with blood eosinophils >=300 cells/uL. Reflects concern about ICS overuse and pneumonia risk in COPD. |
| Goodpasture Syndrome (StatPearls) | StatPearls | ||
| Have we got the right focus in asthma care | RACGP — Australian Journal of General Practice | Asthma presentations are common in general practice, but opportunities to control asthma are often missed. Catalogued from the local copy at evidence/respiratory/_ajgp/asthma-care-right-focus-2021.html. | |
| Health risks from indoor gas appliances | RACGP — Australian Journal of General Practice | Gas combustion products have substantial negative health impacts, and the widespread use of gas in domestic settings is an avoidable health risk. Catalogued from the local copy at evidence/respiratory/_ajgp/health-risks-indoor-gas-appliances.html. | |
| Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults - Official ATS/ERS/JRS/ALAT Clinical Practice Guideline | ATS/ERS/JRS/ALAT | AJRCCM 205(9):e18-e47, May 2022 | First guideline to formally define and address Progressive Pulmonary Fibrosis (PPF) as a unifying concept across non-IPF fibrotic ILDs - a terminology/framework shift since 2020. Local copy of the related ATS CTD-ILD 2020 guideline: evidence/respiratory/_shared/2020_ats_ctd-ild_v13_web.pdf. |
| Influenza | StatPearls (NCBI Bookshelf) | updated 2023-01-23 | Clinical features, complications and management review for respiratory/influenza.md, whose only prior cited source (ajgp-rsv-prevention-2024) actually covers RSV, not influenza. |
| Influenza | MSD Manual Professional Edition | current as at fetch | Cross-check source for respiratory/influenza.md, including antiviral dosing/timing and high-risk-group detail. |
| Influenza vaccinations for adult populations | RACGP — Australian Journal of General Practice | While influenza vaccine uptake in older Australian adults is fairly high, uptake in younger at-risk adults is suboptimal. Catalogued from the local copy at evidence/respiratory/_ajgp/influenza-vaccinations-adult-2021.html. | |
| Latent tuberculosis | RACGP — Australian Journal of General Practice | Management provides a key contribution to lowering individual risk of tuberculosis and reducing Australian tuberculosis incidence towards elimination. Catalogued from the local copy at evidence/respiratory/_ajgp/latent-tuberculosis-2020.html. | |
| Lung Abscess | StatPearls (NCBI Bookshelf) | ||
| Lung Cancer | Community HealthPathways Hunter New England | Last updated April 2026 | Local copy: evidence/respiratory/_shared/HNE-HealthPathways-LungCa.pdf. Red flags, CXR/CT-contrast investigation algorithm, symptom management (pain/breathlessness/cough), SVC obstruction, First Nations-specific pathways. Text-layer copy added 2026-08-18 (was image-only). |
| Lung cancer screening | RACGP — Australian Journal of General Practice | This article discusses the evidence for early detection of lung cancer using low-dose computed tomography (LDCT). Catalogued from the local copy at evidence/respiratory/_ajgp/lung-cancer-screening-2024.html. | |
| Lung Cancer Screening (National Lung Cancer Screening Program) | Community HealthPathways Hunter New England | Last updated Sep 2025 | Local copy: evidence/respiratory/_shared/HNE-HealthPathways-LungCaScreening.pdf. NLCSP launched July 2025 - Australia's first national lung cancer screening program. Eligibility: age 50-70, asymptomatic, current smoker or quit <=10yrs, >=30 pack-year history. Free biennial low-dose CT via Medicare. Nodule risk categories 0-6 with follow-up intervals. Text-layer copy added 2026-08-18 (was image-only). |
| Lung cancer screening: A promising new frontier | RACGP (AJGP) | AJGP, Aug 2024 | Precedes and anticipates the July 2025 NLCSP launch. Local copy: evidence/respiratory/_ajgp/ |
| Malignant Mesothelioma (StatPearls) | StatPearls | ||
| Management of obstructive sleep apnoea in primary care | RACGP (AJGP) | AJGP, Jun 2024 | Local copy: evidence/respiratory/_ajgp/ |
| Management of tuberculosis infection in a general practice setting | RACGP — Australian Journal of General Practice | This project discusses a model of care for safe and effective management of tuberculosis infection. Catalogued from the local copy at evidence/respiratory/_ajgp/tb-infection-management-2025.html. | |
| Management of tuberculosis infection in a general practice setting | RACGP (AJGP) | AJGP, Mar 2025 | GP-delivered LTBI shared-care models. Local copy: evidence/respiratory/_ajgp/ |
| Models of care for tuberculosis infection screening and treatment | RACGP (AJGP) | AJGP, Oct 2024 | Scoping review of GP-delivered LTBI screening/treatment models. Local copy: evidence/respiratory/_ajgp/ |
| Models of care for tuberculosis infection screening and treatment in primary care | RACGP — Australian Journal of General Practice | This article looks at how the cascade of care for tuberculosis infection screening and treatment have been implemented in primary care settings globally. Catalogued from the local copy at evidence/respiratory/_ajgp/tb-models-of-care-2024.html. | |
| Narcolepsy | StatPearls (NCBI Bookshelf) | ||
| National Lung Cancer Screening Program | Australian Government Department of Health, Disability and Ageing / Cancer Australia | Launched July 2025; guidelines PDF dated Jan 2026 | Australia's first national, Medicare-funded lung cancer screening program. Eligibility: age 50-70, asymptomatic, current smoker or quit within 10 years, >=30 pack-year history. ~931,000 estimated eligible at launch. Did not exist at the time of the original notes. |
| Nirmatrelvir and ritonavir PBS item 12996b eligibility criteria | Pharmaceutical Benefits Scheme | Supplied by Steve 2026-08-31. Current PBS eligibility - pbs.gov.au is JS-rendered and cannot be scraped. | |
| Non-acute Chest Pain | Community HealthPathways Hunter New England | GP-facing referral/management pathway for non-acute (stable, community-presenting) chest pain. Local copy (supplied by Steve, text-layer): evidence/common-presentations/chest-pain/hne-healthpathways-non-acute-chest-pain.pdf. Used for the common-presentations/chest-pain.md consolidation (2026-08-24). | |
| Noncardiac chest pain | RACGP — Australian Journal of General Practice | Noncardiac chest pain is a cause of significant morbidity and can be responsible for a high personal cost and healthcare burden. Catalogued from the local copy at evidence/respiratory/_ajgp/noncardiac-chest-pain.html. | |
| Obesity-Hypoventilation Syndrome | StatPearls (NCBI Bookshelf) | ||
| Obstructive Sleep Apnoea (Adult) | Community HealthPathways Hunter New England | Last updated Dec 2022 | Local copy: evidence/respiratory/_shared/HNE-HealthPathways-OSA.pdf. STOP-BANG/OSA-50/Berlin/Epworth screening, Medicare sleep-study funding criteria, home vs lab sleep studies, CPAP first-line, ENABLE NSW subsidised CPAP program, Austroads driving-fitness rules. Text-layer copy added 2026-08-18 (was image-only). |
| Paediatric inhaled airway foreign bodies: An update | AJGP (RACGP) | AJGP Vol 48, Issue 4, April 2019 (Clinical) | Classic three-phase presentation (acute impaction -> asymptomatic latent phase -> chronic complications); ~50% present asymptomatically, >90% have a history of aspiration/choking; up to 25% have a normal CXR; any suspected case warrants tertiary ENT referral for bronchoscopy regardless of normal exam/imaging. Prevention guidance (foods to avoid by age) and the Australian Resuscitation Council choking first-aid algorithm (back blows -> chest thrusts). Local copy: evidence/respiratory/_ajgp/paediatric-inhaled-foreign-bodies.html |
| Pertussis (StatPearls) | StatPearls | ||
| Pleural Effusion | MSD Manual Professional Edition | 2026 | General pleural effusion overview - normal fluid volume, imaging/exam detection thresholds, causes, diagnosis, treatment. Used for respiratory/pleural-effusion.md low-yield fallback, 2026-08-16. |
| Pleural Effusion | StatPearls (NCBI Bookshelf) | Updated 2023 | General pleural effusion overview - normal fluid volume, exam/imaging detection thresholds, transudate/exudate causes, Light's criteria, parapneumonic effusion/empyema drainage indications. Used for respiratory/pleural-effusion.md low-yield fallback, 2026-08-16. |
| Pneumonia and antibiotics | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for respiratory/pneumonia.md. |
| Post COVID 19 syndrome condition or long COVID | RACGP — Australian Journal of General Practice | As the understanding of post-acute COVID-19 is evolving, regularly updated or 'living guidelines' will be crucial for those affected to be provided with best care within the health system. Catalogued from the local copy at evidence/respiratory/_ajgp/long-covid-post-covid-syndrome.html. | |
| Prevention of the spread of respiratory viruses | RACGP — Australian Journal of General Practice | Recent data have shown that SARS-CoV-2 infection is a specific risk factor for a subsequent cardiovascular event, including death. Catalogued from the local copy at evidence/respiratory/_ajgp/prevention-spread-respiratory-viruses.html. | |
| Pulmonary Embolism | Community HealthPathways Hunter New England | Last updated 2 Sep 2025 | Local copy: evidence/respiratory/_shared/HNE-HealthPathways-PulmonaryEmbolism.pdf. Simplified Wells' score + PERC rule, apixaban/rivaroxaban first-line dosing, CTEPH follow-up. Respiratory's chest-pain/dyspnoea pages cross-reference PE red flags from this; cardiology's dvt-ix.md remains the canonical full VTE/PE management page. Text-layer copy added 2026-08-18 (was image-only). |
| Pulmonary embolus | RACGP — Australian Journal of General Practice | Pulmonary embolism is still the third most common cause of death from cardiovascular disease despite improvements in diagnosis and acute management. Catalogued from the local copy at evidence/respiratory/_ajgp/pulmonary-embolus-2022.html. | |
| Q Fever (StatPearls) | StatPearls | ||
| Recurrent wheezing in a toddler | RACGP — Australian Journal of General Practice | A boy aged one year and seven months was brought by his mother to the general practice clinic with a three-month history of recurrent wheezing, especially when active. Catalogued from the local copy at evidence/respiratory/_ajgp/recurrent-wheezing-toddler-2022.html. | |
| Reference values for spirometry and their use in test interpretation: A Position Statement from the Australian and New Zealand Society of Respiratory Science | Australian and New Zealand Society of Respiratory Science (ANZSRS) | Respirology 2016 (endorsing the GLI-2012 multi-ethnic reference equations) | ANZSRS/TSANZ-endorsed adoption of the GLI-2012 (Quanjer et al, ERJ 2012) multi-ethnic spirometry reference equations, replacing older (largely Caucasian-derived, pre-2012) reference sets. Recommends interpreting spirometry using z-scores rather than %-predicted alone, with the lower limit of normal (LLN) defined as the 5th percentile (z-score -1.64) rather than a fixed %-predicted cutoff. Confirmed current for Australia/NZ as of 2026 via WebSearch. |
| Respiratory | RACGP — Australian Journal of General Practice | The Australian public has benefited greatly from the manifold contributions of general practice throughout the COVID-19 pandemic. Catalogued from the local copy at evidence/respiratory/_ajgp/respiratory-editorial-2022.html. | |
| Respiratory inhalers and the environment | RACGP — Australian Journal of General Practice | Respiratory inhalers contribute significantly to climate change, principally because the propellant gases in pressurised metered-dose inhalers are potent global warming gases. Catalogued from the local copy at evidence/respiratory/_ajgp/respiratory-inhalers-environment.html. | |
| Respiratory syncytial virus prevention is finally here | RACGP (AJGP) | AJGP, Oct 2024 | RSV vaccines for adults >=60 (Arexvy/Abrysvo), maternal Abrysvo (ATAGI 28-36wks), infant nirsevimab monoclonal antibody (state-based programs, 2024) - all new since the original notes. Not NIP-funded as of this review. Local copy: evidence/respiratory/_ajgp/ |
| Sarcoidosis | MSD Manual Professional Edition | ||
| Sarcoidosis (StatPearls) | StatPearls (NCBI Bookshelf) | Sarcoidosis overview: non-caseating granulomatous multisystem disease of unknown cause, pulmonary involvement/bilateral hilar lymphadenopathy, extrapulmonary manifestations (erythema nodosum, uveitis), diagnosis by biopsy, serum ACE/hypercalcaemia, and treatment (spontaneous resolution common, corticosteroid indications and dosing). | |
| Silicosis | StatPearls (NCBI Bookshelf) | updated 6 Aug 2023, current as at fetch | The dedicated racp-silicosis-2026 source's real clinical content (types/latency, PMF progression, clinical features) lives in two image-only PDFs (RACP-SilicosisOverview.pdf, RACP-SilicosisAdvice.pdf, both noTextLayer) that cannot be mechanically quote-located; only its HTML landing page (thin policy/advocacy text) is quotable. Fetched to genuinely support occupational-lung-disease.md's classification/latency/clinical-course anchors, stage E low-yield fallback 2026-08-16. |
| Silicosis - Overview and Advice for Physicians | Royal Australasian College of Physicians (RACP), Faculty of Occupational & Environmental Medicine | current (2026) | Local copies: evidence/respiratory/_shared/RACP-SilicosisOverview.pdf, RACP-SilicosisAdvice.pdf. Engineered-stone-associated silicosis epidemic since ~2015 (up to 90% silica content vs ~30% in natural stone); 3 types (chronic/nodular >10yr, accelerated 3-10yr, acute <1yr); National Occupational Respiratory Disease Registry (NORDR) commenced 22 May 2024; health surveillance = spirometry + DLCO + CT. Text-layer copies added 2026-08-18 (were image-only). |
| Sleep health primary care clinical resource | RACGP — Australian Journal of General Practice | This article describes an online clinical resource providing evidence-based information on the aetiology, assessment, management, referral and ongoing care for obstructive sleep apnoea and insomnia. Catalogued from the local copy at evidence/respiratory/_ajgp/sleep-health-primary-care-resource.html. | |
| Snoring | MSD Manual Professional Edition | current as at fetch | Dedicated Snoring topic (pathophysiology/etiology/risk factors/evaluation). Low-yield fallback source for ent/snoring's adult risk-factor content. |
| Spirometry | StatPearls (NCBI Bookshelf) | StatPearls, updated 2026 | Dedicated spirometry technique/interpretation article: indications, contraindications, patient preparation, FVC/FEV1/FEV1-FVC ratio definitions, obstructive vs restrictive patterns, LLN, bronchodilator reversibility criteria, flow-volume loop. |
| Spontaneous Pneumothorax | StatPearls (NCBI Bookshelf) | updated 2025-07-22 | Overview/demographics/clinical-features/recurrence review for respiratory/pneumothorax.md, whose only prior dedicated source (bts-pleural-disease-2023) is a brief summary article covering management alone. |
| Tension Pneumothorax | StatPearls (NCBI Bookshelf) | updated 2025-07-07 | Needle decompression technique/site detail for respiratory/pneumothorax.md's tension pneumothorax section. |
| Testing for COVID-19: a 2023 update | Australian Prescriber | ||
| Treatment of restless legs syndrome and periodic limb movement disorder — AASM clinical practice guideline | American Academy of Sleep Medicine | 2024 | Recommends against long-term use of dopaminergic agents (levodopa, pramipexole, ropinirole, rotigotine) for RLS due to high augmentation risk (7-10%/year) — a major reversal from older guidance. Alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin) are now preferred first-line; iron studies (ferritin/transferrin saturation) should be checked and treated. |
| Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) — PBS listing (check in browser) | Pharmaceutical Benefits Scheme | 2022 PBS listing | CFTR modulator therapy PBS-listed in Australia from 2022 for eligible CF genotypes (~90% of patients) — substantially changed disease trajectory (lung function, nutrition, life expectancy) beyond historical prognosis figures. |
| Upper Respiratory Tract Infections With Focus on The Common Cold (StatPearls) | StatPearls (NCBI Bookshelf) | Common cold/URTI: rhinovirus, coronavirus, RSV, parainfluenza and other viral aetiology, self-limited course, clinical features, postviral/post-infectious cough mechanism (bronchial hyperresponsiveness), and supportive management (no role for antibiotics). | |
| Vaccination for people at occupational risk | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Viral infections and persistent cough | RACGP — Australian Journal of General Practice | These presentations provide fertile ground for educating patients about infections, self-management options, dealing with uncertainty and responsible use of medicines. Catalogued from the local copy at evidence/respiratory/_ajgp/viral-infections-persistent-cough.html. | |
| Wheezing (StatPearls) | StatPearls |
Rheumatology
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| 'Just my gout': A young man with chronic oligoarthritis | RACGP (AJGP) | AJGP 50(5), May 2021 | Case study on diagnostic anchoring in young-onset gout - a reminder not to assume gout explains all oligoarthritis, especially in atypical demographics. |
| 2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis | Bart et al., Heart, Lung and Circulation 2024;33:420-442 | 2024 | First Australia/NZ-specific consensus statement on cardiac amyloidosis diagnosis (incl. nuclear scintigraphy pathway to avoid biopsy in transthyretin amyloidosis) and management (tafamidis for ATTR-CM). No dedicated amyloidosis note currently exists in cardiology — relevant to the restrictive-cardiomyopathy section of cardiomyopathies.md. Applies to: cardiomyopathies. |
| Amyloidosis | StatPearls (NCBI Bookshelf) | Updated 2024 | General overview of systemic amyloidosis (AL/AA/hereditary) - epidemiology, clinical features by organ, diagnosis, treatment. Used for rheumatology/amyloidosis.md low-yield fallback, 2026-08-16. |
| ANCA-Associated Vasculitis | StatPearls (NCBI Bookshelf) | ||
| Australian Living Guideline for Inflammatory Arthritis (pharmacological management of rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and JIA) | ANZMUSC / Australian Rheumatology Association / Cochrane Musculoskeletal | Living guideline, continuously updated (checked 2026-07-23) | GRADE-methodology living guideline, the primary Australian-specific pharmacological recommendation source for RA/axSpA/PsA/JIA. Notable recent update: as of January 2026, PBS restrictions on rituximab for RA have been removed (previously reserved for TNFi/other bDMARD failure). |
| Australian Rheumatology Association Clinical Care Standard for the Diagnosis and Management of Rheumatoid Arthritis in Adults | Australian Rheumatology Association (ARA) | First released November 2023 | Australia's first national RA Clinical Care Standard - 12 quality statements built around 7 guiding principles (high-quality, culturally responsive, holistic, team-based care; effective communication; shared decision-making; self-management). Frames RA diagnosis/management as a systems-level quality standard, not just a drug algorithm. |
| Behcet Disease | StatPearls (NCBI Bookshelf) | updated 2023 | Clinical features (oral/genital ulcers, uveitis, skin lesions), diagnosis, pathophysiology and treatment for rheumatology/behcets-syndrome.md, stage E. |
| Bone Metastasis (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| BSR & BHPR, BOA, RCGP and BSAC guideline for management of the hot swollen joint in adults (2017 evidence update) | British Society for Rheumatology (BSR) | 2006 guideline, 2017 evidence update | Serum procalcitonin (cut-off ~0.4-0.5ng/mL) flagged as a promising but not yet routinely recommended adjunct to discriminate bacterial septic arthritis from other causes of joint inflammation; adjuvant corticosteroids alongside antibiotics have evidence in children with septic arthritis (faster CRP normalisation, shorter antibiotic course) but insufficient adult trial data for a therapeutic recommendation. Local copy: evidence/rheumatology/_bsr/Hot-Joint-guideline-update-2017.pdf |
| BSR axial spondyloarthritis b/tsDMARD guideline: summary sheet | British Society for Rheumatology | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_bsr/AxSpA-Guideline-Summary-Sheet.pdf. | |
| BSR gout guideline audit tool (2017) | British Society for Rheumatology | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_bsr/Gout-audit-tool-2017.pdf. | |
| BSR guideline for the management of the hot swollen joint — 2017 update | British Society for Rheumatology | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_bsr/Hot-Joint-guideline-update-2017.pdf. | |
| BSR lupus nephritis guideline: summary sheet (2025) | British Society for Rheumatology | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_bsr/Lupus-Nephritis-Summary-Sheet-2025.pdf. | |
| BSR Sjogren disease guideline summary sheet (2024) | British Society for Rheumatology | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_bsr/Sjogren-disease-summary-sheet-2024.pdf. | |
| BSR systemic lupus erythematosus guideline: summary sheet (2025) | British Society for Rheumatology | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_bsr/SLE-Summary-Sheet-2025.pdf. | |
| Chronic gout: Barriers to effective management | RACGP (AJGP) | AJGP 47(6), June 2018 | Patient and physician barriers to optimal long-term gout care (adherence, misconceptions about stopping ULT during a flare, under-treatment to target). |
| Connective tissue-related interstitial lung disease primer | American Thoracic Society | Named by hand from the document's own opening text. Local copy at evidence/respiratory/_shared/2020_ats_ctd-ild_v13_web.pdf. | |
| Corticosteroids for pulmonary sarcoidosis | Cochrane | ||
| csDMARD management guide: prescription and monitoring in SARDs (2025) | British Society for Rheumatology | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_bsr/csDMARD-Infographic-Guide-2025.pdf. | |
| Diagnosis and Detection of Sarcoidosis (Medscape summary of the ATS 2020 guideline) | Medscape | Summary of the 2020 ATS/ERS/JRS/ALAT guideline | A Medscape summary OF the ATS 2020 guideline, not the guideline itself - registered separately so a quote located in it is attributed to Medscape rather than to the ATS, which is what the words in the file actually are. Use ats-ers-jrs-alat-sarcoidosis-2020 when citing the guideline by name. Supplied by Steve 2026-08-31. |
| Diagnosis and Detection of Sarcoidosis: An Official ATS Clinical Practice Guideline | American Thoracic Society (ATS/ERS/JRS/ALAT) | 2020 (first official ATS sarcoidosis practice guideline) | Cite by name only - full guideline not independently fetched. First official ATS sarcoidosis guideline: diagnosis requires compatible clinical presentation + non-necrotising granulomatous inflammation on tissue + exclusion of alternative causes; strong recommendation for baseline hypercalcaemia screening; conditional recommendations for baseline renal (creatinine) and hepatic (ALP) screening even without organ-specific symptoms; cardiac MRI preferred over PET/echo for suspected cardiac sarcoidosis. A companion 2021 ERS treatment guideline recommends starting prednisone at 20mg/day (not a fixed weight-based dose) for 1-3 months before reassessment. |
| Duchenne Muscular Dystrophy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| ERS clinical practice guidelines on treatment of sarcoidosis | European Respiratory Society (Baughman et al., Eur Respir J 2021) | 2021 | Companion treatment guideline to the ATS/ERS/JRS/ALAT 2020 diagnosis guideline. Source of the prednisone 20 mg/day starting dose for symptomatic pulmonary sarcoidosis, and of the methotrexate-as-second-line and infliximab-as-third-line sequence. Supplied by Steve 2026-08-31. |
| Ethical aspects of spinal muscular atrophy management | RACGP (AJGP) | AJGP 51(3), March 2022 | Companion piece to the SMA therapeutic-landscape article - discusses equity/access and shared-decision-making complexities now that disease-modifying SMA therapies exist. Local copy: evidence/rheumatology/_ajgp/ |
| Ewing Sarcoma (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Granulomatosis With Polyangiitis | StatPearls (NCBI Bookshelf) | ||
| Guideline for the management of adult and juvenile onset Sjogren disease | British Society for Rheumatology (BSR) | 2023, NICE-accredited | Diagnosis via 2016 ACR/EULAR criteria (score >=4: anti-Ro 3pts, focus score >=1 on lip biopsy 3pts, abnormal ocular staining score >=5 1pt, Schirmer's <=5mm/5min 1pt, unstimulated salivary flow <0.1ml/min 1pt) - ultrasound now an alternative where lip biopsy unavailable; stepwise management (topical/symptomatic -> pilocarpine for systemic dryness -> hydroxychloroquine/other DMARDs); early lymphoma recognition flagged as crucial (Sjogren's carries the highest lymphoma risk of any rheumatic disease). Local copy: evidence/rheumatology/_bsr/Sjogren-disease-summary-sheet-2024.pdf |
| Guideline for the management of children, young people and adults with systemic lupus erythematosus (SLE) | British Society for Rheumatology (BSR) | 2026 | Treat-to-target approach (LLDAS/remission); anifrolumab now preferred first-line biologic for cutaneous disease; belimumab/rituximab/anifrolumab positioned for moderate-severe/resistant disease; annual review covers damage, bone health, CVD risk, vaccination, HCQ monitoring. Local copy: evidence/rheumatology/_bsr/SLE-Summary-Sheet-2025.pdf + Lupus-Nephritis-Summary-Sheet-2025.pdf |
| Guideline for the management of gout | British Society for Rheumatology (BSR) | 2017, NICE-accredited | Allopurinol first-line ULT, started low (100mg/day or lower in CKD) and titrated against serum urate to a target of <300micromol/L; febuxostat second-line, avoided in ischaemic heart disease/CCF; prophylaxis (NSAID or low-dose colchicine) co-prescribed when starting ULT; continue ULT through an acute attack once established (do not stop). Local copy: evidence/rheumatology/_bsr/Gout-audit-tool-2017.pdf |
| Guideline for the management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy (myositis) | British Society for Rheumatology (BSR) | 2022, NICE-accredited | Cite by name only - full guideline not independently fetched. First dedicated BSR guideline spanning paediatric through adult idiopathic inflammatory myopathy. |
| Guideline for the management of systemic sclerosis in people of all ages | British Society for Rheumatology (BSR) | 2024 | Cite by name only - full guideline text not independently fetched (only the figures PDF was accessible, image-only). |
| Guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs (csDMARDs) | British Society for Rheumatology (BSR) | 2025 | Cross-cutting csDMARD safety update: FIB-4 + elastography now recommended over routine liver biopsy for methotrexate liver monitoring in at-risk adults; CV disease and malignancy are explicitly NOT contraindications to csDMARD therapy; csDMARDs should NOT be routinely stopped perioperatively; risk-stratified monitoring intervals (low-risk patients may extend to 6-monthly). Local copy: evidence/rheumatology/_bsr/csDMARD-Infographic-Guide-2025.pdf |
| Guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs | British Society for Rheumatology (BSR) | 2025 | First-line b/tsDMARD is a TNF inhibitor; second-line onwards TNFi, IL-17i (secukinumab/ixekizumab/bimekizumab) or JAKi (tofacitinib/upadacitinib), tailored to extra-musculoskeletal manifestations (psoriasis, uveitis, IBD) since IL-17i can worsen IBD; response assessed via BASDAI/ASDAS; withdrawal of b/tsDMARD not recommended in sustained responders (tapering may be considered instead). Local copy: evidence/rheumatology/_bsr/AxSpA-Guideline-Summary-Sheet.pdf |
| Important safety information for Janus kinase (JAK) inhibitors | Therapeutic Goods Administration (TGA) | 2021, following ORAL Surveillance trial | Class-wide boxed warning added for tofacitinib/baricitinib/upadacitinib: increased MACE, malignancy, VTE and death vs TNF inhibitors, especially in patients 50+ with cardiovascular risk factors. |
| Interventions for renal vasculitis in adults | Cochrane | Walters GD et al, Cochrane Database Syst Rev 2020 Issue 1, CD003232.pub4 — plasma exchange, cyclophosphamide dosing regimens, rituximab/MMF induction, azathioprine/methotrexate/leflunomide maintenance in renal (ANCA-associated) vasculitis. | |
| Living guideline for managing people with Behcet's disease | British Association of Dermatologists / British Society for Rheumatology | 2025 (evidence reviewed to Aug 2023) | First joint BAD/BSR Behcet's guideline; 87 GRADE recommendations across general management, skin, joints, GI, eyes, neurology, vascular, psychological and pregnancy/conception domains, developed with patient/carer involvement. Local copy: evidence/rheumatology/_bsr/Behcets-Plain-Language-Summary.pdf |
| Living guideline on managing people with Behcet's — plain language summary | British Society for Rheumatology | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_bsr/Behcets-Plain-Language-Summary.pdf. | |
| Marfan Syndrome (StatPearls) | StatPearls | ||
| Myopathy (StatPearls) | StatPearls | ||
| Osteochondroma (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Osteomyelitis (StatPearls) | StatPearls | ||
| Osteosarcoma (Osteogenic Sarcoma) (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Pain management in people with inflammatory arthritis | British Society for Rheumatology (BSR) | 2026 | Recommends DMARDs (not analgesics alone) to treat pain from active disease; short-term glucocorticoids as bridging therapy only; against routine neuromodulators (gabapentinoids reserved for neuropathic pain); strong emphasis on non-pharmacological measures (exercise/physiotherapy, OT/ergonomic support, sleep, psychological interventions, weight management). Local copy: evidence/rheumatology/_bsr/Pain-in-IA-guideline-summary-sheet-2026.pdf |
| Pain management in people with inflammatory arthritis: guideline summary sheet (2026) | British Society for Rheumatology | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_bsr/Pain-in-IA-guideline-summary-sheet-2026.pdf. | |
| Paired serology for Ross River virus and Barmah Forest virus | AJGP | ||
| PBS listings for SMA disease-modifying therapies (nusinersen, onasemnogene abeparvovec, risdiplam) | Pharmaceutical Benefits Scheme (Australian Government) | 2018 (nusinersen), 2021 (risdiplam), 2022 (onasemnogene abeparvovec) | Disease-modifying SMA therapies now PBS-funded in Australia, substantially changing prognosis for Type 1 SMA diagnosed early. |
| Polyarteritis Nodosa | StatPearls (NCBI Bookshelf) | ||
| Rhabdomyolysis | StatPearls (NCBI Bookshelf) | ||
| Rituximab in autoimmune diseases | Australian Prescriber | O Connor/Liddle-era review — TGA approved rituximab for ANCA-associated vasculitis 2013; PBS-listed Jan 2016 for induction/re-induction of remission in GPA and MPA. | |
| Sarcoidosis | MSD Manual Professional Edition | ||
| Skin manifestations of rheumatological disease | RACGP (AJGP) | AJGP 50(12), December 2021 | Cutaneous clues across SLE, dermatomyositis, scleroderma, vasculitis and Behcet's - cross-referenced from the relevant connective tissue disease/vasculitis pages rather than duplicated. Local copy: evidence/rheumatology/_ajgp/ |
| Spinal muscular atrophy therapeutic landscape | RACGP (AJGP) | AJGP 51(1-2), Jan-Feb 2022 | SMA transformed from a uniformly fatal disease (severe end of spectrum) to a treatable condition: nusinersen (antisense oligonucleotide, intrathecal, PBS-listed 2018), onasemnogene abeparvovec/Zolgensma (one-off AAV gene therapy, TGA-approved Feb 2021 for <9 months symptomatic/presymptomatic SMA), and risdiplam (oral). Local copy: evidence/rheumatology/_ajgp/ |
| Statin Medications | StatPearls (NCBI Bookshelf) | ||
| Statins and muscle symptoms | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone (dara-VCd) for newly diagnosed AL amyloidosis (ANDROMEDA trial) | FDA / Haematologica / ASH | FDA approval 2021 (traditional approval following ANDROMEDA phase 3 results) | Daratumumab (anti-CD38 monoclonal antibody) + CyBorD is now the first FDA-approved, standard-of-care first-line regimen for newly diagnosed AL amyloidosis - superior major-organ-deterioration-free survival vs CyBorD alone (HR 0.47). Previously daratumumab was only an emerging/relapsed-disease option. |
| Systemic Janus kinase inhibitors in inflammatory dermatoses: a primer for general practitioners | RACGP — Australian Journal of General Practice | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_ajgp/jak-inhibitors-inflammatory-disease-2025.pdf. | |
| Systemic Janus kinase inhibitors in inflammatory dermatoses: A primer for general practitioners | RACGP (AJGP) | AJGP 54(11), November 2025 | Primarily a dermatology-focused JAK-inhibitor primer, but includes a practical monitoring protocol applicable to rheumatological use (upadacitinib PBS-listed for severe RA/PsA/non-radiographic axSpA/AS): baseline FBC, renal/hepatic function, lipid panel, HBV/HCV/HIV/TB screen, pneumococcal + Shingrix vaccination before starting; repeat bloods at 8-12 weeks; ongoing CV/malignancy risk-factor caution per the TGA class warning. Local copy: evidence/rheumatology/_ajgp/ |
| The 'autoimmune screen': more informed but no more enlightened | RACGP — Australian Journal of General Practice | Named by hand from the document's own opening text. Local copy at evidence/rheumatology/_ajgp/the-autoimmune-screen-2019.pdf. | |
| The 'autoimmune screen': More informed but no more enlightened | RACGP (AJGP) | AJGP 48(10), October 2019 (Viewpoint) | Evidence-based caution against ordering blanket 'autoimmune screens' (ANA/ANCA/HLA-B27/ENA/dsDNA panels) for undifferentiated symptoms (fatigue, arthralgia, non-inflammatory back pain): quantifies low pre-test probability (RA ~1-2%, SLE ~1:1000, ANCA-vasculitis ~16:100,000) meaning most positive results in an unselected population are false positives; cites the ARA's own EVOLVE 'top five' list advising against serological testing for low-likelihood SLE. Local copy: evidence/rheumatology/_ajgp/ |
| The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis | British Society for Rheumatology (BSR) / Rheumatology (Oxford) | Rheumatology 64(8), 2025 (first update since 2014) | Not independently verified against the full-text guideline (academic.oup.com blocks automated fetch per this project's standing policy) - key facts corroborated via an independent secondary summary (RheumNow). First major update since 2014: avacopan now recommended as a steroid-sparing induction agent (with or without a short 4-week glucocorticoid taper) alongside cyclophosphamide/rituximab induction; rituximab preferred for relapsing disease and for maintenance (500-1000mg every 4-6 months, 24-48 months); methotrexate/mycophenolate an option for non-organ-threatening disease. Applies to GPA, MPA and EGPA. |
| The management of gout | NPS MedicineWise / Australian Prescriber | ||
| The role of exercise in management of rheumatological disease | RACGP (AJGP) | AJGP 50(5), May 2021 | Exercise as an evidence-based adjunct across inflammatory arthritis, connective tissue disease and osteoarthritis - supports the BSR Pain-in-IA guideline's non-pharmacological recommendations. |
| Vaccination for people who are immunocompromised | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Viral Arthritis (StatPearls) | StatPearls | ||
| When the eyes are dry | RACGP (AJGP) | AJGP 50(6), June 2021 | Dry eye differential in general practice including Sjogren-associated keratoconjunctivitis sicca. Local copy: evidence/rheumatology/_ajgp/ |
Sexual Health
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| Anogenital Ulcers | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/penile-ulcers.md. Australian national STI management guideline syndrome page. | |
| Anogenital Warts | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/genital-warts.md. | |
| Australian STI Management Guidelines for primary care | ASHM | living online guidelines | Includes a dedicated Populations & Situations > Adult sexual assault page (post-assault STI testing/prophylaxis, HIV PEP, hepatitis B) used in Phase 4 (2026-07-08). |
| Chlamydia | Community HealthPathways Hunter New England | Last updated 23 February 2026 | Local copy: evidence/womens-health/_shared/HNE-HealthPathways-Chlamydia.pdf. Brief local pathway page, largely deferring to the Australian STI Management Guidelines for clinical detail; practice-point banner confirms doxycycline has replaced azithromycin as preferred treatment. Recommends phone sexual health specialist assessment for complex cases. |
| Chlamydia | Australian STI Management Guidelines (ASHM) | 2023-2024 review | Doxycycline 100mg BD 7 days is first-line for uncomplicated urogenital/pharyngeal and anorectal chlamydia; azithromycin 1g stat is the alternative (poor adherence, partner-matching), except pregnancy where azithromycin 1g stat is preferred. Anorectal + gonorrhoea co-infection: ceftriaxone 500mg IMI stat plus doxycycline. Test of cure only for pregnancy or azithromycin-treated anorectal infection, NAAT no earlier than 4 weeks. Contact tracing back 6 months; presumptive contact treatment if exposure within 2 weeks; patient-delivered partner therapy an option in some jurisdictions. |
| Chlamydia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Condylomata Acuminata (Genital Warts) | StatPearls (NCBI Bookshelf) | current as at fetch | HPV transmission mechanism, HPV 6/11 as cause of ~90% of cases, diagnosis (usually clinical/visual), biopsy for atypical lesions. Low-yield fallback for womens-health/genital-warts.md, stage E (note's only cited source, ashm-sti, is the ASHM landing page with no cached article text). Also on-topic for mens-health/genital-warts.md (Resource Seeding, 2026-08-23) alongside the existing ajgp-penile-dermatology-2024 (already covers genital warts in its STI section). |
| Donovanosis | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/penile-ulcers.md. | |
| Genital Herpes Simplex Virus (HSV) | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/penile-ulcers.md. | |
| Gonorrhoea | Australian STI Management Guidelines (ASHM) | Rewrite source for womens-health/gonorrhoea.md, whose Treatment/Diagnosis sections were trapped in garbled OCR image alt-text from the OneNote export (e.g. '500mg' as 'soomg', '1g' as 'Ig'). | |
| Herpes Simplex Type 1 | StatPearls (NCBI Bookshelf) | ||
| Herpes Simplex Type 1 | StatPearls (NCBI Bookshelf) | current as at fetch | Orolabial HSV-1 detail (gingivostomatitis, latency, epidemiology, triggers) for dermatology/herpes-simplex.md. |
| Herpes Simplex Type 2 | StatPearls (NCBI Bookshelf) | current as at fetch | Genital HSV clinical detail for dermatology/herpes-simplex.md. |
| Herpes Simplex Virus (HSV) Infections | MSD Manual Professional Edition | current as at fetch | Oral and genital HSV clinical/diagnostic detail for dermatology/herpes-simplex.md, which had no dedicated cited source (only the generic dermnet-nz landing page). |
| HIV and AIDS | StatPearls (NCBI Bookshelf) | updated 2026-01-14 | Pathophysiology, staged natural history, diagnostic work-up and ART management review for infectious-diseases/hiv.md, whose only prior dedicated sources were a PrEP-attitudes survey and a bare ASHM landing page. |
| HIV pre exposure prophylaxis | RACGP — Australian Journal of General Practice | This study provided a timely assessment of general practitioner knowledge and attitudes to prescribing pre-exposure prophylaxis for HIV. Catalogued from the local copy at evidence/infectious-diseases/_ajgp/hiv-prep-2019.html. | |
| HIV pre-exposure prophylaxis | Australian Journal of General Practice (RACGP) | AJGP Vol. 48, No. 10, Oct 2019 | PrEP (tenofovir/emtricitabine) PBS-listed since April 2018; any doctor/NP can prescribe; daily or on-demand (2-1-1) dosing; baseline and 3-monthly HIV/renal/STI monitoring. Local copy: evidence/infectious-diseases/_ajgp/. |
| Human Immunodeficiency Virus (HIV) Infection | MSD Manual Professional Edition | current as at fetch | Cross-check source for infectious-diseases/hiv.md natural history/transmission/diagnosis content alongside statpearls-hiv-aids. |
| Lymphogranuloma Venereum | STI Guidelines Australia (ASHM) | Stage F 2026-08-30, mens-health/penile-ulcers.md. | |
| Mpox | STI Guidelines Australia (ASHM) | Australian mpox diagnosis, testing, isolation, treatment and vaccination guidance for primary care. | |
| PEP to Prevent HIV Infection | StatPearls (NCBI Bookshelf) | ||
| Sexual history (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached) covering how to take a sexual history: last sexual contact, regular vs casual partner, gender of partner(s), condom use, type of sex (vaginal/oral/anal), contact in the last 3 months. |
| Standard Asymptomatic Checkup (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached): routine STI screening for asymptomatic people, and which subpopulations (MSM, sex workers, pregnant people, Aboriginal and Torres Strait Islander people, trans and gender diverse people) have special testing requirements. Source of the note's existing pre-claims-system quote about subpopulations. |
| STIs: syphilis, gonorrhoea and chlamydia (The Curbsiders #127) | The Curbsiders Internal Medicine Podcast | Named by hand from the document's own opening text. Local copy at evidence/mens-health/sti-screening/curbsiders-127-sti-shownotes.pdf. | |
| Syphilis | DermNet NZ | ||
| Syphilis | Australian STI Management Guidelines (ASHM) | ||
| Syphilis the great mimic: Forgotten but not gone | AJGP | ||
| Trichomoniasis | Australian STI Management Guidelines (ASHM) | Rewrite/correction source for womens-health/trichomoniasis.md — the generic ashm-sti registry entry only has the ASHM landing page cached (no article text); this is the actual disease page. Current guideline recommends metronidazole 400mg PO BD for 7 days as first-line, with metronidazole/tinidazole 2g stat as the alternative — the note's OneNote-era image alt-text had these reversed (2g stat as 'Recommended', 400mg BD for 5 days as 'Alternative'). | |
| Trichomoniasis | StatPearls (NCBI Bookshelf) | current as at fetch | Epidemiology (most common nonviral STI worldwide), clinical presentation, diagnosis, and metronidazole/tinidazole treatment. Low-yield fallback for womens-health/trichomoniasis.md, stage E (note's only cited source, ashm-sti, is the ASHM landing page with no cached article text on trichomoniasis itself). Also on-topic for mens-health/trichomoniasis.md (Resource Seeding, 2026-08-23). |
| Updating the management of sexually transmitted infections (Ooi & Lewis, Aust Prescr 2015;38:204-8) | Australian Prescriber / Therapeutic Guidelines Ltd | Practical STI review: who should be screened (anyone requesting, sexually active <29yrs, MSM, sex workers, PWID), chlamydia/HB for all groups, gonorrhoea/HIV/syphilis for MSM/PWID/sex workers, PWID also hepatitis C, MSM testing frequency, contact tracing principles, NAAT-based testing, chlamydia/gonorrhoea/M. genitalium/herpes/HIV/HPV/syphilis/hepatitis A/B/C management summaries. | |
| Urethritis (StatPearls) | StatPearls |
Travel & Toxicology
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| About the Take Home Naloxone program | Australian Government Department of Health, Disability and Ageing | Current program page (accessed 2026-07-23) | National THN Program (from 1 July 2022, following NSW/SA/WA pilots) makes naloxone free and prescription-free via pharmacies, prescribers, needle/syringe programs and AOD outreach services; formulations include injectable naloxone and the intranasal Nyxoid spray (1.8mg/dose). |
| Altitude illness | NaTHNaC (TravelHealthPro) | Current factsheet (accessed 2026-07-23) | UK NaTHNaC factsheet corroborating the eTG Toxicology and Wilderness AMS/HACE/HAPE risk thresholds (>3500m/day ascent, >500m/day sleeping elevation above 3000m) and pregnancy caution. |
| Amebiasis | StatPearls | ||
| Anticholinergic Toxicity (StatPearls) | StatPearls | ||
| Assessing fever in the returned traveller (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | Fever-in-returned-traveller assessment: exposure-history table (mosquito/tick/fly/flea bites etc mapped to likely diagnoses), physical-finding table, and an Australian public-health-response section listing Australia's eight quarantinable diseases (cholera, H5N1 avian influenza, plague, rabies, SARS, smallpox, viral haemorrhagic fevers, yellow fever) and the 65-disease clinician notification requirement. | |
| Australian Immunisation Handbook (check in browser) | Australian Government Department of Health | living online handbook | Connection resets on automated fetch (gov bot-blocking); well-known stable URL - confirm in browser. |
| Australian Immunisation Handbook — Meningococcal disease | Australian Government Department of Health, Disability and Ageing | current (living document) | Conjugate MenACWY vaccines (e.g. Menveo, Nimenrix) have superseded older polysaccharide vaccines (Mencevax, Menomune) for travel and Hajj/Umrah pilgrimage requirements. |
| Australian Immunisation Handbook — Rabies and other lyssaviruses | Australian Government Department of Health, Disability and Ageing | current (living document) | Fetched directly (curl, not blocked). 4 pre-exposure prophylaxis schedules, no preferential recommendation between them: 3-visit IM or ID (days 0, 7, 21-28), or 2-visit IM or ID (days 0, 7). 2-visit schedules give only short-term protection and must NOT be used in immunocompromised people; the 2-visit ID schedule additionally must not be used in adults >50y (poor seroconversion). A single IM booster is recommended 1 year after a 2-visit course if further protection is needed, regardless of original route. ID route is off-label, restricted to providers experienced in the technique, and contraindicated with chloroquine/mefloquine/hydroxychloroquine at time of vaccination or within 1 month after. This is more detailed than the 2025 AJGP article's brief 'two-visit (days 0,7)' summary - AJGP didn't mention the 3-visit option, the >50y ID restriction, or the immunocompromise exclusion. |
| Australian Immunisation Handbook — Tetanus | Australian Technical Advisory Group on Immunisation (ATAGI) | Carries the tetanus-prone wound prophylaxis table. | |
| Australian Immunisation Handbook — Yellow fever | Australian Government Department of Health, Disability and Ageing | current (page updated 2025-05-02, per page's own "Updates made" note) | Fetched directly (curl, not blocked). Confirms: single dose recommended for age >=9 months travelling to at-risk areas, ICVP valid for life since 2016-06-16 policy but becomes valid 10 days after vaccination; booster after >=10 years recommended for specific groups (pregnant/HIV-positive at time of 1st dose, extended stay in high-risk location, ongoing outbreak, post-HSCT). Contraindications: anaphylaxis to vaccine/eggs, infants <9 months (routine), severe immunocompromise, any thymus disorder history. Precaution: adults >=60y have higher risk of severe AEs (neurotropic/viscerotropic disease) - vaccinate only if travelling to endemic country, counsel on (very low absolute) risk. Not recommended in pregnancy/breastfeeding <9-month-old infant except unavoidable exposure. YF-AVD (viscerotropic disease) occurs in 3-4 cases per million doses; cites Lindsey et al 2008 Vaccine as the source for age-stratified adverse event reporting rates, corroborating the age-related AE rate table Steve supplied separately. |
| Chagas Disease | StatPearls | ||
| Chikungunya Fever | StatPearls | ||
| Ciguatera Toxicity | StatPearls (NCBI Bookshelf) | ||
| Common calls to a poisons information centre by general practitioners | RACGP (AJGP) | AJGP 52(6), June 2023 | Queensland PIC 2022 audit of GP calls: paracetamol and household cleaning products among the most common; concrete practical thresholds for paracetamol NAC (>20mg/L or ALT>50), paediatric accidental ingestion (<200mg/kg asymptomatic = reassurance only), household chemical exposure, and ocular decontamination (30min irrigation, pH 6.5-7.4 target). |
| Drowning: Clinical Management | StatPearls (NCBI Bookshelf) | Drowning pathophysiology, classification, ED assessment, ventilation strategy, disposition criteria. | |
| Ebola Virus Disease | StatPearls | ||
| Ebola Virus Disease (StatPearls) | StatPearls (NCBI Bookshelf) | Covers Ebola virus disease epidemiology, transmission, nonspecific flu-like/GI presentation progressing to bleeding/DIC in a minority, isolation and PPE precautions, and supportive management (no approved antiviral for all species; monoclonal antibodies/vaccine for Zaire ebolavirus). | |
| Electrical Injuries (StatPearls) | StatPearls | ||
| Filariasis | StatPearls | ||
| Guideline 9.3.2 - Resuscitation in Drowning | Australian and New Zealand Committee on Resuscitation (ANZCOR) | November 2021 | Rescue, in-water resuscitation, airway management, when to start/stop CPR for drowning. |
| Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report | International Society of Travel Medicine (Journal of Travel Medicine) | J Travel Med 2017;24(Suppl 1):S57-S80 | ISTM expert panel GRADE guideline. Source of the functional (mild/moderate/severe) severity classification, loperamide dosing, bismuth subsalicylate and rifaximin recommendations (rifaximin not in Australian eTG), and the ESBL-PE/MDR colonisation-risk rationale for judicious antibiotic use. Older (2017) than eTG but still the standard international reference, cited by the RACGP's own 2025 AJGP travel medicine article. |
| Heat health in general practice | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 1-2, Jan-Feb 2025 | Heat-related illness spectrum, vulnerable-patient identification, prevention/management for GPs. |
| Heat Stroke | StatPearls (NCBI Bookshelf) | Heat stroke definition, classic vs exertional, cooling methods, complications. | |
| Hypothermia (StatPearls) | StatPearls | ||
| Initial Management of Minor Burns (ANZBA poster) | Australian & New Zealand Burn Association | Supplied by Steve 2026-08-31. Depth assessment, dressings and ANZBA referral criteria. | |
| Injuries in travellers: clinical considerations for GPs | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 10, Oct 2025 (Travel Medicine themed issue) | Travel injuries incl. animal bites and rabies post-exposure prophylaxis, road trauma, envenomation. Local copy: evidence/infectious-diseases/_ajgp/. |
| Leishmaniasis | StatPearls | ||
| Malaria prevention guideline | Australasian College of Tropical Medicine (ACTM) | 2025 | First Australia/NZ-specific malaria chemoprophylaxis guideline (ACTM also publishes rabies and Japanese encephalitis guidelines). Table: atovaquone-proguanil, doxycycline, mefloquine, tafenoquine — site of activity, dosing interval, start/stop timing relative to travel. Cited by AJGP 2025 (ajgp-preparing-for-travel-2025) as a resource alongside CDC Yellow Book/NaTHNaC/CATMAT. |
| Marine envenomations | RACGP (Australian Family Physician) | AFP 44(1-2), January-February 2015 (reprinted) | Comprehensive Australian review of jellyfish stings (linear/tentacle vs Irukandji-like) and penetrating venomous marine injuries (fish/stingray/urchin/sponge), with RCT-level evidence for hot water immersion in bluebottle stings. Sponge stings were a previously-uncovered topic, folded into penetrating-venomous-marine-injuries.md. Local copy: evidence/travel-toxicology/_ajgp/. Table 2's organism note (Vibrio in marine/Aeromonas in freshwater wounds) also cited by infectious-diseases/bites-clenched-fist-injuries.md's water-immersed-wound antibiotic bullets, stage E 2026-08-16. |
| Minor burn management: potions and lotions | Australian Prescriber | Aust Prescr 2015;38:124-27. Carries the ANZBA burn-unit referral criteria box. Australian Prescriber dosing trusted as eTG-equivalent. | |
| Minor Burns | EM:RAP CorePendium | Supplied by Steve 2026-08-31. | |
| Naloxone for opioid toxicity and overdose in the community | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for travel-toxicology/opiate-overdose.md — take-home naloxone, intranasal/IM dosing, recognising opioid toxicity in the community setting. |
| Neuroleptic Malignant Syndrome | StatPearls (NCBI Bookshelf) | current as at fetch | NMS etiology, clinical presentation, investigations, management for mental-health/neuroleptic-malignant-syndrome.md (low-yield fallback — the only dedicated cite was the generic eTG homepage/offline-shell id). |
| Neuroleptic Malignant Syndrome | MSD Manual Professional Edition | current as at fetch | NMS cause, risk factors, onset, diagnosis, management for mental-health/neuroleptic-malignant-syndrome.md (low-yield fallback). |
| Preparing patients for travel: a primary care perspective | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 10, Oct 2025 (Travel Medicine themed issue) | Pre-travel consultation framework: risk assessment by itinerary/traveller factors, routine/required/recommended vaccines, malaria chemoprophylaxis, traveller's diarrhoea self-management, bite avoidance. Local copy: evidence/infectious-diseases/_ajgp/. |
| Prescribing for refugees | Australian Prescriber / Therapeutic Guidelines Ltd | per-article | Found via the local Australian Prescriber sitemap index (scripts/search-aus-prescriber.mjs) as a low-yield fallback source for travel-toxicology/refugee-health.md. |
| Protecting travellers from vaccine-preventable diseases | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 10, Oct 2025 (Travel Medicine themed issue) | Travel vaccination: routine catch-up, required (yellow fever - ICVP certificate; meningococcal for Hajj), and recommended (hepatitis A/B, typhoid, JE, rabies, cholera) vaccines by destination/risk. Local copy: evidence/infectious-diseases/_ajgp/. 2026-07-31: also source for the Pre-Travel Vaccinations page's Table 2 (commonly available vaccines) and Table 3 (new/emerging/hard-to-source vaccines, incl. chikungunya, dengue, TBE, mpox, TB) recreations, and the incidence-vs-impact figure (Steffen/Chen/Leggat 2023). |
| Randomized controlled trial of intravenous antivenom versus placebo for latrodectism (RAVE-II) | Annals of Emergency Medicine | 2014 | Redback spider antivenom showed no clinically meaningful benefit over placebo for pain/systemic effects; analgesia is now emphasised as mainstay treatment, antivenom reserved for uncontrolled pain/repeated opioid need. |
| Rash in a returned traveller from Bali (case) | Australian Journal of General Practice (RACGP) | AJGP Vol. 48, No. 6, Jun 2019 | Case-based approach to rash + fever in a returned traveller (dengue and other differentials). Local copy: evidence/infectious-diseases/_ajgp/. |
| Schistosomiasis | StatPearls | ||
| Scombroid and Histamine Toxicity | StatPearls (NCBI Bookshelf) | ||
| Serotonin Syndrome | StatPearls (NCBI Bookshelf) | current as at fetch | Serotonin syndrome pathophysiology, triad (neuromuscular excitation/autonomic instability/altered mental status), implicated drugs, severity, management for mental-health/serotonin-syndrome.md (low-yield fallback — the only dedicated cite was the generic eTG homepage id). |
| Snake and Spider Bites Clinical Management | NSW Health (Agency for Clinical Innovation) | GL2024_007, 4th edition, June 2024 (replaces GL2014_005) | Major changes from the 2013 3rd edition: snake venom detection kits (VDKs) no longer recommended (high false-positive rate from operator error); point-of-care INR/D-dimer testing not to be used (false negatives in severe VICC); redback spider antivenom no longer recommended as initial treatment (staged analgesia first, antivenom only at senior-clinician discretion after 1-2h) and removed from the NSW Medicines Formulary; antivenom given for signs/symptoms of envenomation before blood results return. Local copy: evidence/travel-toxicology/_shared/ |
| The anticholinergic burden: from research to practice | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| The unwell returned traveller | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 10, Oct 2025 (Travel Medicine themed issue) | Approach to fever in the returned traveller: malaria must be excluded first (thick/thin films or RDT); differential by incubation period and exposure; red flags for haemorrhagic fever/sepsis; notifiable diseases. Local copy: evidence/infectious-diseases/_ajgp/. |
| Traveler's Diarrhea | MSD Manual Professional Edition | ||
| Traveller's diarrhoea | NaTHNaC (TravelHealthPro) | Current factsheet (accessed 2026-07-23) | UK NaTHNaC factsheet corroborating the eTG Antibiotic guideline approach; severity grading (moderate/severe/persistent) and confirmation that no vaccine gives full ETEC protection (Dukoral gives only limited cross-protection, not a licensed indication in either UK or Australia). |
| Travelling with medicines in 2018 (Aust Prescr 2018;41:102-4) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand | Medical Journal of Australia (Chiew et al.) | 2020 | Introduced simplified two-bag NAC regimen (200mg/kg over 4h then 100mg/kg over 16h) replacing the older three-bag regimen; clarified modified-release and massive overdose management. |
| Vaccination for international travellers | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vaccination for migrants refugees and people seeking asylum in Australia | Australian Technical Advisory Group on Immunisation (ATAGI) | Australian Immunisation Handbook chapter. Fetched 2026-08-31 with a plain curl - immunisationhandbook.health.gov.au serves full server-rendered text and does NOT block automated fetch, unlike www.health.gov.au. | |
| Vaccines for preventing diarrhoea caused by enterotoxigenic Escherichia coli bacteria | Cochrane | ||
| Viral Hemorrhagic Fevers | StatPearls | ||
| Zika Virus | StatPearls |
Women's Health
| Source | Publisher | Edition | Notes |
|---|---|---|---|
| 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (check in browser) | Monash University (international multidisciplinary network) | 2023 (updates 2018 guideline) | Supersedes the 2018 Monash PCOS guideline; adds elevated cardiovascular disease risk screening emphasis and AMH as an alternative to ultrasound for polycystic ovarian morphology (especially useful in adolescents, where USS is unreliable). |
| A practical reference for the management of stable vulval lichen sclerosus in general practice | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/womens-health/_ajgp/vulval-lichen-sclerosus-management-2026.pdf. |
| A Practitioner's Toolkit for Managing Menopause | Women's Health Research Program, Monash University | Named by hand from the document's own opening text. Local copy at evidence/womens-health/menopause/menopause-toolkit-update.pdf. | |
| Abnormal Uterine Bleeding | StatPearls Publishing (NCBI Bookshelf) | Last Update: February 21, 2025 | Local copy: evidence/womens-health/endometrial-cancer/. |
| Abuse and violence: working with our patients in general practice (White Book) | RACGP | 5th edition | |
| Academy of Breastfeeding Medicine Clinical Protocol #36: The Mastitis Spectrum, Revised 2022 | Academy of Breastfeeding Medicine (adopted into Community HealthPathways Hunter New England) | Revised 2022 (HealthPathways adoption last reviewed 27 December 2023) | Primary source for the full rewrite of mastitis.md (2026-07-12) — a genuine paradigm shift, not a minor update: milk stasis is no longer believed to cause mastitis, and the old advice to increase feeding/pumping on the affected breast is now considered counterproductive (drives hyperlactation). Mastitis reframed as a spectrum (bleb, galactocele, phlegmon, inflammatory, bacterial, recurrent, abscess) rather than a single infective entity. |
| Accuracy of self collection in human papillomavirus based cervical screening | RACGP — Australian Journal of General Practice | This article provides an in-depth, evidence-based examination of the clinical accuracy of self-collection in cervical screening and provides recommendations for general practice. Catalogued from the local copy at evidence/womens-health/_ajgp/2025-accuracy-of-self-collection-in-human-papillomaviru.html. | |
| Accuracy of self-collection in human papillomavirus-based cervical screening: An evidence-based review | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 12, December 2025 | Evidence review confirming self-collected vaginal samples have sensitivity/specificity for HPV comparable to clinician-collected samples using PCR-based assays, supporting the universal self-collection option in the NCSP. Local copy: evidence/womens-health/_ajgp/. |
| Acute Lower Abdominal Pain in Women | Community HealthPathways Hunter New England | GP-facing pathway for gynaecological causes of acute lower abdominal pain in women (ectopic pregnancy, PID, ovarian torsion/cyst accident, etc). Local copy (supplied by Steve, text-layer): evidence/common-presentations/abdominal-pain/hne-healthpathways-acute-lower-abdominal-pain-women.pdf. Used for the common-presentations/abdominal-pain.md expansion (2026-08-24). | |
| Adenomyosis | StatPearls (NCBI Bookshelf) | ||
| ADIPS 2025 Consensus Recommendations on GDM — FAQ for health professionals | Australasian Diabetes in Pregnancy Society (ADIPS) | 2025 consensus recommendations | |
| Amenorrhoea | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/menstrual-disorders/Amenorrhoea - Therapeutic Guidelines.pdf. | |
| AMS Guide to MHT/HRT Doses in Australia | Australasian Menopause Society | March 2025 (V2) | Australia-specific dosing reference table for menopausal hormone therapy (oral/transdermal oestrogen, progestogens, tibolone). Companion reference to the IMS/AMS 2024 timing-hypothesis framing already cited on menopausal-symptoms.md. Applies to: menopausal-symptoms. |
| An itchy white vulva | RACGP — Australian Journal of General Practice | A woman aged 64 years presented with a three-year history of vulvar itch and skin fragility with associated superficial dyspareunia. Catalogued from the local copy at evidence/womens-health/_ajgp/2022-an-itchy-white-vulva.html. | |
| An itchy white vulva | Australian Journal of General Practice (RACGP) | AJGP Vol. 51, No. 10, October 2022 | Vulvar lichen sclerosus ~1 in 70 women, all ages, commonest postmenopausally; diagnosis delayed 5-15 years. Figure-of-eight vulval/perianal white plaques, hyperkeratosis, purpura, architectural change (labial resorption, buried clitoris, introital narrowing). Ultrapotent topical corticosteroid (clobetasol) induction then maintenance; SCC risk warrants ongoing review. Local copy: evidence/womens-health/_ajgp/. |
| An update on breast cancer prevention | RACGP — Australian Journal of General Practice | This article provides general practitioners with evidence-based strategies for breast cancer prevention. Catalogued from the local copy at evidence/womens-health/_ajgp/2025-an-update-on-breast-cancer-prevention.html. | |
| An update on breast cancer prevention | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 5, May 2025 | Screening does not prevent cancer. ~10% rise in breast cancer in under-50s over 20 years. Modifiable risk: alcohol, high BMI, physical inactivity. Risk-reducing medication (tamoxifen/raloxifene/anastrozole) and risk-reducing surgery for moderate-to-high risk; COSA 2024 patient guide. Use a validated risk tool (iPrevent/FRA-BOC/CanRisk) at intervals. Local copy: evidence/womens-health/_ajgp/. |
| An update on the use of non hormonal therapies for vasomotor symptoms of menopause | RACGP — Australian Journal of General Practice | To aim of this paper is to review the various methods of non-hormonal therapies available to treat women with severe menopause hot flushes and sweats. Catalogued from the local copy at evidence/womens-health/_ajgp/2026-an-update-on-the-use-of-non-hormonal-therapies-for.html. | |
| An update on the use of non-hormonal therapies for vasomotor symptoms of menopause | Australian Journal of General Practice (RACGP) | AJGP Vol. 55, No. 4, April 2026 | Non-hormonal options for vasomotor symptoms when MHT is contraindicated/declined: SSRIs/SNRIs, gabapentin, clonidine, oxybutynin, CBT; and fezolinetant (neurokinin-3 receptor antagonist) as a newer targeted agent. Local copy: evidence/womens-health/_ajgp/. |
| Analgesics and pain relief in pregnancy and breastfeeding | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Analgesics and pain relief in pregnancy and breastfeeding (full article) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Antenatal Care - Initial Visits | Community HealthPathways Hunter New England | Last updated 12 August 2026 | Local copy (supplied by Steve, text-layer): evidence/womens-health/routine-antenatal-care/HNE-HealthPathways-AntenatalCareInitialVisits.pdf. First-visit assessment pathway split out of the GP shared care pathway: EDB dating rules, pre-eclampsia/FGR/preterm-birth risk-factor lists, first-presentation bloods, RHD NIPT, GDM and thyroid high-risk screening triggers, reproductive carrier screening (MBS 73451/73452), first-trimester screening options (cFTS/NIPT/IMAP), public-referral triage categories (7/14/30 days), supplementation, vaccination and alcohol/substance-use management. HNE/NSW-specific service names and referral timings are not generalisable outside the LHD. |
| Anticoagulant Therapy in Pregnancy (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Antidepressants in pregnancy and breastfeeding (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Antiepileptic drugs in pregnancy and lactation | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Antipsychotic drugs in pregnancy and breastfeeding (Aust Prescr) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Assessment of female fertility in the general practice setting | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 6, June 2020 | GP fertility work-up: refer after 12 months trying (or 6 months if >=35 / known risk factor); assess ovulation (mid-luteal progesterone), ovarian reserve (AMH/AFC), tubal patency, semen analysis; lifestyle optimisation. Local copy: evidence/womens-health/_ajgp/. |
| Australian Immunisation Handbook — Pertussis (whooping cough) | Australian Government Department of Health, Disability and Ageing | current (living document) | Childhood NIP schedule: 2, 4, 6, 18 months + 4yrs + 11-13yr booster. Pregnancy vaccination recommended 20-32 weeks gestation (not 28-32). |
| Australian living evidence guideline: endometriosis — quick reference guide for primary care | Australian Living Evidence Collaboration | Named by hand from the document's own opening text. Local copy at evidence/womens-health/pelvic-pain/Endometriosis-Guideline-Quick-Reference-Guide.pdf. | |
| Australian Pharmaceutical Formulary and Handbook — Emergency contraception treatment guide (weight/BMI considerations) | Pharmaceutical Society of Australia | 2024 | Ulipristal acetate is now first-line for people with BMI >26 or weight >70kg, as levonorgestrel efficacy is reduced above this threshold (unknown effectiveness above 85kg/BMI 30). A double dose of levonorgestrel is recommended if ulipristal is unavailable/unsuitable in this group. Ulipristal is generally more effective than levonorgestrel across the 5-day window. Not reflected in the original note, which presents LNG and ulipristal as largely interchangeable options. |
| Australian STI Management Guidelines for primary care | ASHM | living online guidelines | Includes a dedicated Populations & Situations > Adult sexual assault page (post-assault STI testing/prophylaxis, HIV PEP, hepatitis B) used in Phase 4 (2026-07-08). |
| Barrier methods of contraception | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Barrier methods of contraception - Therapeutic Guidelines.pdf. | |
| Breast Density GP Guidance | Australian Government Department of Health, Disability and Ageing | November 2025 | National GP-facing guidance developed with the Cancer in Primary Care Research Group, University of Melbourne; expert consensus as at November 2025. Gives the practical pathway the 2024 position statement (breastscreen-density-position-statement-2024) stops short of: screening interval and supplemental-imaging options laid out by breast density category CROSSED WITH RACGP Red Book family-history risk category, and a supplemental-imaging comparison table (additional cancers detected per 1000 screened, issues, cost, MBS item). Headline points: BI-RADS d + average familial risk - discuss supplemental CEM or MRI; BI-RADS c or d + moderate familial risk - calculate risk with iPrevent or Tyrer-Cuzick to test eligibility for MBS-funded MRI (item 63464, requires age <60, lifetime risk >30% or 10-year risk >5%, AND specialist referral); high genetic risk - refer to a familial cancer service per eviQ. Yields: MRI and CEM ~16 extra cancers/1000, US ~4/1000, DBT ~1.7/1000. CEM has no MBS item for supplemental screening. Two figures (p4 supplemental imaging options, p5 screening options by density) are reproduced on the note page. Local copy: evidence/womens-health/breast-cancer-and-screening/ (supplied by Steve 2026-07-29). Note pages 4-5 are graphical - pdftotext scrambles them, read the rendered page images instead. |
| Breast density in screening mammography | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 11, November 2024 | Dense breasts both mask cancers on mammography and are an independent risk factor. No consensus/insufficient evidence for routine supplemental screening; BreastScreen Australia does not have a national density-notification policy (varies by state). Local copy: evidence/womens-health/_ajgp/. |
| Breastfeeding expressing and supplementing | RACGP — Australian Journal of General Practice | For those families for whom breastfeeding is difficult or contraindicated, advice on expressing and supplementing can aid parents to achieve their breastfeeding goals. Catalogued from the local copy at evidence/womens-health/_ajgp/2022-breastfeeding-expressing-and-supplementing.html. | |
| Breastfeeding: Expressing and supplementing | Australian Journal of General Practice (RACGP) | AJGP Vol. 51, No. 3, March 2022 | Practical breastfeeding support: expressing technique/storage, indications for supplementation, low-supply assessment. Complements the ABM 2022 mastitis-spectrum framework in the mastitis page. Local copy: evidence/womens-health/_ajgp/. |
| BreastScreen Australia eligibility and screening interval | BreastScreen Australia (state program pages, e.g. BreastScreen SA/NSW) | 2026 | Confirms no change to the 50-74yrs actively-invited / 40-49+75yrs eligible-not-invited biennial schedule. New detail not previously in breast-screening.md: Aboriginal and Torres Strait Islander women recommended to screen from age 40. |
| BreastScreen Australia Position Statement on Mammographic (Breast) Density and Screening | BreastScreen Australia Clinical Advisory Group / Australian Government Department of Health, Disability and Ageing | Version 2.0, advice dated 6 November 2024 (review November 2029) | National policy for BreastScreen Australia services. Key positions: women ARE to be informed in writing of their mammographic density measured on their screening mammogram (this supersedes the older 'Australia has no national density-notification policy' framing); mammography benefits women of all densities; BI-RADS a/b/c/d definitions, with c+d = 'dense breasts' and d = 'extremely dense'. Prevalence: ~33% of women 50-74 are BI-RADS c or d, ~10% are d (~25% of women under 50 are d). Program sensitivity ~90% (BI-RADS a/b), 84% (c), 64% (d). Relative risk vs BI-RADS b: category a ~half, c 1.6-fold, d 2.6-fold. Recommends a validated risk tool (iPrevent, Tyrer-Cuzick or CanRisk) to frame screening/prevention discussions. Confirms there is still NO consensus on the optimal supplemental screening test, and no RCT showing supplemental screening saves lives in asymptomatic average-risk women, though the DENSE trial showed MRI detects more cancers in extremely dense breasts. Supplemental screening sits outside the BreastScreen program (GP referral to public/private imaging), raising equity-of-access concerns. Local copy: evidence/womens-health/breast-cancer-and-screening/ (supplied by Steve 2026-07-29). |
| Cancer Council clinical practice guidelines and Optimal Care Pathways | Cancer Council Australia | per-guideline wiki | |
| Cervical Cancer | StatPearls (NCBI Bookshelf) | ||
| Cervical Cancer Screening in Australia and Aotearoa New Zealand (C-Gyn 19) | Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) | Named by hand from the document's own opening text. Local copy at evidence/womens-health/cervical-screening/Cervical-Cancer-Screening-Australia-New-Zealand.pdf. | |
| Cervical Polyps (StatPearls) | StatPearls | ||
| Cervical Screening | Community HealthPathways Hunter New England | Named by hand from the document's own opening text. Local copy at evidence/womens-health/cervical-screening/Cervical Screening - Community HealthPathways Hunter New England.pdf. | |
| Changes to HPV vaccine dose schedule for young Australians | Australian Government Department of Health, Disability and Ageing (National Immunisation Program) | 2023 | From 6 Feb 2023, routine NIP schedule moved from 2-dose to single-dose Gardasil 9 (9-valent, already replaced the quadrivalent vaccine in 2018) for ages 12-25 (immunocompromised still need 3 doses); catch-up program extended to age 25. |
| Chlamydia | Community HealthPathways Hunter New England | Last updated 23 February 2026 | Local copy: evidence/womens-health/_shared/HNE-HealthPathways-Chlamydia.pdf. Brief local pathway page, largely deferring to the Australian STI Management Guidelines for clinical detail; practice-point banner confirms doxycycline has replaced azithromycin as preferred treatment. Recommends phone sexual health specialist assessment for complex cases. |
| Chlamydia | Australian STI Management Guidelines (ASHM) | 2023-2024 review | Doxycycline 100mg BD 7 days is first-line for uncomplicated urogenital/pharyngeal and anorectal chlamydia; azithromycin 1g stat is the alternative (poor adherence, partner-matching), except pregnancy where azithromycin 1g stat is preferred. Anorectal + gonorrhoea co-infection: ceftriaxone 500mg IMI stat plus doxycycline. Test of cure only for pregnancy or azithromycin-treated anorectal infection, NAAT no earlier than 4 weeks. Contact tracing back 6 months; presumptive contact treatment if exposure within 2 weeks; patient-delivered partner therapy an option in some jurisdictions. |
| Choice of contraceptive method | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Choice of contraceptive method - Therapeutic Guidelines.pdf. | |
| Chronic pelvic pain with normal laparoscopic findings | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 1-2, Jan-Feb 2024 | A normal laparoscopy does not invalidate the pain. Framework: divide chronic pelvic pain into pelvic-organ, pelvic-muscle (pelvic floor myalgia), central nervous system (central sensitisation) and psychosocial contributors, and target treatment accordingly. Local copy: evidence/womens-health/_ajgp/. |
| Clinical assessment and management of vaginismus | RACGP — Australian Journal of General Practice | This article summarises the aetiology and contributing factors of vaginismus, how a diagnosis can be made, the implications of vaginismus for primary care clinical practice and treatment options. Catalogued from the local copy at evidence/womens-health/_ajgp/2024-clinical-assessment-and-management-of-vaginismus.html. | |
| Clinical assessment and management of vaginismus | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 1-2, Jan-Feb 2024 | ~14% of Australian women report dyspareunia in the last year; vaginismus is a leading cause. Persistent/recurrent difficulty allowing vaginal entry despite wishing to. GP role: validate, diagnose, exclude other causes (vulvodynia), refer. Multidisciplinary multimodal therapy (pelvic floor physio, vaginal trainers/dilators, psychology/CBT, lubricant) - trial and error but usually positive outcomes. Local copy: evidence/womens-health/_ajgp/. |
| Clinical care for women seeking pregnancy after miscarriage | RACGP — Australian Journal of General Practice | This article aims to address the question of when it is deemed safe to attempt conception after a miscarriage and discuss strategies to promote a healthy pregnancy. Catalogued from the local copy at evidence/womens-health/_ajgp/2024-clinical-care-for-women-seeking-pregnancy-after-mi.html. | |
| Clinical management of patients presenting following a sexual assault | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 7, July 2020 | GP response to a disclosure of recent sexual assault: refer to a specialist sexual assault service for forensic examination (patient-led, time-sensitive), emergency contraception, STI testing/prophylaxis and baseline serology, HIV PEP if <72h, HBV vaccination, injury care, careful contemporaneous documentation, mandatory reporting for minors, and psychosocial/safety support. Local copy: evidence/womens-health/_ajgp/. |
| Clinical practice guidelines for the management of hyperemesis gravidarum: A systematic review and quality appraisal with AGREE II | Australian Journal of General Practice (RACGP) | AJGP Vol. 51, No. 10, October 2022 | AGREE-II appraisal of hyperemesis gravidarum guidelines; supports the SOMANZ 2019 approach (stepwise antiemetics, rehydration, thiamine, ketosis/weight-loss/electrolyte red flags). Local copy: evidence/womens-health/_ajgp/. |
| Combined hormonal contraception | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Combined hormonal contraception - Therapeutic Guidelines.pdf. | |
| Common breast conditions | Jean Hailes for Women's Health | 2026 | Covers mastalgia (evening primrose oil ~3g/day), fibroadenoma, breast cysts, fibrocystic disease, nipple discharge, mastitis. Note: this page's mastitis section still recommends 'continued milk drainage', which is now superseded by the ABM 2022 protocol already implemented in mastitis.md — do not let this source override that page. |
| Condylomata Acuminata (Genital Warts) | StatPearls (NCBI Bookshelf) | current as at fetch | HPV transmission mechanism, HPV 6/11 as cause of ~90% of cases, diagnosis (usually clinical/visual), biopsy for atypical lesions. Low-yield fallback for womens-health/genital-warts.md, stage E (note's only cited source, ashm-sti, is the ASHM landing page with no cached article text). Also on-topic for mens-health/genital-warts.md (Resource Seeding, 2026-08-23) alongside the existing ajgp-penile-dermatology-2024 (already covers genital warts in its STI section). |
| Congenital Cytomegalovirus Infection | StatPearls (NCBI Bookshelf) | ||
| Contraception options during pubertal transition: Risks, benefits and considerations | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 10, October 2024 | Contraception in adolescents: LARC (implant/IUD) are safe and first-line at this age (no adverse effect on peak bone mass from the implant); DMPA BMD caution under 18; balancing non-contraceptive benefits (acne, HMB, dysmenorrhoea) with method suitability. Local copy: evidence/womens-health/_ajgp/. |
| Demystifying menopausal hormone therapy prescribing | RACGP — Australian Journal of General Practice | This article provides an updated overview of the basic principles of prescribing MHT, including the risks and benefits and practical information for tailoring treatment to the individual. Catalogued from the local copy at evidence/womens-health/_ajgp/2026-demystifying-menopausal-hormone-therapy-prescribin.html. | |
| Demystifying menopausal hormone therapy prescribing | Australian Journal of General Practice (RACGP) | AJGP Vol. 55, No. 4, April 2026 | Practical MHT prescribing: transdermal oestrogen preferred (no excess VTE/stroke at standard dose); micronised progesterone favourable profile; individualise dose; body-identical options. Complements the AMS dosing tables. Local copy: evidence/womens-health/_ajgp/. |
| Depot medroxyprogesterone contraception | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Depot medroxyprogesterone contraception - Therapeutic Guidelines.pdf. | |
| Dermatoses of Pregnancy (StatPearls) | StatPearls | ||
| Diethylstilbestrol (DES) Exposure and Cancer | National Cancer Institute (NCI) | ||
| Dysmenorrhea | RACGP — Australian Journal of General Practice | Dysmenorrhoea is the most common gynaecologic condition affecting people assigned female at birth. This article discusses the management of dysmenorrhoea in a primary care setting. Catalogued from the local copy at evidence/womens-health/_ajgp/2024-dysmenorrhea.html. | |
| Dysmenorrhea: An update on primary healthcare management | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 1-2, Jan-Feb 2024 | Primary vs secondary (~10% secondary). NSAIDs first-line: start 1-2 days pre-menses, loading-then-scheduled dose. Continuous/extended CHC preferred over cyclical; LNG-IUS effective for primary AND secondary and safe in nulliparous/adolescents. Ginger has supportive evidence. Local copy: evidence/womens-health/_ajgp/. |
| Early medical abortion provision via telehealth in Victoria: A qualitative descriptive study | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 11, November 2024 | Qualitative study supporting telehealth models of early medical abortion provision as safe and acceptable, improving access (esp. rural). Local copy: evidence/womens-health/_ajgp/. |
| Educating antenatal patients about cytomegalovirus infection | AJGP | ||
| Emergency contraception | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Emergency contraception - Therapeutic Guidelines.pdf. | |
| Endometrial Cancer | StatPearls Publishing (NCBI Bookshelf) | Last Update: April 20, 2024 | Local copy: evidence/womens-health/endometrial-cancer/. |
| Endometriosis | RACGP — Australian Journal of General Practice | Endometriosis is a chronic inflammatory condition defined as endometrial-like tissue proliferating outside the uterus. This paper summarises recommendations for diagnosing and managing endometriosis. Catalogued from the local copy at evidence/womens-health/_ajgp/2024-endometriosis.html. | |
| Endometriosis | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/pelvic-pain/Endometriosis - Therapeutic Guidelines.pdf. | |
| Endometriosis: A review of recent evidence and guidelines | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 1-2, Jan-Feb 2024 | Aligns with RANZCOG/NICE: prompt clinical diagnosis (laparoscopy NOT required to diagnose or start treatment); a normal USS does not exclude endometriosis; empiric first-line NSAIDs + hormonal therapy. RANZCOG referral triggers: imaging suggesting higher-stage/deep disease or endometrioma/adenomyosis, severe/persistent/recurrent symptoms, signs on exam, or failed/contraindicated initial management. Refer under-17s to a paediatric/adolescent gynaecologist. Local copy: evidence/womens-health/_ajgp/. |
| Epilepsy in pregnancy — management principles and focus on valproate (Int J Mol Sci 2022;23(3):1369) | International Journal of Molecular Sciences | ||
| ESHRE guideline: recurrent pregnancy loss — 2022 update | European Society of Human Reproduction and Embryology | 2022 update | Recurrent pregnancy loss (RPL) definition changed from 3+ consecutive miscarriages to 2+ pregnancy losses (not necessarily consecutive) — lowers the threshold for initiating workup, allowing earlier investigation/support for couples. Also added a new recommendation on adenomyosis investigation in women with RPL. |
| Etonogestrel contraceptive implant | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Etonogestrel contraceptive implant - Therapeutic Guidelines.pdf. | |
| Exercise after pregnancy | RACGP — Australian Journal of General Practice | Exercise is a critical protective factor for most chronic medical conditions and is strongly recommended during pregnancy and the postpartum period. Catalogued from the local copy at evidence/womens-health/_ajgp/2022-exercise-after-pregnancy.html. | |
| Female Infertility (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Fertility awareness methods of contraception | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Fertility awareness methods of contraception - Therapeutic Guidelines.pdf. | |
| First Presentation Antenatal Investigations | Community HealthPathways Hunter New England | Last updated 26 November 2025 | Local copy: evidence/womens-health/routine-antenatal-care/HNE-HealthPathways-FirstPresentationAntenatalInvestigations.pdf. First-visit bloods/screening panel, reproductive carrier screening (CF/SMA/FXS, MBS items 73451/73452), GDM risk stratification and OGTT/HbA1c protocol including bariatric-surgery-adapted algorithm, thyroid disease risk factors, and abnormal-result management pointers. |
| Gestational Diabetes (Endotext) | Endotext / NCBI Bookshelf | ||
| Gestational Diabetes Mellitus (GDM) | Community HealthPathways Hunter New England | Last updated 11 May 2026 | Local copy (supplied by Steve, text-layer): evidence/womens-health/pregnancy/HNE-HealthPathways-GestationalDiabetes.pdf. Local GDM pathway built on the ADIPS 2025 consensus: high-risk screening triggers, OGTT contraindications, the adapted capillary-glucose algorithms for previous bariatric/metabolic surgery and for PCOS on metformin, local glycaemic targets, fasting ketone monitoring, insulin/metformin choice, routine timing of birth by treatment type, and postnatal BGL monitoring plus 6-12 week OGTT. HNE/NSW referral routes not generalisable outside the LHD. |
| Gonorrhoea | Australian STI Management Guidelines (ASHM) | Rewrite source for womens-health/gonorrhoea.md, whose Treatment/Diagnosis sections were trapped in garbled OCR image alt-text from the OneNote export (e.g. '500mg' as 'soomg', '1g' as 'Ig'). | |
| Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care (2024) | National Blood Authority Australia | 2024 | |
| Guidelines for human papillomavirus (HPV) vaccine (C-Gyn 18) | RANZCOG | Named by hand from the document's own opening text. Local copy at evidence/womens-health/cervical-screening/Guidelines-HPV-Vaccine.pdf. | |
| Heavy menstrual bleeding (menorrhagia) | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/menstrual-disorders/Heavy menstrual bleeding (menorrhagia) - Therapeutic Guidelines.pdf. | |
| Indications for commencing aspirin | RACGP — Australian Journal of General Practice | Hypertensive disorders of pregnancy are a leading cause of maternal, fetal and neonatal morbidity. Catalogued from the local copy at evidence/womens-health/_ajgp/2022-indications-for-commencing-aspirin.html. | |
| Indications for commencing aspirin for the prevention of pregnancy-induced hypertension and pre-eclampsia spectrum disorders | Australian Journal of General Practice (RACGP) | AJGP Vol. 51, No. 10, October 2022 | Low-dose aspirin (usually 150 mg nocte) from 12-16 weeks (before 16 weeks) until ~36 weeks reduces pre-eclampsia risk in women with a high-risk factor or >=2 moderate-risk factors. Local copy: evidence/womens-health/_ajgp/. |
| Initial Antepartum Care (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Interconception care | RACGP — Australian Journal of General Practice | Interconception care is becoming increasingly important, with rising rates of overweight, obesity, diabetes and hypertension among people of reproductive age. Catalogued from the local copy at evidence/womens-health/_ajgp/2020-interconception-care.html. | |
| Interconception care | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 6, June 2020 | Care between pregnancies: postpartum contraception/birth spacing, follow-up of GDM (2-yearly OGTT) and hypertensive disorders (cardiometabolic risk), weight and mental health, optimising the next pregnancy. Local copy: evidence/womens-health/_ajgp/. |
| International evidence-based guideline for the assessment and management of polyendocrine metabolic ovarian syndrome (formerly PCOS) — 2026 terminology update | Monash University / international guideline development group | Named by hand from the document's own opening text. Local copy at evidence/womens-health/menopause/Updated-PMOS-Guideline-12-June26.pdf. | |
| International evidence-based guideline for the assessment and management of premature ovarian insufficiency | ESHRE / ASRM / IMS / CRE-WHiRL (joint international guideline) | 2024 update (successor to the 2015/2016 ESHRE POI guideline) | Primary source for the t-premature-ovarian-insufficiency.md rewrite (2026-07-12): diagnostic criteria (FSH>25 IU/L x2, AMH as adjunct not primary diagnosis), mandatory karyotype + FMR1 premutation testing, 21OH-antibody autoimmune screening, bone/cardiometabolic/neurological/psychological/sexual health screening recommendations, HT dosing (including puberty induction protocols), fertility/pregnancy guidance including oocyte donation and sister-donor cycle-cancellation risk. PDF supplied by Steve, saved to evidence/womens-health/poi/. |
| Interventions for leg cramps during pregnancy (CD010655) | Cochrane | ||
| Interventions for treating severe nausea and vomiting during pregnancy (hyperemesis gravidarum) | Cochrane | ||
| Intrahepatic Cholestasis of Pregnancy: Diagnosis, Management, and Future Directions — A Review of the Literature (2025) | PMC (open access review) | 2025 | |
| Intrauterine contraceptive devices | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Intrauterine contraceptive devices - Therapeutic Guidelines.pdf. | |
| Investigation of intermenstrual and postcoital bleeding (best practice statement) | RANZCOG | Named by hand from the document's own opening text. Local copy at evidence/womens-health/menstrual-disorders/Investigation-Intermenstrual-Postcoital-Bleeding.pdf. | |
| Lactational amenorrhoea method of contraception | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Lactational amenorrhoea method of contraception - Therapeutic Guidelines.pdf. | |
| Long acting reversible contraceptives | RACGP — Australian Journal of General Practice | This article compares intrauterine devices now available in Australia to support informed patient choice. Catalogued from the local copy at evidence/womens-health/_ajgp/2022-long-acting-reversible-contraceptives.html. | |
| Long-acting reversible contraceptives: New evidence to support clinical practice | Australian Journal of General Practice (RACGP) | AJGP Vol. 51, No. 4, April 2022 | LARC (implant, LNG-IUD, copper IUD) are the most effective reversible methods and should be offered first-line, including to nulliparous women and adolescents. Compares the devices available in Australia. Local copy: evidence/womens-health/_ajgp/. |
| Management of genitourinary symptoms of menopause | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/womens-health/menopause/Management of genitourinary symptoms of menopause - Therapeutic Guidelines.pdf. | |
| Management of heavy menstrual bleeding in Australian general practice | RACGP — Australian Journal of General Practice | This study provides insights into the management of heavy menstrual bleeding (HMB) prior to the release of the HMB clinical care standard. Catalogued from the local copy at evidence/womens-health/_ajgp/2021-management-of-heavy-menstrual-bleeding-in-australi.html. | |
| Management of heavy menstrual bleeding in Australian general practice: An analysis of BEACH data | Australian Journal of General Practice (RACGP) | AJGP Vol. 50, No. 8, August 2021 | BEACH-data descriptive research on how Australian GPs managed HMB prior to the ACSQHC Heavy Menstrual Bleeding Clinical Care Standard - documents historical over-reliance on referral/COCP and under-use of LNG-IUD. Context, not directive. Local copy: evidence/womens-health/_ajgp/. |
| Management of hyperemesis gravidarum | RACGP — Australian Journal of General Practice | Severe nausea and vomiting is a common indication for hospitalisation among pregnant women, leading to an average of five days of hospital admission. Catalogued from the local copy at evidence/womens-health/_ajgp/2022-guidelines-for-the-management-of-hyperemesis-gravi.html. | |
| Management of hypertension in pregnancy (Aust Prescr 2021, 44:148-52) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Management of menopause | Magraith K et al., Australian Prescriber 2023;46(3) | 2023 | Australian Prescriber overview of menopause management corroborating the IMS/AMS 2024 timing-hypothesis reframing already cited on menopausal-symptoms.md. Applies to: menopausal-symptoms. |
| Management of menopause (Magraith, Aust Prescr 2023;46(3)) | Australian Prescriber | Named by hand from the document's own opening text. Local copy at evidence/womens-health/menopause/magraith-management-of-menopause-ausprescr-2023.pdf. | |
| Management of pelvic girdle pain in pregnancy (NICE Guideline NG201 evidence review, 2021) | NICE | ||
| Managing menopausal symptoms (C-Gyn 9) | RANZCOG (Women's Health Committee, with AMS input) | Current September 2020 | Primary source for the menopause.md rewrite (2026-07-12): WHI-timing-hypothesis, MHT-and-cancer-type table, VTE/stroke route-of-administration distinction, tibolone/testosterone positioning, non-hormonal options, paroxetine/fluoxetine-tamoxifen interaction. Applies to: menopause, menopausal-symptoms. |
| Mastitis and Breast Abscess | Community HealthPathways Hunter New England | Named by hand from the document's own opening text. Local copy at evidence/womens-health/breast/Mastitis and Breast Abscess - Community HealthPathways Hunter New England.pdf. | |
| Maternal Postnatal Check | Community HealthPathways Hunter New England | Last updated 04 June 2026 | Local copy (supplied by Steve, text-layer): evidence/womens-health/pregnancy/HNE-HealthPathways-MaternalPostnatalCheck.pdf. Local postnatal-check pathway: red flags and escalation routes (on-call O&G registrar under 6 weeks, gynaecology registrar after), history/examination checklist, EPDS timing and severity bands, ANRQ psychosocial screening, community treatment of non-severe postpartum endometritis with eTG-derived antibiotics, rectus divarication referral threshold, immunisation catch-up including the live-vaccine interval after transfusion, and contraception/dyspareunia advice. |
| Medical abortion | RACGP — Australian Journal of General Practice | Medical abortion is a more accessible and less invasive option than surgical termination and can be provided in primary care settings. Catalogued from the local copy at evidence/womens-health/_ajgp/2020-medical-abortion.html. | |
| Medical abortion | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 6, June 2020 | Medical abortion (MS-2 Step: mifepristone 200mg then misoprostol 800mcg 36-48h later) is within community GP scope, PBS-listed, available in Australia up to 63 days (9 weeks) gestation. Contraindications: chronic adrenal failure, long-term steroids, coagulopathy/anticoagulation, allergy, (suspected ectopic). Anti-D not routinely needed before 10 weeks. NOTE: this article predates the TGA's July 2023 removal of the MS-2 Step prescriber-certification and pharmacist-registration requirements. Resources: MS-2 Step (ms2step.com.au), CERSH, 1800 My Options. Local copy: evidence/womens-health/_ajgp/. |
| Menopause | Jean Hailes for Women's Health | 2026 | Patient-facing menopause guidance; corroborates existing menopause.md/menopausal-symptoms.md content. Practical contraception detail: continue contraception until 1-2 years after final period depending on age at menopause. |
| Menopause and MHT in 2024: addressing the key controversies (White Paper) (check in browser) | International Menopause Society / Australasian Menopause Society | 2024 | Reframes WHI-era absolute risk figures via the timing hypothesis — MHT started within 10 years of menopause/under 60 has a more favourable benefit-risk profile than the original WHI headline results suggested. |
| Menopause and osteoporosis: Epidemiology, pathophysiology, screening and diagnosis | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/endocrinology-diabetes/_ajgp/menopause-osteoporosis-epidemiology-screening-2026.pdf. |
| Menopause and osteoporosis: Non-pharmacological and pharmacological management | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/endocrinology-diabetes/_ajgp/menopause-osteoporosis-management-2026.pdf. |
| Menopause, cardiovascular health and the role of hormone therapy | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/womens-health/_ajgp/menopause-cardiovascular-health-2026.pdf. |
| Metformin in pregnancy and lactation | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| Miscarriage, Recurrent Miscarriage and Ectopic Pregnancy (C-Gyn 38) | Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) | Version 1, March 2025 (RANZCOG's first dedicated guideline on this topic) | Primary source for the full rewrites of miscarriage.md, ectopic-pregnancy.md, and recurrent-miscarriage.md (2026-07-12). Major genuine changes: suction aspiration now explicitly preferred over D&C/sharp curettage with antibiotic prophylaxis recommended at surgery; anti-D/Rh D testing no longer routinely recommended before 10 weeks' gestation for threatened miscarriage/miscarriage (reversal of blanket anti-D advice); specific hCG/mass thresholds and MTX single- vs two-dose tiers for ectopic pregnancy management; salpingectomy now explicitly preferred over salpingotomy; recurrent miscarriage screening panel substantially pared back (day-3 hormone panel, AMH, androgens, vitamin D, homocysteine, inherited thrombophilia now NOT routinely recommended) while septum resection for RPL is now explicitly not recommended (reversing older surgical practice assumptions); stratified hypothyroidism/APS/IVIg/progesterone treatment recommendations added. |
| Models of care for intrauterine device provision in Australian general practice | RACGP — Australian Journal of General Practice | This study aims to describe the models of care (MoC) used in the provision of IUDs by Australian GPs. Catalogued from the local copy at evidence/womens-health/_ajgp/2023-models-of-care-for-intrauterine-device-provision-i.html. | |
| Nabothian Cyst (StatPearls) | StatPearls | ||
| National Cervical Screening Program: a summary guide for healthcare providers | Australian Government Department of Health / Cancer Council Australia | Named by hand from the document's own opening text. Local copy at evidence/womens-health/cervical-screening/ncsp-summary-guide-for-health-care-providers.pdf. | |
| National Cervical Screening Program: A Summary Guide for Healthcare Providers | Cancer Council Australia / Australian Government Department of Health and Aged Care | 2025 (incorporating 2024/2025 NCSP Guideline updates) | Primary source for the cervical-screening.md rewrite (2026-07-12): Test of Cure after HSIL treatment changed from co-testing to HPV-only annual testing (2025 update); AIS surveillance changed from indefinite annual co-testing to 5 years annual then 3-yearly, with a 25-year exit pathway (2025 update); universal self-collection eligibility confirmed; direct-to-colposcopy risk criteria at 12-month follow-up (age 50+, ATSI, overdue by 2+ years); NCSR opt-out process change (labs no longer act on 'not for register' on request forms). |
| National Immunisation Program Schedule | Australian Government Department of Health, Disability and Ageing | current from June 2026 | Official NIP schedule table (childhood/adolescent/adult/pregnancy/medical-risk-condition schedules). Current schedule gives MMR alone at 18 months (Priorix) and moves varicella to the 4-year dose combined with MMR as MMRV (Priorix-Tetra), alongside the DTaP/IPV booster. |
| Nausea and Vomiting of Pregnancy (NVP) | MotherSafe - Royal Hospital for Women (NSW Medications in Pregnancy and Breastfeeding Service) | Updated November 2021, citing SOMANZ Guideline 2019 | Free NSW telephone counselling service (9382 6539 metro / 1800 647 848 non-metro) plus patient/clinician factsheets on medication safety in pregnancy/breastfeeding. This factsheet confirms doxylamine+pyridoxine as first-line NVP treatment and gives brand names (Restavit, Dozile). Other factsheets available: eczema, cold sores/genital herpes, hayfever/allergy, depression/anxiety, asthma, caffeine, constipation, heartburn, herbal medicines, insomnia, migraine, UTI, vaccines, alcohol, pain, thrush, travel — but not epilepsy, thyroid disease, or antidepressants specifically as of 2026-07-12. |
| Nonhormonal therapy for menopausal symptoms | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/womens-health/menopause/Nonhormonal therapy for menopausal symptoms - Therapeutic Guidelines.pdf. | |
| Obstetric Cholestasis (Green-top Guideline No. 43) | Royal College of Obstetricians and Gynaecologists (RCOG) | 2022 | Bile-acid-stratified delivery timing (35-36 weeks for severe ICP); UDCA reframed as symptomatic-only per PITCHES trial. |
| Ovarian Cancer | Cancer Council Australia | 2026 | Confirms no national ovarian cancer screening programme exists in Australia (already reflected in ovarian-cancer.md); ~1805 diagnoses in 2024; risk/protective factor list consistent with existing note. |
| Ovarian Cyst (StatPearls) | StatPearls | ||
| Ovarian Torsion (StatPearls) | StatPearls | ||
| Overview of menopause | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/womens-health/menopause/Overview of menopause - Therapeutic Guidelines.pdf. | |
| PCOS (polyendocrine metabolic ovarian syndrome) | Jean Hailes for Women's Health | 2026 | Independent Australian confirmation that PCOS->PMOS rename has been adopted (acronym breakdown: Polyendocrine, Metabolic, Ovarian, Syndrome); diagnostic criteria (2 of 3: androgen excess, irregular/absent periods, polycystic ovaries) unchanged. |
| Pelvic inflammatory disease and infertility | Australian Journal of General Practice (RACGP) | AJGP Vol. 52, No. 4, April 2023 | Low threshold to suspect PID (often subtle/subclinical). Despite good antimicrobial response, long-term tubal-factor infertility/ectopic/chronic-pain risk is high - a PID history warrants early fertility review in couples planning conception. ATSI PID rates reported up to ~32%. Local copy: evidence/womens-health/_ajgp/. |
| Perinatal Depression (StatPearls) | StatPearls | ||
| Polycystic ovary syndrome | Therapeutic Guidelines Ltd (eTG complete) | Named by hand from the document's own opening text. Local copy at evidence/womens-health/pcos/Polycystic ovary syndrome - Therapeutic Guidelines.pdf. | |
| Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process (check in browser) | The Lancet / International PMOS Network (Monash MCHRI, AE-PMOS Society, Verity), in partnership with ASRM, Endocrine Society, ESE, ESHRE | May 2026 | PCOS formally renamed polyendocrine metabolic ovarian syndrome (PMOS) following a 14-year, 56-organisation global consensus process (22,000 survey responses; consensus reached Feb 2026). Diagnostic criteria and management recommendations are explicitly unchanged — only the name changes. 'PCOS' and 'PMOS' co-exist for a 3-year transition period. Corroborated via independent coverage from Yale Medicine, Johns Hopkins Medicine, University of Rochester Medicine, Endocrine Society, STAT News and AJMC (all May 2026). |
| Postmenopausal Bleeding | Community HealthPathways Hunter New England | Named by hand from the document's own opening text. Local copy at evidence/womens-health/menstrual-disorders/Postmenopausal Bleeding - Community HealthPathways Hunter New England.pdf. | |
| Postnatal care: The general practitioner visit | Australian Journal of General Practice (RACGP) | AJGP Vol. 51, No. 3, March 2022 | Structuring the postnatal GP visit: maternal physical recovery, mood (EPDS), breastfeeding, contraception, immunisations, chronic-disease/cardiometabolic follow-up after GDM/pre-eclampsia, and the infant check. Local copy: evidence/womens-health/_ajgp/. |
| Preconception care | RACGP — Australian Journal of General Practice | The aims of this paper are to discuss the evidence for and components of preconception care, as well as the role of the general practitioner in the delivery of preconception care. Catalogued from the local copy at evidence/womens-health/_ajgp/2024-preconception-care.html. | |
| Preconception care | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 11, November 2024 | Preconception care: folate (5 mg if high-risk) + iodine, immunisation/serology, chronic-disease optimisation and teratogenic-medication review, weight/lifestyle, carrier screening, mental health. Local copy: evidence/womens-health/_ajgp/. |
| Preconception Counseling (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Preeclampsia (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Pregnancy Care Guidelines (check in browser) | Australian Government Department of Health | living online guidelines | Connection resets on automated fetch (gov bot-blocking); confirm in browser. |
| Premature ovarian insufficiency (POI) 2024 — international evidence-based guideline (full text) | ESHRE / ASRM / IMS / CREI | Named by hand from the document's own opening text. Local copy at evidence/womens-health/poi/INTERNATIONAL GUIDELINE ON POI_2024_2.pdf. | |
| Premature ovarian insufficiency diagnosis and management in general practice | RACGP — Australian Journal of General Practice | The aim of this article is to provide GPs with a concise, evidence-based summary of the 2024 international POI guideline, focusing on diagnosis and management relevant to primary care. Catalogued from the local copy at evidence/womens-health/_ajgp/2026-premature-ovarian-insufficiency-diagnosis-and-mana.html. | |
| Premature ovarian insufficiency diagnosis and management in general practice: A review based on the 2024 international guideline | Australian Journal of General Practice (RACGP) | AJGP Vol. 55, No. 4, April 2026 | GP-focused review of the 2024 ESHRE/ASRM/IMS POI guideline: diagnosis (menstrual disturbance + FSH >25 on two occasions >4 weeks apart, <40yrs), causes/work-up, and hormone therapy until at least the natural menopause age (~51). Corroborates the existing POI page. Local copy: evidence/womens-health/_ajgp/. |
| Premenstrual Disorders (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Premenstrual syndrome and premenstrual dysphoric disorder | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/menstrual-disorders/Premenstrual syndrome and premenstrual dysphoric disorder - Therapeutic Guidelines.pdf. | |
| Primary dysmenorrhoea | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/menstrual-disorders/Primary dysmenorrhoea - Therapeutic Guidelines.pdf. | |
| Progestogen-only oral contraception (POP) | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Progestogen-only oral contraception (POP) - Therapeutic Guidelines.pdf. | |
| Pruritus in Pregnancy (StatPearls) | StatPearls | ||
| RANZCOG statements and guidelines directory | RANZCOG | 150+ documents, 5-year review cycle | URL updated 2026-07-07 (old /resources/statements-guidelines/ now 404). |
| Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium (Green-top Guideline No. 37a) | Royal College of Obstetricians and Gynaecologists (RCOG) | 3rd edition, 2015 (still current, no 4th edition published) | Confirmed still the current unreplaced edition on re-check 2026-07-12. Backs the HNE-adapted VTE risk-assessment tool in vte-prophylaxis.md. |
| Reducing unnecessary investigations in adolescent gynaecology: The utility of pelvic ultrasonography for adolescents presenting with heavy menstrual bleeding | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 1-2, Jan-Feb 2020 | Pelvic ultrasound is usually unnecessary as a first-line investigation for adolescent HMB (typically anovulatory/immature HPO axis or a bleeding disorder). Consider von Willebrand disease / platelet disorders in severe HMB from menarche. Local copy: evidence/womens-health/_ajgp/. |
| Respiratory syncytial virus (RSV) vaccine — maternal immunisation (Abrysvo) | Australian Government Department of Health, Disability and Ageing / Australian Immunisation Handbook | TGA approved March 2024; NIP-funded from 3 February 2025 | New addition to routine antenatal immunisation not covered in the original 2020 note: Abrysvo (bivalent RSV prefusion F vaccine, Category A) recommended from 28 weeks gestation (ideally before 36 weeks) each pregnancy, to protect infants from RSV via transplacental antibody transfer. Window corroborated by HNE HealthPathways (28-36 weeks; infant not protected unless born ≥2 weeks post-vaccination). |
| RhD Immunoglobulin (Anti-D) Prophylaxis in Pregnancy | Community HealthPathways Hunter New England | Last updated 10 June 2026 | Local copy (supplied by Steve, text-layer): evidence/womens-health/pregnancy/HNE-HealthPathways-RhDImmunoglobulinProphylaxis.pdf. Local anti-D pathway: RHD NIPT offer to all RhD-negative women (12-26 weeks, limited pathology providers, out-of-pocket cost), sensitising-event list by trimester, 28/34-week prophylaxis with the 1-7 day pre-dose antibody screen, dose by gestation (250 units under 13 weeks, 625 units after and postnatally), Kleihauer/flow-cytometry quantitation, IM administration technique, and local escalation contacts. |
| Risk factors for venous thromboembolism in pregnancy (NICE evidence review) | National Institute for Health and Care Excellence (NICE), via NCBI Bookshelf | ||
| Routine antenatal assessment in the absence of pregnancy complications (C-Obs 3b) | RANZCOG | ||
| Routine Antenatal Care - GP Shared Care | Community HealthPathways Hunter New England | Last updated 22 October 2025 | Local copy: evidence/womens-health/routine-antenatal-care/HNE-HealthPathways-RoutineAntenatalCareGPSharedCare.pdf. Full risk-stratified referral criteria (low/moderate/high risk, referral-by timing), early pregnancy assessment checklist, visit-by-visit GP-shared-care schedule to 40 weeks, EDD dating rules, RhD NIPT, stillbirth risk (Safer Baby Bundle) and FGR risk assessment prompts. HNE/NSW-specific referral pathways and service names not generalisable outside the LHD. |
| Routine Antenatal Care - GP Shared Care (2026 revision) | Community HealthPathways Hunter New England | Last updated 12 August 2026 | Local copy (supplied by Steve, text-layer): evidence/womens-health/routine-antenatal-care/HNE-HealthPathways-RoutineAntenatalCareGPSharedCare-2026.pdf. 2026 revision of the GP shared care pathway, supersedes the 2025 local copy registered as hne-healthpathways-antenatal-care-gp-shared-care (kept because existing claims quote it). The initial-visit content has moved to hne-healthpathways-antenatal-care-initial-visits; what remains is the visit-by-visit schedule from the 14-16 week booking-in visit to 40 weeks, second/third-trimester bloods, anti-D timing, vaccination windows, stillbirth (Safer Baby Bundle) and FGR reassessment points. |
| Routine Antenatal Examination | Community HealthPathways Hunter New England | Last updated 06 August 2025 | Local copy: evidence/womens-health/routine-antenatal-care/HNE-HealthPathways-RoutineAntenatalExamination.pdf. Defines the routine antenatal check components (BP technique, dipstick proteinuria, fundal height from 24 weeks, fetal heart rate from 16 weeks, presentation from 36 weeks, weight) referenced at every GP-shared-care visit. |
| Rubella | StatPearls (NCBI Bookshelf) | Updated 2023 | General rubella overview - epidemiology, transmission, clinical features (prodrome, rash, arthralgia, Forchheimer sign), congenital rubella syndrome, diagnosis, vaccination timing. Used for dermatology/rubella.md low-yield fallback, 2026-08-16. |
| Rubella | MSD Manual Professional Edition | 2026 | General rubella overview - clinical features, congenital rubella syndrome, diagnosis, prevention/vaccination. Used for dermatology/rubella.md low-yield fallback, 2026-08-16. |
| Rubella (german measles) | DermNet NZ | ||
| Self collection to increase choice within the National Cervical Screening Program | Australian Government Department of Health, Disability and Ageing | 2022 | From 1 July 2022, self-collection eligibility expanded from a restricted group (never-screened or overdue by 2+ years, age 30+) to all eligible people aged 25-74, offered as an equal choice alongside clinician-collection. |
| Sexual dysfunctions and sex therapy | RACGP — Australian Journal of General Practice | General practitioners play a significant part in recognising the need and appropriate timing to address sexual problems and initiate sex-related discussions with their patients. Catalogued from the local copy at evidence/womens-health/_ajgp/2020-sexual-dysfunctions-and-sex-therapy.html. | |
| Sexual history (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached) covering how to take a sexual history: last sexual contact, regular vs casual partner, gender of partner(s), condom use, type of sex (vaginal/oral/anal), contact in the last 3 months. |
| Skin changes of the female breast: A guide to assessment and management | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 5, May 2025 | Breast skin changes: infectious (mastitis), inflammatory (eczema, contact dermatitis) and malignant (Paget disease, inflammatory breast cancer). Any nipple/areolar eczematous change not resolving with 2 weeks of topical treatment needs specialist referral to exclude Paget disease. Local copy: evidence/womens-health/_ajgp/. |
| Skin Conditions (Rash and Itch) in Pregnancy | Community HealthPathways Hunter New England | Last updated 16 June 2026 | Local copy (supplied by Steve, text-layer): evidence/womens-health/pregnancy/HNE-HealthPathways-SkinConditionsRashItchPregnancy.pdf. Local pathway for rash and itch in pregnancy: the practice point that itch without rash is always investigated for intrahepatic cholestasis, the local bile-acid upper limit of normal and repeat-testing interval, physiological skin changes of pregnancy, pemphigoid gestationis and pustular psoriasis of pregnancy as the urgent-referral conditions, and eTG-derived local antihistamine and topical-corticosteroid choices for PEP and atopic eruption. |
| Standard Asymptomatic Checkup (Australian STI Management Guidelines for Use in Primary Care) | ASHM | living online guidelines | Specific sub-page (registry's ashm-sti id only had the site landing page cached): routine STI screening for asymptomatic people, and which subpopulations (MSM, sex workers, pregnant people, Aboriginal and Torres Strait Islander people, trans and gender diverse people) have special testing requirements. Source of the note's existing pre-claims-system quote about subpopulations. |
| Sterilisation | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Sterilisation - Therapeutic Guidelines.pdf. | |
| Syphilis | Australian STI Management Guidelines (ASHM) | ||
| Systemic menopausal hormone therapy (MHT) | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/menopause/Systemic menopausal hormone therapy (MHT) - Therapeutic Guidelines.pdf. | |
| Tamoxifen and the endometrium (C-Gyn 12) | Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) | Reviewed July 2019 | Source for the new tamoxifen/endometrium section added to breast-cancer.md (2026-07-12), a topic entirely absent from the original note. Key points: no routine endometrial screening in asymptomatic tamoxifen users; low threshold for biopsy with any abnormal bleeding; risk is postmenopausal-specific; LNG-IUD not evidence-based for endometrial protection in this group; non-hormonal contraception advised premenopausally. |
| Teenage pregnancy | RACGP — Australian Journal of General Practice | Adverse maternal and neonatal outcomes can be ameliorated through antenatal and postnatal care that attends to the special needs of this group. Catalogued from the local copy at evidence/womens-health/_ajgp/2020-teenage-pregnancy.html. | |
| Teenage pregnancy | Australian Journal of General Practice (RACGP) | AJGP Vol. 49, No. 6, June 2020 | Teenage pregnancy: higher obstetric/psychosocial risk; non-judgemental options counselling (continue/parenting, adoption, abortion), confidentiality, safeguarding, and support. Local copy: evidence/womens-health/_ajgp/. |
| The assessment and management of genitourinary syndrome of menopause in primary care | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/womens-health/_ajgp/genitourinary-syndrome-of-menopause-2026.pdf. |
| The early detection of breast cancer An update from the Red book | RACGP — Australian Journal of General Practice | This paper provides an overview of breast cancer screening recommendations, emphasising the role of general practitioners in assessing individual risk and guiding preventive strategies. Catalogued from the local copy at evidence/womens-health/_ajgp/2025-the-early-detection-of-breast-cancer-an-update-fro.html. | |
| The early detection of breast cancer: An update from the Red book | Australian Journal of General Practice (RACGP) | AJGP Vol. 54, No. 5, May 2025 | Red Book breast screening update. Lifetime risk 1 in 8 (13%) by age 85; age 50 carries 10x the risk of age 30. Insufficient evidence to recommend routine supplemental screening (e.g. USS) for women with dense breasts. BreastScreen biennial mammography 50-74 (invited), 40-49/75+ eligible. Local copy: evidence/womens-health/_ajgp/. |
| The Initial Management of Chronic Pelvic Pain (Green-top Guideline No. 41) | Royal College of Obstetricians and Gynaecologists (RCOG) | May 2012 (2nd edition; no subsequent update identified) | Light-touch update source for pelvic-pain.md (2026-07-12): CA-125 testing criteria, chronic pelvic pain red-flag list, confirmation LUNA is ineffective. No newer edition found — genuinely slow-moving evidence area. |
| The menopause consultation | RACGP — Australian Journal of General Practice | The aim of this paper is to summarise key components of a menopause consultation. Catalogued from the local copy at evidence/womens-health/_ajgp/2026-the-menopause-consultation.html. | |
| The menopause consultation | Australian Journal of General Practice (RACGP) | AJGP Vol. 55, No. 4, April 2026 | Structuring a menopause consultation. Clinical diagnosis in women >45 with typical symptoms - FSH not required over 45; FSH (x2, 4-6 weeks apart) only if 40-45 with atypical features or <40 (query POI). Assess symptom domains (vasomotor, genitourinary/GSM, sleep, mood/cognition, sexual, musculoskeletal), cardiometabolic/bone risk, and contraceptive need in perimenopause. Local copy: evidence/womens-health/_ajgp/. |
| The menstrual cycle and the impact of menstrual disorders | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/menstrual-disorders/The menstrual cycle and the impact of menstrual disorders - Therapeutic Guidelines.pdf. | |
| The primary care management of perimenopausal depression | RACGP — Australian Journal of General Practice | The aim of this article is to provide primary healthcare practitioners with evidence-based guidance to recognise and treat perimenopausal depression. Catalogued from the local copy at evidence/womens-health/_ajgp/2026-the-primary-care-management-of-perimenopausal-depr.html. | |
| The vulvar ulcer that did not heal: An approach to vulvar ulceration in a postmenopausal woman | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 11, November 2024 | A non-healing vulvar ulcer (here on a background of long-standing lichen sclerosus) needs biopsy to exclude squamous cell carcinoma / differentiated VIN - do not treat presumptively as infection indefinitely. Local copy: evidence/womens-health/_ajgp/. |
| Thyroid Disease and Pregnancy (StatPearls) | StatPearls | ||
| Thyroid Disease in Pregnancy, Postpartum, and Preconception | Community HealthPathways Hunter New England | Last updated 21 July 2026 | Local copy (supplied by Steve, text-layer): evidence/womens-health/pregnancy/HNE-HealthPathways-ThyroidDiseasePregnancyPostpartumPreconception.pdf. Local thyroid-in-pregnancy pathway: high-risk screening trigger list, trimester-specific TSH ranges, the local new-diagnosis levothyroxine thresholds (start at TSH > 5.1 mIU/L, TPO-antibody-guided below that), levothyroxine increase and 10% titration rule with monitoring schedule to 28-32 weeks, iodine supplementation policy, postpartum cessation rules, postpartum thyroiditis screening, and the serious-complication list requiring emergency assessment. |
| Thyroid disorders in pregnancy and postpartum (Aust Prescr 2017, 40:214-9) | Australian Prescriber / Therapeutic Guidelines Ltd | ||
| TORCH Complex (StatPearls) | StatPearls (NCBI Bookshelf) | ||
| Toxoplasmosis | StatPearls | ||
| Transvaginal mesh for incontinence and prolapse | RACGP — Australian Journal of General Practice | The introduction of mesh procedures for vaginal prolapse and incontinence was not managed well. Introduction of new devices or techniques must be accompanied by rigorous evaluation and ongoing audit. Catalogued from the local copy at evidence/womens-health/_ajgp/2024-transvaginal-mesh-for-incontinence-and-prolapse.html. | |
| Transvaginal mesh for incontinence and prolapse: Where are we now and how did we get here? | Australian Journal of General Practice (RACGP) | AJGP Vol. 53, No. 1-2, Jan-Feb 2024 | History/current status of transvaginal mesh: transvaginal mesh for prolapse was removed from the Australian market (TGA 2017) after a high complication rate; mid-urethral slings for stress incontinence remain but under scrutiny. GPs should recognise mesh complications (chronic pain, erosion, dyspareunia, recurrent UTI) and refer affected women to a specialist mesh service. Local copy: evidence/womens-health/_ajgp/. |
| Trichomoniasis | Australian STI Management Guidelines (ASHM) | Rewrite/correction source for womens-health/trichomoniasis.md — the generic ashm-sti registry entry only has the ASHM landing page cached (no article text); this is the actual disease page. Current guideline recommends metronidazole 400mg PO BD for 7 days as first-line, with metronidazole/tinidazole 2g stat as the alternative — the note's OneNote-era image alt-text had these reversed (2g stat as 'Recommended', 400mg BD for 5 days as 'Alternative'). | |
| Trichomoniasis | StatPearls (NCBI Bookshelf) | current as at fetch | Epidemiology (most common nonviral STI worldwide), clinical presentation, diagnosis, and metronidazole/tinidazole treatment. Low-yield fallback for womens-health/trichomoniasis.md, stage E (note's only cited source, ashm-sti, is the ASHM landing page with no cached article text on trichomoniasis itself). Also on-topic for mens-health/trichomoniasis.md (Resource Seeding, 2026-08-23). |
| Troubleshooting menopause hormone therapy | RACGP — Australian Journal of General Practice (AJGP) | August 2026 | AJGP Vol. 55, No. 8, August 2026 (menopause-themed issue). Supplied directly by Steve as a PDF (not scraped from the AJGP website) and filed at evidence/womens-health/_ajgp/troubleshooting-menopause-hormone-therapy-2026.pdf. |
| Unnecessary investigations in adolescent gynaecology | RACGP — Australian Journal of General Practice | Paediatric and adolescent females with heavy menstrual bleeding are frequently undergoing unnecessary pelvic ultrasonography as a first-line investigation. Catalogued from the local copy at evidence/womens-health/_ajgp/2020-unnecessary-investigations-in-adolescent-gynaecolo.html. | |
| Updating the management of sexually transmitted infections (Ooi & Lewis, Aust Prescr 2015;38:204-8) | Australian Prescriber / Therapeutic Guidelines Ltd | Practical STI review: who should be screened (anyone requesting, sexually active <29yrs, MSM, sex workers, PWID), chlamydia/HB for all groups, gonorrhoea/HIV/syphilis for MSM/PWID/sex workers, PWID also hepatitis C, MSM testing frequency, contact tracing principles, NAAT-based testing, chlamydia/gonorrhoea/M. genitalium/herpes/HIV/HPV/syphilis/hepatitis A/B/C management summaries. | |
| Urinary Tract Infection in Pregnancy (StatPearls) | StatPearls | ||
| Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial | Chappell et al., The Lancet | Lancet 2019; 394:849-860 | PITCHES RCT: ursodeoxycholic acid did NOT reduce the composite adverse perinatal outcome (perinatal death, preterm birth, neonatal unit admission) in ICP. UDCA's role is symptomatic (maternal pruritus) only, not disease-modifying. Underpins the RCOG GTG 43 (2022) position. |
| Uterine artery embolisation for the treatment of uterine fibroids (C-Gyn 23) / Fibroids in Infertility (C-Gyn 27) | Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) | C-Gyn 23 reviewed March 2020; C-Gyn 27 reviewed March 2018 | Update source for uterine-fibroids.md (2026-07-12): specific UAE outcome/complication data (~35% eventual hysterectomy at 10 years, minor complications 30-45%, major ~5%), explicit fertility caution against routine UAE in women wanting to conceive, and myomectomy benefit stratified by fibroid location (submucosal > intramural > subserosal) from the companion Fibroids in Infertility statement. |
| Uterine Cancer | Cancer Council Australia | Last updated 6 July 2026 | Clinically reviewed by Prof Alison Brand, Director of Gynaecological Oncology, Westmead Hospital. Corroborates existing endometrial-cancer.md risk factor/staging content; multi-modal treatment approach (surgery, chemo, radiation, hormone, targeted, immunotherapy). |
| Vaginal Bleeding | MSD Manual Professional Edition | Full Review: Jun 2024 | Anatomic-site breakdown of vaginal/cervical/uterine bleeding causes, incl. PALM-COEIN; used for intermenstrual-and-post-coital-bleeding stage-F rewrite. |
| Vaginal Bleeding (StatPearls) | StatPearls | ||
| Vulvovaginitis caused by Candida and related species in adults | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/vulvar-disorders/Vulvovaginitis caused by Candida and related species in adults - Therapeutic Guidelines.pdf. | |
| Withdrawal method of contraception | Therapeutic Guidelines Ltd (eTG complete) | Catalogued from the local copy at evidence/womens-health/contraception/Withdrawal method of contraception - Therapeutic Guidelines.pdf. |